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Abstract 
 
Networks of biomacromolecular interaction form the core of internal cellular logic where 
a wide range of input signals get analysed and results in a genetically programmed output. 
This description holds not only for healthy cells but is true also for those virally infected 
when a virus implements new biomacromolecular elements and modifies existing networks. 
Those hostile interactions are crucial for the HIV virus replication cycle. Due to the scale-free 
nature of biomacromolecular interaction networks they are prone to malfunction if a hub 
(node with the highest interactions) is damaged. Perhaps the best example of such a situation 
can be observed in the apoptotic machinery. Overexpression, deletion or mutations 
(depending on the context) in apoptotic proteins can lead to various diseases, most 
prominently cancer. Therefore current research efforts concentrate on designing inhibitors of 
malfunctioning interactions. Occasionally interaction between the two binding partners relies 
on a well-defined secondary structures element. This allows to engineer this element and use 
it to bias the given interaction equilibrium towards dissociation. One such approach 
concentrates on α-helices that are crosslinked with azobenzene derivatives. This permits not 
only to increase the helical content of a peptide, which translates to increased affinity 
(potency), but transplants a photo-controllability. Photoswitchable peptides created in this 
way can be controlled externally; their affinity towards targets can be effectively photo-
modulated.  
The first chapter of the thesis concentrates on the development and evaluation of photo-
controllable peptides derived from the arginine rich region of the HIV type I Rev protein. 
Rev, which is an early product generated from the HIV genome, binds to RRE containing 
mRNA and removes it from the nucleus, allowing expression of unspliced or singly spliced 
mRNA into different protein products. As a consequence the RRE-Rev interaction controls 
the infection cycle of the HIV type 1, as these later products are necessary for virus particle 
assembly. The α-helical peptide derived from Rev was shown to retain most of the affinity to 
RRE. Rev-RRE serves as a prototypical protein-RNA interaction; a model for the 
development of the first photo-controllable peptide that targets RNA. This research presents 
two approaches for the peptide production: chemical synthesis and biosynthesis 
(overexpression of the Rev peptide gene). Initially the water soluble azobenzene derivative 
was used bearing two negatively charged sulphonate substituents on the aromatic rings. 
Surprisingly, the first generation of the peptides had substantially decreased affinity to RRE 
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as compared to the wild type Rev peptide. By applying computational chemistry techniques a 
possible rationalisation was found: sulphonates interact strongly with crucial arginines on the 
peptide making them unavailable to engage the phosphate backbone; additionally the peptide 
was forced into non-helical conformation prior to binding. This hypothesis was validated by 
crosslinking Rev peptides with azobenzene derivative deprived of the sulphonates. The 
second generation of Rev peptides binds RRE with high affinity and the interaction in 
question can be controlled effectively by light. 
The second chapter of the thesis focuses on the structural characterization of a photo-
controllable Bak peptide bound to Bcl-xL – a prominent member of the Bcl-2 family of 
proteins. The Bcl-2 family of proteins includes the major regulators and effectors of the 
intrinsic apoptosis pathway. Cancers are frequently formed when activation of the apoptosis 
mechanism is compromised either by misregulated expression of prosurvival family members 
or, more frequently, by damage to the regulatory pathways that trigger intrinsic apoptosis. 
Short peptides derived from the pro-apoptotic members of the Bcl-2 family can activate 
mechanisms that ultimately lead to cell death. The recent development of photocontrolled 
peptides that are able to change their conformation and activity upon irradiation with an 
external light source has provided new tools to target cells for apoptosis induction with 
temporal and spatial control. In this thesis the first NMR solution structure of a 
photoswitchable peptide derived from the proapoptotic protein Bak in complex with the 
antiapoptotic protein Bcl-xL is reported. This structure provides insight into the molecular 
mechanism, by which the increased affinity of such photopeptides compared to their native 
forms, is achieved, and offers a rationale for the large differences in the binding affinities 
between the helical and nonhelical states. 
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1 INTRODUCTION 
1.1 Protein Structure 
1.1.1 Amino acids and primary structure of proteins and peptides 
Proteins and peptides are macromolecular polymers composed of amino acids. 
Definitions of proteins and peptides vary but are loosely based on the polymer chain length, 
so that short chains, between 2 and 30 amino acids, are considered to be peptides. 
Polypeptides that are longer and more sophisticated in higher order structures tend to be 
called proteins. Apart from a relatively small group of short peptides, all proteins are 
biosynthesized by ribosomes that use a strand of mRNA, transcribed from a DNA sequence, 
as a template that encodes a protein sequence in triplets of nucleobases together with 
complementary tRNA molecules loaded with corresponding amino acids. Jointly these 
molecules translate the encoded sequence into a one-dimensional protein sequence. Naturally 
occurring proteins and peptides are composed of 22 proteinogenic amino acids: alanine (Ala, 
A), arginine (Arg, R), aspartate (Asp, D), asparagine (Asn, N) cysteine (Cys, C), glycine (Gly, 
G), glutamate (Glu, E), glutamine (Gln, Q), isoleucine (Ile, I), histidine (His, H), leucine (Leu, 
L), lysine (Lys, K), phenylalanine (Phe, F), methionine (Met, M), proline (Pro, P), pyrrolysine 
(Pyl, O), selenocysteine (Sec, U), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), 
tyrosine (Tyr, Y), valine (Val, V). Although many other amino acids are biosynthesized and 
sometimes incorporated into polypeptides by non-ribosomal mechanism, only the 
aforementioned 22 are encoded by triplets of mRNA nucleobases (N.B. pyrrolysine and 
selenocysteine have additional requirements to be incorporated).1-3 Amino acids share a 
common scaffold of an amino group and a carboxylic acid group bound to a central alpha 
carbon (Cα). It is the side chain of amino acids, also connected to the alpha carbon, which 
gives them their unique properties. Amino acids can be categorized into groups of similar 
size, hydrophobicity, charge or aromaticity based on the properties of their side chains. 
Amino acids in peptides or proteins may also be selectively post-translationally modified by 
attachment of a variety of chemical groups including lipids, sugars, nucleic acids, hydroxyls, 
methyl groups or other products of a secondary metabolism. Amino acids within a protein are 
linked by a peptide bond, which due to delocalisation, has a partial double bond character and 
a tendency to remain planar (Figure 1). It is the sequence of amino acids connected by these 
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peptide bonds that defines the primary structure of protein and peptides. As the peptide bond 
is asymmetric, the polypeptide strand also has directionality with distinct N-, and C-termini. 
 
 
 
Figure 1: A model of two peptide bonds with φ(φ’) and Ψ(Ψ’) angles indicated. 
1.1.2 Secondary structure 
The one dimensional primary structure is driven, predominantly by the formation of 
hydrogen bonds between peptide bonds, to fold into few privileged three-dimensional 
secondary structures. The lowest energy arrangements of ϕ and ψ angles (which are 
correlated to hydrogen bonds patterns and steric effects) also contribute to secondary structure 
formation. The most frequently adopted secondary structures are the β-sheet and α-helix 
(Figure 2). The β-strands are an extended helical arrangement of a peptide chain where 2 
amino acids form each turn (2 amino acids per pitch). Because the peptide chain has 
directionality, β-strands can associate into two sorts of β−sheets with the relative direction of 
the strands parallel or anti-parallel. In a parallel β-sheet ϕ/ψ angles are close to -139°/-135° 
and in an antiparallel -119/+113°.4 In the α-helical arrangement, polypeptide chains are 
twisted into a characteristic right-handed helix with hydrogen bonds occurring between amino 
acids 4 residues apart giving a helix pitch of 3.6 amino acids (Figure 2); ϕ and ψ angles of 
such alpha helix cluster around the values of -57°/-47°, respectively (left-handed 
arrangements also occur, but relatively rarely).4  
Depending on the environment around an α-helix, they can be predominantly 
hydrophobic (e.g. the core of a globular protein, or spanning a lipid bilayer), hydrophilic (e.g. 
helices that contact other macromolecules via electrostatic interactions) or amphipathic with 
hydrophobic and hydrophilic regions either perpendicular or parallel to the direction of the 
helix (e.g. localized at the interface between hydrophilic and hydrophobic environment). The 
helical structure is usually reinforced by other elements of the overall protein structure, as the 
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hydrogen bonds alone do not provide enough energy to stabilise an isolated α-helix. α-
Helices deprived of their scaffold tend to be unfolded in aqueous solutions; however the 
structure depends on the additives present in a solution and its pH. 
 
Figure 2: Example of protein secondary structure: a helical projection of a right-handed α-helix (on the right), model 
of a right-handed α-helix presented along the long axis (in the middle) and an antiparallel β-sheet (on the 
left). Hydrogen bonds are indicated in green; the intensity of the gray lines corresponds to the depth. 
Due to the presence of so many hydrogen bonds aligned in the same direction, helices 
are dipolar with the negative pole at the C-terminus. That increases the energetic cost of 
assembling the helix and is very often compensated for by oppositely charged residues at 
respective ends, i.e. arginines at the C-terminus. α-Helical peptides are usually synthesized 
with a C-terminal amide cap that removes the negative charge of the carboxy acid terminus 
and N-terminal acetyl cap that removes the positive one of the N-terminus. In addition to α-
helices, there are four other helical type secondary structures: π  helix 
(ϕ/ψ −57/−70°), 310 helix (-49/-26°) and two types of secondary structure adopted only by 
polyprolines: poly(Pro) I (ϕ/ψ −83/−158°) poly(Pro) II (ϕ/ψ −78/−149°). 4 Two different 
geometries of turns are also classified: a four-residue β-turn and a three-residue gamma turn. 4 
 Amino acids can be divided into groups based on their propensity to form and stabilize 
different types of secondary structure; both statistical methods and direct biochemical 
investigation provide similar results. Glutamate, methionine, alanine appear often in α-
helices, whereas valine, isoleucine and tyrosine are typical of β−sheets. Proline and glycine 
have tendency to break helices and are often found in parts of protein structure that change 
direction. Loops are long stretches of polypeptide sequences that do not appear to have any of 
the mentioned structures. Often they are flexible and probe many conformations, but 
occasionally loops are very stable but just do not fall into any canonical category of torsion 
angles. 
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1.1.3 Tertiary, quaternary structure and protein domains 
 Tertiary structure refers to the positions of all atoms within the given protein. Some 
proteins can be additionally subdivided into domains; elements of the protein structure, which 
can fold independently. The driving force for this larger scale folding and association is 
predominantly the hydrophobic effect; as the protein folds it places hydrophobic regions 
together excluding many ordered water molecules (water clusters around hydrophobic areas) 
and making the process entropically favourable despite the increased order of the protein. 
Hydrogen bonds, van der Waals interactions (dipole-dipole, dipole-induced dipole, and 
induced dipole/induced-dipole) and electrostatic interactions (salt bridges) can also promote 
folding, as can the presence of disulfide bridges between cysteines. Folded proteins can 
further interact with each other to form stable protein complexes, constituting the quaternary 
structure of proteins. Protein interactions will be discussed further later. Although it was once 
believed that proteins form rigid and well defined structures, many examples are now known 
of proteins that are natively unfolded and even more often only a part of the protein structure 
is well defined, with the remainder being natively unfolded. The advantage of this 
arrangement is that inherent structural flexibility allows them to adapt to many conditions and 
interact with many different proteins. 
1.2 Protein interactions 
1.2.1 Overview of protein interaction 
There are four main categories of macromolecular interactions that a protein can be 
involved in: protein-protein (PPI), protein-DNA, protein-RNA and protein-polysaccharides 
(sugar trees) interactions. Proteins can also interact with many different types of small 
molecules including but not limited to polysaccharides, lipids, amino acids or molecules that 
are hybrids of aforementioned both in terms of covalent attachment and non-covalent 
complexes. The scope of this thesis is confined to protein-protein and protein-RNA 
interactions. 
1.2.2 Protein-protein interactions 
 The average protein in the yeast proteome interacts with five other proteins, which 
leads to a total of 25,000 to 35,000 protein-protein interactions.5 This number is estimated to 
be even higher for Homo sapiens at around 650,000 total interactions.6 Such large numbers 
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underscore the crucial importance of protein-protein interactions which underpin almost all 
cellular functions. The average surface area of two interacting proteins is approximately 1600 
Å2.2,7 Many such interfaces involve elements of secondary structure but are generally flat and 
were long considered poor targets for small molecule drugs, which are better suited to 
targeting deep pockets than shallow protein-protein interfaces.8 Although such interfaces 
encompass many hydrophilic and hydrophobic residues, only certain percentage of amino 
acids forming the interface contribute significantly to the binding energy;9 these are called 
“hot-spots”, residues which upon mutation decrease the binding affinity the most.9 It has also 
been observed that the larger the area of the interface, the more hydrophilic residues it 
contains; this effect corresponds to the necessity of dissociated units to remain in solution 
long enough to find their binding partner.10 Not all protein interfaces are flat and dispersed 
over large areas, in a number of cases only a certain key element of the secondary structure is 
responsible for the majority of the binding energy. Bioinformatic methods reveal that 62% of 
protein-protein complexes structures deposited in protein data bank (PDB) contain an  
α−helix as one of the elements of the interface.11 Of those 16% (10% of the total) contain key 
hot-spot residues within an α-helix and could be targeted by helix mimics.11 Broadly, those 
interfaces may be divided into two categories; those with binding clefts where the distance 
between flanking hotspot residues is less than 7 Å and those with extended interfaces where it 
is between 7 and 30 Å.11 In principle, α-helix protein interactions could be approximated by a 
peptide corresponding to the given α-helix and its binding protein, however such a peptide 
deprived of its structural scaffold is unfolded or adopts a different conformation in solution. 
The associated entropic cost of rearrangement upon binding of such peptide may significantly 
decrease its binding affinity. In the case of intrinsically (natively) unfolded proteins this 
difference might be less pronounced. 
1.2.2.1 Targeting helix-binding clefts 
 Considerable efforts in recent years have led to the development of a number of 
different approaches to target helix-binding clefts and disrupt protein-protein interactions. 
Four major strategies have been adopted: the development of “classic” small molecule 
inhibitors, mimicking α−helical conformation through modular non-peptide scaffolds, using 
β−amino acid peptides and finally, modifying existing α-helical peptides to reinforce their 
structure and increase binding and/or stability or transplanting the binding epitope onto a 
stable, small protein.12 
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1.2.2.2 Classic small molecule inhibitors targeting helix-binding clefts 
  A limited number of successful small molecule inhibitors of protein-protein 
interactions have been reported so far. The list of somewhat successful inhibitors of protein-
protein interactions is too long to be contained in this thesis. The engagement of various 
elements of protein structure in the binding interface reflects (at least to the first 
approximation) the statistical distribution within Protein Data Bank; this implies that only a 
subset of compounds within that group targets an α-helix binding cleft. This thesis will be 
only concerned with that type of protein-protein interactions. 
Typical targets of those molecules are well-characterized members of the B cell 
lymphoma 2 (Bcl-2) family and human double minute 2/X (HDM2/X) protein; both of which 
are well-known oncogenes, making inhibitors promising targets for a cancer therapy. The two 
acylsulfonamide compounds W1191542 and ABT-737 target respectively B cell lymphoma 
extra-large (Bcl-xL) and Bcl-2 proteins (Figure 3) with nanomolar dissociation constants. 
 
Figure 3: Surface representation of: Bcl-xL with the W1191542 inhibitor (left) and Bcl-2 with ABT-737 inhibitor 
(right); PDB entries: 3INQ, 1YSW. 
ABT-737 was shown to induce regression of solid tumours (Figure 3). Both compounds 
mimic the interactions present between the Bcl-2 homology domain 3 only (BH3-only) 
proteins as do others that aim to mimic the periodic structure of α−helix in a modular 
fashion.13-15 
Interesting PPI occurs between eukaryotic translation initiation factor EIF4E and 
EIF4G. This complex is directly involved in the recognition of 5′, 7- methylguanosine mRNA 
cap and mRNA translocation to the ribosome for subsequent translation. The EIF4E gene was 
found to be recurrently overexpressed in cancer cells.16 EIF4G was crystallized with a 14 
amino acids long peptide derived from EIF4G (Figure 4).17 The bound peptide is 
predominantly α-helical, but five amino acids run perpendicularly to the helix; one of the 
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amino acids form this secondary structure uncategorized stretch belongs to the group that 
most significantly contributes to the binding energy.  
 
Figure 4: Structure of the 4E1RCat inhibitor of the EIF4E/EIF4G interaction (left); model of the crystal structure 
between EIF4E and its binding peptide (4E-BP1). Key residues are shown in read. PDB entries: 1EJ4. 
This structure was used to design an inhibitor with Kd of 16 µM.18 This inhibitor was shown 
to alter chemoresistance in a mouse model.18 Unfortunately no structure of EIF4E with any of 
the inhibitors bound exists but the interaction site with the mRNA cap can also be targeted 
and these structures are available.19 The mode of binding was confirmed by NMR techniques 
and the inhibitor binds in the same pocket as the wild type peptide.  
The only other proteins whose structure with the α-helical part of the binding partner 
(a peptide) was solved is Z interacting protein A (ZipA) and the 17 amino acids long peptide 
derived from filamenting temperature-sensitive mutant Z (FtsZ);20 both of which are E. coli 
cell division proteins. Although, similarly as in the case of EIF4E/peptide interaction α-helix 
is accompanied by even longer structurally uncategorized binding segment, all residues 
contributing significantly to the binding energy cluster in the middle of the α-helix. This PPI 
was deemed undruggable according to some researchers.21 Nevertheless a series of inhibitors 
were synthesised the best of which exhibited Ki of 12 µM.22-24 Structure of this compound 
bound to ZipA was solved by X-ray techniques (Figure 5).23 
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Figure 5: Structure pyridylpyrimidine inhibitor of the ZipA/FtsZ interaction (left); the inhibitor bound to ZipA; 
ZipA/FtsZ structure. Key residues are shown in read. PDB entries: 1YTF, 1F47. 
At this point a distinction between classic small molecules and peptidomimetics has to 
be made. Given a simple interaction between an α-helical peptide and a target protein or a 
potent enough inhibitor and the target protein it is highly possible that the structure of the 
inhibitor would mimic the α-helical peptide. This rule might be broken in situations were the 
interaction in question is more complex (larger surface area and various elements of protein 
structure involved) or a significant conformational shift occurs upon binding. In the former 
situation, the inhibitor might mimic an epitope rather than a distinct secondary structure 
element. In the latter, the conformation of the inhibitor/protein could be trapped somewhere 
along the conformational shift coordinate due to some additional, sufficiently deep energetic 
minima present. Therefore, the difference between classic small molecule inhibitors and an α-
helical peptidomimetic lies in the concept rather than the final outcome. Small molecules are 
developed to fit the binding pocket with disregard to the natural binder that is to be displaced, 
whereas peptidomimetics are designed specifically to mimic hotspot residues and their 
respective position in an α-helix (or broader in any structural element of a protein). Moreover 
peptidomimetics structures can be subdivided into scaffold (an equivalent of a protein 
backbone) and substituents (corresponding to protein amino acid sidechains). In the end 
peptidomimetics are going to be subdivided into modular, semi-modular and “custom-made”. 
Custom-made peptidomimetics relay on a scaffold that can’t be easily extended and can’t be 
straightforwardly subdivided into modules that could be connected by simple synthetic routes 
or wouldn’t be stable in reality. 
Different scaffolds have been developed in order to replicate a small helical section of 
p53 as bound to HDM2/X. Targeting the p53 HDM2/X interaction is ostensibly simple as just 
three residues contribute to the majority of the binding affinity with the remainder acting as a 
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scaffold. One compound resulting from this approach, a pyrrolopyrimidine-based inhibitor, 
has an affinity similar to its parent peptide, as strategically positioned chemical substituents 
mimic the three hot-spot residues: Phe19, Trp23 and Leu26 (Figure 6).25 p53-HDM2/X is a 
crucial interaction that, amongst other roles, controls activation of the intrinsic apoptotic 
pathway in response to a range of different stress making it an important therapeutic target. 
 
Figure 6: MDMX (murine HDMX analog) bound to p53 peptide (left); p53 compared to pyrrolopyrimidine-based 
inhibitor (right). Key residues of p53 and corresponding substituents of the inhibitor are shown in red 
The most recent inhibitor for which a model of a crystal structure exists is based on 
piperidinone scaffold.26 It was shown to be a potent binder of HDM2 with Kd of 0.4 nM. 
Moreover, in a mouse model it was able to suppress the tumour growth. Similarly as in the 
previous case, this inhibitor protrudes three substituents into corresponding binding pockets 
on HDM2.26 The structure of the inhibitor can be subdivided into scaffold and “sidechains” 
(Figure 7) and although this design resembles a peptidomimetic it was created by screening a 
library of compounds based on previous successful inhibitors rather than the p53 peptide. 
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Figure 7: Structure compound 9 inhibitor of the HDM2 interaction (upper right); the inhibitor bound to HDM2 
(upper left); HDM2/p53 peptide structure (down). Key residues are shown in read. PDB entries: 1YCR, 
4ERF. 
1.2.2.3 Modular peptide mimics inhibitors targeting helix-binding clefts 
 As mentioned previously, modular approaches to constructing α−helical mimics can 
be taken by providing a repeating scaffold that can be extended for different lengths of 
helices. The most widely used group of those mimetics is derived from a para-oligophenyl 
scaffold.27,28 The “backbone” is functionalized appropriately in the ortho or meta positions to 
mimic i, i+4 or i, i+7, etc. side chain placements on an α−helix. Hamilton and co-workers 
developed this approach and applied it to target Bcl-xL/Bak interaction.29 The most successful 
from this series of inhibitors displaced Bak wild type peptide with Ki of 114 nM validating 
the method (Figure 8).29 The same scaffold was shown to disrupt the HIV glycoprotein (gp41) 
helical hydrophobic core formation30 and p53/HDM2 interaction.31,32 The biggest issue with 
this type of scaffold and “sidechains” is the solubility of those compounds that limits possible 
applications. 
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Figure 8: The general para-oligophenyl scaffold (A); the same scaffold with a set of “sidechains” that was shown to 
bind Bcl-xL with 114 nM affinity (B); idealized α-helix with sidechains positions that are mimicked. Please 
not that the above structures do not represent the minimal energy conformation. 
 Similar approaches use amide bonds between pyridine rings and phenyl 
(oligobenzamides, oligopyridylamides). The former scaffold is additionally reinforced (has 
reduced degrees of freedom) by the extensive network of hydrogen bonds between amide 
hydrogen, carbonyl oxygen (Figure 9). This in theory reduces the entropic cost upon binding. 
Oligopyridylamides with appropriate “sidechains” were utilized to disrupt the Bcl-xL/Bak 
interaction with an order of magnitude worse Ki as compared to the oligophenyl based 
scaffolds (vide supra).33  
 
Figure 9: Oligopyridylamides (left) and oligobenzamides (right) peptidomimetics scaffolds. Please not that the above 
structures do not represent the minimal energy conformation. 
More recent investigation revealed that a simpler scaffold of oligobenzamides, which lacks 
the bifurcated hydrogen bonds of oligopyridylamides allows easier access to conformations 
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more favourable for engaging Bcl-xL as well as exposes more hydrophobic surface to 
complement the binding grove.34 Also, both of those scaffolds are more water soluble. 
 The modular and universal designs of repeating identical units outline above was 
further developed into scaffolds that break this simplicity. Combinatorial and rational 
approaches used all scaffolds outlined above as starting points. Both modification of terminal 
or middle units was tested and lead to results (semi-modular peptidomimetics) ranging from a 
mild improvement to a mild decrease of the affinity (Figure 10).35-37 This indicates a trend to 
combine “universal and minimalistic” peptidomimetics with classic small molecule design 
approaches. 
 
Figure 10: A sample of semi-modular peptidomimetics design to target Bcl-xL, Ki=0.78 µM (A); HDM2, Ki=8 µM (B) 
and again Bcl-xL, Ki=2.4 µM 
 The great number of iterative and novel designs of peptidomimetic scaffolds does not 
allow for a full overview of the field. The conclusion can be made that to the best of my 
knowledge none of the modular or semi-modular peptidomimetics had higher affinity to a 
given protein as compared to “custom-made” peptidomimetics or classic small molecule 
binders. This does not mean that modular peptidomimetics do not have potential to become 
truly universal and potent, but it indicates that this generally simple and clever concept needs 
more development.  
 One of the missed points in this field is lack of any research that would systematically 
screen scaffolds once a small set of possibly optimal sidechains is found. In a number of 
important cases crystal structure of the complexes are available and sidechains can be readily 
identified. The reason why screening for optimal sidechains is the routine nowadays lies in 
the scaffolds themselves, because scaffolds are not ideal and this needs to be compensated by 
 13 
 
sidechains. This could provide solutions to three issues haunting some of the 
peptidomimetics: affinity as contributed by the position of the sidechain, solubility and 
affinity contributions from the backbone. Of course, the rich data acquired so far allows for 
somewhat similar in effect retro-analysis but it wouldn’t replace the experimental scaffolds 
screening. 
1.2.2.4 Beta and gamma a amino acids peptide inhibitors targeting helix-
binding clefts 
An interesting group of strategies targeting helix-binding clefts involves the use of β- 
or γ-amino acids (Figure 11). Those singly or doubly homologated amino acids to come 
existence after insertion of CH2 groups at any position between NH2 and C=O without 
altering the sidechains.38 Two positions for β- and three for γ-amino acids are possible for 
sidechain extension (β2, β3 and γ2, γ3, γ4). Moreover occasionally amino acids are synthesized 
with more than one sidechain either on the same carbon (e.g. β2, 2, γ 3, 3) or on different ones 
(e.g. β2, 3, γ 3, 4), or a combination of those (e.g.  β2, 2, 3, γ 3, 3, 4). Additionally, some of the 
recurring types of amino acids are cyclised.  Those peptides are nowadays rarely constructed 
solely from the un-natural amino acids, but rather β- or γ-amino acids are intertwined with 
regular α-amino acids.  
 
Figure 11: Examples of α, β and γ amino acids used in the construction of peptides. 
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The main advantage of constructing helix mimics from β/γ-amino acids over naturally 
occurring α-amino acids is their stability towards enzymatic degradation.39 The extensive 
studies of proteolytic stability of all β- or γ-peptides (including stability against 20S 
proteasome) revealed that all peptides examined were stable for at least 48 h as compared to 
the 15 min stability of a regular poly-α-alanine peptide.39 α/β/γ −amino acid (in any 
combination) containing peptides have been studied extensively and structural paradigms 
have been established for their design.40-43 An especially interesting pattern has been recently 
examined: αγααβα (hexad) which is isoatomic to ααααααα (heptad).44 This patter was shown 
to form a regular α-helix structure.44  
Some of those peptides have been successfully used as inhibitors of protein-protein 
interaction and they retain the affinity of the sequences they are derived from (Ki of 2 nM).45 
Bim peptide was mimicked by a peptide that has its one half composed entirely of α-amino 
acids and the other half of the αβ mix (Figure 12). All β-amino acids in the sequence have 
their sequence cyclised and serve as a scaffold. 
 
Figure 12: Structural model of α /β  amino acids peptide bound to Bcl-2; βamino acids are indicated in red. PDB 
entries: 3FDM. 
It was also possible to create a peptide mimicking the Bim peptide using αααβ pattern 
that had similar affinity to Bcl-xL as the wild type α-peptide (50 nM vs. 23 nM).46 The crystal 
structure reveals that β-amino acids are positioned not only on the outer face of the helix, but 
also contribute to the binding interface (Figure 13).  
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Figure 13: The crystal structure model of αααβ peptide bound to Bcl-xL; β−amino acids are indicated in red. PDB 
entries: 4A1W 
1.2.2.5 Modified peptide inhibitors targeting helix-binding clefts 
 Introduction of bridging or crosslinking elements into a peptide structure can stabilize 
their α-helical structure and make them more resistant to a proteolytic degradation. The most 
straightforward and readily available crosslinking elements are cysteines. Unfortunately 
crosslinking two L-cysteines, even with optimal spacing i,i+3, is not ideal for the α-helix 
nucleation as sidechains are not pointing towards each other and the length of the disulfide 
bond is not sufficient to deal with this problem one can introduce D-cysteine at the i position 
while keeping L-cysteine at i,+3 (S-S distance is 6.7 Å in an idealized α-helix); although 
strictly speaking this bridging forces formation of a helical but non-α-helical conformation it 
still can be utilized for α-helical binding clefts (Figure 14).47,48 The estrogen receptor α is a 
transcription factor that upon binding of its small molecule activator undergoes a 
conformational shift that allows it to bind a coactivator peptide; only then it becomes fully 
activated and can promotes specific genes expression. The so called NR motif (LXXLL) is 
known to be almost exclusively responsible for the binding of the coactivator peptide. It was 
possible to engineer the peptide by introducing D- and L-cysteines to stabilize the structure 
(PERM 1) and increase binding affinity to 25 nM (Figure 14).48 Interestingly, this potent 
binder appears to have almost no helical character in solution as judged by CD 
spectroscopy.48 This observation is congruent with the effect that i,i+3 spaced, disulfide bond 
forming D- and L-cysteine has on the conformation (vide supra).47 
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Figure 14: X-ray structure model of PERM 1 peptide bound to estrogen receptor α (left); close-up on the disulfide 
bond within the PERM 1 peptide. Key residues are shown in read. PDB entries: 1PCG 
The reversible character of true disulfide bridges often makes them unsuitable for in 
vivo applications as the intracellular environment has a reducing potential,48 but constructing 
a covalent bridge as a stable analogue lowers the entropy of the free peptide considerably. 
Within this strategy there is a broad range of linkages that can be used which may include 
synthesising a small molecule crosslinker or appropriately modified/extended amino acids to 
incorporate a bridging element whose length would match the calculated distances in the 
idealized α-helix. Usually, residues that are modified or crosslinked are spaced in the peptide 
sequence according to the multiples of the helix pitch (3.6 residues per pitch), which forms so 
called i, i+4, i, i+7; i, i+11 configurations. 
Though covalent modifications are the method usually chosen, metal chelation 
approaches have also been reported.49 p53/HDM2 interaction served as a prove of principle 
target. Two rhodium atoms are chelated by two glutamate carboxylic sidechains in i, i+4 
spacing and two molecules of acetic acid effectively crosslinking the p53 peptide (Figure 15). 
The problem of multiple carboxylic acid residues in p53 peptide (both part of sidechains and 
C-terminus) was solved by orthogonal protection (sidechains) and preparative 
chromatography (C-terminus). The peptide affinity to HDM2 was not improved; Kd of 66 vs. 
77 nM for the wild type and the crosslinked peptide respectively. Nevertheless, as the 
dirhodium centre can serve as a catalyst of carbon-hydrogen insertion reactions which opens 
up interesting possibilities for directing the catalyses via protein-protein interaction. 
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Figure 15: An idealized α-helix crosslinked via dirhodium chelation. 
Arguably the most elegant embodiment of this method creates an additional amide 
bond parallel to the helix. To achieve this pyrrolopyrimidine-based orthogonal amino acid 
sidechain protection can be employed during chemical peptide synthesis to selectively form a 
number of peptide bonds between Glu/Asp and Lys. Non-proteinogenic amino acids may also 
be incorporated (ornithine instead of lysine) to create an optimal crosslink length (Figure 16). 
This methodology has been used to create stable peptides capable of binding their targets 
improving affinities for their targets compared to non-crosslinked equivalents.48,50,51 Indeed, 
the smallest ever stable alpha helix reported was created using this strategy.52 Particularly 
successful were inhibitors of Human respiratory syncytial virus (RSV) cell fusion. The main 
disadvantage of this method is that simple amides may still be proteolysed in vivo. RSV F 
glycoprotein is responsible for the recognition of host cell receptors and fusion with the host 
cell membrane. The interaction is associated with a major rearrangement of the fusion protein. 
Peptides derived from this protein is α-helical segments could in principle block the transition 
to a 6 α-helix bundle (three HR-C and three HR-N). The synthetic doubly constrained peptide 
derived from the HR-C α-helix (Figure 16) was able to inhibit the cell fusion event at IC of 
190 pM, which was a four orders of magnitude improvement over the wild type peptide; it is 
essential to mention that the constrained peptide had 1-naphthylalanine residue at N-term, 
whilst this was absent in the control peptide.50 
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Figure 16: Model of doubly constrained α-helix inhibitor of RSV cell fusion. The peptide crosslinked in two places by 
forming lactam rings between lysine and aspartate residues (red) in i, i+4 configuration. 
A similar method uses a short hydrocarbon bridge to stabilise α−helices.53 A peptide is 
chemically synthesized with two non-natural amino acids, each bearing an olefin sidechain, 
which is subsequently closed by a metathesis reaction catalysed by Grubbs’ first generation 
catalyst to form a ring (Figure 17).54 In the literature this form of crosslinking is referred to as 
a staple. Although other functionally and chemically equivalent methods exist, hydrocarbon 
stapling has been reported as additionally conferring the sought after property of cell 
permeability, making stapled peptides promising therapeutics.55 This strategy has been shown 
to effectively enhance properties of a number of medically and biologically relevant 
peptides.56-59 The nearly archetypical PPI inhibitor target, the p53/HDM2 interaction, was 
perhaps the most successful complex to be disrupted by stapled peptides. The best inhibitor 
bound p53 with Kd of 0.92 nM, which is nearly 500 fold better than the wild type peptide and 
still better than any of the “natural” p53 peptides with improved affinities (vide supra).60 
Unfortunately the peptide was unable to cross the cell membrane possibly due to 
accumulation of negative charges. Further engineering made the peptide positively charged 
and the staple position was altered, thus decreasing the affinity to 55 nM but making the 
peptide cell permeable and proapoptotic (active in vivo).60 The recently solved crystal 
structure of the aforementioned peptide bound to HDM2 hints that the staple not only 
stabilizes the helix and helps the peptide to cross the cell membrane, but also makes positive 
contributions to the binding affinity (Figure 17).61 ERα and coactivator peptide interaction 
succumbed to the stapled peptides too. The stapled peptide sequence (SP-2) most directly 
comparable to the wild type was a seven fold better binder.58 Addition of Glu and Lys at the 
N-term and repositioning of the staple lead to further increase and the peptide (SP-6) had a Kd 
of 75 nM (2500 nM for the wild type). The crystal structure of the ERα bound to SP-2 was 
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solved (Figure 17).58 The most interesting feature of this complex is the correspondence 
between Leu 693 of the wild type (LXXLL) absent in the SP-2 sequence and the staple. It’s 
clear that part of the staple acts as the missing leucine.58 
 
Figure 17: The wild type coactivator peptide bound to ESα (A); stapled coactivator peptide bound to ESα (B); the 
wild type p53 peptide bound to HDM2 (C); stapled p53 peptide bound to HDM2 (D). Key residues are 
shown in read; additionally Leu 693 is shown in blue (LXXLL); hydrocarbon staples are shown in blue. 
PDB entries: 3G03, 3V3B, 2YJA, 2QGT. 
Many groups reported similar chemical approaches to crosslinking using azide click 
reactions or photoinduced cycloaddition schemes.62,63 A somewhat different group of 
crosslinking strategies employ more elaborate photoswitchable chemical groups to stabilize or 
destabilize α-helix formation in response to light. These will be discussed in more detail later. 
 The formation of hydrogen bond surrogates (HBS) as another interesting technique to 
stabilise α−helical structure has been described in the literature (Figure 18). In this approach, 
part of the pattern of internal hydrogen bonds in the helix is mimicked by a short hydrocarbon 
chain to produce a peptide that is forced to adopt α-helical conformation around the modified 
hydrogen bond, nucleating overall helix formation.64,65 This strategy allows for a creation of 
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peptides that are free to interact from any of their faces, unlike other crosslinkers which can 
obscure a considerable area of a face of the helix, thus imposing a compromise between 
crosslinker position, steric clashes and hot-spot residues mutation in any designed binders. 
Also, it was shown that HBS makes peptides more resistant to proteolysis (e.g. Bak HBS 
peptide is 30 fold more resistant to trypsin than Bak wild type peptide).66 Interestingly, HBS 
peptides tend not to have dramatically increased affinity to their respective targets, although 
the increase is helicity between HBS and wild type peptide is often dramatic.66,67 HBS Bak 
peptide affinity to Bcl-xL is in fact decreased by two fold from 154 to 325 nM.66 The affinity 
of a HBS peptide derived from Hypoxia Inducible Factor 1 to its native target CBP/p300 is 
two fold better as compared to the wild type peptide (825 vs. 420 nM) but in vitro potency to 
stop the transcription activated by aforementioned complex is nearly six time better for the 
HBS peptide.67 
 
Figure 18: Representation of a standard α-helix (on the left) versus hydrogen bond surrogate α-helix (on the right). 
The hydrogen bond replaced by carbon-carbon bond in indicated with a red frame. 
1.2.2.6 Miniature protein targeting helix-binding clefts 
 The miniature protein approach capitalizes upon the high stability of some known 
small proteins to reinforce binding helices (Figure 19). Naturally evolved structures that 
tolerate certain degrees of mutations are used to both transplant the binding epitope onto the 
helical element of a protein and retain its conformation. Usually peptides are derived from 
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avian pancreatic protein, Trp cage proteins, zinc finger proteins or the Z domain of 
staphylococcal protein A.12 
 
Figure 19: Miniature proteins used as a based for binding epitope transplant. The exposed side of the helix capable of 
accepting the mutation is always on the left side of each image; (A) avian pancreatic peptide, (B) zinc 
finger domain, (C) Trp-cage, (D) Z domain of staphylococcal protein A. PDB entries: 1PPT, 1L2Y, 1A1L, 
2B88. 
The interaction between Kinase inducible activation domain (KID) of cAMP-response 
element-binding protein (CREB) and KIX domain of CREB binding protein (CBP) is an 
unusual one (Figure 20).68 Not only the helix-binding cleft is very shallow, but phosporylation 
of Ser 133 of KID is necessary for the binding as it provides crucial hydrogen bonding (the 
typical situation being a phosphorylation that abolishes binding).68 Although KIX binds as 
two perpendicular α-helices only the C-terminal helix contributes significantly to the binding 
affinity. It was possible to graft the binding epitope of KIX onto avian pancreatic peptide, 
while retaining its native properties (Figure 20).69 This was done via rational positioning of 
the crucial residues and using a phage display to provide a selection pressure over a library of 
randomized at 5 positions residues on the antiparallel extended helix. The first generations of 
peptides were able to bind KID, but still were dependent on the phosporylation of KID Ser 
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133; the later generations were able to bind KID regardless of phosporylation with affinity 
only 2 fold lower (1.5 µM) than the wild type KIX peptide to the phosporylated KID.69 
 
Figure 20: Solution structure models of KID-KIX complex (A); avian pancreatic overlaid with the KIX peptide in the 
KID-KIX complex (B); avian pancreatic peptide with four crucial hydrophobic residues grafted from KIX 
and randomized positions for phage display selection (C); the crucial residues of KIX are in red and 
randomized position are in blue. PDB entries: 1KDX, 1PPT. 
 p53/HDM2 and p53/HDMX interaction was disrupted using the binding epitope 
grafting approach. Relaying on the stability of venomous protein from scorpion’s and bee’s 
venom (apamin and BmBKTtx1 respectively) a series of inhibitors was developed (Figure 
21).70,71 Apamin served as a starting point for a peptide (stingin 1) that bound HDM2 with Kd 
of 25 nM and HDMX with 11 nM (respectively 3 and 8.5 nM for wild types).70 The structure 
was of the stingin 1 bound to HDM2 was solved by means of X-ray crystallography (Figure 
21).70  
 
Figure 21: X-ray structural model of stingin 1 bound to HDM2 (A); stoppin (based on the structure of BmBKTtx1) 
overlaid onto stingin 1 bound to HDM2 (B); HDM2/p53 peptide; PDB entries: 1R1G, 3IUX, 1YCR (C) 
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Interestingly, the α-helices of apamin and wild type p53 peptide are positioned in respect to 
each other at a non-zero angle; apamin forms a regular α-helix and p53 start as a regular one 
and gets tighter towards C-terminus (Figure 21). BmBKTtx1 scorpion toxin is heavily 
stabilized by 3 disulfide bridges and is a markedly bigger peptide (18 vs. 27 amino acids).71 
Stoppin 1 construct has a Kd of 790 and 994 nM, correspondingly to HDM2 and HDMX, as 
compared to the wild type peptide in this assay 123 and 279 nM respectively.71 It was 
suggested by the authors that his relatively low binding affinity is a consequence of different 
positions of the helices (stoppin 1 vs. p53);71 this explanation is unsatisfactory, because it is 
not congruent with the apamin/HDM2 system.  
Bcl-xl and Bcl-2 proteins were targeted by miniature proteins derived from avian 
pancreatic peptide. Remarkably, those designs managed to outcompete the wild type Bak 
peptide, which they aimed to mimic, by nearly 2 orders of magnitude achieving low 
nanomolar affinities (Table 1).72 Moreover the group was able to reverse the selectivity of the 
designed peptide, which originally was bound Bcl-xL one order of magnitude better than Bcl-
2; the reversal of selectivity pushes the affinity into the high nanomolar range (Table 1).72 
Peptide/Sequence Affinity to Bcl-xL (nM) Affinity to Bcl-2 (nM) 
Bak 180 6100 
PPBH3-1 7 52 
PPBH3-6 5400 540 
Table 1: Affinities of Bak, PPH3-1 and PPH3-6 miniature proteins to Bcl-xL and Bcl-2. 
1.2.3 Protein-RNA interactions 
  Protein-RNA interactions are characterised by markedly different features compared 
to protein-protein interactions. Unlike protein-protein interfaces where protein surfaces 
evolved to contain large hydrophobic patches, RNA is composed of aromatic nucleobases 
attached via polar ribose sugars to a negatively charged phosphate backbone, limiting the 
opportunity to make hydrophobic interactions and making positively-charged amino acids 
essential.  
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Figure 22: Four standard RNA secondary structure elements: (A) hairpin, (B) loop, (C) bulge, (D) duplex.  
The conformational flexibility of single stranded RNA can allow access to a variety of 
secondary structures exposing different features that can differentiate RNA from less flexible 
double stranded DNA (Figure 22).73  
Statistical analysis revealed that positively-charged arginine and lysine have the 
highest propensity to be found in the interface of protein-RNA complexes.74-76 Other residues 
frequently reported include the aromatic amino acids tyrosine and tryptophan and the 
hydroxyl bearing amino acids serine and threonine. Residues that seem to have consistently 
low propensity are negatively charged (Glu, Asp) or hydrophobic (Ile, Leu, Val, Ala, Cys, 
Phe).76 The high frequency of positive residues can be easily attributed to electrostatic 
interactions with the phosphate backbone. Tyrosine and tryptophan can intercalate/stack 
between aromatic nucleosides and form hydrogen bonds, as can serine and threonine. 
Hydrogen bonding seems to be very important for specificity, the hydroxyl groups of ribose 
are often found engaged in donating or accepting hydrogen bonds.77 Hydrogen bonding is 
frequently mediated through water molecules, which seem to play more significant role than 
in protein-DNA or protein-protein interactions, with large water filled cavities frequently 
found as a part of a binding interface.78 
 The average protein-RNA interface area is reported to be similar to that of protein-
protein interfaces75,79 with most contacts being between amino acids and the phosphate 
backbone and ribose. Although hydrogen bonds are crucial, van der Waals dipolar 
interactions are even more numerous. The involvement of protein secondary structure 
elements is not frequent enough to assume high statistical significance, but it appears that 
helices are much less frequent than previously thought and β-hairpins predominate.75 The 
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notable exception to this is in viral RNA, where α-helices have a higher propensity to be 
used.75 Clearer trends may occur as more protein-RNA structures are solved. 
1.2.3.1 Small molecule inhibitors targeting RNA 
 Small molecules that can target RNA and disrupt the protein-RNA interactions are 
relatively scarce and predominantly target interactions crucial for HIV-1 life cycle, oncogenic 
mRNA or the bacterial ribosome A-site. The HIV-1 interactions are the Rev Response 
Element – Regulator of Viron (RRE–Rev) and the Trans-Activation Response Element–
Transactivator of Transcription (Tar–Tat) complexes. High throughput screening and rational 
design has yielded a few groups of compounds capable of binding Tar and RRE sequences 
with high affinity (Figure 23).80-84 In turn, these have allowed NMR and crystallography 
studies to reveal structural details of their interactions providing clues as to how to improve 
their designs.82,85-87  
 
Figure 23: Various successful inhibitors of Tat-Tar and RRE-Rev interactions 
Unfortunately, of the two crucial RNA-protein interactions RRE-Rev and Tat-Tar the 
latter one is more frequently featured in literature as a target of small molecule inhibitors 
research. One of the high throughput screenings revealed an in vitro potent binder85; the 
compound bound Tar RNA with Kd of 39 nM. The NMR structure revealed an interesting 
feature of the formed complex (Figure 24). Although the inhibitor binds approximately in the 
same place as the Tat peptide the RNA adopts a dramatically different conformation.  
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Figure 24: Tar-Tat interaction inhibitor bound to Tar (left); structure of the inhibitor (right). PDB entire: 1UTS. 
Oncogenic mRNA (result of a transcription of fused genes BCR-ABL and PAX3-
FKHR) has been targeted with aminoglycosides derivatives,88 based on scaffolds like 
neomycin B or kanamycin. Most molecules used to bind to the A-site of the bacterial 
ribosome are also based on aminoglycosides (neamine dimers, neomycin E, geneticin).89,90 
They form a class of relatively old antibiotics which block bacterial translation (Figure 25). 
 
Figure 25: Structure of Neomycin E bound to RNA derived from ribosome A-site (left); structures of three common 
aminoglycoside antibiotics (right). PDB entries: 1J7T. 
Newer targets include the RNA that causes myotonic dystrophy 2 or 1 via interaction 
between the r(CCUG) expansion in zinc finger 9 or rCUG expansion in the dystrophia 
myotonica protein kinase and muscleblind protein respectively, which result in an alternative, 
pathological splicing of the main muscle chloride channel and the insulin receptor. Both 
interactions have been successfully targeted by a modular approach where peptoid sidechains 
were functionalized with azido-aminoglycosides.91,92 This study not only yielded a potent 
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binder, but created a basis for rational structure-activity relationship studies of further RNA 
targets.91,92 
 
Figure 26: Structure of the peptoid binder of r(CCUG) expansion. 
1.2.3.2 Peptides targeting RNA 
 Tar and RRE are the major focus of research towards RNA binding peptides. Peptides 
mimicking the original Rev sequence or comprised of new, independently evolved arginine 
rich sequences have been crosslinked with orthogonal amide bonds.50,93 The work capitalizing 
on the evolved arginine rich sequences lead to a development of a peptide that has two fold 
better affinity and specificity to RRE (100 vs. 45 nM and specificity of 16 vs. 26 nM).93 
Key Rev residues have also been transplanted to zinc finger scaffold.94 This bulky 
designed peptide showed Zn2+ dependent helical content and binding affinity.94 The affinities 
of a Revwt isolated helix and the designed zinc finger peptide were comparable at the assay 
conditions (330±40 nM vs. 330±20 nM).94 Unfortunately, although no structure of this 
complex was solved by overlaying a structure of the Zinc Finger (Zif268) that was used as a 
starting point reveals how this relatively bulky miniprotein fits into the very deep binding 
grove of RRE and at the same time all key residues of Rev are retained (Figure 27).94 That 
type of approach was employed and another modified Zinc Finger targeting RRE was 
developed and its structure was solved by NMR methods.95,96 The binding affinity was 
improved to 55 nM and the actual sequence that forms the binding epitope bears very little 
resemblance to the original Rev; three residues are retained of which only one is considered to 
be the key residue.  
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Figure 27: NMR structural model of the Rev peptide bound to RRE (A and B); Zinc Finger (Zif268) with Rev binding 
epitope transplanted overlaid onto Rev in complex with RRE structure (C and D). Key Rev residues are in 
red; two cysteines and histidines chelating a zinc ion are in yellow; zinc ion is in blue. PDB entries: 1ETF, 
1A1J. 
The sequence was not rationally designed but evolved through phage display.95,96 Stunningly, 
by overlaying this Zinc Finger – Rev hybrid onto the Rev/RRE structure it becomes apparent 
that the beta-sheet part of the Zinc Finger clashes severely with RNA. This suggests a 
powerful adaptable potential of RRE structure which either undergoes dramatic 
rearrangement or binds to a very different amino acid patter and the sequence based overlay is 
misleading. 
The importance of stereochemistry and directionality of the sequence of Rev peptides 
have been thoroughly investigated by Litovchick, A. et al.97 D-Amino acid mirror image as 
well as reverse sequences of Rev were synthesized and their binding to RRE IIB RNA 
assessed.97 Results show a remarkably small differences between these constructs, the highest 
being approximately four fold.97 Constrained β-sheet peptides that mimicked a crucial β-sheet 
section of the Tat protein were synthesised and were found to bind Tar well98-100 as did 
cysteine-constrained cyclic peptides that targeted the bovine immunodeficiency virus 
equivalent of Tar.101 The latest peptide found by Robinson et al. had affinity of 1 nM (25 nM 
in the presence of tRNA excess) and its structure has been solved by NMR techniques (Figure 
28).100 The peptide incorporates D-Pro-L-Pro template to promote a β-hairpin formation (D-
Pro at C- and L-Pro at N-terminus) and a disulfide bond in the middle of the sequence to 
further stabilize the interaction. 
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Figure 28: Structure of the cyclic Tar-derived evolved peptide bound to Tar RNA. D- and L-Pro are in gray and the 
disulfide bond is in yellow. PDB entries: 2KX5 
Curiously, it was also possible to use a similar approach (β-sheets) to design inhibitors 
of Rev/RRE interaction by mimicking key residues position of Rev.102 Small cyclic β-sheets 
capable of mimicking α-helical sidechain positions were designed and effectively targeted 
RRE with the affinity similar to the Revwt. A Kd of 100 nM was reported for the best designs 
and Rev peptide (in the presence of large excess of tRNA but in a low ionic strength 
buffer).102  
A study of the acceptor stem of an Escherichia coli alanine tRNA identified a 10 
residue peptide recognition element that was able to discriminate between G-U and G-C, U-G 
and inosine (I)-U base pairs.103 In particular, peptides used to discriminate G-U versus I-U 
differ by only a single amino group, showing that this short peptide is capable of 
discriminating this minute change in the chemical composition of RNA (Figure 29).103 
Unfortunately no Kd or IC50 values are quoted and only offer a graph visualizing 
displacement of the wild type RNA (G-U containing) from a the RNA-peptide complex with 
the same RNA (G-U containing) or mutated (I-U containing).103 
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Figure 29: G-U and I-U base pairs (A); graphs showing displacement of wild type RNA (G-U containing) from the 
RNA-peptide complex with wild type (G-U containing) or mutated RNA (I-U or G-C or U-G containing); 
reproduced from103 (B). 
Another short peptide (three residues) was crosslinked with an intercalating group to 
form a so called helix-threading peptide and successfully bound to microRNA (miRNA) with 
the affinity as high as 52±17 nM.104,105 Similarly, so called γ-AA (with sidechains protruding 
from nitrogen) peptides were able to bind well to RNA.106 
1.3 HIV and AIDS 
1.3.1 Overview 
Human immunodeficiency virus type 1 (HIV-1) is a virus that belongs to the 
Retroviridae family.107 It is a close relative of simian immunodeficiency virus (SIV), which is 
believed to be an HIV-1 ancestor that was transmitted from chimpanzee (Pan troglodytes 
troglodytes) to humans in a process called zoonosis.108 The origins of HIV-1 can be traced to 
the late 19th or early 20th century and traditional hunting activities in Africa.109,110 The current 
hypothesis is that hunters could be infected with SIV through the blood of killed chimpanzees 
and subsequently acquired mutations allowed the virus to cross the species barrier and find a 
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new stable host in humans.109 It is established that HIV is the factor responsible for acquired 
immunodeficiency syndrome (AIDS); a disease that slowly depletes the immune systems 
defences leaving individuals prone to opportunistic infections. In 2009 AIDS was the cause of 
death for 1.8 million people. With 33.3 million people infected AIDS is a pandemic with no 
vaccine currently available.111,112 AIDS is not only a major health problem in the developing 
countries it originates from (sub-Saharan Africa), developed ones are heavily affected by this 
disease.112 
1.3.2 Biology of the HIV virus 
 HIV infects some lymphocytes including CD4+ T cells (mature helper T cells) with a 
particular preference for CD4+ T cells that recognise HIV.113 The crucial role of CD4+ T 
cells in activating the immune response and the decline in number of these cells following the 
HIV infection is the direct cause of AIDS. The HIV virus is capable of recognizing CD4 
protein, expressed abundantly in CD4+ T cells but also to lesser extent in macrophages and 
dendritic cells,107,114 through interaction with HIV envelope glycol protein 120 (gp120).107 
1.3.3 Structure 
 A typical HIV virion is 145±25 nm in diameter and approximately spherical.115,116 It is 
surrounded by a lipid bilayer acquired from the host cell during budding (Figure 30) which is 
abundant in membrane embedded proteins including glycoprotein 41 (gp41, TM) bound to 
glycoprotein 120 (gp120, SU) which plays a crucial role in virus adsorption and entry.117 
Within the membrane, packed in protein 17 and protein 15, resides the viral capsid which is 
composed of protein 24 and encloses 2 copies of single stranded positive sense HIV RNA 
tightly bound to protein 7.107,115 Three HIV-coded enzymes are also present inside the capsid: 
protein 10 or HIV protease, protein 66/51/reverse transcriptase and protein 32/integrase.115 No 
crystal structure exists of the whole virus; however a low-resolution reconstruction of the 3D 
structure has been made based on an electron micrograph.115,116 
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Figure 30: Schematic representation of the structure of the HIV-1 virion. Some proteins present inside were omitted 
for clarity. 
1.3.4 Genome organization and coded proteins 
The HIV genome is around 9 kbp long and possesses 3 open reading frames 
containing the genes: 1 – gag, vif, nef; 2 – vpu; 3 – pol, vpr, and env (Figure 31). Tat and rev 
are separated between the 1st/2nd and 2nd/3rd ORFs, respectively.118 Viral pre-mRNA can be 
subjected to none, single or multiple splicing events giving rise to 9, 4 and 1.8 kbp splice 
variants, respectively.118,119 Unspliced mRNA can either form the HIV genome or can be 
translated into Gag-Pol or Pol precursor multiproteins that are autocatalytically cleaved into 
the component proteins of the virion, while multiple splicing produces mRNA for the 
regulatory proteins Rev, Tat and Nef.107 Interestingly the secondary structure of HIV RNA 
inversely corresponds to protein tertiary structure; unstructured regions of RNA correspond to 
highly structured regions on multiproteins and vice versa, this allows for pauses in translation 
and independent folding of domains/proteins of multiprotein HIV gene products.118 Only 
multiply spliced mRNA does not contain the RRE sequence.120 HIV-1 genome terminates in 
5’ and 3’ long terminal repeats (LTR). 
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Figure 31: Map of the HIV-1 genome colour coded according coherently to Figure 30. Tat and rev genes are indicated 
in blue and red respectively. 
1.3.5 Regulatory elements 
 Initial transcription and translation of viral genes is slow and only fully spliced HIV-1 
mRNA is produced. The fully spliced variants include mRNA that codes for Tat protein, 
which is responsible for transcription initiation complex assembly. Tat binds to the Tar 
sequence present in the LTR.121 Tat phosphorylates RNA polymerase II and recruits essential 
transcription factors, which increase viral gene expression by more then two orders of 
magnitude.121 On the other hand, Rev (also translated from fully spliced mRNA) is 
responsible for the nuclear export of singly spliced and unspliced mRNA variants. 120,122 Rev 
is imported to the nucleus and binds the RRE sequence present in singly spliced and unspliced 
variants and promotes their export to the cytoplasm and subsequent translation.120,122,123 
1.3.5.1 RRE/Rev 
 RRE is a 350 nucleotide long RNA sequence that has not yet been completely mapped 
(Figure 32).118 It overlaps with the gp41 coding region and it contains a large number of RNA 
secondary structure elements.118 The precise secondary and tertiary structure of the RRE is 
still a matter of debate and somewhat different RNA maps have been proposed in the 
literature.118,124 However, it has been established that minimal RRE length required for 
function is approximately 250 bp and encompasses regions I to V.125 Rev is a 116 amino acid 
long protein whose complete structure remains unknown.126,127 Only the N-terminal region 
has been structurally characterized, which has been shown to form an eccentric helix-loop-
helix motif.127  
 34 
 
 
Figure 32: Topology of the core RRE element with binding sites annotated appropriately and RRE IIB indicated in 
red (right); enlargement of the RRE IIB element (bottom right) 
This part of Rev contains the arginine-rich region known to bind with high affinity to 
RRE; a peptide derived from the arginine-rich sequence is capable of strongly interacting with 
RRE (Figure 33).128-130 Rev has the highest affinity for the stem loop IIB part of the RRE 
sequence.131 The N-terminal region of Rev is known to be responsible for oligomerization; in 
the current model, binding of the first molecule of Rev to RRE IIB nucleates oligomerization 
and binding to the remaining sites on the mRNA.125,127 Nuclear localization sequences (NLS) 
which overlap with the arginine-rich region are concealed by this interaction and 
oligomerization organises nuclear export sequences into a multivalent array, which can 
interact sufficiently strongly with Chromosome Region Maintenance 1 protein (Crm1) protein 
to facilitate nuclear export.127,132 This allows singly spliced and unspliced mRNAs to be 
exported from the nucleus before further splicing occurs, thus allowing the remaining HIV-1 
genes to be expressed.123  
The arginine-rich region of Rev spans residues 34 to 50 and its sequence is 
TRQARRNRRRRWRERQR, where the underlined residues are those which decrease affinity 
by more than 10-fold upon mutation to alanine (Figure 33).133 The structure of this and similar 
peptides bound to RRE IIB have been solved by NMR and crystallography techniques.133-135 
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Figure 33: Structural models of Rev peptide bound to RRE IIB RNA (A) with key residues in red; N-terminal 
domains of Rev protein dimer of dimers aligned onto Rev bound to RRE IIB (B) with arginine-rich region 
in red. PDB entries: 1ETF, 3LPH. 
Structural reports on the RRE/Rev interaction all describe a remarkable structural 
flexibility of the RNA structure, which in order to accommodate the Rev peptide, needs to 
widen by approximately 5 Å (Figure 34).133 Moreover, in the complex the peptide sits in a 
very deep grove, with 270° of its surface surrounded by RNA  (Figure 34). 
 
Figure 34: Structural models of the complex of Rev derived peptide (not shown) and RRE IIB (A); free RRE IIB (B); 
complex of Rev derived peptide and RRE IIB with residues that decrease binding affinity by more then 10 
fold indicated in red (C); overlay of RREIIB free (red) and bound (black) to Rev derived peptide (not 
shown); black and red bars are proportional to the grove width.   PDB entries: 1ETF, 1DUQ. 
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1.4 Photocontrol of Structure 
1.4.1 Natural examples 
During the course of life’s history light not only has been used as a source of energy 
throughout all kingdoms of life, but light sensitive switching mechanisms have evolved 
independently many times. Even the simple unicellular organism Chlamydomonas reinhardtii 
possesses an “eyespot” that allows it to exhibit phototaxis and photophobia reactions.136 The 
proteins, which carry out this function, are light-gated ion channels: channelrhodopsin-1 
(ChR1) and channelrhodopsin-2 (ChR2).137 They contain a light sensitive chromophore, 
retinal, which undergoes a reversible isomerisation from all-trans retinal to 13-cis-retinal. 
This conformational change in the chromphore induces a larger conformational change in the 
transmembrane region of the channel, opening it to both monovalent and divalent cations. 
Within micro seconds 13-cis-retinal thermally relaxes to its ground state, which eventually 
closes the channel.137 A similar mechanism can be observed in the human retina. The retinal 
containing protein rhodopsin is a transmembrane protein, but unlike ChR it is not an ion 
channel, but a G-protein coupled receptor.138 Interestingly the ground state of its retinal 
cofactor is 11-cis-retinal and upon absorption of light it changes configuration to all-trans. 
The resulting conformational change in the protein activates interacting G-protein on the 
cytosolic side of the membrane.138 A different chromophore is used by phytochromes, a group 
of proteins found in plants, bacteria and fungi, which incorporate a billin-derived 
chromophore.139 In most cases two thermodynamically stable forms of this chromophore exist 
that can be shifted between one another upon absorption of red or far-red photons (Pr and Pfr 
forms).140,141  Therefore, unlike the retinal based light-sensing proteins, the change in 
chromophore conformation is not immediately reversed to the previous state.140,141  Plants 
have evolved a whole ensemble of light sensing proteins. In addition to few different types of 
phytochromes, cryptochromes, phototropins and superchrome classes exist. Phototropins use 
flavin as their chromophore (contained within LOV domains),142 the absorption of light and 
subsequent formation of a bond between flavin and a cysteine residue in its binding pocket 
abolishes an interaction essential for the stabilization of amphipathic, and partially water 
exposed helix.143 Release of this helix can trigger kinase activity and transfer the signal 
further down a pathway (Figure 35). 
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Figure 35: Structural model of a LOV domain in the dark state (black); a model of the helix unfolding after blue light 
irradiation is schematically represented (red); flavin chromophore is visible in the protein hydrophobic 
core (red). PDB entries: 2VOU. 
1.4.2 Photo-control of structure in chemistry 
 One of the earliest examples of light induced control of synthesized compounds 
structure involves a group of molecules called azobenzenes (Figure 36). These chemical 
compounds are capable of photo-isomerisation around the N=N double bond.144 Usually the 
trans configuration is thermally stable and upon absorption of a photon of approximately 360 
nm wavelength, the trans configuration switches to cis, creating a more compact molecule 
with end-to-end distances between para ring positions differing by approximately 3.5 Å 
compared to the trans form.145 The cis form of the azobenzene thermally reverts to trans and 
this process can be accelerated by illumination with light matching the absorption maximum 
of the cis form (450 nm). 
 
Figure 36: Azobenzene trans-cis photoisomerization; R1 and R2 indicate different possible substituents. 
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Different substituents around the aromatic ring systems can alter the overall properties of an 
azobenzene chromophore, affecting its reactivity, absorption maximum, thermal relaxation 
rate, and state cis/trans ratio at the photostationary state.146 The cis form of azobenzene is 
usually thermally unstable, but when a bridged (constrained) version of azobenzene was 
synthesised, the cis state was found to be thermally stable and could be switched to trans by 
irradiation in a structural transition that is accompanied by a dramatic change in colour.147  
Other popular photo-switchable molecules include derivatives of spiropyran (Figure 
37). Upon irradiation of spiropyran it is isomerised to a merocyanine form. As a result the 
initially largely hydrophobic compound becomes zwitterionic. This change is thermally 
reversible and can be made more rapid by irradiation at the absorption maximum of 
merocyanine. Those properties have been used to control rheology by doping micelles with 
spiropyran-derived detergent, force light-induced patterning or control liquid-crystal 
phases.148-150 
 
 
Figure 37: Photoisomerization of spiropyran to merocyanine; R indicates a possible substituent. 
Researchers are keen to create light-driven motors, ideally producing unidirectional, 
light-driven motion at molecular level to mimic in naturally occurring motor complexes. 
Considerable successes have been achieved using both helical alkenes and rotaxanes. In the 
former approach a chiral, helical alkene is designed such that its two subunits are connected 
by a double bond and one type of rotation, anti or clockwise has lower energy barrier (Figure 
37).151 Light can then be used to isomerise the molecule around the double bond. A different 
wavelength of light is then used in order to rotate back to initial state.151  
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Figure 38: Helical alkene cycle. Optical filters cut-off and temperatures used for the isomerisation are noted 
appropriately.  
In the latter approach macroassemblies called rotaxanes are used. Those systems are 
composed of long molecules with bulky chromophores at each end, trapped within another 
molecule in the shape of a closed ring (Figure 39).152 The change in protonation states 
induced by light changes the binding preference of the ring molecule for chromophore over 
the other, this process is reversible by light and represents a prototypical molecular piston.152 
 
Figure 39: Representation of the molecular shuttle cycle; hydrogen bonds are indicated with a dashed red line 
(upper); surface representation with bulky “stopper” substituents in blue, macrocycle “shuttle” in red, 
hydrogen bonding interaction sites in yellow (lower).  
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1.4.3 Photocontrol of protein structure 
1.4.3.1 Overview 
Three typical approaches to protein-structure photocontrol are found in the published 
literature: photo-caging, conjugation of photo-switchable molecules and optogenetics. The 
former pair relies on the introduction of light-reactive molecule to otherwise natural system, 
while optogenetics capitalizes on naturally evolved proteins which, after appropriate genetic-
engineering, serve as photoswitches in a variety of arrangements. The latter two have the 
significant advantage of possessing a degree of reversibility. 
1.4.3.2 Photocaging  
 Photo-caged molecules are the oldest way of introducing light reactivity to 
polypeptides. The general strategy introduces a photo-labile group into a protein or peptide 
that either forces a peptide into certain conformation or masks amino acids that are 
responsible for interaction. Upon irradiation with light the chemical group is cleaved off. 
Usually peptides revert to their natural (or close to natural) function and therefore are 
activated, but there exist examples of the opposite switching effect. Recent research describes 
photocaging of an arginine-glycine-aspartate peptide widely recognised for its ability to 
promote cell adhesion (Figure 40).153 In this case a 2-nitrobenzyl group was introduced at the 
peptide bond to create a peptoid incapable of binding its partner protein. Brief irradiation with 
365 nm light removed the 2-nitrobenzyl group and the resulting peptide regained its ability to 
stimulate cell adhesion.153  
 
Figure 40: Photocleavage of the 2-nitrobenzyl blocked arginine-glycine-aspartate peptide. 
Interestingly, despite UV light exposure taking place after the cells to be tested for adherence 
had been introduced to the experimental setup, this group reports no signs of deterioration 
induced by harmful radiation.153  
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Similarly, introducing the photolabile group directly at a peptide bond protected a 
peptide against proteolytic cleavage, this protection is lost and peptide degraded after UV 
irradiation in presence of a proteolytic enzyme.154 
1.4.3.3 Attachment of a photo-switchable molecule  
 The photo-switchable molecules most widely employed in attempts to design 
photocontrolled proteins or peptides are spiropyrans and azobenzenes.  The earliest attempts 
to use azobenzene derivatives were based on synthesizing poly-L-p-(phenylazo) 
phenylalanine.155,156  
 
Figure 41: Photoisomerization of a cysteine reactive azobenzene crosslinker (top), peptide with cysteine reactive 
azobenzene crosslinker attached in i, i+11 (middle) and i, i+7 (bottom) configurations. 
 These polymeric, azobenzene-functionalised peptides were shown to undergo dramatic 
structural rearrangement upon irradiation.155,156 The first reports of designs combining 
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azobenzenes with natural amino acids were based on cyclising peptides with azobenzene-
derived amino acids.157 Those constructs exhibited a transition from a disordered state to a β-
turn when the azobenzene conformation switched from trans to cis.157 A similar result is 
obtained when an azobenzene is coupled to two polypeptide chains that are prone to form a β-
sheet.158 The resulting functionalised peptide is a linear equivalent of the cyclic peptide and 
reacts analogously to irradiation. Cyclic azobenzene amino acid bearing peptides were 
recently applied to control muscle contraction.159   
The next generation of photocontrolled peptides provided a range of sophisticated 
tools as they granted reversible control of the degree of helicity of a peptide sequence.160,161 
Across a number of studies a range of peptides have been shown to undergo conformational 
transitions upon irradiation. The difference in end-to-end distance of the cis compared to trans 
state of cysteine-reactive azobenzene derivatives allowed for a variety of designs where the 
degree of helicity can be up- or down-regulated depending on the arrangement of cysteines 
(Figure 41). In arrangements where end-to-end distance better matches the trans distance (e.g. 
i, i+11), stabilisation of an alpha helix in dark state is achieved. Conversely, spacing 
approximating distances in the cis configuration (e.g. i, i+7; i, i+4) yield a peptide a more 
helical peptide after exposure to UV light. This flexibility allows the design of a plethora of 
α-helical binding peptides using azobenzene to control their conformation and their affinity to 
relevant targets. Especially successful were BH3 region/domain derived peptides targeting 
Bcl-xL and antiapoptotic members of Bcl-2 family.162 Not only is their in vitro affinity before 
and after irradiation significantly different, but according to preliminary data, their activity in 
vivo can be controlled by light, so that apoptosis induction is achieved. (R.J. Mart, personal 
communication) An added benefit of structural reinforcement by azobenzene crosslinking is 
that the resulting peptides afford a degree of protection against proteolytic activity by their 
restricted conformations (unpublished data). The affinity of DNA-protein interactions both in 
vitro and in vivo can be controlled by azobenzene crosslinked helical peptides, as can collagen 
triple-helix formation.163-166 Recent research expands the scope of this technique from 
peptides to full-size proteins; azobenzene photo-switching was shown to alter the structure of 
Fyn SH3 domain and subsequently to control enzymatic activity of a restriction enzyme.167,168 
Apart from such direct integration in protein structure, azobenzene crosslinkers have also 
been used to control the opening of ion channels by positioning an azobenzene derivative 
such that an agonist substituent can be pulled out or replaced in its binding site to modulate 
the channel activity.169 This has been demonstrated for the nicotinic acetylcholine receptor, 
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the voltage-dependent K+ channel Shaker and used to construct a light-gated glutamate 
receptor.169-171 Further developments include the evolution of chromophore structures to 
modify spectral properties, alter thermal relaxation times and improve solubility.161,172-174 
Similar sheet and helical control strategies were adopted using spiropyran 
derivatives.175 Perhaps the most elegant example of this research involves modification of E. 
coli mechanosensitive channel (Mscl). This membrane protein opens up in response to a 
pressure change along the membrane, but it found that mutating members of a group of 
neutral residues inside the channel to charged ones also opens the protein channel.176 Using 
the capability of spiropyran to shift from neutral to charged, an engineered, stable and 
reversible light responsive channel was created. Moreover, researchers were able to introduce 
membrane patches containing the photo-controlled channel to hollowed polymersomes and 
create artificial photo-controlled microcontainers.176 Hemithioindigo derivatives have also 
used to control a channel by conjugation to a pore-forming bacterial peptide, gramicidin, 
which enabled the ionic current across the membrane to be modulated in response to light.177 
 The least “invasive” chromophore involves modification of the peptide bond itself. 
The carboxylic oxygen of the peptide bond is replaced with selenium or sulphur and these 
modified bonds can be isomerised from the usual trans configuration to cis by irradiation and 
the change in configuration of a single peptide bond can disrupt the secondary structure.178,179 
The biggest disadvantage of this strategy is the need to use very high-energy radiation to 
induce the isomerisation – 280 nm UV light is needed which make such engineered peptides 
unsuitable for in vivo applications and also some more sensitive in vitro were systems.178,179 
1.4.3.4 Optogenetics 
 The ability of natural light-sensitive proteins to undergo sometimes a very dramatic 
shift in structure and their responsiveness to less energetic light makes them suitable for in 
vivo applications. Moreover, no chemical intervention is necessary as the appropriate genes 
can be transfected into cells. Channelrhodopsin is a particularly popular protein channel used 
extensively in neurological studies. Optogenetic techniques were applied to this protein to 
study the sleep/awakening transition.180 Similarly, precise spatiotemporal control of neuronal 
activity allowed for identification of neurons crucial for the treatment Parkinsonism181 and 
allowed an insight into learning mechanisms of mice.182 Rhodopsins have been also reported 
as useful tools for control and analysis of other animal behaviour.183 It is not only 
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neuroscience that benefits from optogenetic technology; a recent study employed engineered 
phytochromes to precisely control cellular trafficking.184  
1.5 Programed Cell Death 
1.5.1 Overview 
Cell death may be due to an acute effect beyond the cells control or genetically 
encoded and directly regulated. This second option, programmed cell death, allows a 
multicellular organism to choose for some cells to die to benefit the whole organism. Various 
forms of programmed cell death are crucial for the homeostasis of a multicellular organism 
(although it has been observed in some unicellular species as well) allowing infected, 
oncogenic, damaged, detached or otherwise abnormal cells that could pose a threat to the 
whole organism or colony to be purged. The demise of some cells is a necessary 
developmental step or part of a tissue function.185-188 The first documented examples of 
programmed cell death describe the process of cornification, where keratinocytes (live 
epithelial skin cells), undergo transformation into dead corneocytes that form a tight barrier 
around bodies of some vertebrates.185 Once programmed cell death processes have been 
triggered, they can generally still be reversed until a certain threshold is crossed; but as yet no 
such points have been specified with a satisfactory level of accuracy and confidence. The 
current proposal of the Nomenclature Committee on Cell Death is to treat a cell as dead if its 
plasma membrane is ruptured or has lost its integrity or if the cell, including its nucleus, has 
been fragmented and/or engulfed by neighbouring cells. This cautious definition clearly 
describes cells long after the point of no return has been crossed, and even this practical 
definition fails to account for corneocytes (death epithelial cells) which do not meet either 
criteria. On the contrary, their lipid bilayer is heavily modified and reinforced to the point 
where it no longer resembles the structure it originated from.189 Other more specific 
definitions not based on morphology have been brought forward, but in each case the 
proposed irreversible event has been refuted, these include: mitochondrial depolarization, 
massive activation of caspases, surface exposure of phosphatidylserine or loss of clonogenic 
survival (possibly to undergo mitosis).  
1.5.2 Apoptosis 
Although the programmed cell death itself was explicitly proposed in 1964, the term 
apoptosis was first coined six years later.190,191 The process was not very well characterized 
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until the seminal work of Robert Horvitz describing the development of Caenorhabditis 
elegans and the role that apoptosis plays in it.192 A series of gene knockouts revealed a 
complex system of proteins involved in controlling the fate of the 1031 cells of the 
hermaphroditic form of this nematode, of which 131 undergo apoptosis.192 There is a 
remarkable resemblance between human apoptotic pathways and those in C. elegans, 
suggesting it is an old, evolutionarily conserved phenomenon among eukaryotes. Although it 
was originally thought that apoptosis-related genes were simply controlling tissue organism 
development, apoptosis is also a stress response phenomenon. The most prominent features of 
apoptosis include massive caspase activation, the involvement of mitochondria and 
mitochondrial proteins in signal transduction and a characteristic final morphology with the 
cell blebbing and forming of spherical apoptotic bodies. Unfortunately, there is little 
consensus in closely defining apoptosis, especially in the light of recent evidence of other 
processes with an apoptosis-like morphology, but without the use of canonical signal 
transduction pathways. NCCD recommends using the term apoptosis as it was originally 
conceived, to describe purely the morphological aspect ignoring that various pathways that 
may lead to the same final appearance.189 Current opinion classifies apoptosis as belonging to 
the group of typical programmed cell deaths: programmed necrosis (necroptosis), autophagy 
(or rather autophagy related cell death), cornification and apoptosis rather than the atypical 
categories of mitotic catastrophe, anoikis, excitotoxicity, Wallerian degradation, paraptosis, 
pyroptosis, pyronecrosis and entosis.189  
1.5.2.1 Morphology 
By current definition all apoptotic cells feature the same characteristic morphology 
(Figure 42),189 whose most prominent feature is massive cell membrane blebbing and 
formation of apoptotic bodies of various sizes.191 The shape of those structures is either 
spherical or near-spherical and they contain apparently intact (not only morphologically but 
often also biochemically) cellular organelles or condensed fragments of chromatin derived 
from nuclear fragmentation (karyohexis); another hallmark of apoptosis.191 In contrast to 
necrotic processes, the blebbing cell membrane remains intact although the overall cell 
volume is decreased (pyknosis) and it acquires a round shape. Pseudopods, if present, are 
retracted.189,193 The presence of phosphatidylserine and other signalling molecules on the 
outer surface of the cell membrane and the release of nucleotides encourage the engulfing of 
apoptotic bodies by residing phagocytes. If the efficiency of this process is insufficient, 
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apoptotic bodies can acquire a necrotic morphology in a process termed secondary 
necrosis.189,194 
 
Figure 42: Top: Schematically depicted apoptotic morphology highlighting apoptotic blebbing and engulfment of 
apoptotic bodies by residing phagocytes. Apoptotic cells with (bottom from left to right) ROCK I protein 
disabled (no blebbing); Rho protein disabled; just apoptotic. Bottom: SEM picture adapted from 
reference.195 
1.5.2.2 Extrinsic vs. intrinsic apoptosis 
The apoptotic program operates by default in most cells and needs to be actively 
inhibited in order to maintain homeostasis.196 Currently distinct intrinsic and extrinsic 
pathways are recognised, with different signal initiation pathways but converging at the 
effector level (massive caspase activation). The extrinsic apoptotic pathway is mediated via 
ligands and their cell membrane receptors, that belong to the TNF protein family and 
comprise the TNF-related apoptosis-inducing ligand receptors (TRAILR1/DR4 and 
TRAILR2/DR5), DR3 and DR6, CD95 (APO-1, Fas) and TNF receptor 1 (TNFR1) itself. 
Although their main function seems to be the reception and relaying of cell death signals, in 
some cases these proteins have been observed to stimulate necrosis or even cell survival.193 A 
large group of ligands has been described so far, some of which are receptor specific and 
some bind to a few different targets. These include: Apo2L (TRAIL), TNF and FAS ligand 
(FasL, CD95L, and Apo1L). The TRAIL/TRAILR (both DR4 and DR5) ligand and receptor 
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pair exemplifies the signalling cascade of this pathway (Figure 43); DR TRAILR is a 
transmembrane protein containing a so-called death domain (DD) on the cytosolic site and a 
cysteine rich domain on the extracellular side. Receptors oligomerize prior to binding via 
interaction of Preligand Binding Assembly Domains (PLAD) of each subunit; such 
preassembly seems to be a general phenomenon for all death receptors. 197,198-200 TRAIL 
ligation then promotes assembly of even higher molecular weight oligomers, which in turn 
drives interaction with Fas Associated Death Domain (FADD) or TNF Receptor Associated 
Death Domain (TRADD) proteins through death domains (DD).201,202 Association of one of 
those two factors promotes recruitment of initiatory caspases 8 and 10 through death effector 
domains (DED) and leads to their autoactivation. This response is moderated in some contexts 
by recruitment of the caspase mimicking, but catalytically inactive FLICE inhibitory protein 
(c-FLIP).203,204 The cytosolic part of the multiprotein structure is referred to as the death 
inducing signalling complex (DISC) and the caspases it activates propagate the proteolytic 
signal to caspases 3, 6 and 7. 
 
 
Figure 43: Model of TRAILR/TRAIL interaction and subsequent activation of the extrinsic apoptotic pathway. 
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The activation of effector caspases through DISC depends on the cell type. In type I cells 
there is sufficient caspase 8 or 10 activity present to propagate the proteolytic death signal 
further, but in type II cells lower levels necessitate stimulation of intrinsic pathway.205 Current 
findings hint that in order to fully activate initiatory and effector caspases, it is necessary to 
polyubiquitinate bound caspases, which promotes translocation of the entire DISC to 
ubiquitin rich foci and increases their effective concentration.206 Both type I and type II cells 
process the protein Bid to form truncated Bid (tBid), which activates the intrinsic apoptotic 
pathway.205 
 
 
Figure 44: Intrinsic and extrinsic pathway crosstalk and convergence at final apoptosis execution itself (black arrow 
indicates inhibition and red arrows activation).  
In contrast to the extrinsic apoptotic pathway, the intrinsic one occurs in response to 
intracellular stressors including UV light, ionizing radiation, infection, ER stress, heat shock 
and oxidative stress (Figure 44).207 These stimuli are directly or indirectly sensed by so called 
BH3-only proteins that in turn activate proapoptotic multi-region Bcl-2 family members (Bak 
and Bax). Upon activation Bak/Bax homooligomerize and cause mitochondrial outer 
membrane permabilization, probably by forming pores whereby the soluble contents of 
mitochondria are released to cytosol.208 Among them are cytochrome c, second mitochondria-
 49 
 
derived activator of caspases/direct IAP binding protein with low pI (SMAC/Diablo), 
apoptosis inducing factor (AIF) and endonuclease G (EndoG). SMAC/Diablo inhibits X-
linked inhibitor of apoptosis (XIAP), which removes its inhibition of downstream caspases. 
Cytochrome c assembles into a complex with apoptotic protease-activating factor 1 (Apaf-1, 
Figure 45) known as the apoptosome which, after a large conformational change oligomerises 
into a 7-fold symmetrical multiprotein complex. 
 
Figure 45: Monomer of an apoptosome; domains of Apaf-1 with cytochrome c bound are indicated. The CARD 
domain (yellow) is responsible for the homotypic interaction with CARD on caspase 9. The WD40 domain 
(grey) responsible for the binding of cytochrome c (red). The  ATPase domains (pink and green) are 
responsible in this model for oligomer formation. Also illustrated are the winged-helix and superhelical 
domains (purple and blue). Apaf-1 structure adapted from reference 104. 
Caspase 9 is the primary initiatory caspase of the intrinsic pathway and is activated by 
dimerization facilitated by the apoptosome (Figure 46). Two hypotheses to explain this have 
been brought forward so far; in the first the small amount of caspase 9 dimer already present 
in solution interacts with the CARD domains of the apoptosome via a homotypic interaction, 
which triggers formation of a stable dimer possibly via kinetic trapping of the activated dimer 
conformation. In the second model each subunit interacts with apoptosome separately and 
after such activation they assemble in solution. Once there is sufficient active caspase 9 in the 
cell the signal can propagate via proteolytic activation of effector caspases.  
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Figure 46: Apoptosome assembly triggered by cytochrome c release from the mitochondria caused by the other 
mitochondrial membrane permabilization; assembled apoptosome dimerizes caspase 8, which in turn 
triggers the proteolytic cascade of executor caspases. Structure of Apaf-1 and apoptosome adapted from.209 
1.5.2.3 Caspase overview 
Caspases are intracellular cysteine-dependent aspartate-specific proteases that carry 
out several distinct cellular processes.210 They are a conserved and old eukaryotic family of 
proteins and share a common ancestor protein.211 Although caspases are principly known for 
their crucial role in the propagation of apoptosis, they are also involved in proliferation and 
inflammation.212 Caspases are broadly classified into two groups based on what their role is 
believed to be. Caspases 2, 3, 6, 7, 8, 9 and 10 are apoptotic and 1, 4, 5, 11, 12, 13 are most 
often related to inflammation.212 Caspase 14 is thought to be solely engaged in keratinocyte 
maturation.213 However, it is worth noting that some members of each group are implicated in 
multiple processes.214 Classification within the group of caspases related to apoptosis 
distinguishes initiator (apical) caspases from effector (executioner, downstream) caspases. 
This grouping overlaps with mechanistic aspects of activation and structural features as the 
propeptide domain of initiator caspases with activity triggered by dimerization, rather then 
proteolytic cleavage as for downstream caspases whose zymogen is already dimeric (Figure 
47). All caspases posses a catalytic dyad of a cysteine and a histidine which are used to cleave 
peptide bonds with specificity strongly biased towards substrates containing aspartic acid, 
with proteolysis commonly occurring after this residue.210  
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Figure 47: Caspases structural organization; three distinc domain indicated (propeptide, large domain and small 
domain) with residues that undergo cleavage (D) and the catalytic dyad (C and H). 
Most caspases are able to cleave a wide range of proteins; nevertheless a certain 
tendency to target specific multiprotein complexes and proteins involved in specific pathways 
has been reported.215 It is caspase activity within a cell which confers the characteristic 
apoptotic morphology;216 apoptotic blebbing has been identified as being a consequence of 
the activation of Rho effector protein (ROCK I) by proteolytic cleavage.195 ROCK I activation 
also causes increased condensed chromatin translocation. Cleavage of lamins by caspases 
contributes to the weakening of the nuclear envelope and fragmentation of DNA is achieved 
via caspase activated DNases that lead to the characteristic DNA ladder seen by 
electrophoresis techniques. Cellular shrinkage is attributed to the proteolysis of various 
cytoskeleton proteins.217 The activity of caspases can be controlled by three different 
regulatory methods: the turnover of activated caspases is very high as they are rapidly 
directed to the proteosome,214 “decoy” proteins like c-FLIP can compete with caspases for the 
adaptors (e.g. at DISC), and numerous inhibitors of apoptosis (IAP) directly or indirectly 
affect the activity of caspases. 
1.5.2.4 Bcl-2 family 
The main controllers of the intrinsic pathway of apoptosis are the B cell lymphoma 2 
family of proteins (Bcl-2 family). This functionally and structurally diverse family of proteins 
is characterized by presence of one or more so called Bcl-2 homology regions (BH 
regions).218 The family was named after the prototypical member whose gene was discovered 
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to be interrupted in ~60% cases of human follicular lymphomas; as the research was 
conducted on B cell lymphomas the gene was nicknamed bcl-2, which was later, according to 
the convention, transferred to its product the Bcl-2 protein.219 The family can be divided into 
three distinct subgroups: multi-region antiapoptotic proteins possess BH1-4 regions; multi 
region proapoptotic proteins possess BH1-3 regions (according to more recent literature BH4 
regions also present in sequences of multi region proapoptotic proteins), and proapoptotic 
BH3-only proteins (Table 2).208 Although BH regions are persistently called “domains” in the 
literature, this is incorrect as domains are capable of folding independently and performing 
their function, which is not the case with most of BH regions.  
Antiapoptotic  
Bcl-2 BH1 BH2 BH3 BH4 TM 
Bcl-xL BH1 BH2 BH3 BH4 TM 
Bcl-w BH1 BH2 BH3 BH4 TM 
Bcl-2A1 BH1 BH2 BH3         TM 
Mcl1 BH1 BH2 BH3 BH4 TM 
Bcl-b BH1 BH2  
Proapoptotic multi-region  
Bax BH1 BH2 BH3 BH4 TM 
Bak BH1 BH2 BH3 BH4 TM 
Bok BH1 BH2 BH3 BH4 TM 
Proapoptotic BH3-only  
Bid                 BH3 
Bik                 BH3         TM 
Bim                 BH3         TM 
Puma                 BH3 
Noxa                 BH3 
Bad                 BH3 
Hrk                 BH3         TM 
BNip1                 BH3 
BNip2                 BH3 
BNip3                 BH3 
Table 2: The overview of the Bcl-2 family members; gray colour indicates uncertainty in classification. 
In addition to BH regions, the antiapoptotic group and multi-region proapoptotic group (Bak 
and Bax) share C-terminal transmembrane region/domain (TM) that allows them to locate to 
the surface of the outer mitochondrial membrane.218 Bik is the sole BH3-only protein shown 
to possess a TM region.220 Five antiapoptotic members of the Bcl-2 family are known, those 
are Bcl-2, Bcl-xL, Bcl-2A1, Mcl1 and Bcl-b. As all five of them possess a TM region, they are 
usually found localized in the other mitochondrial membrane, but also on the endoplasmic 
reticulum; this subcellular localization is not surprising given the amount of continuity 
between these membranes.218 Although initially Mcl-1 was believed to lack a BH4 region, 
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careful signature analysis allows a BH4 region/domain to be identified; likewise Bak and 
Bax.221 
The two known proapoptotic multi-region proteins, Bak and Bax, are responsible for 
the permabilization of the outer mitochondrial membrane in a process that almost certainly 
involves a formation of protein pores (mitochondrial apoptotic channels, MAC), although 
neither the existence nor the nature of those pores has yet been established. Two models have 
been proposed involving either proteinaceous or lipidic pores, with current data mostly 
supporting up the latter hypothesis.222-225 Another multi-region proapoptotic member of the 
Bcl-2 family Bcl-2 ovarian killer/Matador (Bok/Mtd) has yet to receive the attention given to 
Bak and Bax, but is suggested to act in a similar fashion. Its expression seems to be very 
tissue specific and it has been implicated in human placental development.226-229 
Two distinct models and a compromise between them have been proposed to try to 
explain the interplay between Bcl-2 family members (Figure 48). The direct activation model 
subcategorizes BH3-only proteins into two groups; sensitizers (Bad, Bmf, Bik, Hrk, Noxa, 
Beclin-1) and activators (Bim, tBid, Puma). The role of activators is to trigger a structural 
change in Bax/Bak to ready them for oligomerization and pore formation. Sensitizers are 
proposed to liberate activators from unproductive complexes with antiapoptotic members of 
Bcl-2 family. In the displacement model, Bak and Bax are either already active, or the act of 
release from an inhibitory complex itself triggers activation. In the latter case the sole role of 
BH3-only proteins would be to displace Bax/Bak from complexes with antiapoptotic proteins. 
The third, ‘embedded together’, model suggests that both of those scenarios occur and both 
activation and release from antiapoptotic members of Bcl-2 play a role in the intrinsic 
pathway. Embedding the proteins together in the outer mitochondrial membrane alters the 
local concentrations and dissociation constants of the different complexes to introduce 
subtleties that might not be reflected by in vitro measurements. Regardless of which model 
best describes reality, and the process could differ according to tissue or environment, it is 
certain that BH3-only proteins activate apoptosis. To do so they need to sense an apoptotic 
signal, respond to it and relay it to other members of Bcl-2 family. Human BH3-only proteins 
have evolved a whole variety of solutions to this problem. For example, Bad is 
dephosporylated if the level of growth factors drops below a certain threshold. 
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Figure 48: Three models of Bcl-2 proteins interplay. (A) Embedded together model; (B) direct activation model; (C) 
displacement model. “Bcl-xL“ stands for any antiapoptotic member of Bcl-2 family; “Act.” stands for 
activator and “Sens.” stands for sensitizer. 
The lack of this strategically positioned phosphate group allows Bad to interact with Bcl-2 
and Bcl-xL, releasing proapoptotic proteins from complexes with these proteins.230 
Phosphorylated Bak not only has lower affinity to Bcl-xL and Bcl-2, but also is sequestered 
from mitochondria by 14-3-3 proteins.231,232 Bmf and Bim act as sensors of UV damage and 
cell detachment by being released from their resting complexes (myosin V motor chains for 
Bmf and microtubules for Bim) to displace proapoptotic proteins from complexes with Bcl-
xL, Bcl-w and Bcl-2.233 Additionally, Bad and Bim synthesis is upregulated and their 
dephosphorylation accelerated when a cell is deprived of survival factors.234 Puma, Noxa and 
Bik are not constitutively produced, but their translation is upregulated by p53 protein if 
certain apoptotic stimuli are present (DNA damage, oxidative stress).220,235,236 
As noted previously, the intrinsic and extrinsic apoptotic pathways cross-talk at the 
level of Bid activation (Figure 22). Bid treated with caspase 8, caspase 3, calpain or granzyme 
B is truncated at the C-terminus to tBid which is postulated to insert into the outer 
mitochondrial membrane and induce Bax to permeabilize the membrane.237 Although 
transferring apoptotic information from death receptors to Bax/Bak seems to dominate, there 
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are some cases where Bax activation through membrane embedded death receptors is not 
mediated by tBid. In addition, p53 itself is known to bind Bax and to induce activation of the 
intrinsic pathway. It seems that Bak responds to a variety of stimuli to surmount the 
conformational change activation barrier and induce pore formation; physical factors like 
temperature and acidity have been reported to be among them.238 Apart from their roles as 
regulators of apoptosis, Bcl-2 family members have also been reported as engaged in various 
other cellular pathways; Bcl-xl and Bcl-2 are known to modulate mitochondrial fission and 
Bad is involved in the regulation of glycolysis.230,239 In addition to the Bcl-2 family members 
already discussed, yet others have been identified (e.g. Bcl-g, Bcl-Rambo, Bcl-b) and 
probably many remain to be found.238 Some of the additional members are known to be 
involved in apoptosis, but too little data is available for any rigorous classification. 
1.5.2.5 Structural Biology of Bcl-2 family members 
Unfortunately, structures of Bcl-2 family members are often elusive; of all the BH3-
only proteins only that of Bid are known.240 Experiments suggest that the other BH3-only 
proteins are natively unfolded and obtain more pronounced tertiary structure upon binding to 
other proteins, a quality that perhaps reflects the multitude of environments and adaptors they 
need to interact with in order to sense and relay apoptotic signals241 (similar behaviour is 
observed for p53).242 Analysis of the published structures allows a fairly rigorous 
classification of structural elements of the Bcl-2 family members, defining helices (numbered 
from α1 to α8), loops (some of which serve functions other than just connecting two helices), 
regions/domains (BH and TM) and binding grooves (Figure 49 and 50). 
 
Figure 49: Bcl-2 family members helix annotation (based on Bcl-2). Please notice that last helix (α8) is not always 
present and is not represented on this structure. BH1 – green, BH2 – orange, BH3 – blue, BH4 – red. PDB 
entry: 1G5M. 
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Figure 50: Structural comparison of Bcl-2 family members. PDB entries: 1WSX, 1R2D, 1O0L, 1G5M, 2JCN, 2K7W, 
2BID. 
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Although the members of the family often show low sequence identity, the overall 
structure is conserved, for example Bcl-xL and Bid share only 11.2% sequence identity but 
have an overall RMSD of 3.8 Å (Figure 50).243 Known structures show all α−helical, globular 
proteins, connected predominantly by short loops with a fold organized around a central α5 
helix that forms the hydrophobic core and is surrounded by amphipathic alpha helices. 
Although it is difficult to analyse the structure-sequence relationship between proteins that 
share so little sequence identity yet so much in architecture, a set of key residues that define 
the Bcl-2 family topology/fold has been identified. Data mining revealed 72 structurally 
equivalent residues 22, of which are at the same time of similar size make the same inter-
residue contacts and share solvent accessibility with the Bcl-2 family helix bundle fold.243 By 
extending this technique and considering the 72 positions only for viral Bcl-2 homologues 
sequences with known structures it was possible to successfully identify new viral 
homologues of antiapoptotic proteins.243 
Unfortunately, the published literature lacks a coherent helix numbering scheme, α6‘ 
is sometimes referred to as α7, which accordingly changes numbering of the following 
helices (Figure 49). The notation used in this thesis is described in Figure 49. In some 
structures, α8 (Bax, Bcl-w) is also visible. This helix is often found in the canonical BH3 
peptide binding grove formed by α3 and α4244-246 unless displaced by a BH3 peptide. It is 
possible that the lack of a resolved α8 or its displacement from the BH3 binding grove in the 
published structures of Mcl-1, Bcl-xL and Bcl-2 is an artifact of protein engineering, as all of 
those proteins were truncated at the C-terminus in order to improve their properties for NMR 
sample production. However, some structures of proteins in complexes with BH3 peptides 
show a “displaced” helix at full length C-terminal helix.247-251 It is hypothesised that α8 is 
displaced upon binding of a BH3 domain and inserted into structure of its binding partner to 
compensate for its partial unfolding or that exposure of the loop between α7 and α8 facilitates 
membrane insertion.  
Although most loops present in the structures of Bcl-2 family proteins are short and 
well ordered, there are two exceptions. The loop connecting α3 and α4 is flexible and allows 
for the significant reshaping of the binding grove (helices α3 and α4).247,248 The disorder of 
this loop in the free protein is reflected in a lack of long range NOEs and the disappearance of 
amide N-H NMR peaks in a manner characteristic of fast exchange with water (unpublished 
data), but once a ligand is bound the loop seems to be very ordered. The other flexible loop 
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has a variable length and connects α1 and α2 (also BH4 and BH3). In all cases except Bcl-w 
it is found to be highly disordered and while its function has yet to be determined, it connects 
two BH region/domains and possibly works (at least in case of proapoptotic Bcl-2 family 
members) as a flexible tether allowing BH3 region/domain to reach its target. What is certain 
is that in the case of antiapoptotic proteins deletion of this loop, a common practice in 
structural studies, does not affect the binding of BH3 region/domain extracted peptides or in 
vivo activity.247-249,252 Some studies suggest that phosphorylation within this loop abolishes 
Bcl-2/p53 interaction.253   
A striking characteristic of Bcl-xL is its ability to form domain swapped dimers 
(Figure 51). Three different arrangements are known, one of which has been suggested to be 
solely a crystallization artifact, due to a deliberately shortened loop connecting helix α1 with 
α2.45,254,255 However, the binding of other proteins to the loop may effectively shorten that the 
average distance between those helices, leading to a natural situation similar to that seen in 
the crystal structure of the mutated protein. Proteins embedded in the outer mitochondrial 
membrane exist in an environment that is still very difficult to research or model, and could 
possibly engage aforementioned loop. In the second domain swap dimer an even more 
significant reorganization is observed to be triggered by temperature. The BH2 region/domain 
is swapped between two monomers and a long helix forms between BH1 and BH2.256 Similar 
domain swap dimers have been reported for Bcl-w, but different helices are swapped.257  
The fold of proapoptotic Bcl-2 family members requires a major reshaping to expose 
their BH3 domains (vide Bak/Bcl-xL) as the amphipathic BH3 helix is packed centrally and 
some residues face into the hydrophobic core. This suggests that the protein itself must have a 
surmountable barrier to unfolding under certain conditions to adapt its shape for the binding 
purposes or to allow membrane insertion. This implies that at least 3 (likely more) very 
different conformations of Bak exist, and possibly even more if the previously discussed, 
often-removed α8 of Bcl-xL, Mcl-1 and Bcl-2 replaces partially unfolded Bak, Bax or Bid. 
There are no published structures of the antiapoptotic Bcl-2 family members in complex with 
full-size BH3-only proteins or Bak/Bax, despite a multitude of X-ray and NMR structures of 
complexes of BH3 domain derived peptides of various lengths.258 
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Figure 51: Overlaid structures of Bcl-xL (black) and Bcl-xL in complex with Bim (orange), Bak (light-purple), Bad 
(red), Bax (green) and Beclin-1 (blue) peptides derived from the respective BH3 region/domains. Helices α3 
and α4 are indicated. PDB entries: 1R2D, 3PLX, 2P1L, 1BXL, 2BZW and 3PL7. 
 
                                                                                                    
As structures of new small molecule inhibitors of antiapoptotic members of the Bcl-2 
family enter the populate Protein Data Bank they reveal a surprising degree of flexibility in 
Figure 52: Comparison of different Bcl-xL forms; Bcl-xL monomer, Bcl-xL domain swap dimer (BH1-2) 
and Bcl-xL domain swap dimer (BH4).  PDB entries: 2P1L, 1R2D, 2B48. 
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the canonical BH3 binding grove (between helices α3 and α4). Helix α4 moves towards the 
peptide or inhibitor with a concomitant shift of the helix α3 that widens the binding grove to 
adapt to the ligand and reshapes the connecting loop (Figure 52 and 53). 
Upon closer examination of Bcl-xL structures in complex with its four different 
ligands, we can see that not all of them perfectly overlay with each other as judged by the 
carbon alpha position (Figure 52 and 53). The most significant deviations are seen in the Bcl-
xL in complex with Beclin-1 and Bak (Figure 52). In the first case, it perhaps reflects this 
peptide’s dissimilarity as compared to others. In the second case, quality of the NMR 
structure is not sufficient to determine if the change is genuine or is just an artifact of the 
structure solving algorithm. Pronounced differences can be found in side chain positions even 
when carbon alpha positions are very similar. This is a direct consequence of differing 
sidechains.  
 
Figure 53: Overlaid structures of Bcl-xL (black) and Bcl-xL in complex with Bax (red) and a small molecule inhibitor 
(blue). The inhibitor is visible in the middle of the picture (orange). Helices α3 and α4 are indicated PDB 
entries: 1R2D, 3PLX and 3INQ. 
Indeed, the adaptability of the BH3 binding is well illustrated by a structure of Bcl-xL 
in complex with a small molecule ligand (Figure 53).15 The small molecule used in this study 
bound well to Bcl-xL, yet induced a conformational change that was not as pronounced as that 
observed upon BH3 peptide binding.15 This structure lies somewhere between free Bcl-xL 
structure and that of Bcl-xL complexed to a BH3 peptide and sheds some light on how the 
transition in conformation upon binding might take place. It seems that first helix α3 widens 
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the grove when the C-terminal part of the peptide binds and then helix α4 follows to engage 
the N-terminal part (Figure 52 and 53).15 
 Both structural biology studies and alanine scanning have been used to reveal the 
residues that contribute most to the binding energy of the antiapoptotic protein Bcl-xL to a 
Bak BH3 peptide (Figure 54). The most important residues on the Bak side are valine 74, 
arginine 76, leucine 78, isoleucine 81 and 85, aspartate 83. For Bcl-xL, phenylalanine 97 and 
105, tyrosine 101 and 195, valine 126 and 141, glutamate 129 and arginine 139 are most 
important.247,258 The binding is driven predominantly by the hydrophobic effect, when leucine 
78 of the Bak peptide was mutated to alanine binding was practically abolished.247,258 
However there are also two important salt bridges between arginine 76 and aspartate 83 on 
the peptide to glutamate 129 and arginine 139 of the protein.247 The existence of those two 
salt bridges is somewhat controversial. The analysis of the only published structure of Bcl-xL 
in complex with Bak (1BXL) reveals that the distance between those residues might not be 
sufficient to report an electrostatic interaction (vide infra). These patterns differ noticeably for 
other peptides binding to this grove on Bcl-xL as well as between other antiapoptotic members 
of the Bcl-2 family.  
 
Figure 54: Surface representation of the Bcl-xL in complex with Bak with residues contributing most to the binding 
energy on Bcl-xL (left, Bak not visible); same surface representation with Bak helix and amino acid side 
chains of Bak contributing most to the binding energy (right). 
One of the remarkable observations in studies detailing the interactions between Bcl-2 
proteins and BH3 peptides is that one of the best binding Mcl-1 peptides is derived from the 
BH3 domain of Mcl-1 itself. This result is echoed by the finding that Bcl-w forms a self-
inhibiting C-terminal α−helix, a feature that might be universal amongst Bcl-2 proteins.244,245 
This raises a very interesting question about binding equilibria of the whole population of 
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those proteins, especially when artificial peptides derived from BH3 regions are added to the 
system, further increasing the overall complexity.59 This situation although not naturally 
occurring is of the highest interest due to possible medical applications of engineered BH3 
peptides. It is difficult to predict the effect of BH3 peptides on the equilibrium of Bcl-2 family 
of proteins.  
It seems that this group of proteins evolved around the same topology, the same fold 
and to contain similar regions (BH3), so that parts of their structure can be exchanged 
(although perhaps only transiently) between themselves either to activate/deactivate a protein 
or to allow for oligomer formation (MAC formation). One can further theorize that formation 
of oligomers may be one of the ways to deactivate selected Bcl-2 family members and clear 
them via relevant pathways. This model of virtually exchangeable protein units 
(domains/regions) shines a new light on how proteins in general may interact and it is a way 
more similar to some nucleic acid structures rather than canonical protein-protein interactions. 
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2 Results and Discussion 
2.1 Photocontrol of Rev/RRE interaction 
2.1.1 Aims and Objectives 
 The aim of this study was to synthesise a photoswitchable RNA binding peptide and 
evaluate its absolute and relative (irradiated vs. dark-adapted) affinities to a target RNA 
sequence. Since peptides derived from Rev can act as antagonists of the Rev-RRE interaction 
and serve as models for the development of methodology for the photocontrol of peptide-
RNA interactions, the photoswitchable peptides were based on the sequence of the minimal 
Rev peptide retaining high affinity to RRE.128-130 
2.1.2 Biosynthesized Rev Peptides 
2.1.2.1 Design Cloning, Expression and Crosslinking of the Rev peptides 
The initial peptide design was performed by Dr Sabine Kneissl. The Rev wild type 
peptide sequence was modified in order to accommodate the crosslinker (Table 3). Two 
appropriately spaced residues on the solvent exposed face of the Rev α-helix and opposite to 
the residues involved in RNA binding had to be mutated to cysteine. For the Revi, i+4 Ala 37 
and Arg 41; for Revi, i+7 Arg 38 and Trp 45; for Revi, i+11 Arg 38 and Glu 49 were mutated to 
cysteine. Additionally, Arg 41 (Revi, i+7) and/or Arg 42 (Revi, i+7 and Revi, i+11) and/or Arg 42 
and Trp 45 (Revi, i4 and Revi, i+11) were changed to alanine to prevent potentially unfavourable 
interactions with the crosslinker (Table 2). Peptides were produced in E. coli using pET 31b 
expression system (Novagene) and all of them contain (depending on conditions) homoserine 
or homoserine lactone (Hs) at their C-terminus, which is an artefact amino acid left by CNBr 
cleavage of a peptide at a methionine site (vide infra) and their name/abbreviation will be 
presided by letter “b” designating their origin as biosynthesized peptides (Material and 
Methods).259 
Peptide Sequence 
bRevwt 33DTRQARRNRRRRWRERQR50-Hs	 
bRevi, i+11 50DTRQACRNRARRARERCR-Hs	 
bRevi, i+7 50DTRQACRNAARRCRERQR-Hs	 
bRevi, i+4 50DTRQCRRNCRRRARERQR-Hs	 
Table 3: Sequence of modified bRev peptides and the wild type. Hs = homoserine or homoserine lactone 
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Oligonucleodites coding for bRev peptides were optimised for E. coli codon usage 
(Material and Methods)260 and contained tandem repeats of each peptide separated by a 
methionine and overhangs to facilitate cloning via the AlwN1 cleavage site of pET 31b 
plasmid. Initial clones were screened by AlwN1 restriction to detect the presence of its 
cognate restriction site which is abolished by successful ligation (Figure 33). The presence of 
the given insert was confirmed by DNA sequencing.  
 
Figure 55: An exemplary bRev clones AlwN1 screening assay. DM - 1kbp DNA marker; A - positive control (plasmid 
with an insert); 1 - 9 clones screened; 4, 6 possible clones without an insert. 
Interestingly despite of multiple attempts in varying conditions in all cases the final 
vector contained either frameshift mutations or complete deletion of the second peptide of the 
tandem. 
Peptide Sequence 
bRevi, i+11 MetDTRQACRNRARRARERCRMetLLEHHHHHHSTOP	 
bRevi, i+7 MetDTRQACRNAARRCRERQRMetLLEHHHHHHSTOP	 
bRevi, i+4 MetDTRQCRRNCRRRARERQRMetDTRQCRRNCCSSTTTT…	 
bRevwt MetDTRQARRNRRRRWRERQRMetAARAPPPPPLRSGCSTOP	 
Table 4: Exemplary sequencing results of Rev clones; the sequence is translated to the corresponding amino acid 
sequence and only the part after KSI is shown; Methionine and translation STOP is indicated in red. 
Peptides were produced in E. coli BL21(DE3) expression system fused to ketosteroid 
isomerase (KSI), which promotes the formation of inclusion bodies, to enable separation of 
the product fusion peptide from soluble proteins before further purification in denaturing 
conditions (vide infra).259,261  In the case of bRevi, i+4 a mutation lead to expression of a 
“fusion protein” that considerably increased the size of produced protein and decreased the 
 65 
 
final yield of the peptide (Table 4, Figure 56). Nevertheless all peptides apart from bRevwt 
were biosynthesised and purified. Although different expression conditions, clones and cell 
lines were tried, no overexpression for bRevwt gene was observed for any of the clones even 
though sequencing determined that they contained the correct insert sequence (Table 4, Figure 
56). In order to provide positive control for further experiments Revwt synthesised by Fmoc 
protocols was provided by Dr Sabine Kneissl. 
 
Figure 56: SDS-PAGE analysis of the Rev peptides expression. A - bRevwt; bRevi, i+4; bRevi, i+7; bRevi, i+11; 1 - cell 
culture before IPTG induction; 2 cell culture 6 h after IPTG induction.  
Following expression, cells were harvested by a centrifugation and frozen frozen for 
storage (-80 °C). Pellets were then thawed and lysed by ultrasonication. After centrifugation 
the pellet containing the KSI fused peptides was washed (3x) (Material and Methods). 
Finally, the pellet was dissolved in a buffer containing 6M guanidinium hydrochloride, any 
remaining insoluble debris were removed by centrifugation and the supernatant was dialysed 
against water (Material and Methods). The pellets were treated with CNBr, liberating the 
desired peptides via cleavage at the methionine site, which as aforementioned produces a 
homoserine lactone at C-terminus. Peptides were purified by HPLC and their mass was 
confirmed by mass spectrometry (Figures 57 – 59, Table 5, Material and Methods). In all 
cases two peaks corresponding to each peptide were identified as the open and lactonized 
form of the C-terminal homoserine are observed under purification conditions. This suggests 
that a similar equilibrium might exist during binding measurements, effectively producing 
two populations of peptides. It is difficult to assess the significance of this change on the 
properties of the peptide and it is difficult to change the population distribution for the 
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duration of subsequent assays in order to assess possible different affinities of those two 
forms because the technique that was going to be used requires either acidic or basic 
condition both of which catalyze homoserine lactone to open form interconversion. Moreover 
determining the lactone/open ratio under given conditions is somewhat complicated as the 
HPLC technique changes them (most notably by the pH of the mobile phase). The presence of 
the lactone form considerably increases reactivity of the peptides especially towards 
amines.261 
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Figure 57: (A) HPLC chromatogram from the purification of the CNBr cleavage mixture of bRevi, i+4 with the open 
homoserine form indicated with black arrow and closed with green. MALDI MS traces of bRevi, i+4; (B) 
closed homoserine form and (C) open. 
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Figure 58: (A) HPLC chromatogram from the purification of the CNBr cleavage mixture of bRevi, i+7 with the open 
homoserine form indicated with black arrow and closed with green. MALDI MS traces of bRevi, i+7; (B) 
closed homoserine form and (C) open. 
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Figure 59: (A) HPLC chromatogram from the purification of the CNBr cleavage mixture of bRevi, i+11 with the open 
homoserine form indicated with black arrow and closed with green. MALDI MS traces of bRevi, i+11; (B) 
closed homoserine form and (C) open. 
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Figure 60: Scheme of the XL-SO3H crosslinker used in this study and the crosslinking reaction mechanism. 
Purified peptides were crosslinked similarly as it was described previously.162 Briefly, 
peptide and the crosslinker were dissolved in 50 mM Tris:HCl, 2 mM TCEP, pH 8.3 to 1 
mg/mL. The crosslinker solution was added in three portions followed by 2 h incubation at 
the room temperature and then overnight at 4 °C. In each case precipitation was observed and 
the precipitate had to be resuspended in 1:1 MeCN/H2O before further purification (Material 
and Methods). From this moment on peptides crosslinked with the azobenzene derivative 
containing sulfonate substituents (Figure 60) will bear the name of the parent peptide suffixed 
with XL-SO3H. Crosslinking bRevi, i+4  proved difficult, altering the procedure by UV 
irradiating the reaction mixture or increasing temperature to improve the probability of correct 
cyclisation still yielded only minute amounts of crosslinked peptide (Material and Methods). 
All crosslinked products were subjected to HPLC purification and once again similar peaks 
corresponding to the open and closed form of homoserine were observed; the masses of 
crosslinked peptides were verified by mass spectrometry techniques (Figures 61 – 63, Table 
4, Material and Methods).   
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Figure 61: (A) HPLC chromatogram from the purification of the CNBr cleavage mixture of bRevi, i+4-XL-SO3H with 
the open homoserine form indicated with black arrow and closed with green (A). MALDI MS traces of 
bRevi, i+4-XL-SO3H; (B) closed homoserine form and (C) open. 
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Figure 62: (A) HPLC chromatogram from the purification of the CNBr cleavage mixture of bRevi, i+7-XL-SO3H with 
the open homoserine form indicated with black arrow and closed with black (A). MALDI MS traces of 
bRevi, i+7-XL-SO3H; (B) closed homoserine form and (C) open. 
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Figure 63: (A) HPLC chromatogram from the purification of the CNBr cleavage mixture of bRevi, i+11-XL-SO3H with 
the open homoserine form indicated with black arrow and closed with black (A). MALDI MS traces of 
bRevi, i+11-XL-SO3H; (B) closed homoserine form and (C) open. 
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Peptide  Calculated [M+H]+ 
Observed 
[M+H]+ 
bRevi,i+4 (Hs-open)  2517.298[a] 2516.72 
bRevi,i+4 (Hs-lactone)  2499.287[a] 2498.36 
bRevi,i+7 (Hs-open)  2347.170[a] 2348.08 
bRevi,i+7 (Hs-lactone)  2329.159[a] 2329.24 
bRevi,i+11 (Hs-open) 2375.213[a] 2374.74 
bRevi,i+11 (Hs-lactone) 2357.202[a] 2357.68 
bRevi,i+4-XL-SO3H (Hs-open) 2969.307 2970.90 
bRevi,i+4-XL- SO3H (Hs-lactone) 2951.296 2953.88 
bRevi,i+7-XL-SO3H (Hs-open) 2799.179 2797.80 
bRevi,i+7-XL- SO3H (Hs-lactone) 2781.168 2779.98 
bRevi,i+11-XL-SO3H (Hs-open) 2827.222 2825.54 
bRevi,i+11-XL- SO3H (Hs-lactone) 2809.211 2807.59 
Table 5: Observed and calculated masses of purified bRev peptides; [a] calculated assuming reduced cysteines 
2.1.2.2 CD and UV 
The kinetic parameters of peptides relaxing after UV irradiation were estimated by 
measuring relaxation rates (k) at various temperatures (T) and plotted. Relaxation rates were 
measured by following a decrease in 365 nm absorbance of the crosslinked peptides over time 
after irradiation with 365 nm UV light (Material and Methods) and fitting a first order kinetics 
equation (Equation 1) to that data. Measurements were performed using Chirascan CD 
spectrometer by either taking a full spectrum (180 to 600 nm) after each interval for 
temperatures 4 °C to 20 °C or by measuring at 208, 222 and 365 nm for temperatures 25 °C to 
40 °C. 
 
Equation 1: The first order kinetics equation fitted to a plot of 365 nm absorbance against time; where A365 is 
absorbance at any time; A365ir. is absorbance after irradiation (t=0); A365dark is absorbance before 
irradiation; k is the rate constant and t is time. 
To analyze the kinetic parameters the logarithmic (linear) version (Equation 3) of 
Arrhenius equation (Equation 2) was fitted to the plot of the natural logarithm of relaxation 
rates (lnk) against the reciprocal of temperature (1/T). This allows estimating activation 
energy (Ea) and preexponential factor A expressed as lnA (Figure 64). 
 
Equation 2: Arrhenius equation; where k is a rate constant; A is a preexponential factor; Ea is an activation energy; R 
is the gas constant and T is temperature. 
 
Equation 3: Linear form of the Arrhenius equation.  
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Both peptides exhibit slower kinetics as compared to the free crosslinker which has been 
observed before. At 15 °C i, i+7 spacings makes the crosslinked peptide relax slower as 
compared to i, i+11 (Table 6). The slower relaxation is determined by the activation energy 
which is 5 kJ/mol lower for i, i+7 peptide, but at the same time lnA is higher and not enough 
so to compensate for the increase in the activation energy barrier. This is further discussed 
together with the results for Fmoc synthesized peptides (vide infra). 
 
Figure 64: Arrhenius plots of bRevi, i+7-XL-SO3H (left) and bRevi, i+11-XL-SO3H (right). 
 Peptide Half  Life at  15 °C [min] 
Activation 
Energy [kJ/mol] lnA 
bRevi, i+7-XL-SO3H 217.7 ± 16.5 83.0 ± 4.4 25.6 ± 1.78 
bRevi, i+11-XL-SO3H 123.0 ± 11.3 78.0 ± 1.8 23.9 ± 1.84 
Table 6: Kinetic parameters of UV363 relaxation after UV363 irradiation for all crosslinked bRev peptides. 
Both bRevi, i+7-XL-SO3H and bRevi, i+11-XL-SO3H exhibit changes in their CD spectra 
upon irradiation, indicating structural changes (Figure 65). Although the effect is much 
stronger for bRevi, i+11-XL-SO3H, transition from more to less helical peptide can be observed 
for bRevi, i+11-XL-SO3H and vice versa for bRevi, i+7-XL-SO3H. Both characteristic alpha 
helical minima (208, 222 nm) and one maximum (190 nm) in their CD spectra change 
intensity and a peak wavelength shift is observed for 208 nm. Upon irradiation bRevi, i+11-XL-
SO3H loses α-helical character; bRevi, i+7 becomes more α-helical after irradiation. It is 
important to note that the conversion from trans to cis state of the crosslinker is not complete, 
and therefore the CD spectra of peptides after UV irradiation represent the contribution of 
both forms with the trans-cis conversion between 70 and 80% complete. 
 Interestingly, both peptides exhibit CD signals arising from the azobenzene: with 
maxima at 265 nm (small) and 360 nm and a minimum at 440 nm. bRevi, i+11-XL-SO3H also 
exhibits a small maximum at 250 nm. All signals apart from the one at 265 nm have been 
reported previously, however it was initially suggested that only the non-sulfonated 
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crosslinker exhibited them. Although the crosslinker itself is not chiral it contacts a chiral 
environment provided by the chiral peptide. The intensity of those signals is much stronger 
for bRevi, i+11-XL-SO3H then bRevi, i+7-XL-SO3H. Moreover, the change in intensity upon 
irradiation is reversed for bRevi, i+11-XL-SO3H compared to bRevi, i+7-XL-SO3H. Taken 
together this suggests a direct correlation between crosslinker CD signal intensity and the 
average amount of helicity. Indeed by examining the CD spectra of bRevi, i+11-XL-SO3H taken 
at different temperatures one can see a concomitant shift in helicity and intensity of the 
crosslinker CD signals (data not shown). This property might allow estimation of a helical 
content of crosslinked peptides in conditions that are not conducive for other techniques of 
structure determination. 
 
Figure 65: CD spectra of bRevi, i+7-XL-SO3H (A, B) and bRevi, i+11-XL-SO3H (C, D). The green line corresponds to the 
UV irradiated peptide and red to dark adapted. 
2.1.2.3 Transcription and purification of RRE 
 RRE IIB sequence was synthesised using the Superscript kit (Ambion) according to 
manufacturer’s specifications. Briefly, RNA polymerase and the four nucleotides are mixed 
together with the DNA template strand and the enzymatic synthesis is allowed to proceed at 
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37 °C. For the purpose of radioactive labelling of RRE RNA in vitro transcription mixture 
was supplemented with α-32P-UTP. The following DNA sequence was used for the 
transcription: 
5’AATTTAATACGACTCACTATAGGGTCTGGGCGCAGCGCAAGCTGACGGTAC
AGGCC-3’ (sense strand, coding strand, RRE sequence in bold font) and 5’-
GGCCTGTACCGTCAGCTTGCGCTGCGCCCAGACCCTATAGTGAGAGTCGTATTAA
ATT-3’ (antisense strand, template). Before transcription the two complementary strands 
were annealed by heating up to 95 °C and cooling down to 15 °C over 16 h (Material and 
Methods). RRE IIB in vitro transcription gave a single product as determined by denaturing 
PAGE and visualized by exposing a phosphorimager plate followed by scanning with 
Typhoon Gel Imager (Figure 66). The product was refolded by heating up to 95 °C and 
cooling down to 15 °C over 16 h (Material and Methods). 
 
Figure 66: Denaturing-PAGE analysis of RRE in vitro transcription products. 1 and 2 - RRE in vitro transcription 
after 2 and 6 hours; 3 - pTRI-Xef control template transcription product. The black bar indicates the 
postion of RRE. 
 
2.1.2.4 Electrophoretic mobility shift assay (EMSA) of RRE/Rev interaction 
In order to estimate the binding affinities of the bRev peptides an electrophoresis 
mobility shift assay (EMSA) was established. In this experiment 32P labelled RNA is titrated 
with a peptide. Any complexes formed upon binding of the ligand usually have sufficiently 
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different physical properties to migrate with different speed through a polyacrylamide gel as 
compared to free RNA. In this way a ligand concentration dependent binding curve can be 
plotted and a Kd estimated. The densitometric intensity of bands appearing at the RNA-
peptide complex gel position or disappearing at the free RNA position can be used and plotted 
against the concentration of the peptide. Alternatively an upper limit for the Kd can be 
provided based on visual analysis the bands intensities. 
A number of attempts were made to identify conditions suitable for visualizing the 
Rev-RRE interaction; however none showed any shift with either crosslinked or 
uncrosslinked peptides as a titrant. The only case where a shift was visible corresponded to 
the Revwt peptide and the Kd was estimated to be lower than 25 nM (Figure 67), which is in 
good agreement with previous reports.129 The figure below summarizes all results (Figure 68). 
These results were in contrast to the initial findings of Dr Sabine Kneissl, and suggested that 
one of the following might be occurring: the conditions of the gel electrophoresis are not 
suitable for peptides crosslinked with the azobenzene derivative used in this study; presence 
of an additional reactive amino acid (homoserine lactone) interfered with the assay or the 
initial results were misleading and the system requires redesigning. Redesigning could be 
necessary due to suboptimal position of the crosslinker (mutation introducing cysteines), 
interference of the crosslinker with the Rev-RRE or compromised upon clash-relieving 
mutations.   
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Figure 67: EMSA gel scan visualizing the interaction between RRE (constant concentration) and increasing 
concentrations (5, 10, 25, 50, 100, 200, 500, 1000, 2000, 5000 and 10000 nM) of Revwt. The black bars 
indicates the position of free RRE and bound to Revwt. 
        
 
Figure 68: EMSA gel visualizing the interaction between (A) RRE and Revwt or both not crosslinked and crosslinked 
bRevi, i+7 (B and D respectively) and bRevi, i+11 (C and E respectively). Concentration of the RRE is held 
constant and Rev peptides are added at 250 nM concentration. Lanes labelled as 0* contain RRE without 
peptide. 
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2.1.3 Fmoc synthesized Rev peptides 
2.1.3.1 Designing, synthesis and purification of Rev peptides 
 Due to low and variable yields, potential interference from the homoserine cleavage 
artefact and labelling limitations imposed by biosynthesis of peptides it was decided to 
optimize the Fmoc synthesis of Rev peptides. The same basic design as for the biosynthesized 
peptides was retained with two exceptions: peptides did not contain free C-terminal 
carboxylic acid but an amide at C-terminus (Table 3). Additionally Revi, i+4 was not 
synthesised as it was already known that its crosslinking was difficult. Since Rev peptides are 
rich in arginine, their chemical synthesis via Fmoc protocols might be troublesome; sidechain 
protected Fmoc-arginine is bulky and one of the most expensive amino acids.  Initially 
synthesis of Rev peptides failed to provided purifiable mixtures, yielding only a distribution 
of arginine deletion mutants that could be indentified from the complex chromatograms by 
mass spectroscopy. Double coupling of arginines, a well calibrated and perfectly functional 
peptide synthesizer and longer cleavage durations in a large volume of trifluoroacetic acid 
with very fresh scavengers were crucial for success. Fmoc chemistry allowed for easy N-
terminal carboxyfluorescein labelling and opened opportunities for the development of 
sensitive and “real-time” assays for the affinity measurements. 
Peptides were synthesized on a CEM peptide synthesizer on a rink amide resin with 
HBTU as the activator. Coupling temperatures were adjusted from standard 75 °C to 50 °C 
for cysteines and arginines were additionally sidechain protected with acetic acid anhydride 
and double coupled (Material and Methods). After final deprotection the resin bound peptide 
was incubated in 20 ml of the cleavage cocktail (Material and Methods) for 6 h and filtered. 
After evaporation under nitrogen flow cold diethyl ether was added (49 ml) and this 
suspension was incubated at -20 °C overnight the precipitate was recovered by centrifugation, 
dissolved in water (+0.5% TFA) and purified via HPLC techniques (Material and Methods). 
When it was required resin-bound peptides before the final deprotection were labelled with 
fluoresceineamide (FAM). FAM labelling was performed by immersing the resin-bound 
peptide in 1.5 ml of DMF containing 50 mg of FAM, 20 mg of HOBT and 26 µl 
diisopropylcarbodiimide for at least 2 h prior to sidechain deprotection. 
Eventually all six basic uncrosslinked peptides (Revwt, Revi, i+7, Revi, i+11, FAM-Revwt, 
FAM-Revi, i+7, FAM-Revi, i+11) were acquired in relatively high yields and their masses were 
verified by MS techniques (Figure 69–74, Table 7). 
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Figure 69: (A) HPLC chromatogram (red 210 nm, green 280 nm absorption) from the purification of the crude Revwt 
indicated with black arrow. (B) MALDI MS trace of Revwt. 
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Figure 70: (A) HPLC chromatogram (red 210 nm absorption) from the purification of the crude Revi, i+7 indicated 
with black arrow.  (B) MALDI MS trace of Revi, i+7. 
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Figure 71: (A) HPLC chromatogram (red 210 nm absorption) from the purification of the crude Revi, i+11 indicated 
with black arrow.  (B) MALDI MS trace of Revi, i+11. 
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Figure 72: (A) HPLC chromatogram (red 210 nm, green 495 nm absorption) from the purification of the crude FAM-
Revwt indicated with black arrow. (B) MALDI MS trace of FAM-Revwt. 
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Figure 73: (A) HPLC chromatogram (red 210 nm, green 495 nm absorption) from the purification of the crude FAM-
Revi, i+7 indicated with black arrow.  (B) MALDI MS trace of FAM-Revi, i+7 . 
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Figure 74: (A) HPLC chromatogram (red 210 nm, green 495 nm absorption) from the purification of the crude FAM-
Revi, i+11 indicated with black arrow. (B) MALDI MS trace of FAM-Revi, i+11. 
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Figure 75: (A) Structure of azobenzene derived crosslinkers XL-H and XL-SO3H and the interconversion between the 
trans and cis forms. Helical wheel representations of Revi, i+7 (B) and Revi,i+11 (C). Dark grey: cysteine 
residues introduced to allow cross-linking; light grey: residues replaced to avoid steric clash with the 
azobenzene cross-linker.  
Crosslinking with the water soluble azobenzene crosslinker (XL-SO3H) was achieved 
as it was described above and the same precipitation issues as for crosslinking biosynthesized 
Rev peptides was observed. After evaluation of binding affinities and molecular dynamics 
studies on the system were performed by Dr A. Ricci and Dr A. Brancale (vide infra)262 it was 
decided to assess the effect of the less water soluble unsubstituted azobenzene crosslinker 
(XL-H) on peptide structure and affinity (Figure 75). A new, simpler and more efficient 
method of crosslinking was developed relaying on volatile THF rather than the more difficult 
to remove DMSO. Crosslinking with XL-H was accomplished by dissolving peptides at 1 
mg/mL in water/THF mixture (1:1) buffered to pH 8.3 with Tris:HCl (50 mM) containing 
TCEP (2 mM). The same solvent was used to dissolve the XL-H crosslinker  at concentration 
equivalent to a 10× molar excess over the peptide to be crosslinked. A single equivalent was 
added over the course of 2 hours, the remainder was added in further aliqouts over 3 hours of 
the solution volume. If precipitation occurred, additional water/TFA was added. After 
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overnight reaction, solutions were freeze-dried, resuspended in water containing 0.5% TFA, 
spun down and the supernatant was recovered.  Crosslinked and labelled peptides were also 
synthesized bearing both crosslinker and fluorescein. All peptides were purified by HPLC 
techniques and their mass was verified by MALDI mass spectrometry (Figures 76–83, Table 
7). The purity of peptides used in the subsequent FRET binding assay was confirmed by 
HPLC analysis (Figure 84–87). 
 
Figure 76: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of Revi, i+7-XL-SO3H indicated with black arrow. (B) MALDI MS trace of Revi+7-XL-SO3H. 
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Figure 77: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of Revi, i+11-XL-SO3H indicated with black arrow. (B) MALDI MS trace of Revi, i+11-XL-SO3H. 
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Figure 78: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of Revi, i+7-XL-H indicated with black arrow. (B)  MALDI MS trace of Revi, i+7-XL-H. 
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Figure 79: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of Revi, i+11-XL-H indicated with black arrow. (B) MALDI MS trace of Revi, i+11-XL-H. 
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Figure 80: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of FAM-Revi, i+7-XL-SO3H indicated with black arrow. (B) MALDI MS trace of FAM-Revi, i+7-
XL-SO3H. 
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Figure 81: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of FAM-Revi, i+11-XL-SO3H indicated with black arrow  (B) MALDI MS trace of FAM-Revi, 
i+11XL-SO3H. 
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Figure 82: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of FAM-Revi, i+7-XL-H indicated with black arrow. (B)  MALDI MS trace of FAM-Revi, i+7-XL-
H. 
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Figure 83: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of FAM-Revi, i+11-XL-H indicated with black arrow. (B) MALDI MS trace of FAM- Revi, i+11-XL-
H. 
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Peptide  Calculated [M+H]+ 
Observed 
[M+H]+ 
Observed 
[M+2H]2+ 
Revwt 2551.439 2551.31 N/A 
FAM-Revwt 2909.487 2906.86 1454.15 
Revi, i+7 2245.149[a] 2245.05 1123.77 
Revi, i+11 2273.192[a] 2273.02 1137.13 
FAM-Revi, i+7 2603.197[a] 2602.94 1302.05 
FAM-Revi, i+11 2631.239[a] 2631.37 1316.26 
Revi, i+7-XL-SO3H 2697.159 2695.66 1348.66 
Revi, i+7-XL-H 2537.245 2535.97 1269.35 
Revi, i+11-XL-SO3H 2725.201 2724.62 1362.88 
Revi, i+11-XL-H 2565.288 2565.02 1283.12 
FAM-Revi, i+7-XL-SO3H 3055.207 3053.94 N/A 
FAM-Revi, i+7-XL-H 2895.293 2895.42 N/A 
FAM-Revi, i+11-XL-SO3H 3083.249 3082.11 1541.57 
FAM-Revi, i+11-XL-H 2923.336 2922.9 1462.06 
Table 7: Observed and calculated masses of purified Rev peptides; [a] – calculated assuming reduced cysteines 
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Figure 84: Analytical HPLC chromatograms of (A) Revwt and (B) FAM-Revwt; red 210 nm, green – 280 nm 
absorption for A; green- 495 nm absorption for B 
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Figure 85: Analytical HPLC chromatograms of (A) Revi, i+7-XL-SO3H and (B) Revi, i+7-XL-H; red 210 nm, green – 363 
nm absorption. 
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Figure 86: Analytical HPLC chromatogram of (A) Revi, i+11-XL-SO3H and (B) Revi, i+11-XL-H; red 210 nm absorption; 
green – 363 nm absorption. 
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Figure 87: Analytical HPLC chromatograms of (A) FAM-Revi, i+7 and (B) FAM-Revi, i+11; red 210 nm, green 495 nm 
absorption. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 101 
 
 
2.1.3.2 CD and UV 
In order to estimate activation energy and preexponential factors of the cis-trans 
relaxation, rate constants (k) for the cis to trans reversion were measured at different 
temperatures to create Arrhenius plots (Figure 88, 89). Differently to equivalent 
measurements for biosynthesized Rev peptides these were done four in parallel for each point 
and one was excluded. Measuremnts were perfomered on UV-VIS spectrometer by 
monitoring absorbtion at 365 nm as a function of time. The acquired data was fitted to 
Equation 1 to estimate first order relaxation constants (k).   Interesting patterns arise in 
relation to both different spacings (i, i+7 vs. i, i+11) and different crosslinkers (XL-H vs. XL-
SO3H). At 15 °C both for i, i+7 and i, i+11 spacings XL-H peptides relax more quickly with 
half lives of 93 and 50 min respectively versus 299 and 135 min for XL-SO3H (Table 8) 
nearly identical values were reported for biosynthesized bRev-XL-SO3H peptides 217 and 
123 min. It has been reported previously that peptides crosslinked with XL-H relax quicker 
than those with XL-SO3H.161 However, the activation energy values are similar between 
peptides with the same spacing irrespective of the crosslinker; for i, i+7: 88.4 and 93.4 (83.0 
for bRevi, i+7-XL-SO3H); for  i, i+11: 77.6 and 71.5 (78.0 for bRevi, i+11-XL-SO3H). Moreover 
the values of preexponential factors for both biosynthesized (for bRevi, i+7 lnA is 25.6 and for 
bRevi, i+11 lnA is 23.9) and Fmoc synthesized peptides (for bRevi, i+7-XL-SO3H lnA is 27.1 and 
for bRevi, i+11-XL-SO3H lnA is 23.0) are similar and keep the same described here tendencies 
(Table 6 and 8). 
 Fascinatingly, the shorter half lives at 15° C for XL-H peptides are achieved in an 
opposite way for each spacing. In the case of i, i+7 the activation energy is actually higher for 
XL-H, but it is compensated by higher preexponential factor values. For i, i+11 
preexponential factors are lower for XL-H (slower kinetics) however it is compensated by 
lower activation energy.  
 
 
 
Equation 4: Eyring –Polanyi equation; where k is a rate constant; kB is Boltzmann constant; h is Planck constant; ΔHǂ 
is activation enthalpy; ΔSǂ is activation entropy; Ea is an activation energy; R is the gas constant and T is 
temperature. 
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The relation between parameters of Arrhenius equation (equation 1) derived from gas 
collision theory and Eyring–Polanyi equation (equation 5) derived from transition state theory 
is following: preexponential factor values correlate to values of difference in entropy between 
the cis-peptide and the transition state (lnA ~ ΔSǂ) according to equation 6 and activation 
energy to values of difference in enthalpy between the cis-peptide and the transition state (Ea 
~ ΔHǂ) according to equation 7. 
 
 
 
Equation 5: The relationship between activation entropy and preexponential factor 
 
 
 
Equation 6: The relationship between activation enthalpy and activation energy 
 
Higher values of ΔSǂ for i, i+7 could be explained by the increasing disorder of the peptide 
along the relaxation coordinate (vide CD results). The opposite is true for the i, i+11. Lower 
values of entropy reflect the increasing helicity (order) along the relaxation coordinate.  
It is more complex to fully explain the differences in ΔHǂ between the two cysteine 
spacings, because it not trivial to describe the exact geometry and rationalize the enthalpy 
difference between the transitions states of the two spacings. Nevertheless if we assume 
similar enthalpy of the transition state for i, i+7 and i, i+11 the following partial explanation 
can be provided: higher values of ΔHǂ for i, i+7 reflect relatively low enthalpy of the peptide 
in the cis-state. The cis configuration “fits” i, i+7 spacing more, is less strained and therefore 
has lower enthalpy, which in effect increases ΔHǂ (activation energy). Again, opposite is true 
for i, i+11 spacings were more strain is caused in the cis configuration as crosslinked peptides 
with this spacing are designed to be more strained in the cis configuration than trans. Overall 
peptides with i, i+7 spacings relax more slowly than i, i+11 spacings with the respective 
crosslinker. 
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Figure 88: Arrhenius plots of UV363 relaxation after UV363 irradiation for (A) Revi, i+7-XL-SO3H; (B) Revi, i+11-XL-
SO3H ; (C) Revi, i+7-XL-H; (D) Revi, i+11-XL-H. 
 
Peptide Half  Life at  15 °C [min] 
Activation 
Energy [kJ/mol] lnA 
Revi, i+7-XL-SO3H 299 ±98.3 88.4±1.70 27.1±0.71 
Revi, i+7-XL-H 93 ±16.9 93.4±4.90 30.0±1.94 
Revi, i+11-XL-SO3H 135 ±5.4 77.6±2.42 23.0±0.98 
Revi, i+11-XL-H 50 ±0.7 71.5±0.46 21.5±0.19 
Table 8: Kinetic parameters of UV363 relaxation after UV363 irradiation for all crosslinked Rev peptides.  
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Figure 89: Absorption spectra (210 – 600 nm) of UV363 relaxation after UV363 irradiation taken at time 0 and then 
every 30 min for total 240 min for (A) Revi, i+7-XL-SO3H; (B) Revi, i+11-XL-SO3H; (C) Revi, i+7-XL-H; (D) 
Revi, i+11-XL-H.  Dark adapted states are shown in black. 
Both peptides with crosslinker XL-H and XL-SO3H confer structural photocontrol, 
exhibiting CD spectra typical of an α-helix with minima at 208 and 222 nm in dark state for 
Revi,i+11XL and Revi,i+7XL after UV irradiation for (Figure 67 and 68). The expected 
reduction in helical character when Rev i, i+11 is irradiated and for Rev i, i+7 in the dark state 
is observed as a decrease in 222 nm signal intensity and a peak shift from 208 nm towards 
202 nm; characteristic of short unstructured peptides. Both the absolute values and relative 
changes of helicity between XL-H and XL-SO3H peptides are almost identical. This similarity 
suggests that both crosslinkers impose similar level of structure photocontrol. Compared to 
parent uncrosslinked peptides attachment of the crosslinker in i, i+7 causes further reduction 
of the α-helical character and irradiation restores the level of helicity present in the parent 
peptide (Figure 67). For the i, i+11 spacing attachment of the crosslinker increases helicity 
considerably and irradiation decreases it almost to the level of the parent uncrosslinked 
peptide. 
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Interestingly, for both crosslinkers and cysteine spacings, both relative and absolute 
helicity is somewhat higher for the Fmoc synthesized peptides compared to the 
biosynthesized ones (Figure 65 vs. 90). This suggests that either homoserine has a negative 
impact on the helical character of Rev peptides or that the C-terminal amide has a helix 
stabilising effect on Fmoc synthesized Rev peptides. As for the biosynthesized crosslinked 
peptides, CD signals corresponding to the crosslinker are visible and follow the same pattern 
of response to irradiation for Revi, i+11 XL with the sole exception that 265 nm signal is not 
visible for  Revi, i+11 XL-H (Figure 65, 90, 91). However for Revi, i+7 XL-H the dark adapted 
state exhibits almost an exactly inverse CD signal for the crosslinker compared to irradiated 
state (Figure 91). This hints that although the peptide bond transitions CD regions are 
approximately identical the peptide might adopt very different conformations depending on 
the nature of the substituent present on the azobenzene croslinker as judged by the reversal of 
the 265, 360 and 440 nm CD signals present only when XL-H is used rather than XL-SO3H. It 
is important to note that CD measures the average helical content, and may result from an 
equilibrium distribution of helical and non- or less-helical conformation, or peptide that is part 
strongly and constantly helical but, for instance, has disordered C and N-termini. For 
uncrosslinked peptides CD signals were only observed in the peptide bond region, the 
attached fluorescein is generally CD silent (Figure 90) except for FAM-Revi, i +11 where a 
small minimum around 510 nm and FAM-Revwt where an even smaller maximum around 500 
nm are present (Figure 90); this feature of these two CD spectra might suggest that 
fluorescein might interact with these peptides. 
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Figure 90: CD spectroscopy results, dark adapted (dark red) and after 3 min of UV363 irradiation (yellow-green) for 
Revi, i+7-XL-SO3H (A and B); Revi, i+11-XL-SO3H (C and D). Collection of CD plots for peptides not 
containing a crosslinker (E and F), Revwt (dark red); FAM-Revwt (yellow-green); FAM-Revi, i+7 (orange); 
FAM-Revi, i+11 (blue). 
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Figure 91: CD spectroscopy results, dark adapted (dark red) and after 3 min of UV363 irradiation (yellow-green) for 
Revi, i+11-XL-H (A and B); Revi, i+11-XL-H (C and D). 
2.1.3.3 Rev/RRE FRET binding studies 
A FRET binding assay was developed in order to measure the binding affinities 
between Rev peptides and RRE RNA. Peptides were labelled with fluorescein at their N-
terminus and Cy3 labelled RRE was titrated in. The emission wavelength of the fluorescein 
matches the excitation wavelength of Cy3, so a decrease in fluorescein signal is observed as 
the increasing concentration of Cy3-RRE results in binding and intermolecular resonance 
energy transfer rather than fluorescence takes place. At first a direct binding assay was tested 
using doubly modified Rev peptides (crosslinker + FAM), unfortunately such peptides were 
poorly soluble and tended to form aggregates and precipitate. Interestingly, although they 
were soluble during the purification conditions, once freeze-dried they could not be 
redissolved in the same conditions. This suggests either an irreversible aggregation or very 
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slow redissolution process. This type of behaviour has been observed previously for some 
peptides (T. Fricke, personal communication) containing an octaarginine sequence. Also, a 
direct interaction with FAM and an anzobenzene crosslinker has been reported previously. 
Intra or intermolecular interactions between negatively charged crosslinker or fluorescein 
moieties and positively charged arginine sidechains or aromatic stacking between fluorescein 
and the crosslinker may cause such behaviour. Therefore an indirect, displacement assay was 
developed whereby FAM-Revwt bound to Cy3-RRE was titrated with crosslinked peptides 
without a fluorescent dye and the recovery of fluorescein signal as the wild type peptide was 
displaced from a complex with RRE RNA was observed. 
Initial results indicated that the modifications introduced to allow the attachment of a 
crosslinker had a deleterious effect on the affinity of fluorescently-labelled Revi,i+7 and 
Revi,i+11 peptides to RRE RNA compared to the wild type sequence (Figure 92; Table 9). 
Additionally, mutation of Arg 38 (Revi, i+7 and Revi, i+11), Arg 41 (Revi, i+11) and Arg 42 (Revi, 
i+7 and Revi, i+11) to Ala also might have decreased the affinity. The CD spectra of all three 
peptides are similar suggesting that the helical content does not determine their affinity. 
Indeed, Revwt appeared to have the least helical character but was the best binder. 
A saturable increase in fluorescence was observed when Revwt was released from the 
complex and a dissociation constant of 247 ± 19 nM could be estimated for the RRE complex 
of Revi,i+11-XL-SO3H from the apparent IC50, which was only a modest increase over the 
uncrosslinked peptide (Table 9 and 10). Revi,i+11-XL-SO3H responds to irradiation and the 
affinity drops to 418 ± 28 nM. This change directly correlates to the decrese of an α-helical 
character as judged by CD spectroscopy. No RRE binding was observed for Revi,i+7-XL-
SO3H in either the dark or the irradiated state for concentrations of up to 1 µM (Figure 92). 
Simple inspection of superpositions of Revi,i+11-XL-SO3H and Revwt with the published 
structure of the RRE complex did not suggest any obvious steric reasons for the low binding 
affinity. Also, literature precedent contains several bulkier custom peptides that have 
relatively good affinities to RRE; the Rev binding epitope transplanted to zinc finger protein 
had Kd of 330 ± 40 nM (vs. 330 ± 20 nM for the wild type under the assay conditions) and β 
sheet peptide 2 nM.94,102 Additonaly, electrostatic repulsion between the crosslinked peptides 
and the negatively charged phosphate backbone seemed at first a likely cause for the low 
binding affinities of Revi,i+11-XL-SO3H and Revi,i+7-XL-SO3H but inspection of the overlaid 
structures suggested that distances between sulfonates and phosphate groups were too grate 
for a significant charge-charge repulsion. There could have been a more subtle effect at play 
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and to investigate this aspect, we performed a series of molecular dynamics (MD) studies of 
Revi, i+11 peptides crosslinked with both XL-H and XL-SO3H bound to RRE structures. MD 
trajectories revealed that the sulfonate groups perturbed the α-helical structure of Revi,i+11-
XL-SO3H. Further details on this subject are provided at 2.1.3.4 Molecular dynamics 
simulation of Revi, i+11-XL-SO3H and Revi, i+11-XL-H. 
The non-sulfonated crosslinker (XL-H) produced peptides with substantially improved 
affinities; Revi,i+11-XL-H showed improved affinity for RRE with a Kd of 24 ± 9 nM (Table 
10), approximately one order of magnitude lower than the dissociation constant measured for 
non-alkylated Revi,i+11 (Kd = 854 ± 40 nM) (Table 10). After irradiation with 363 nm light, the 
affinity decreased to 66 ±17 nM (Table 10). This threefold change in apparent affinity was in 
agreement with the observed change in the CD signal of Revi,i+11-XL-H (Figure 91) and with 
the low photo-conversion of only approximately 50% (Figure 89). A Kd of 1029 ± 65 nM 
could now be measured for Revi,i+7-XL-H (Table 2), while light-activated Revi,i+7-XL-H RRE 
complex showed a Kd of 607 ± 39 nM.  
The absolute and relative affinities for peptides crosslinked with XL-H follow the 
trends expected from the degree of helicity present in their CD spectra, but whilst peptides 
crosslinked with XL-SO3H demonstrate the expected relative affinities, they have poor 
absolute binding affinities compared to molecules incorporating XL-H. Such reductions in 
binding affinity when using XL-SO3H would explain the results of EMSA studies performed 
on biosynthesized Rev peptides. Since the biosynthesized Rev peptides showed even lower 
helicity, the use of the XL-SO3H and possibly the conditions used during electrophoresis 
disfavoured binding, reducing the affinity of the biosynthesized Rev peptides. Tellingly, the 
average helical content as judged by the CD is almost identical between peptides crosslinked 
with XL-SO3H and XL-H, refuting previous assumptions that the major determinant of the 
success in this type of designs is high helicity of the Rev prior to binding. 
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Figure 92: FAM Rev wt displacement plots, dark adapted (dark red) and after 3 min of UV363 irradiation (yellow-
green) for (A) Rev i, i+7 XL-SO3H; (B) Rev i, i+11 XL-SO3H; (C) Rev i, i+7 XL-H; (D) Rev i, i+11XL-H.  (E) Direct 
binding curves for FAM-Revwt (yellow-green); FAM-Rev i, i+7 (green); FAM-Rev i, i+11 (dark-red). 
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Peptide         Kd 
FAM-Revwt 5.8  ± 1.3 nM 
FAM-Revi+7 561 ± 112 nM 
FAM-Revi+11 424 ± 128 nM 
Table 9: Binding affinities of the FAM labelled Rev peptides 
 
 
 
Peptide Kd 
Revi, i+7-XL-SO3H NB 
Revi, i+7-XL-SO3H UV NB 
Revi, i+11-XL-SO3H 247 ± 19 nM 
Revi, i+11-XL-SO3H UV 418 ± 23 nM 
Revi, i+7-XL-H 1029 ± 65 nM 
Revi, i+7-XL-H UV 607 ± 39 nM 
Revi, i+11-XL-H 24 ± 9 nM 
Revi, i+11-XL-H UV 66 ± 17 nM 
Table 10: Binding affinities estimated form the FRET displacement assay for Rev peptides crosslinked with XL-SO3H 
and XL-H, in dark and after UV363 irradiation (UV). NB signifies No Binding. 
2.1.3.4 Molecular dynamics simulation of Revi, i+11-XL-SO3H and  
Revi, i+11-XL-H 
 To fully explore the system Quantum mechanics (QM) calculations and molecular 
dynamics (MD) studies were performed in collaboration with Dr Andrea Brancale and Dr 
Antonio Ricci.262 It was decided to consider all four possible crosslinker conformations 
obtainable from peptides incorporating XL-SO3H (Figure 94). The azobenzene functionality 
has been extensively studied; particularly its cis-trans isomerisation and the dihedral angle 
formed between the two nitrogens of the azo group and the two ipso carbons of the aromatic 
moiety (Figure 93). In gas phase, it has been shown that these angles oscillate between two 
minima at ± 19° with a low-energy (0.3 kcal/mol) planar transition state.263 Other studies145 
have described its conformation as planar, with a D2h point group symmetry. Since our focus 
was on any change in geometry caused by the two sulfonate groups, we used HF/6-31G* and 
B3LYP/6-31+G** levels of theory to perform calculations rather than the more accurate 
MP2/6-31+G*. In particular, the choice of the HF/6-31G* basis set was made according to 
the requirements of the RESP and ESP charge derive (R.E.D.) software for deriving restrained 
electrostatic potential (RESP) charge values.264 Minimum energy conformations were 
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obtained for both anti and syn isomers and their vibrational analyses (Figure 93, Table 10) 
were checked for consistency. Both levels of theory described the anti-disubstituted 
azobenzene as the preferred conformation over the syn. The planarity of the system was not 
perturbed by the sulfonate substituents, allowing to use the plain azobenzene parameters as 
reasonable approximation in the molecular dynamics (MD) experiments. R.E.D. software was 
used to derive RESP charges for the crosslinkers to model their properties in the MD set-up.  
 
Figure 93: Geometries of the two isomers obtained from B3LYP/6-31+G* QM calculations. Anti conformation of XL-
SO3H (A); syn conformation of XL-SO3H (B). 
 HF/6-31G* B3LYP/6-31+G** 
 A[b] B[b] A[b] B[b] 
ΔG (Kcal/mol)a 0.00 3.90 0.00 4.19 
Bond (Å)     
C-N 1.42 1.42 1.45 1.42 
N-N 1.22 1.22 1.23 1.22 
Angle (Degrees)     
C2-C3-N1 115 115.5 114 115 
C1-C3-N1 125 124.5 125 124 
Dihedral 
(Degrees)     
C1-C3-N1-N2 180 174.5 179.5 174.5 
C3-N1-N2-C4 180 179.5 179.9 179.5 
Table 11: Relative Free Energy and selected geometrical parameters measures; [a] ΔG = Electronic and Nuclear 
Repulsion Energy + Zero Point Energy; [b] same nomenclature as Figure 93 
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The parameterization of the linker was achieved with the AmberTools package, using the 
General AMBER force field (GAFF).265,266 Finally, the parameters obtained were added to the 
AMBER99 force-field in the GROMACS 4.5 package. To assure planarity of the azobenzene 
system, a further improper harmonic potential was added to the C-N-N-C and C-C-N-N 
dihedral. The value chosen for the force constant was calibrated to allow the C-C-N-N 
dihedral to oscillate between an angle of ±30° with a minimum energy value corresponding to 
the planar conformation (Table 11), in accordance with the experimental results.267,268 
MD experiments were set up with the molecules to be studied were placed into a cubic 
TIP3P water box (with a 1.0 nm distance for the periodic boundary condition), neutralized 
with Cl- or Na+ ions and minimized according to the steepest descent algorithm. A 100 ps 
thermal equilibration (v-rescaling thermostat) followed by a 200 ps pressure equilibration 
(Berendsen rescaling algorithm) was initially performed keeping the positions of the heavy 
atoms fixed. Following short simulations, the positional restraint constants were gradually 
reduced to homogenize the systems. Finally, 5 ns production simulations were recorded for all 
the system investigated. The snapshots of averaged structures from the simulations of Revi, 
i+11-XL-H and the four conformers of Revi,  i+11-XL-SO3H are pictured in Figure 95. 
These systems were also superimposed upon the non-substituted azobenzene in order 
to measure the deviation from the original linear structure (RMSD of the Cα, Figure 95) and 
the Rev peptide found in the Rev/RRE NMR structure (1ETF). MD simulations were run of 
the Rev/RRE complexes obtained to study the difference in interactions obtained between the 
various sulfonate substituted Rev peptide conformers and the RNA. Figures 96 and 97 allow 
comparison between the four Rev isomers/RRE complexes and the calculated non-substituted 
Rev/RRE structure.  
MD trajectories revealed an interesting result: for Revi i+11-XL-SO3H isomers the 
sulphate groups perturbed the α-helical structure of the isolated peptide, bending it out of a 
regular helix (Figure 94). This behaviour seemed to be caused not only by the steric hindrance 
of the sulfonate moieties, but also by the electrostatic interactions between these groups and 
the positively charged arginine sidechains of the Rev peptide. In some cases the 
intramolecular interaction between an arginine sidechain and the crosslinker sulfonates found 
in the isolated peptides is conserved, suggesting an impaired peptide-RNA binding interaction 
due to the reduced arginine/phosphate interactions. Moreover, the non-linear structure 
adopted by the substituted Rev peptide changes the morphology of the interaction RRE site, 
suggesting dynamic topological changes between the two interacting systems is at least partly 
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responsible for the different affinities. Taken together, these factors suggest a possible 
explanation for the different dissociation constants found as an ensemble of different 
contributions: i) intramolecular electrostatic attraction between arginine and sulfonate groups 
distorting the peptide before binding; ii) intermolecular electrostatic repulsion between 
sulfonate and phosphate groups on the RRE disfavouring binding and iii) distortion of the 
linearity of the α-helical secondary structure once bound (Figure 95 vs. 96). 
 
 
 
Figure 94: MD snapshots of (A) Revi+11 XL-H and all the 4 possible Revi+11 XL-SO3H isomers (B – E) with the 
backbone RMDS of the respective MD simulations (all frames) from MD simulations (all frames) of Revi, 
i+11-XL-H is show below each isomer. Crosslinkers are in red; all arginine sidechains in Revi+11 XL-H, and 
those interacting with sulfonates of XL-SO3H in Revi, i+11-XL-SO3H are in blue. 
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Figure 95: MD snapshot of the Revi, i+11 XL–H/RRE complex 
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Figure 96: MD snapshots of the four different (A-D) Revi, i+11 XL-SO3H/RRE complexes. Please note the 
intramolecular electrostatic interaction between the arginine and the sulfonate groups and the 
distortion of the binding site compared to Figure 71. 
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2.1.4 Conclusions 
Peptides derived from the arginine rich region of Rev protein were both 
biosynthesized using the E. coli system and chemicly synthesized utilizing Fmoc chemistry. 
Optimized Fmoc synthesis allows production of higher amounts of Rev peptides and removes 
the possibility of C-terminal homoserine or homeserine lactone interference. Although the 
same biosynthetic approch was used earlier to produce  Bak derived peptides in high 
quantities and double tandem oligonucleotides repeats was reported to be incorporated into 
the KSI plasmid (pET-31b) with ease it is not the case for Rev derived peptides.261 The KSI 
system is difficult to optimize for this particular sequence and is not an efficient source of 
these peptides but at the same time it proved to be good source of poly-arginine peptides 
(Thomas Fricke personal communication)269. In general, therefore, it seems that the pET-31b 
expression system is not of general use and some careful consideration needs to be taken into 
account before utilising it for untried sequences. 
It appears that although thorough biophysical characterization of the XL-SO3H 
crosslinked biosynthesized peptides was performed and CD-derived structural features 
suggested a well designed system for further affinity studies, no binding to the RRE was 
detected. This problem was traced later to the crosslinker (XL-SO3H) but this could not fully 
explain the lack of binding in the experimental set-up for the biosynthesized Rev derived 
peptides (EMSA). 
The XL-SO3H crosslinked Rev (Fmoc synthesized) had surprisingly low affinity to 
RRE. MD simulations performed on the Revs crosslinked with XL-H or XL-SO3H both free 
and in complex with RRE provided a strong suggestion about the cause of this behaviour. 
Results of these simulations pointed unexpectedly not to charge-charge repulsion between 
phosphate backbone and sulphonates or steric hindrance, but to intramolecular interaction 
between the sulphonates and arginines. Strain imposed by those interactions translates into a 
bent conformation of the peptide, which together with the nonavailabality of intermolcularly 
interacting arginines to engage phosphate backbone is the most likely reason for the very low 
affinities. Those in silico findings were confirmed by crosslinking peptides with XL-H which, 
despite having virtually identical CD spectra, bind at least an order of magnitude more tightly. 
Previous reports suggest that a high helical content is the principal requirement for the 
construction of high affinity Rev peptides. However, our system illustrates that the obtained 
CD spectra, typical of a high degree of helicity, may not indicate an ideally preorganised 
conformation for tight binding and a relatively minor change in the substitution of the 
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crosslinker was observed to effect in a dramatic change in the affinity. An implication of this 
is the possibility that various sequences of peptides might interact with the crosslinker. 
Depending on the nature of the crosslinker and the given sequence those interactions might 
have various natures and are not necessarily limited to electrostatic interactions. 
The biophotonic peptides derived from Rev targeting the HIV type 1 Rev Response 
Element  present a first peptide/RNA system,  whose stability can be tuned with light. The 
pitfalls of designing such systems have been clearly demonstrated and helpfully directed by 
computational studies. Although this research will serve as a base for future studies of 
photoswitchable peptides targeting RNA thorough computational evaluation of the next 
generations of biophotonic peptides designs (not only targeting RNA) is highly 
recommended.  
The high binding affinities and relatively long-lived photoswitched conformations of 
the XL-H crosslinked peptides suggest that they can serve as useful probes and modulators of 
protein RNA interactions both in vitro and in vivo as part of a rapidly expanding toolbox of 
photo-controllable peptides. 
A number of caveats need to be noted regarding the present study. Most importantly a 
rather limited Rev derived peptides sequence space has been explored which was a 
consequence of the aims of this study; it was intended to establish a prove-of-principle 
peptide photoswitch binding to RNA rather than rigorous optimization of the sequence. 
Moreover, not a full scope of available azobenzene crosslinkers was explored. Lastly, 
although the computational studies provide a probable model of photoswitchable Rev 
peptides in complex with RRE and generate interesting hypothesises, can not replace NMR of 
X-ray derived structural models. 
A future study investigating structures of the photoswitchable peptides bound to RRE 
would be very interesting. NMR techniques derived structures could provide necessary details 
of the interactions. The issue of the distribution of four Revi+11 XL-SO3H isomers (free and in 
complex RRE bound) is an intriguing one which could be explored in further research. A 
reasonable approach to tackle this issue could be to use Carr-Purcell-Meiboom-Gill (CPMG) 
relaxation-dispersion methods of NMR spectroscopy. This would also allow to kinetically 
characterise the transition between all four isomers. 
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2.2 Solution structure of Bcl-xL 
2.2.1 Aims and Objectives 
 The aim of this study was to solve the NMR structure of Bcl-xL protein in 
collaboration with Mathew Crump (University of Bristol). Whilst  the structure of Bcl-xL has 
previously been solved by both NMR and X-ray, it was important to provide a directly 
comparable model to the studies of the Bcl-xL/BakI81Fi, i+11-XL-SO3H that followed and has 
the potential to guide the more intricate problem of solving a solution structure of a protein-
peptide complex. 2D and 3D NMR spectra were acquired with the aim of achieving high 
quality structure. The previously published NMR structure is of a low quality and it was 
important to provide an independent refinement of this vital structure.  
2.2.2 Biosynthesis, purification and NMR sample preparation of Bcl-xL 
A loop and C-terminally truncated Bcl-xL mutant (1-209 Δ45-84, Δ210-233) was used 
for the structural studies. These modifications have been shown not to disrupt the protein’s 
activity in vivo or affinity to BH3 peptides in vitro and they were necessary for the 
preparation of high concentration samples for NMR studies.248 Bcl-xL was expressed in E. 
coli with a C-terminal His-tag that allowed straightforward affinity chromatography via 
NiNTA-sepharose to be applied. The protein was purified in one step to high homogeneity, 
dialysed into NMR sample buffer and concentrated to 1.2-1.5 mM (Figure 93, Materials and 
Methods). 
 
Figure 97: SDS-PAGE purification profile. PM – protein marker; 1 – cell culture sample prior to IPTG induction and 
1 – five hours after; S – supernatant from cell debris separation; FT – flow through; A, B, C, D (1, 2, 3) 
fraction from NiNTA/Histag chromatography (A 100 mM, B 150 mM, C 200 mM, D 500 mM imidazole). 
The black bar indicates the postion of Bcl-xL. 
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2.2.3 NMR spectra acquisition 
Initial data were acquired on 600 MHz Varian Inova NMR spectrometer equipped 
with a room temperature probe. At the beginning of each set of NMR acquisitions an 1H-15N 
HSQC was taken as a reference point. It was followed by HNCA, HNCACB, HN(CO)CACB, 
HN(CO)CA, HNCO and HN(CA)CO experiments which allowed the backbone chemical shift 
assignments. Sidechain assignments were facilitated by C(CO)NH, HCC(CO)NH, HCCH-
TOCSY, 13C-HSQC spectra and in more difficult cases were aided by 13C/15N 3D separated 
NOESY. Inter-proton NOE signals were identified with the help of 13C/15N 3D separated 
NOESY. On two occasions additional 1H-15N HSQC spectra were recorded was taken to 
ensure that protein was unaffected by prolonged storage at 25 ºC. 
2.2.4 NMR spectra assignment 
 Most of the Bcl-xL 1H-15N HSQC signals arising from backbone or sidechain amides 
and tryptophan indole NH protons and were well separated suggesting a largely folded 
protein.270 This is especially true for the tryptophan indole chains, predominantly localized in 
the hydrophobic core, which were spread across a wide chemical shift area; often a signature 
of a tightly packed, well formed protein interior. However some more central areas of the 1H-
15N HSQC showed a significant signal overlap, suggesting a presence of flexible protein areas 
and posing difficulties in determining an unambiguous assignment.270  
Ultimately, 96.4% of backbone amides signals were indentified. The only residues 
which did not have an identifiable related peak in 1H-15N HSQC spectrum were Met 1, Gln 3 
and Arg 103, His 113, Gly 117, Ala 119 and Phe 123. The first pair correspond to the N-
terminus, which often is flexible and the first methionine in E. coli can undergo a variety of 
modifications, further increasing heterogeneity.271,272 It is also possible that the Met 1 is not 
present at all, as it often occurs in proteins biosynthesised in prokaryotic expression system. 
The second group are related to the BH3 domain binding site and most likely their poorly 
defined resonances represent its flexibility. A few residues could be assigned to more than 
one, or to a much broadened peak in the 1H-15N HSQC. Those are residues in the C-terminal 
part (Asn 197, Ala 199, Asn 207, Glu 208), which is known to be flexible and these residues 
probing a larger conformational space with what seems to be a few distinct minima.248 
Sidechain assignments reflected the difficulties in backbone assignments and had to be 
heavily aided by 13C/15N 3D separated NOESY in less well defined areas. Especially difficult 
were the inherently flexible parts of the protein between residues Asn 20 and Ser 43. 
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Although the signals associated with those residues were strong, unfortunately the overlap in 
proton-proton space was high. Fortunately, this loop is an artefact of the truncation of an even 
larger loop and both are expected to be unstructured.248 Eventually 84.7% of carbon, 92.1% 
nitrogen and 77.5% of proton resonances were indentified. Interproton NOEs were manually 
extracted from 13C/15N 3D separated NOESY. Ambiguous peaks were deliberately left 
unassigned to be taken care of by Aria 2.3 algorithms.273   
Atom type % Assigned  
Carbon 84.7 
Nitrogen 92.1 
Proton 77.5 
Table 12: Assignment completeness for free Bcl-xL; histidines from the C-terminal HisTag are excluded from the 
calculation 
2.2.5 Bcl-xL Structure Calculation 
 Interproton NOEs from 13C/15N 3D separated NOESY were used to calculate distance 
restraints by automatic Aria 2.3 protocols.273,274 Those calculations were corrected for spin 
diffusion and log harmonic distance potential restraints were used in simulated annealing with 
CNS 1.21 as the structure calculation engine followed by structure refinement calculations 
using a thin shell of water.275-277 Initial structures were used to correct misassigned NOEs by 
analysing those rejected or violated by Aria. In the final protocol 500 structures were 
calculated in the last iteration, 20 were water refined. These 20 structures were overlaid, 
coordinates averaged and the resulting structure underwent a brief energy minimazation to 
relieve clashes (CNS default protocols). Unless otherwise stated the comparisons or protein 
visualizations featuring a single structure are based on this average and energy minimazed 
structure. 
2.2.6 Final Bcl-xL structure ensemble 
 Calculations led to a structure ensemble with low RMSD values: 0.46 Å for backbone 
heavy atoms and 0.89 Å for all heavy atoms (Figure 98). Virtually all quality statistics surpass 
those of previously published Bcl-xL NMR structures (Figure 99, Table 13 and 18). 
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Figure 98: NMR ensemble of the Bcl-xL. HisTag has been removed for clarity 
 
Figure 99: Ramachandran plot of the final water refined NMR ensemble of Bcl-xL (residues 3 to 19 and 44 to 196 of 
Bcl-xL and 72 to 87 of BakI81Fi, i+11-XL-SO3H). Allowed region (red), additionally allowed regions (yellow) 
and generously allowed regions (pale yellow) are indicated. Glycines are indicated by triangles. 
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Table 13: Bcl-xL NMR structural ensemble validation statistics. BB – backbone; AH – all heavy. 
The RMSD between the published and the structure reported here is 3.67; it is a very 
large difference between structures that are supposed to be very similar.248 On the other hand 
if we compare it to two crystal structures of Bcl-xL the values are 1.80 Å for 1MAZ and 1.75 
Å for 1R2D (Figure 76), i.e. the NMR structure described in this thesis more closely matches 
the high quality X-ray structures.248,278 Nonetheless, there are some differences (the 2 crystal 
structures have RMSD values between each other of 0.65 Å). They cluster mainly around the 
binding sites, which as mentioned previously is flexible and responsive to changes in the local 
Statistic Bcl-xL  
Number of restraints   
Total 3319  
Unambiguous 2758  
Ambiguous 561  
Intra-residue 1084  
Sequential 711  
Short range 470  
Long range 375  
DANGLE   φ /ψ 2x157  
RMSD to restraints   
Bonds (Å) 0.003  
Angles (°) 0.41  
NOE (Å) 0.043  
DANGLE (°) 0.36  
Precision (RMSD to mean, Å)   
BB atoms (A.3-19,A.44-196,B.72-87) 0.46±0.08  
AH atoms (A.3-19,A.44-196,B.72-87) 0.89±0.10  
Ramachandran plot regions (%)   
Most favoured 92.9%  
Additionally allowed 6.8%  
Generously allowed 0.1%  
Disallowed 0.1%  
WHATCHECK Structure Z scores 
 1.853±0.559 
 
First-generation packing quality  
Second-generation packing quality   4.658±1.236  
Ramachandran plot appearance  -2.455±0.350  
χ1/ χ2  rotamer normality  -0.826±0.473  
Backbone conformation   0.194±0.225  
WHATCHECK  RMS Z-scores   
Bond lengths 1.000±0.001  
Bond angles 0.285±0.003  
Omega angle restrains 0.579±0.026  
Side chain planarity 0.486±0.120  
Improper dihedral distribution 0.453±0.082  
Inside/Outside distribution 0.940±0.011  
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environment, and mainly concern helix α3, which appears to be longer in our structure and 
slightly shifted towards α2. Taking into account the very good NMR quality statistics I 
hypothesise that the difference is due to a real structural diversity rather than being an artifact 
of NMR structure solution protocols. Such a change in a binding site known to reshape upon 
binding could be induced by the very high protein concentration essential to acquire NMR 
(molecular crowding) or the scarcity of ions in the NMR buffer, contrasted the rich and 
complex crystallization buffers. Additonaly, altered protein dynamics could contribute to the 
change in the binding site rendition. 
 
 
Figure 100: Comparison between shown here NMR structure of Bcl-xL structure (black) and X-ray structure of the 
same protein (red). PDB entries: 1R2D. 
In contrast to the published NMR structures of Bcl-xL, the one reported herein appears 
with the C-terminal helix α8. Unfortunately, all crystal structures antiapoptotic members of 
the Bcl-2 family are based on deletion mutants deprived of the all residues beyond Gly 196 
(helices α8 and α9) and therefore a direct comparison is not possible. Our NMR Bcl-xL 
structure contains residues from Gly 196 to Arg 209 but not residues from Phe 210 to Lys 
233; this part is predicted to form a transmembrane helix which is postulated to sometimes 
dock into the BH3 peptides binding site. The only structures available that are not truncated at 
equivalent positions are of Bcl-w and in this case helix α8 folds onto the canonical BH3 
binding site (Figure 77).244,245 For the NMR spectra of the structure reported here no, NOEs 
were found suggesting such a conformational state but the Histag and lack of mentioned C-
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terminal sequence most likely precludes the folding of α8 on the rest of the protein as most 
likely it would be predominantly driven by interaction with the BH3 binding site.  
 
Figure 101: Comparison between the Bcl-xL NMR structure and NMR structure of Bcl-w. Helix α8 is indicated in 
both proteins. Please notice the difference in length due to C-terminal truncation. PDB entries: 1O0L 
2.2.7 Conclusions 
 The calculated Bcl-xL NMR structure has very good quality statistics and served as a 
good base for subsequent structural studies of Bcl-xL/BakI81Fi, i+11-XL-SO3H. Using the same 
conditions allows for a direct structural comparison between the two structures and could also 
help in initial spectra assignment of the complexed structure. Moreover, the structure on its 
own is the best solution structure of Bcl-xL determined so far, closely matching those acquired 
by X-ray techniques. The somewhat different binding site organization hints that it not only 
responds by reshaping when binding a BH3 sequence, but also can be influenced by the 
environment in monomeric state. This suggests that perhaps the environment could shape 
affinities for different BH3 peptides as reorganization cost to form differently shaped binding 
sites could be also dissimilar. A further study could assess what is or rather what are the 
structures of the binding site. This research should therefore concentrate on the investigation 
of dynamics of the binding site also in response to mutations as well as in response to binding 
events also away from the binding site. 
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2.3 NMR structural studies of Bcl-xL in complex with BakI81Fi, i+11-
XL-SO3H 
2.3.1 Aims and Objectives 
 The aim of this work was to gain a comprehensive structural description of Bcl-
xL/BakI81Fi,i+11-XL-SO3H using NMR techniques, the first description of an azobenzene 
modified peptide bound to its target. Initial work involved calculation of a backbone amide 
chemical shift perturbation map by comparing 1H-1H HSQCs of free Bcl-xL and in complex 
with BakI81Fi, i+11-XL-SO3H. After acquiring a full set of NMR spectra and assigning them, 
molecular dynamics simulations using NMR-derived restraints were run in order to give the 
structure of Bcl-xL/BakI81Fi, i+11-XL-SO3H. The goal is to understand the similarities and 
differences between Bcl-xL bound to wild type Bak peptide (Bakwt) and BakI81Fi, i+11-XL-
SO3H. 
2.3.2 Biosynthesis, purification and NMR sample preparation of Bcl-
xL/BakI81Fi, i+11-XL-SO3H 
 The protein was biosynthesized and purified in the same way as for the free Bcl-xL 
NMR studies it was then dialyzed into a suitable buffer for NMR acquisition and mixed with 
BakI81Fi, i+11-XL-SO3H at a 1:1.1 ratio and concentrated. In later experiments to acquire 
isotope filtered spectra for BakI81Fi, i+11-XL-SO3H resonance assignments the ratio used was 
either was 1:1.1 or 1:0.5 and the NMR buffer was prepared in oxygen free conditions and 
without β-mercaptoethanol. In order to prepare samples in D2O, an equivalent buffer was 
prepared in D2O (correcting for differences between pH and pD) and exchanged with the 
original protic one over a spin concentrator to a final concentration app. 1 mM. 
2.3.3 Synthesis and purification of Bak derived peptides 
BakI81Fi,i+11, FAM-Baki,i+11, FAM-BakI81Fi,i+11 and FAM-Bakwt were synthesized 
according to standard Fmoc protocols and purified by HPLC techniques (Figure 102 and 103; 
Table 14). All were capped with an amide group at C-terminus and either modified with 
carboxyfluorescein or capped with an acetyl group at the N-terminus. FAM-BakI81Fi,i+11, 
FAM-Baki,i+11 and FAM-Bakwt were provided by Dr Robert Mart. Crosslinking and 
purification of Bak peptides was achieved as it was described previously.162 FAM-BakI81Fi, 
i+11-XL-SO3H, FAM-Baki, i+11-XL-SO3H were provided by Dr Robert Mart. Purity of the 
relevant peptides was confirmed by HPLC techniques (Figures 104-106). 
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Peptide                        Sequence 
Bakwt 	 Ac-72GQVGRQLAIIGDDINR87-NH2	 
Baki, i+11 72	 	 Ac-GCVGRALAAIGDCINR-NH2	 
BakI81Fi, i+11 72	 	 Ac-GCVGRALAAFGDCINR-NH2	 
FAM- Baki, i+11 72FAM-GCVGRALAAIGDCINR-NH2	 
FAM-BakI81Fi, i+11 72FAM-GCVGRALAAFGDCINR-NH2	 
Table 14: Sequences of Bak peptides used in this study. 
 
 
 
 
Figure 102: (A) HPLC chromatogram (red 210 nm, green 280 nm absorption) from the purification of crosslinking 
reaction of crude BakI81Fi, i+11 indicated with black arrow. (B) MALDI MS spectrum of BakI81Fi, i+11. 
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Figure 103: (A) HPLC chromatogram (red 210 nm, green 363 nm absorption) from the purification of crosslinking 
reaction of BakI81Fi, i+11-XL-SO3H indicated with black arrow. (B) MALDI MS spectrum of BakI81Fi, i+11-
XL-SO3H. 
Peptide Observed Calculated 
BakI81Fi, i+11 1663.805  [M+H]+ 1663.17 [M+H]+ 
BakI81Fi, i+11-XL-SO3H 2137.795 [M+Na]+ 2137.38* [M+Na]+ 
Table 15: Observed and calculated masses of purified Bak peptides. 
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Figure 104: Analytical HPLC chromatograms of BakI81Fi, i+11-XL-SO3H; red 210 nm, green 363 nm absorption. 
 
 
 
Figure 105: Analytical HPLC chromatograms of FAM BakI81Fi, i+11-XL-SO3H; red 210 nm, green 363 nm absorption. 
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Figure 106: Analytical HPLC chromatograms of FAM Baki, i+11-XL-SO3H; red 210 nm, green 363 nm absorption. 
2.3.4 Preliminary chemical shift map of Bcl-xL vs. Bcl-xL/BakI81Fi, i+11-XL-
SO3H 
Samples were prepared by Dr Sabine Kneissl in 10 mM sodium phosphate buffer pH 
7.3, 5 mM 2-mercaptoethanol at a 0.3 mM concentration of Bcl-xL (15N labelled) and at 1:1.1 
ratio with Bcl-xL/BakI81Fi, i+11-XL-SO3H were spiked with 5% D2O (v/v). Spectra were 
acquired on a Varian INOVA 600 MHz NMR spectrometer (University of Bristol). The 
analysis of data, provided by Dr Sabine Kneissl, was done in cooperation with Dr Joel 
Loveridge and Dr Sabine Kneissl using Analysis 1.0.15 software.162 Assignment of 1H-15N 
HSQC spectrum of Bcl-xL in complex with BakI81Fi, i+11-XL-SO3H was accomplished by 
comparing peak positions with known assignments for Bcl-xL complexed with Bad, a 25 
residue peptide derived from, a BH3 domain of the pro-apoptotic protein, which is known to 
bind in the same place as Bakwt.249 
The 1H-15N HSQC spectrum of Bcl-xL in complex with Bakwt exhibits a high degree of 
similarity with the 1H-15N HSQC spectrum of Bcl-xL in complex with Bad or Bakwt.249,279 
Assignments were confirmed using the 15N-edited TOCSY-HSQC. The difference in peak 
positions between 1H-15N HSQC spectra of the Bcl-xL and its complex with BakI81Fi, i+11-XL-
SO3H was defined as the length of a vector (Ω) connecting the centres of the corresponding 
peaks, calculated after weighting the differences between the 1H and 15N ppm dimensions 
(Equation 7, Figure 107). 
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Equation 7: Equation use to calculate chemical shift perturbation  
Residues were defined as having a significant shift if Ω/Ωmax > 0.15 (Ωmax =0.938 for Phe 
131). 
 
Figure 107: 1H-15N HSQC of free Bcl-xL (gray) and a complex of Bcl-xL with BakI81Fi, i+11-XL-SO3H (red). The 
equation used to calculate the chemical shift perturbation Ω (upper right corner). Arrow indicates the 
change in Gln 94 peak position as an example. 
It can be seen that the residues that show the highest values of Ω/Ωmax cluster around 
the binding sites (helices alpha α2, α3, α4) with the highest values of Ω/Ωmax (> 0.5) 
exhibited by residues Phe 97, Leu 99, Phe 105, Thr 109, Phe 131, Asp 133, Phe 146 (Figure 
108 and 109). All of those residues are in the close proximity to the Bakwt in the solution 
structure of its complex with Bcl-xL, but none of them are recognized as directly important for 
binding.247 It seems that the highest chemical shift perturbations are assosiated with residues 
that comprise the most mobile elements of the Bcl-xL, areas that are known to significantly 
change position upon binding. It must be bourne in mind that values of chemical shift are 
directly related to the enviroment probed by the given nucleus, and in some cases nearby 
residues might be changed yet still be in a very similar type of enviroment giving 
misleadingly low values of Ω/Ωmax. Thus, it is possible that a partially buried residue becomes 
more solvent exposed during binding even as the binding site undergoes reshaping to 
accommodate a ligand yet in the final state/structure of the complex this residue packs agains 
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the peptide ligand and shows little change in the shift. This chemical shift perturabation 
mapping provides a strong evidence that BakI81Fi, i+11-XL-SO3H adopts the same binding 
mode as the Bakwt. This in turn suggests that the crosslinker, as intended, only influences the 
structure of the peptide, not the way it binds to the target. 
 
Figure 108: Backbone amide chemical shift perturbation map of free Bcl-xL vs. Bcl-xL in complex with BakI81Fi, i+11-
XL-SO3H; red colour indicates residues that have values of Ω/Ω max higher then 0.15. 
 
Figure 109: Chemical shift perturbation map from figure 108 transferred onto structure of Bcl-xL in complex with 
Bakwt. 
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2.3.5 Refined chemical shift map of Bcl-xL vs. Bcl-xL/BakI81Fi, i+11-XL-SO3H 
 Using the NMR assignments of the Bcl-xL (see Appendix) and Bcl-xL/BakI81Fi, i+11-XL-
SO3H (see Appendix) acquired during the structure solving process a more refined chemical 
shift map has been calculated. It benefitted from using a more comprehensive set of NMR 
spectra that allowed to unequivocally determine the 1H and 15N resonances of the backbone 
amide for Bcl-xL/BakI81Fi, i+11-XL-SO3H and verify or correct some of the already published 
assignments for the free Bcl-xL. The refined map confirmed with much higher greater 
accuracy that the crosslinked peptide adopts the same binding mode as the wild type (Figure 
110 and 11). The significant shift differences clustered predominantly at the canonical BH3 
binding grove located between helices α3 and α4. Some minor changes were also visible in 
the regions adjacent to structural elements that are known to reshape upon binding. Most 
importantly the residue with the highest Ω value is different, 1.185 for Leu 108 as opposed to 
0.938 for Phe 131 in the previous map.162 Moreover the overall characteristics of the chemical 
shift perturbation graph (see Figure 86) are different. Relatively similar values of Ω/Ωmax tend 
to cluster as opposed to the jagged plot in the previous case. The average value of Ω/Ωmax is 
higher: 0.172 vs. 0.159 even though the data was normalized to slightly higher value of Ωmax 
in the former case; suggesting that previously a number of assignments had been made based 
on imperfect assumption of proximity to either free Bcl-xL peaks or in complex with Bad on 
1H-15N HSQC spectra. The set of residues with the highest values of Ω/Ωmax (> 0.5) is also 
somewhat different and does not include Phe 91 despite it previously defining Ωmax.  
The per residue RMSD values between free Bcl-xL and Bcl-xL/Bakwt or Bcl-
xL/BakI81Fi, i+11-XL-SO3H excluding the unstructured regions of the long loop region (Lys 19 
to Glu 44) and flexible C-terminus (from Gly 196) onwards correlate very well to the 
chemical shift perturbation map (vide infra). This again suggests that this technique is better 
suited to recognize the mobile elements of a binding interaction than residues more directly 
engaged in this interaction. 
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Figure 110: Refined backbone amide chemical shift perturbation map of free Bcl-xL vs. Bcl-xL in complex with 
BakI81Fi, i+11-XL-SO3H; red colour indicates residues that have values of Ω/Ωmax higher then 0.15. 
 
 
 
Figure 111: Chemical shift perturbation map from Figure 110 transferred onto structure of Bcl-xL in complex with 
BakI81Fi, i+11-XL-SO3H 
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2.3.6 NMR spectra acquisition 
The first data set was acquired on 600 MHz Varian Inova NMR spectrometer 
equipped with a room temperature probe (University of Bristol). It included all spectra 
necessary for the backbone, sidechain and NOEs assignments (for the protein: 1H-15N HSQC, 
HNCA, HNCACB, HN(CO)CACB, HN(CO)CA, HNCO, CC(CO)NH, HCC(CO)NH, 
HCCH-TOCSY, 13C HSQC, 13C/15N 3D separated NOESY; for the peptide: 13C, 15N F1, F2 
filtered 1H-1H NOESY, 13C, 15N F1, F2 filtered 1H-1H TOCSY and F2 filtered 1H-1H 
NOESY.280 However, it soon became apparent that the signal-to-noise ratio was insufficient 
for complete backbone and sidechain assignments, despite the methodology employed for 
data acquisition being the same as used for Bcl-xL (apart from the additional filtered 
experiments). The reasons for this were traced to the different physical properties of the Bcl-
xL/BakI81Fi, i+11-XL-SO3H complex, which is more prone to aggregation and therefore has a 
lower maximum attainable concentration; precipitation also shortens the useful life of the 
NMR sample. Most likely the conformational rearrangement induced by binding of the 
peptide makes Bcl-xL more prone to domain swapping or similar higher order oligomer 
formation, a situation especially pronounced at the high concentration necessary for the NMR 
sample preparation. Such domain swapping has been observed before for some members of 
the Bcl-2 family and seems to be a hallmark of this group of proteins.256,257  Therefore whilst 
these proteins are roughly spherical and middle-sized, solving their structures is far from 
routine due to these physical characteristics. Additionally, the presence of the crosslinker 
itself might influence the stability of the protein. Although any oligomers formed would 
tumble much more slowly in the solution, causing their NMR signal to be much weaker and 
broader and therefore either not visible or easily indistinguishable from the signal arising 
from the monomer of the complex it was decided to limit the time span for each data set 
acquired on every sample and instead prepare multiple fresh samples as often as necessary in 
order to avoid collecting data on possibly altered states of the protein complex. 
 In order to address the low signal-to-noise ratio problem, subsequent sets of NMR 
acquisition was performed on Varian VNMRS 600 MHz (1H) spectrometer equipped with 
cryogenically cooled 5 mm z-gradient HCN probe. The same set of spectra as previously was 
acquired. Moreover a new set of 13C/15N separated 3D NOESY (dual acquisition) was 
obtained. Additionally, 13C, 15N F1, F2 filtered 1H-1H NOESY, 13C, 15N F2, F1 filtered 1H-1H 
TOCSY, F2 filtered 1H-1H NOESY and 15N F1, F2 filtered 1H-1H TOCSY spectra were 
collected.280 This new set of data allowed practically complete backbone and much improved 
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sidechain assignments. Initial interproton NOEs has been also indentified, but unfortunately 
both the quality and signal-to-noise ratio of the crucial 13C 3D separated NOESY, from which 
most of the distance restrains are derived, was still insufficient for the structure calculation. 
The set of filtered experiments allowed only some assignments to be made of the BakI81Fi, i+11-
XL-SO3H. Only when Varian INOVA 900 MHz (1H) spectrometer equipped with a 
cryogenically cooled 5 mm z-gradient HCN probe was employed for 13C/15N 3D separated 
NOESY, were the quality of spectra and signal intensity adequate for structure calculations 
were obtained. These spectra also allowed complete sidechain assignments. 
 Because the BakI81Fi, i+11-XL-SO3H assignments remained a problem a new set of 
samples was prepared to solve this issue. Bcl-xL/BakI81Fi, i+11-XL-SO3H samples without 5 
mM β-mercaptoethanol was prepared in oxygen free conditions including one sample with a 
higher Bcl-xL to BakI81Fi, i+11-XL-SO3H ratio to filter out signal arising from the free BakI81Fi, 
i+11-XL-SO3H and another sample in D2O without the reducing agent to facilitate 
identification of non-exchangeable protons. The same suite of filtered and half-filtered 
experiments was acquired and 13C, 15N filtered 1H-1H COSY were attempted, but no usable 
COSY spectra were collected from any of the aforementioned samples (Varian VNMRS 600 
MHz (1H) spectrometer equipped with cryogenically cooled 5 mm z-gradient HCN probe). 
2.3.7 NMR spectra assignment 
 Backbone assignments posed a somewhat bigger challenge than in the case of free 
Bcl-xL. The middle regions of the filtered 1H-15N HSQC exhibited a marginally higher level 
of overlap between peaks (e.g. residues Glu 32, Phe123, Val 141, Ile 182) similarly, as for the 
free Bcl-xL. Residues Asn 157, Ala 159, Ala 160 and Ala 161 were represented by broad or 
multiple peaks. Some residues backbone resonance could not be assigned (Met 1, Ser 2, Gln 
3, Tyr 101, Arg 102, Arg 103, Gly 117, and Glu 171) and these residues differed from those 
not assignable for Bcl-xL. Again, the residues that could not be assigned belonged to the 
flexible parts of the Bcl-xL protein. Unfortunately the HCCH-TOCSY, CC(CO)NH TOCSY 
and especially the HCC(CO)NH TOCSY spectra had a lower signal-to-noise ratio then their 
equivalents for the free protein and were on their own not sufficient for sidechain 
assignments. Assignment was therefore heavily aided by 13C/15N separated 3D NOESY 
(Figure 88 and 89) and in the case of some more difficult backbone assignments 15N separated 
3D NOESY provided useful information about i, i ± 1 connectivity (Figure 112).  
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Figure 112: 15N separated 3D NOESY of Bcl-xL/BakI81Fi, i+11-XL-SO3H complex. Strips of Leu162 to Trp169 backbone 
amides originating NOEs are shown and crosspeaks to adjacent residues are indicated with a red line. 
 As in the case of the free Bcl-xL, interproton NOEs were manually assigned with less 
certain ones left unidentified for Aria automatic disambiguation protocols. Although the 
initial set of 13C/15N separated 3D NOESY had a very low signal-to-noise ratio, the set 
acquired on 900 MHz spectrometer provided a good quality, intense spectrum (Figure 113). 
Unfortunately due to limitations of the technique it is very difficult to obtain TOCSY type or 
filtered spectra on 900 MHz spectrometer.  
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Figure 113: 15C separated 3D NOESY of Bcl-xL/ BakI81Fi, i+11-XL-SO3H complex. Four strips are shown exemplifying 
the long range NOEs assignment. Corresponding crosspeaks are indicated with a red line with the given 
proton they match to on the right. Green peaks are positive and blue ones are negative. 
 Assignment of the non-isotopicaly labelled peptide resonances was achieved via the 
previously mentioned filtered experiments in which signals of protons attached to 13C and/or 
15N are rejected, thus only those on isotopicly not labeled peptide are detected. In order to aid 
the assignment and also to solve the structure of the free BakI81Fi, i+11-XL-SO3H a set of 2D 
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spectra of the peptide alone were acquired. Unfortunately at the concentrations required for 
NMR the peptide itself tends to aggregate and does not exhibit NMR spectra typical of an α-
helix, despite the CD spectrum clearly indicating this structure. Interestingly in the earlier 
research it has been observed that at lower concentrations this peptide shows up as practically 
100 % helical.162 Although it was not possible to obtain any restraints that could be used to 
estimate the structure of the free peptide, these spectra aided in filtering out signal arising 
from the unbound peptide in the sample of the complex with Bcl-xL. Only proton resonances 
of the non-isotopically labelled peptide could be accessed and 13 of a total of 16 residues, Cys 
73 to Ile 85 (Table 16), yielded at least one associated resonance (87.5% assigned in total); 
the work posed a significant challenge due to high signal overlap, low intensity of some of the 
signals and influence of the crosslinker which shifts the usual patterns of amino acids into less 
obvious areas (Figure 114). 
 Bcl-xL/BakI81Fi, i+11-XL-SO3H protein-peptide NOEs were extracted primarily from 13C 
separated 3D NOESY, but also from F2f 1H-1H NOESY (Figure 90) and to a lesser extent 15N 
separated 3D NOESY. Most of those signals between residues 74 to 81 were clustered with 
no interproton peptide-protein NOEs identified for the first  N-terminal residue (Gly 72) or 
the last 2 C-terminal residues (Asn 86, Arg 87). Residues on the water exposed/crosslinker 
shielded face showed no NOEs to Bcl-xL. 
 
 
Figure 114: 15C separated 3D NOESY (black), 13C, 15N F1, F2 filtered 1H-1H NOESY (blue) and F2f 1H-1H NOESY 
(green)of Bcl-xL/BakI81Fi, i+11-XL-SO3H complex. Strips exemplify protein-peptide NOEs by demonstrating 
Val 126 (Bcl-xL) to Val 74 and Leu 78 (BakI81Fi, i+11-XL-SO3H) NOEs. Corresponding crosspeaks are 
indicated with a red line with the given proton they match to on the right. Red circles indicate peptide-
protein NOEs that are present in F2f 1H-1H NOESY and missing in 13C, 15N F1, F2 filtered 1H-1H NOESY. 
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Atom type % assigned  
Carbon 69.1 
Nitrogen 69.3 
Proton 85.6 
Table 16: Assignment completeness for free Bcl-xL in complex with BakI81Fi, i+11-XL-SO3H 
2.3.8 Bcl-xL/ BakI81Fi, i+11-XL-SO3H structure calculation 
Interproton NOEs from the 13C/15N 3D separated NOESY spectrum were used to 
calculate intra-Bcl-xL distance restraints. Protein-peptide distance restraints were extracted 
from the 13C/15N 3D separated NOESY and F2f 1H-1H NOESY spectra. Intramolecular 
restraints for the BakI81Fi, i+11-XL-SO3H originated from the 13C, 15N F1, F2 filtered 1H-1H 
NOESY spectrum. All NOEs were selected manually, but were calculated by Aria 2.3 
protocols correcting for spin diffusion with CNS 1.21 as the structure calculation engine and 
the structures refined in a thin shell of water.273,275-277 In order to ensure that protein-peptide 
distance restraints are preserved by Aria during the simulated annealing iterations they were 
removed from the list of restraints that could be rejected by Aria to prevent ejection of the 
peptide from Bcl-xL during the high-energy early stages of the simulation. Instead those 
restraints were manually analyzed after each calculation for violations and, if necessary, 
corrected. Initial structures were used to correct misassigned NOEs by analysing those 
restraints rejected by Aria or violated. The protocol for simulated annealing was modified to 
extend the cooling times as suggested in the literature in order to better deal with ambiguous 
assignments.281 In the final protocol 500 structures were calculated in the last iteration, and 
the best 20 were water refined. Coordinates of those 20 structures were averaged and the 
resulting structure was subjected to a short energy minimization (CNS default settings) to 
ease any possible clashes and correct any aberrant geometries. 
Initial crosslinker parameterization was achieved with the help Dr Marc van der Kamp 
(University of Bristol) and then refined.282 There are two possible arrangements of the free 
crosslinker sulfonate groups: syn with both sulfonates on the same side of the crosslinker and 
anti with them opposite. However, when crosslinked to a peptide, the directionality of the 
constituent amino acids split each of the arrangements creating four possibilities. By varying 
parameters of the crosslinker in calculations at late stages of refinement it was found that only 
one syn and one anti arrangement appear in the final ensemble of structures. One of those 
ensembles, the syn, was violated to lower degree and had more favourable overall energies; 
therefore it was taken to better represent the arrangement of the crosslinker. 
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2.3.9 Final Bcl-xL/ BakI81Fi, i+11-XL-SO3H structure ensemble 
The quality of the final structure surpasses most of the published NMR structures of 
Bcl-2 family proteins (Table 21). The RMSD between free Bcl-xL (see previous chapter) and 
Bcl-xL bound to BakI81Fi, i+11-XL-SO3H backbone atoms is 2.27 Å. As in the case of similar 
structures with different BH3 peptides, the principal differences between free and complexed 
Bcl-xL concern the parts of α2 and α3, α4 helices and the loop connecting them. In fact if 
those (residues 94-138) are excluded from the RMSD calculation the value drops to 0.96 Å 
with the structures virtually identical in respect to the non-binding site fragments.  
 
Figure 115: NMR ensemble of the Bcl-xL in complex with BakI81Fi, i+11-XL-SO3H. HisTag has been removed for clarity. 
When compared to the published structures of wild type Bcl-xL bound to Bakwt the 
RMSD is 2.37 Å for backbone atoms, but care has to be taken in assessing similarities 
between those as the quality of the mentioned Bcl-xL/Bakwt structure is quite low.247 The 
residues Phe 105 to His 113 which form part of helix α3 appear to be disordered in the 
published structure of Bcl-xL/Bakwt but appear in our structure as only slightly distorted 
helices, making this region more similar in secondary structure to some other structures of 
Bcl-xL bound e.g. Bad (RMSD 1.59 Å and 1.19 Å when residues 94-138 are not considered) 
than the NMR structure with Bakwt (Figure 118 and 94). Finally if we once again exclude the 
whole binding site (residues 93 – 134) from comparison, the RMSD value for backbone is 
1.66 Å and 2.68 Å for all heavy atoms. This is a remarkable discrepancy, with the RMSD 
values between free Bcl-xL and BakI81Fi, i+11-XL-SO3H, crudely suggesting that my structure is 
more similar to the free Bcl-xL than the Bcl-xL/Bakwt is. Other differences in our structure 
compared to the wild type structure include the transition between helix α2 and α3, which is 
smooth (there is no well defined breakpoint) in our structure as opposed to turning rapidly at 
residue 98 (Figure 118). Part of helix α2 (residues Leu 99 to Phe 105) which forms a bent 
helix connecting α2 and α3, however the same region in Bcl-xL/Bakwt NMR structure 
continues straight on as a part of α2. Differences in this region could either be a consequence 
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of the low quality of this region in the Bcl-xL/Bakwt structure (the disorderly character of this 
region contrasts well defined structure seen in virtually every other Bcl-xL/BH3 peptide NMR 
or X-Ray structural model) or it could be attributed to the interaction between the one of the 
crosslinker sulfonate groups and Arg 100 or/and 103. However, such interactions are likely to 
be of transient nature as although mentioned arginines indeed occupy the right space for a 
possible interaction with the crosslinker in the final structures sulfonates are further then 5 Å 
from any possible positively charged residues with minimum for a salt bridge being 4 Å.283. 
 
Figure 116: Ramachandran plot of the final water refined NMR ensemble of Bcl-xL bound to BakI81Fi, i+11-XL-SO3H 
(residues 3 to 19 and 44 to 196 of Bcl-xL and 72 to 87 of BakI81Fi, i+11-XL-SO3H). Allowed region (red), 
additionally allowed regions (yellow) and generously allowed regions (pale yellow) are indicated. Glycines 
are represented by triangles. 
The last major difference between Bcl-xL/Bakwt and Bcl-xL bound to BakI81Fi, i+11-XL-
SO3H is found in two closely interacting regions: helix α7 (residues 175 to 185) and the loop 
connecting helices α4 and α5. It appears that both the position of the helix α7 and the loop is 
significantly different between the structures. The change in the position of the loop possibly 
occurs via altered interactions with the peptide between the two structures with a concomitant 
shift in helix α7 as in both structures the helix and loop appear bound together via the 
interaction of a hydrophobic patch formed by a of Leu 178, Trp 181 on the loop with Val 135 
of the helix wedged between them. Again, at least one residue in the Bcl-xL/Bakwt structure 
that forms the loop localizes far from the most probable Ramachandran space. 
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 Free Bcl-xL 
Structures Bcl-xL/Peptide Complex Structures 
Structure 
PDB ID 
Bcl-xL 
2LPC 
Bcl-xL 
1LXL 
Bcl-xL/BakI81Fi, 
i+11-XL 
2LP8 
Bcl-
xL/Bakwt 
1BXL 
Bcl-xL/Badwt 
1G5J 
First-generation packing 
quality 
1.811 -1.590 -0.139 -1.592 -1.822 
Second-generation 
packing quality 
4.467 -1.740 1.756 -1.846 -2.303 
Ramachandran plot 
appearance 
-2.405 -5.378 -4.826 -6.212 -5.307 
χ1/χ2 rotamer normality -0.887 -7.763 -4.960 -6.970 -7.681 
Backbone conformation 0.104 -1.044 -1.124 -0.446 -0.508 
Ramachandran plot (%)      
Core 92.7 77.0 88.0 85.1 86.6 
Allowed 7.1 18.9 10.8 11.2 10.6 
Generous 0.1 1.6 0.5 3.0 2.1 
Disallowed 0.1 2.5 0.7 0.7 0.7 
Table 17: Comparison of WhatIf Z-score quality analyses provided by the iCING server of common.  residues (1-19, 
85-196) of the structural statistics of the NMR structures reported here and those. of previously 
determined structures 
 Bcl-xL/BakI81Fi, i+11-XL-SO3H  
Number of restraints   
Total 4641  
Unambiguous 3939  
Ambiguous 702  
Intra-residue 1603  
Sequential (|i-j|=1) 801  
Short range (2≤|i-j|≤3) 1037  
Medium range (4≤|i-j|<5) 729  
Long range(5≤|i-j|) 471  
DANGLE   φ /ψ 154  
RMSD to restraints   
Bonds (Å) 0.005  
Angles (°) 0.65  
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Table 18: 
Bcl-
xL/BakI81Fi, 
i+11-XL-
SO3H NMR 
structural 
ensemble 
validation 
statistics. 
BB – 
backbone; 
AH – all 
heavy. 
 
 
 
 
Figure 118: (A) Comparison between Bcl-xL in complex with BakI81Fi, i+11-XL-SO3H (red, 2PL8) and Bakwt (blue, 
1BXL). (B) Comparison between Bcl-xL in complex with BakI81Fi, i+11-XL (red, 2PL8) and Bad (blue, 1G5J). 
Only backbone and crosslinker atoms are shown for the peptides. Overlay of BakI81Fi, i+11-XL with (C) 
Bakwt and (D) Bad based on alignment of the Bcl-xL/BakI81Fi, i+11-XL-SO3H (2PL8) model with Bcl-xL/Bakwt 
(1BXL) or Bcl-xL/Bad (1G5J). Four peptide residues making important hydrophobic contacts are 
indicated in pink or blue. Fluorescence anisotropy binding assays 
NOE (Å) 0.051  
DANGLE (°) 0.97  
Precision (RMSD to mean, Å)   
BB atoms (A.3-19,A.44-156,B.1001-1017) 0.57±0.09  
AH atoms (A.3-19,A.44-156,B.1001-1017) 1.40±0.20  
Ramachandran plot regions (%)   
Most favoured 88.2%  
Additionally allowed 10.6%  
Generously allowed 0.6%  
Disallowed 0.5%  
WHATCHECK Structure Z scores 
-0.020± 0.633 
 
First-generation packing quality  
Second-generation packing quality   1.365±1.355  
Ramachandran plot appearance  -4.757±0.203  
χ1/ χ2  rotamer normality  -5.054±0.285  
Backbone conformation  -1.201±0.281  
WHATCHECK  RMS Z-scores   
Bond lengths 1.007±0.002  
Bond angles 0.376±0.007  
Omega angle restrains 0.928±0.045  
Side chain planarity 0.682±0.232  
Improper dihedral distribution 0.634±0.107  
Inside/Outside distribution 1.039±0.011  
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Curiously, the BakI81Fi, i+11-XL helix is shifted by approximately ½ helix pitch towards 
the N-terminus compared to Bakwt (Figure 117, 118), similar to the position of the peptide in 
the Bad/Bcl-xL complex.249 Comparing the RMSD between BakI81Fi, i+11-XL and Bakwt or Bad 
(1.88 and 0.731 respectively) suggests better agreement with the position of Bad rather than 
Bakwt. The positions of the ‘hot-spot’ residues of BakI81Fi, i+11-XL that make hydrophobic 
contacts with Bcl-xL are also different from those observed in the Bakwt complex (Figure 117, 
118, 119). Clearly, some of these distortions are imposed by the crosslinker that forces the 
hydrophobic side chains out of the positions adopted by the wild type peptide. However, 
instead of the side chains of the peptide adjusting their position to retain optimal hydrophobic 
interactions, the binding site of Bcl-xL displays a large degree of plasticity and remodels itself 
to make more favourable interactions with the constrained peptide (Figure 118 and 119). Such 
adjustments may be expected for a protein with a large number of similar but distinct binding 
partners.15,284-286 
The two salt bridges reported between Bxl-xL and Bakwt cannot be found in our 
structure, but the Bxl-xL/Bakwt structure places Glu 129 and Arg 76 and Arg 139 and Glu 83 
further then 7 Å apart. They are closer to each other in our structure yet still not close enough 
to report a definite electrostatic interaction, indeed Arg 76 is revealed by alanine scanning not 
to contribute to the binding energy. Moreover, due to significant signal overlap it was not 
possible to determine chemical shift and NOE signal patterns for the last two C-terminal 
residues of the BakI81Fi, i+11-XL-SO3H. In the published structure of Bcl-xL bound to Bakwt 
most assignments of the peptides C-terminal section are exactly the same as 
corresponding/similar residues in the N-terminal part suggesting, that the helical 
conformation, although most probable, was artificially forced.247 It is difficult to assess which 
of those two models better represents reality. 
 
Residue 
Unambiguous  
peptide-protein 
NOEs 
Gly 72 0 
Cys 73  1 
Val 74 20 
Gly 75 8 
Arg 76 1 
Ala 77 2 
Leu 78 13 
Ala 79 19 
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Ala 80 0 
Phe 81 7 
Gly 82 3 
Asp 83 0 
Cys 84 1 
Ile 85 3 
Asn 86 0 
Arg 87 0 
 
Table 19: Number of peptide-protein NOE restraints by peptide residue 
 
 
 
 
Residue Backbone RMSD Sidechain RMSD 
Gly 72  2.27  - 
Cys 73  1.21  1.26 
Val 74  1.03  1.08 
Gly 75  0.84  - 
Arg 76  0.75  1.75 
Ala 77  0.70  0.73 
Leu 78  0.54  0.86 
Ala 79  0.49  0.56 
Ala 80  0.56  0.63 
Phe 81  0.57  0.98 
Gly 82  0.52  - 
Asp 83  0.70  1.08 
Cys 84  0.91  0.98 
Ile 85  1.39  1.98 
Asn 86  2.42  3.51 
Arg 87  3.83  6.29 
Azobenzene crosslinker  2.04 - 
Table 20: Peptide backbone and sidechain RMSD values for all members of the ensemble 
On average residues Val 74 and Cys 75 of the crosslinked peptide show dihedral 
angles slightly outside the alpha helical region of the Ramachandran plot (Figure 116). Those 
residues comprise the cysteine that is directly attached to the crosslinker and the adjacent 
valine. One possible explanation is that the presence of the crosslinker forces those residues 
into unusual conformations but because our structure is the first of this type reported no direct 
comparison exists to assess the normality of this deviation of in the Ramachandran plot. 
Nevertheless, the other side of crosslinker attachment (Cys 84) shows no Ramachandran 
distortion, however as it has been mentioned the C-terminus appear to be more disordered and 
shows much less contact to the protein therefore making this part of the BakI81Fi, i+11-XL-
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SO3H less strained overall and perhaps more able to relax into more favourable regions of 
Ramachandran plot. 
Even though the crosslinker shows multiple NOEs to the peptide, no signals to Bcl-xL 
were found and in the final ensemble of structures it was found not to interact directly with 
the protein (Figure 115, 117, 120). Although intuitively Arg 100 and 103 seem possible 
candidates for an interaction with the crosslinker sulfonate this was not confirmed by NOEs 
or the distance analysis on the ensemble structures.  This finding is in contrast to those with a 
hydrocarbon staple which was shown to participate in hydrophobic interactions.57,58,61 The 
final calculated ensemble of structures shows the crosslinker probing a fairly limited 
conformational space. It locates closer to the α3/α2 helix than α4 leaving a large open cavity 
between the crosslinker and helix α4. Conformational stability and positional bias towards 
α3/α2 is most likely caused by the interaction with Phe 83. Remarkably, and in contrast to 
our observations of azobenzene-modified peptides binding to RNA, attachment of the fairly 
bulky crosslinker seems not to interfere with the binding in steric or electronic fashion and 
only stabilizes the conformation of the peptide.  
 
Figure 119: Comparison between BH3 binding site of Bcl-xL in complex with BakI81Fi, i+11-XL-SO3H (blue, 2PL8) and 
Bakwt (pink, 1BXL). Hydrophobic residues forming the binding site are highlighted and labelled. 
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Figure 120: Structure of the Bcl-xL/BakI81Fi, i+11-XL-SO3H highlighting four peptide residues making important 
hydrophobic contacts (V74, L78, F81, and I85). Bcl-xL hydrophobic residues within 4 Å from the peptide 
are labelled 
Fascinatingly, Phe 83 which replaces leucine in the wild type Bak peptide (a 
modification reported to increase affinity to Bcl-xL)287 gave strong NOE signals to 
azobenzene crosslinker aromatic rings. In the calculated structure the phenylalanine was 
found outside the canonical hydrophobic pocket and flanked by hydrophobic patch formed by 
Tyr101, Phe105 and the crosslinker itself. Although it was proposed that the leucine to 
phenylalanine substitution increases affinity as it better fills the canonical pocket, it appears 
that in our system Phe 83 preferentially interacts with the crosslinker. 
In order to test whether this isoleucine to phenylalanine substitution enhances affinity 
or decreases Baki, i+11-XL-SO3H affinity to its target we performed fluorescence anisotropy 
binding studies. Fluorescence anisotropy binding measurements revealed that BakI81Fi, i+11-XL 
bound to Bcl-xL with a KD = 30.5 ± 5.7 nM, an affinity comparable to that measured for Baki, 
i+11-XL-SO3H KD = 15.2 ± 1.3 nM (Figure 121). By contrast, it is known that in the wild type 
peptide mutation from isoleucine to alanine (I81A) causes decreases from 340 nM to 17000 
nM suggesting that the interaction is crucial.247 Whilst BakI81F fits well into the binding 
pocket of the Bakwt/Bcl-xL structure, the presence of the azobenzene crosslinker and the 
remodelling of the binding site in the BakI81Fi,i+11-XL/Bcl-xL complex clearly favour this 
different conformation of Phe81. 
 149 
 
 
Figure 121: Fluorescence anisotropy binding curves for FAM-Baki, i+11-XL-SO3H (red) and FAM-BakI81Fi, i+11-XL-
SO3H (green) titrated with Bcl-xL. 
2.3.10 Conclusions 
 Azobenzene-based biophotonically switchable peptides have now been shown to be 
able to bind a plethora of targets and effectively disrupt interactions between 
biomacromolecules. Their ability to undergo a photo-activated conformational rearrangement 
allows external, non-invasive control over their affinity to their respective targets and 
therefore the interaction in question. Keeping in mind the overwhelming complexity of the 
protein-protein interactions in a given cell and their crucial role in virtually every aspect of 
molecular biology, biophotonic switches can provide highly desirable tools to probe these 
interactions or form a new generation of photodynamic drugs. However, very few structural 
details are known about the binding of azobenzene peptides to target proteins. The orientation 
of the crosslinker, its dynamics, positive interactions or clashes with the protein or peptide 
structures, the effect on the structure of the peptide in its bound form all remained unexplored. 
The structure of BakI81Fi, i+11-XL-SO3H in complex with Bcl-xL reported here is the first ever 
solved and begins to address those issues. 
 The chemical shift perturbation map previously produced from preliminary data 
supported the hypothesis that the biophotonic Bak binds in the same grove as wild type 
peptides, but this technique has limitations: The slow exchange regime of the interaction in 
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question posed a significant challenge and the hotspot residues of this interaction do not 
necessarily correlate to the highest values of Ω. Instead it was observed that the mobile 
elements tend to change the environment most and therefore their chemical shift is most 
perturbed. Completing the NMR assignment of the backbone and sidechains revealed that the 
most difficult areas to assign are within the binding site itself and the disappearance of some 
of the peaks there suggest a conformational exchange process taking place that broadens 
peaks till they are indistinguishable from noise. 
 The calculation of the structure underlined the issue of multiple orientations of the 
sulfonated azobenzene crosslinker. Although BakI81Fi, i+11-XL-SO3H might adopt a single 
orientation of the crosslinker sulfonates in solution, when bound a different orientation might 
be more energetically stable and given enough time the system might relax into that 
conformation. Nevertheless it was difficult to rationalize the position that was found to give 
the lowest violation and in silico energy. One of the possibilities was suggested by the 
presence of arginines in the vicinity for hydrogen or electrostatic bonding, yet NOEs and the 
final calculated structure suggest these are improbable. In fact it was observed that the bulky 
crosslinker does not interfere directly with the binding site. At the same time the crosslinker 
does cause Phe 81 to somewhat flip out of the canonical binding site and interact with 
crosslinkers aromatic rings. Therefore although I81F mutation was on multiple occasions 
related to higher affinity this is not necessarily true for our peptide and might reflect a general 
tendency of azobenzene peptides. The observation that the crosslinker probes a rather limited 
conformational space may be a direct effect of the interaction with Phe. Moreover the final 
position of the crosslinker could be a direct consequence of the same interaction, suggesting 
that in case of possible steric clashes when designing new peptides it might be possible to bias 
the crosslinker over one side of the peptide by strategically positioning a Phe residue. 
The NMR solution structure of the complex of BakI81Fi, i+11-XL-SO3H and Bcl-xL 
indicates that, while the photo-peptide bound to the canonical binding site, a remodeling of 
the binding site occurred that led to a shift in α-helical register and a perturbation of the 
complex structure of BakI81Fi, i+11-XL-SO3H relative to that observed with the wild-type 
peptide. Although the peptide was expected to be helical it appears that the attachment of the 
crosslinker slightly distorts the peptide from an ideal α−helix at the point of attachment. The 
most interesting observation comes from the comparison between the structure of Bcl-
xL/BakI81Fi, i+11-XL-SO3H with Bcl-xL/Bakwt. Not only are the binding sites quite different to 
each other, but the position of the crosslinked peptide is significantly shifted. The difference 
 151 
 
between those two NMR structures is surprisingly greater then between Bcl-xL/BakI81Fi, i+11-
XL-SO3H and free Bcl-xL. This variability in structure between the two complexes cannot be 
attributed solely to the different solution conditions for NMR. Though the ability of the Bcl-
xL BH3 binding site to accommodate a whole spectrum of peptides and small molecules by 
means of conformational flexibility is well established, it is intriguing to imagine that the 
presence of Phe 81 and the crosslinker cooperatively cause the complex to form a different 
overall structure and this structure is more reminiscent of activator rather than sensitizer BH3 
peptide complexes. Regrettably the Bcl-xL/Bakwt NMR structure is of rather poor quality and 
neither full NOE assignment nor even the ensemble of structures is available for closer 
inspection.247 If, indeed, the differences arise from a miscalculated structure it would mean 
that one of the most cited structural papers about Bcl-2 family may be leading scientists 
astray. Nonetheless, the lack of a crystal structure of the same complex precludes any final 
statements about the reliability of the structure presented there, despite my structure 
surpassing the Bcl-xL/Bakwt in quality indicators it is, after all, of a somewhat different 
complex. The need to provide an “internal” control for NMR structure solution is apparent, as 
well as the need to critically evaluate influential structures. 
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3 Material and Methods 
3.1 General remarks 
 
Unless otherwise specified 15 MΩ H2O was used. RNAse free H2O (18 MΩ) from an ELGA 
LabWater purifier for all experiments involving RNA was used and care has been taken to 
avoid contamination of RNA samples. All chemicals for RNA work used for buffer 
preparation and purification were designated for RNA work only and were not used before for 
any other purpose. 
3.2 Buffers and Media 
3.2.1 FRET buffer93 
30 mM  HEPES 
100 mM KCl 
40 mM NaCl 
10 mM  NH4OOCCH3 
10 mM  Gdm:HCl 
2 mM  MgCl2 
0.5 mM  EDTA 
0.1%  Triton X-100 
pH 7.5 
18 MΩ H2O 
3.2.2 CD and UV buffer (for Rev and Bak peptides) 
5 mM  K2HPO4/KH2PO4 
pH 7.5 
18 MΩ H2O 
3.2.3 Anisotropy buffer 
100 mM Na2HPO4/NaH2PO4 
10 mM  NaCl 
pH 7.5 
18 MΩ H2O 
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3.2.4 Annealing Buffer 
100 mM  KCl 
2 mM  MgCl2 
5 mM  HEPES  
pH 7.5 
18 MΩ H2O 
3.2.5 Ampicillin Stock 
10%  Ampicilin 
50% H2O 
50% CH3CH2OH 
Stored at -20 °C 
3.2.6 Kanamycin Stock 
5%  Kanamycin sulphate 
Sterile filtered and stored at -20 °C 
3.2.7 SDS-PAGE stacking (upper) gel buffer288 
0.5 M  Tris:HCl 
pH 6.8 
3.2.8 SDS-PAGE resolving (lower) gel buffer288 
1.5 M  Tris:HCl 
pH 8.8 
3.2.9  5x SDS-PAGE running (lower) gel buffer288 
0.125 M  Tris base (TRIZMA) 
0.96 M Glycine 
0.5 %  SDS 
H2O to 1 L total volume 
3.2.10 Acetic Acid saturated phenol 
50% 2 M sodium acetate pH 4.2 
50% phenol 
Phenol phase recovered 
 154 
 
3.2.11 Bcl-xL purification buffers 
Base: 
100 mM  Na2HPO4/NaH2PO4 
500 mM  NaCl 
10 mM  2-Mercaptoethanol 
pH 7.5 
 
Lysis buffer is the Base buffer plus: 
5 mM  Imidazole 
1 mM  PMSF 
 
Equilibration buffer is the Base buffer plus: 
5 mM  Imidazole 
 
Wash buffer is the Base buffer plus: 
50 mM  Imidazole 
 
Elution buffers (A, B, C and D) are the Base buffer plus: 
100 mM Imidazole (A) 
150 mM Imidazole (B) 
200 mM  Imidazole  (C) 
500 mM  Imidazole (D) 
3.2.12 Crosslinking buffer for XL-SO3H 
50 mM  Tris:HCl 
2 mM  TCEP 
pH 8.3 
3.2.13 Crosslinking buffer for XL-H 
25 mM  Tris:HCl 
2 mM  TCEP 
50%  THF 
pH 8.3 
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3.2.14 MALDI matrix 
Sat. α-Cyano-hydroxy-cinnamic acid 
50% MeCN 
50%  18 MΩ H2O 
The suspension is mixed and centrifuged briefly to sediment the excess of matrix 
3.2.15 10x M9 minimal salt 
71.6 g   Na2HPO4 
30 g  KH2PO4 
5 g  NaCl 
H2O to 1L total volume 
Autoclaved 
3.2.16 100x Trace elements solution 
0.3 mM  ZnCl2    
0.7 mM FeCl3???2O   
0.06 mM CuCl2???2O   
0.05 mM MnCl2???2O   
0.03 mM Na2B4O7????2O  
0.006 mM (NH4)6Mo7O24???2O  
H2O to 1L total volume 
3.2.17 M9 minimal media 
100 mL  M9 salts 
10 mL Sterile-filtered 5% NH4Cl (or 15NH4Cl) 
20 mL Sterile-filtered 15-20% D-glucose (or uniformly 13C labelled D-glucose) 
10 mL Trace elements solution 
0.1 mL Sterile-filtered 1 M CaCl2 
2 mL Sterile-filtered 1 M MgSO4 
H2O to 1L total volume 
3.2.18 5x Tris/Borate/EDTA (TBE) buffer 
108 g Tris base (TRIZMA) 
55 g Boric acid 
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40 mL  0.5 M EDTA (pH 8.0) 
H2O to bring it to 1 L total volume 
3.2.19 50 x Tris/Acetic acid/EDTA (TAE) buffer 
242g Tris base (TRIZMA) 
57.1 mL Glacial CH3COOH 
100 mL 0.5 M EDTA (pH 8.0) 
18 MΩ H2O to 1 L total volume 
3.2.20 10x DNA Loading Buffer 
2.5 g Ficoll-400 
1 ml Tris:HCl (pH 7.4) 
2 mL 0.5 M EDTA (pH 8.0) 
pH 7.4 
15 MΩ H2O to 10 ml total volume 
3.2.21 4x Protein Loading Buffer 288 
2.4 ml 1 M Tris pH 6.8 (Upper gel buffer) 
0.8 g SDS 
4 mL 100% Glycerol 
0.01%  Bromophenol blue 
1 mL  2-mercaptoethanol 
H2O to bring it to 10 ml 
3.2.22 Lysogeny broth (LB)289 
10 g Tryptone. 
5 g Yeast extract. 
10 g NaCl 
H2O to 1L total volume 
Autoclaved and cooled to RT before proceeding. 
3.2.23 LB Agar 
1 g Tryptone 
0.5 g Yeast extract 
1 g NaCl 
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1.5 g Agar 
H2O to 100 ml total volume 
Autoclaved, cooled to app. 50 °C, antibiotic added, mixed thoroughly and poured onto plastic 
Petri dishes. 
3.3 Molecular Biology Methods 
 
3.3.1 Cloning of Rev peptide DNA sequences 
Sense and antisense oligonucleotides required for the biosynthesis of Rev peptides 
were acquired from Eurofin MWG Operon. Following phosphorylation by polynucleotide 
kinase (NEB) at 5’ end they were annealed overnight (see Nucleotide Annealing section). 
Double stranded DNA with overhangs corresponding to those generated by restriction 
enzyme AlwNI (NEB) were ligated into pET-31b plasmid pre-cut with the AlwN1 and 
dephosphorylated by Antarctic phosphatase (NEB). The resulting plasmid was propagated 
and extracted as described and positive clones were identified by performing AlwN1 cleavage 
and analysing the result via agarose electrophoresis. 
 
bRevwt  sense: 
5’’GACACCCGTCAGGCGCGTCGTAACCGTCGTCGTCGTTGGCGTGAACGTCAGCG
TATGGACACCCGTCAGGCGCGTCGTAACCGTCGTCGTCGTTGGCGTGAACGTCAG
CGTATG 3’ 
 
bRevwt antisense: 
5’’CATACGCTGACGTTCACGCCAACGACGACGACGGTTACGACGCGCCTGACGGG
TGTCCATACGCTGACGTTCACGCCAACGACGACGACGGTTACGACGCGCCTGACG
GGTGTC 3’ 
 
bRevi,  i+4sense: 
5’’GACACCCGTCAGTGCCGTCGTAACTGCCGTCGTCGTGCGCGTGAACGTCAGCG
TATGGACACCCGTCAGTGCCGTCGTAACTGCCGTCGTCGTGCGCGGAACGTCAGC
GTATG 3’ 
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bRevi,  i+4 antisense: 
5’CATACGCTGACGTTCACGCGCACGACGACGGCAGTTACGACGGCACTGACGGG
TGTCCATACGCTGACGTTCACGCGCACGACGACGGCAGTTACGACGGCACTGACG
GGTGTC 3’ 
 
bRevi,  i+ 7 sense: 
5’’GACACCCGTCAGGCGTGCCGTAACGCGGCGCGTCGTTGCCGTGAACGTCAGCG
TATGGACACCCGTCAGGCGTGCCGTAACGCGGCGCGTCGTTGCCGTGAACGTCAG
CGTATG 3’ 
 
bRevi,  i+7 antisense: 
5’’CATACGCTGACGTTCACGGCAACGACGCGCCGCGTTACGGCACGCCTGACGGG
TGTCCATACGCTGACGTTCACGGCAACGACGCGCCGCGTTACGGCACGCCTGACG
GGTGTC 3’ 
 
bRevi,  i+11 sense: 
5’’GACACCCGTCAGGCGTGCCGTAACCGTGCGCGTCGTGCGCGTGAACGTTGCCG
TATGGACACCCGTCAGGCGTGCCGTAACCGTGCGCGTCGTGCGCGTGAACGTTGC
CGTATG 3’ 
 
bRevi,  i+11 antisense: 
5’’CATACGGCAACGTTCACGCGCACGACGCGCACGGTTACGGCACGCCTGACGGG
TGTCCATACGGCAACGTTCACGCGCACGACGCGCACGGTTACGGCACGCCTGACG
GGTGTC 3’ 
3.3.2 In vitro transcription 
A DNA RRE IIB template containing T7 promoter sequence was ordered from 
Eurofins. RRE IIB in vitro transcription was achieved according to the Megascript™ (Albion) 
protocol. Briefly, 20 µl of enzymatic reaction mixture was assembled containing four 
unlabeled NTPs, annealed RRE IIB template (below), 1x reaction buffer, T7 polymerase 
(enzyme mix). The mixture was supplemented with trace amount of 32P-α-UTP. A control 
reaction using pTRI-Xef as a template was assembled separately. 
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Template for RRE IIB sense: 
5'AATTTAATACGACTCACTATA'GGGTCTGGGCGCAGCGCAAGCTGACGGTACAG
GCC 3'  
 
Template for RRE IIB antisense: 
5'GGCCTGTACCGTCAGCTTGCGCTGCGCCCAGACCCTATAGTGAGTCGTATTAAA
TT3'  
 
The reaction was incubated at 37 °C for 4 or 16 h. At the end the reaction DNAase I was 
added and the mixture was incubated for further 30 min, the mixture was then quenched with 
5M sodium acetate and 100 mM EDTA (130 µl), and purified as described in the Purification 
Methods section. 
3.4 Protein Biosynthesis 
3.4.1 Purification Methods 
3.4.1.1 Expressed peptides purification 
 Cells were resuspended in potassium phosphate buffer (50 mM, pH 7.0) with NaCl 
(100 mM) and sonicated on ice with 3 x 30 pulses (1 sec pulse at 40 % intensity, 1 sec pause) 
then centrifuged (20 min, 4°C, 12000 x g). The supernatant was removed and the pellet was 
resuspended in potassium phosphate buffer (50 mM, pH 7.0) with NaCl (100 mM) and 0.5 % 
Tween 20. It was stirred for 2 h and centrifuged (20 min, 4°C, 12000 x g). The supernatant 
was removed and the pellet was resuspended in potassium phosphate buffer (50 mM, pH 7.0) 
with NaCl (1 M). It was stirred for 2 h and centrifuged (20 min, 4°C, 12000 x g). The pellet 
was dissolved in guanidine hydrochloride (6 M) and stirred over night at 4 °C then 
centrifuged (30 min, 4°C, 25000 x g). The supernatant was dialysed at 4 °C against H2O (3 L) 
using a 12-14 kDa cut off dialysis membrane. The suspension was centrifuged (20 min, 4 °C, 
12000 x g) to remove precipitated protein, the pellet was resuspended in 15 ml 80 % formic 
acid and transferred to a 50 ml round bottom flask and CNBr (0.6 g) was added. The flask 
was wrapped in an aluminium foil and suspension was stirred under N2 atmosphere for 18-22 
h. The flask was attached to rotary evaporator and the solution was evaporated at 40 °C until a 
gel like consistency. The gel was resuspended in monobasic potassium phosphate (10 ml, 25 
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mM) containing one average crystal of TCEP adjusted to pH 7.5 with KOH. The suspension 
was stirred for 1 h, and the pH was adjusted again to 7.5. Finally it was stirred for a further 1 
h and centrifuged (20 min, 4°C, 25000 x g). The supernatant was applied on C18 reverse 
phase column on HPLC and purified by a 10-100% methanol + 0.1% TFA gradient. 
3.4.1.2 Synthesized peptide purification and purity 
Peptides were purified by reversed phase HPLC using a Phemonenex Gemini 10 µm, 
110 Å, 10×250 mm C18 column with gradients from 100% water (+ 0.1%) TFA to 100% 
acetonitrile (+ 0.1%) over 100 minutes at a flow rate of 5 mL. For analysing the purity of 
product peptides a Dionex Acclaim, 3 µm, 120 A, 4.6×150 mm C18 column was used with a 
gradient from 100% water (+ 0.1% TFA) to 100% acetonitrile (+ 0.1% TFA) over 50 minutes 
(1 mL/min). Peptide masses were verified as described below. 
3.4.1.3 Bcl-xL biosynthesis and purification 
A pET 19 plasmid containing a gene coding for loop truncated (1-209 Δ45-84, Δ210-
233) Bcl-xL was used to transform E. coli BL(21)DE3 strain. This bacterial culture was grown 
at 37 °C until OD600 reached 0.8, then expression was induced by addition of IPTG (0.5 mM). 
The culture was harvested after 6 h. Following one freeze-thaw cycle, the bacterial pellet was 
resuspended in sodium phosphate (100 mM), NaCl (500 mM), imidazole (5 mM), 2-
mercaptoethanol (10 mM) pH 7.5 buffer. Cells were lysed by sonication and cell debris was 
removed by centrifugation. The supernatant containing Bcl-xL was subjected to NiNTA 
affinity chromatography and the protein was eluted by applying a step gradient of imidazole 
(50, 100, 150, 200, 500 mM). Fractions containing Bcl-xL were pooled and dialysed against 
buffer containing sodium phosphate (5 mM), 2-mercaptoethanol (5 mM). Protein was mixed 
with equimolar BakI81Fi, i+11-XL-SO3H and concentrated to app. 1 mM. For binding studies 
expression was carried out in LB media and for the NMR sample preparation M9 media 
supplemented with 15NH4Cl and U13C-D-glucose as sole sources of nitrogen and carbon 
respectively was used. 
3.4.2 Purification of in vitro transcription products 
Quenched in vitro transcription reaction mixtures were mixed with sodium acetate 
(150 µl, 0.3 M, pH 5.0) saturated phenol/chloroform mixture (1:1) and mixed vigorously for 1 
min. The mix was centrifuged (1 min, 16 000 g) and the upper phase was recovered. It was 
mixed with pure chloroform (150 µl), mixed vigorously, centrifuged (1 min, 16 000 g) and 
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the upper phase was recovered. 2 volumes of ice-cold isopropanol were added to the upper 
phase and it was incubated for 2 h at -20 °C. The mixture was centrifuged (10 min, 0 °C, 16 
000 g), the supernatant was discarded and the precipitate containing RRE IIB was 
resuspended in H2O and stored at -80 °C till needed. 
3.5 Analytical Methods 
3.5.1 General acrylamide gels preparation protocol288 
For SDS-PAGE an acrylamide:N, N'-methylenebisacrylamide ratio of 37.5:1 was 
used. For EMSA and urea gels this ratio was 29:1. 30% acrylamide mix, gel buffer stock 
(stacking, resolving, 1x TBE or 0.5x TBE) and 15 MΩ water were mixed and for SDS-PAGE 
the mix was supplemented with 10% SDS stock solution to 0.1% final concentration. 10% 
(w/v) ammonium persulfate stock solution was added to a final concentration of 0.1% and 
mixed thoroughly, followed by TEMED to a final concentration of 0.01% with further 
mixing.  A gel was immediately cast. For SDS-PAGE resolving gels, the gel was first covered 
with isopropanol layer, which was removed after polymerization, washed, excess water was 
drained and the stacking gel was cast over the resolving gel. 
3.5.2 SDS-PAGE288 
Samples were prepared by mixing the solutions to be analyzed with protein loading 
buffer and incubating them for 10 min at 95 °C. Samples were then briefly centrifuged, 
allowed to cool to room temperature and loaded into gel wells. For all protein analysis 15% 
SDS-PAGE gels were used. Electrophoresis was carried out at 180 V for 1 h or until 
bromophenol blue migrated out of the gel.  
3.5.3 EMSA  
5% Acrylamide gels were prepared as described in the gel preparation section. Gels 
were pre-run in 0.5x TBE buffer for 1 h at 4 °C, 50 V. Buffer was circulated between the 
upper and lower chambers. Samples were prepared in one of the EMSA sample buffers 
(Buffers and Media Section) containing approximately 1 nM of RRE IIB in 25 µl and 
increasing amounts of one of the bRev peptides (0, 25, 50, 100, 200, 500, 1000, 2000, 5000 or 
10000 nM). After 30 min incubation, the entire volume was loaded into the gel wells with a 
flat-end Hamilton syringe and the gel was run for 3 h at 4 °C, 225 V with buffer circulated 
between the upper and lower chambers. Gels were transferred to 3M filter paper, covered with 
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cling film and dried on a gel drier for 10 h at 65 °C. A phosphorimager was exposed to the gel 
for 10 h and subsequently scanned on Typhoon Gel Imager. 
3.5.4 Urea gels 
20% acrylamide gels with 8M urea and 1x TBE were prepared as described in 
previously. Samples of RRE IIb or pTRI-Xef were prepared in formamide gel loading buffer 
supplied with Megascript™ (Ambion) and were heated to 80 °C for 5 min, then immediately 
cooled to 4 °C before loading into pre-rinsed gel wells. Electrophoresis was run for 3 h at 300 
V in 1x TBE. Excess buffer was removed from the gel with paper towels and the gel was 
tightly wrapped with cling film. A phosphorimager was exposed to the gel for 1 h and then 
scanned on Typhoon Gel Imager. 
3.5.5 DNA agarose gels 
Agarose gels were prepared by dissolving 1 - 1.5% agarose in 1x TEA buffer. DNA 
samples were mixed with DNA loading buffer and transferred into gel wells. Electrophoresis 
was run at 80 V for 45 to 60 min. Gel was placed in a solution of 1x TEA buffer and 5 mg/L 
ethidium bromide for staining and visualized under a transiluminator. 
3.5.6 Fluorescence spectroscopy – Rev/RRE binding studies 
 Cy3 labelled RRE sequence (Cy3 5’ 
GGUCUGGGCGCAGCGCAAGCUGACGGUACAGGCC 3’) was purchased from Eurofins. 
All measurements were performed on LS 55 Luminescence Spectrometer (Perkin Elmer) 
equipped with F 25 temperature control unit (Julabo). The temperature was kept constant at 
15 °C and solutions were allowed to equilibrate for 20 minutes before use. The cuvette was a 
standard 3 mL quartz cuvette and the initial volume of all assays was 2.5 mL. Fluorecsence 
assays were performed in FRET buffer at 15 °C. This buffer composition simulates the high 
ionic strength and the ionic composition found in nucleus and includes detergent to minimize 
possible adherence of the peptides to the walls of the cuvette. 
 At each measurement point three complete spectra from 510 to 535 nm were acquired 
and averaged (excitation/emission slits: 5/10 nm, scan speed: 50 nm/s, excitation wavelength: 
495 nm). Concentrations and fluorescence intensities were corrected for the effects of 
dilution. All titrations were fitted independently in SigmaPlot and reported Kd values are an 
average of those fits. To estimate apparent binding affinities from IC50 values Cheng-Prussof 
equation was used.  
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Equation 8: Where Kd is an apparent dissociation constant; IC50 is the concentration of antagonist required to 
displace 50% of ligand; Kd wt is the apparent dissociation constant of FAM Revwt and [FAM Rev-wt] is the 
concentration of FAM Revwt. 
The equation used to calculate IC50 values was a linear equivalent of the Hill slope equation 
used for displacement assays data after log10 transformation of concentration values and is 
given below. 
 
Equation 9: Where [Rev] is the concentration of added Rev peptide; IC50 is the concentration of antagonist required 
to displace 50% of ligand; B is the equivalent of Hill slope; NpF is the value of fluorescence normalized to 
predicted fluorescence values at a saturation point and maxNpF is the maximum value of NpF, that by 
definition must equal 1. 
The direct binding assay data was fitted to the single site binding equation. 
 
Equation 10: Where NF is the values of normalized fluorescence; [RRE] is the concentration of added Cy3 RRE; Kd is 
an apparent dissociation constant; maxNF is the predicted maximal values of normalized fluorescence 
For data visualisation corresponding normalised points were averaged and standard deviation 
of the mean for three measurements at each data point was calculated, plots were then 
normalized to calculated saturation values (Sigma Plot). Due to high concentration of Cy3 
RRE needed for experiments using FAM-labelled non-crosslinked peptides it was necessary 
to make corrections for a small degree of Cy3 emission overlapping with the FAM emission. 
None of those mathematical transformations effect data content and estimated IC50 or Kd.  
 
3.5.7 UV spectroscopy 
Measurements were performed on Jasco V-660 spectrometer equipped with DAC-743 
R temperature control unit (JASCO Inc.) and AWC 100 heat exchanger (Julabo). The 
relaxation of the cis to trans form was observed by monitoring the recovery in absorption at 
363 nm due to increasing quantities of the trans isomer. Absorbance readings were recorded 
every 120 seconds for total of 40 minutes (37, 30 °C), 80 minutes (25 °C) or 120 minutes (20, 
15 °C) to provide suitable data to achieve good quality fits to equation below. 
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3.5.8 CD spectroscopy 
 All measurements were performed on Chirascan (Applied Photophysics) equipped 
with a TC 125 temperature controller (Quantum Northwest) and AWC 100 heat exchanger 
(Julabo). The temperature was held at 15 °C and solutions were allowed to equilibrate for 10 
minutes before measurements except for those of the irradiated states of peptides, where they 
were recorded immediately after the exposure to UV light. Data is expressed as mean residue 
ellipticity (MRE) calculated using the following equation: 
 
Equation 11: MRE Where Θ is measured ellipticity in mdeg; n is the number of amino acids minus 1; c is 
concentration in mol/L and l is the pathlength in mm 
3.5.9 Mass Spectrometry 
 The masses of Rev peptides were checked by matrix assisted laser desorption 
ionisation using a MALDI micro MX, MALDI TOF MS (Waters) in reflectron mode. α-
cyano-hydroxy-cinnaminic acid in 1:1 acetonitrile water (2 µL) was used as the matrix And 
mixed on a spot on a MALDI plate with analyte solution (2 µL). 
3.5.10 NMR Spectroscopy 
NMR spectra were acquired at 25 °C on 600 MHz (with room temperature or 
cryogenically cooled probe) and 800 Mhz (with cryogenically cooled probe) Varian Inova 
instruments. In all cases 13C and 15N labelled Bcl-xL was used. For the purpose of backbone 
assignments a following spectra were collected 1H-15N-HSQC, HNCA, HN(CO)CA, 
CACBNH, CACB(CO)NH, HNCO, HN(CA)CO; sidechain assignment was facilitated by 
CCOHN, HCCOHN and HCCH-TOCSY, 13C-HSQC and aided by 3D 1H-15N NOESY-
HSQC and 3D 1H-13C NOESY-HSQC. 
In order to assign the non-isotopically labelled BakI81Fi, i+11-XL-SO3H we collected a 
set of 13C, 15N or just 15N filtered  1H-1H NOESY, 1H-1H TOCSY. To assist the assignment of 
peptides aromatic residues a sample in D2O was prepared and 13C, 15N filtered 1H-1H 
NOESY, 1H-1H TOCSY spectra were acquired. Interproton protein-protein distance restrains 
were derived from 3D 1H-15N NOESY-HSQC and 1H-13C NOESY-HSQC. Interproton 
peptide-peptide distance restrains were derived from 13C, 15N filtered 1H-1H NOESY. 
Interproton peptide-protein distance restrains were derived from F2F filtered 1H-1H NOESY, 
3D 1H,15N NOESY-HSQC and 3D 1H,13C NOESY-HSQC spectra. Dihedral restraints were 
calculated using DANGLE and manually checked for consistency.290 All spectra were 
processed in NMRPipe and analysed in ccpnNMR Analysis 2.1.5.279,291 
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3.6 Synthetic Chemistry Methods 
3.6.1 Peptides Synthesis 
All peptides were synthesized according to standard fluorenylmethylcarbamoyl 
(Fmoc) solid phase synthesis protocols using a CEM Liberty microwave-assisted peptide 
synthesizer. Protected amino acids with trityl (Trt), tert-butyl (tBu), butoxycarbonyl (Boc) or 
2,2,4,6,7- pentamethyldihydrobenzofurane (Pbf) sidechain protecting groups as required, O-
benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU), 
hydroxybenzotriazole (HOBt), N-methylpyrrolidinone (NMP) and dimethylformamide 
(DMF) were purchased from AGTC Bioproducts. Dichloromethane (DCM), trifluoroacetic 
acid (TFA) and diethyl ether were sourced from Fisher. Piperidine, acetic anhydride, tri-iso-
propylsilane (TIS), N,N-diisopropylethylamine  (DIEA), 4-(2-hydroxyethyl)-1-
piperizineethanesulfonic acid (HEPES) and triscarboxyethylphosphine (TCEP) were 
purchased from Sigma Aldrich. Rink Amide resin (0.72 mMol/g) and 5(6)-carboxyfluorescein 
were purchased from NovaBiochem. The following solutions were used for peptide synthesis: 
Activator   0.45M HBTU in DMF 
Deprotection Mix  20% Piperidine, 0.1M HOBt in DMF 
Activator Base  2M DIEA in NMP 
Capping Solution  20% Acetic acid anhydride in DMF 
Amino Acid Solutions 0.1 M Fmoc-protected amino acids in DMF;  
 Fmoc-Ala-OH 
 Fmoc-Arg(Pbf)-OH 
 Fmoc-Asp(tBu)-OH  
 Fmoc-Asn(Trt)-OH 
 Fmoc-Cys(Trt)-OH 
 Fmoc-Glu(tBu)-OH 
 Fmoc-Gln(Trt)-OH 
 Fmoc-Gly-OH 
 Fmoc-Ile-OH 
 Fmoc-Leu-OH 
 Fmoc-Phe-OH 
 Fmoc-Thr(tBu)-OH 
 Fmoc-Trp(Boc)-OH 
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 Fmoc-Val-OH 
Cleavage Cocktail  95% TFA, 2.5% TIS, 2.5% water 
 
Resin (140 mg, 0.1 mMol scale) was transferred to the reaction chamber in a 1:1 mixture of 
DMF and DCM and allowed to swell for 15 minutes. 
Following swelling and at each following step, deprotection was achieved by addition to 
washed resin of 7 mL of the deprotection mix described above, followed by microwave-
assisted deprotection. Heating was provided for 180 seconds using 20 W to achieve a 
maximum temperature of 75 °C with 3 seconds of nitrogen bubbling every 7 seconds. The 
resin was then cooled and washed with DMF (3 × 5 mL). 
Such is the difficult of constructing poly-arginine peptides that double couplings were used 
throughout. Coupling of amino acids was achieved by adding the required amino acid solution 
(2.5 mL), activator (1 mL) and of activator base (0.5 mL) followed by microwave-assisted 
coupling. The heating regime was varied according to the amino acid: 
 
Arginine: No heating was provided for 1800 seconds, then heating was provided for 600 
seconds using 20 W to achieve a maximum temperature of 75 °C. The resin was agitated 
throughout with 3 seconds of nitrogen bubbling every 7 seconds. The resin was then cooled 
and washed with of DMF (3 × 5 mL). Due to the hindering nature of the Pbf sidechain 
protecting group, arginine couplings were followed by a capping step. Capping solution (7 
mL) was added allowed to react for 600 seconds without additional heating. The resin was 
then washed with of DMF (2 × 8 mL). 
 
Cysteine: No heating was provided for 300 seconds, then heating was provided for 900 
seconds using 20 W to achieve a maximum temperature of 50 °C. The resin was agitated 
throughout with 3 seconds of nitrogen bubbling every 7 seconds. The resin was then cooled 
and washed with of DMF (3 × 5 mL). 
 
All other amino acids: Heating was provided for 600 seconds using 20 W to achieve a 
maximum temperature of 75 °C with 3 seconds of nitrogen bubbling every 7 seconds. The 
resin was then cooled and washed with of DMF (3 × 5 mL). 
Final deprotection of the resin-bound peptide chain utilised a two-part deprotection. 
Deprotection mixture (7 mL) was added and heated using 20 W to achieve a maximum 
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temperature of 75 °C for 180 seconds. The solvent was then drained and the resin was washed 
with DMF (3 × 5 mL). A second addition of the deprotection mix (7 mL) was added and 
heated for 180 seconds using 20 W to achieve a maximum temperature of 75 °C with 3 
seconds of nitrogen bubbling every 7 seconds. The resin was then cooled and again washed 
with DMF (3 × 5 mL). 
 
When required, FAM labelling was achieved as previously reported.162 
 
The resin was transferred to 50 mL Falcon tube, drained on a sintered glass filter and 
suspended in cleavage cocktail (20 mL). The cleavage reaction was carried out at room 
temperature for 6 h with shaking, then the resin was filtered and the filtrate was evaporated 
under nitrogen flow until the volume was reduced to approximately 1 mL. This suspension 
was diluted with 49 mL of cold diethyl ether to precipitate the product. After chilling 
overnight at -20 °C, the resulting precipitate was spun down, resuspended in water (+0.5 % 
TFA), filtered and subjected to HPLC purification. 
3.6.2 Crosslinker Synthesis 
 Synthesis of XL-SO3H was achieved as described previously.161,292 XL-H was 
synthesised as detailed in the literature,160 but the last step of chloride substitution with iodine 
was omitted.  
3.6.3 Crosslinking 
Crosslinking with XL-SO3H was achieved by dissolving peptides at 1 mg/mL in pH 
8.3 with Tris:HCl (50 mM) containing TCEP (2 mM). This buffer was also used to disolve 
the XL-SO3H crosslinker at 10x molar excess over the peptide (app. 1 mg/ml). The 
crosslinker solution was transferred in three equal aliquots to the peptide solution. After each 
addition reaction was allowed to proceed for 2h at room temperature and finally the 
temperature was decreased to 4 °C. After an overnight incubation the reaction mixture was 
spun down and the supernatant was subjected to HPLC purification. 
Crosslinking with XL-H was accomplished by dissolving peptides at 1 mg/mL in 
water/THF mixture (1:1) buffered to pH 8.3 with Tris:HCl (50 mM) containing TCEP (2 
mM). The same solvent was used to dissolve the XL-H crosslinker  at concentration 
equivalent to a 10× molar excess over the peptide to be crosslinked. A single equivalent was 
added over the course of 2 hours, the remainder was added in further aliqouts over 3 hours of 
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the solution volume. If precipitation occurred, additional water/TFA was added. After 
overnight reaction, solutions were freeze-dried, resuspended in water containing 0.5% TFA, 
spun down and the supernatant was purified by HPLC. The masses of the crosslinked peptides 
were verified as described below. 
3.6.4 NMR statistics 
 Number of restraints and RMSD of restraints values were derived from final CNS 1.21 
statistics.275,293 The number of proton, nitrogen and carbon assignments was taken from 
Analysis 2.1.5.279 All remaining statistics were calculated with the help of iCING server that 
internally or externally uses PROCHECK and WHATCHECK for quality statistics.294,295 Z-
scores were calculated by comparing appropriate statistic with the average derived from a 
database of high quality crystal structures. 
3.7 Other Methods 
3.7.1 UV light source 
 All irradiations were performed with a UV-P 280 light source (UV Light Technology 
Ltd.) coupled to 360 nm band pass filter (10 nm bandwidth). The lamp was allowed to warm 
up for 30 min before use. The achievement of photostationary state was monitored by 
Nanodrop 1000 spectrophotometer (Thermo Scientific) and always occurred in less than the 
standard 3 minute irradiation time. For binding assays peptides solutions were irradiated in 
thin-walled PCR tubes, which were showed to be transparent for the wavelength of light used. 
3.7.2 Nucleotide Annealing 
Equimolar amounts of each strand were prepared in the annealing buffer (100 mM 
KCl, 2 mM MgCl2, 5 mM HEPES pH 7.5). Annealing was carried out in a PCR thermocycler 
with heated lid. Samples were initially warmed up to 95 °C for 10 min and then slow cooling 
program to 15 °C over 16 h was applied. 
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5 APPENDIX 
Number Shift (ppm) SD (ppm) Assign. Name Residue Isotope 
1 4.34 0.008 Ha 1Met 1H 
2 21.74 0.000 Ce 1Met 13C 
3 2.26 0.008 Hga 1Met 1H 
4 2.31 0.007 Hgb 1Met 1H 
5 1.91 0.002 Hb3 1Met 1H 
6 1.91 0.002 Hb2 1Met 1H 
7 36.36 0.008 Cg 1Met 13C 
8 30.58 0.000 Cb 1Met 13C 
9 56.61 0.034 Ca 1Met 13C 
10 175.76 0.000 C 1Met 13C 
11 1.19 0.006 He* 1Met 1H 
12 122.26 0.051 N 2Ser 15N 
13 7.95 0.003 H 2Ser 1H 
14 59.96 0.042 Ca 2Ser 13C 
15 64.96 0.084 Cb 2Ser 13C 
16 3.81 0.024 Hb2 2Ser 1H 
17 4.27 0.002 Ha 2Ser 1H 
18 3.83 0.027 Hb3 2Ser 1H 
19 7.67 0.003 He2b 3Gln 1H 
20 112.34 0.263 Ne2 3Gln 15N 
21 2.11 0.015 Hba 3Gln 1H 
22 2.31 0.002 Hg2 3Gln 1H 
23 2.11 0.015 Hbb 3Gln 1H 
24 2.31 0.002 Hg3 3Gln 1H 
25 33.67 0.050 Cg 3Gln 13C 
26 56.62 0.099 Ca 3Gln 13C 
27 29.22 0.023 Cb 3Gln 13C 
28 4.39 0.000 Ha 3Gln 1H 
29 179.08 0.023 C 3Gln 13C 
30 6.87 0.003 He2a 3Gln 1H 
31 179.57 0.022 Cd 3Gln 13C 
32 8.65 0.007 H 4Ser 1H 
33 117.10 0.086 N 4Ser 15N 
34 175.93 0.034 C 4Ser 13C 
35 58.99 0.039 Ca 4Ser 13C 
36 63.49 0.037 Cb 4Ser 13C 
37 4.47 0.015 Ha 4Ser 1H 
38 3.91 0.004 Hba 4Ser 1H 
39 4.06 0.008 Hbb 4Ser 1H 
40 8.60 0.010 H 5Asn 1H 
41 122.48 0.070 N 5Asn 15N 
42 8.02 0.005 Hd2b 5Asn 1H 
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43 112.37 0.143 Nd2 5Asn 15N 
44 56.15 0.072 Ca 5Asn 13C 
45 38.36 0.055 Cb 5Asn 13C 
46 177.38 0.007 C 5Asn 13C 
47 4.74 0.012 Ha 5Asn 1H 
48 3.09 0.008 Hbb 5Asn 1H 
49 2.75 0.009 Hba 5Asn 1H 
50 7.50 0.006 Hd2a 5Asn 1H 
51 175.02 0.018 Cg 5Asn 13C 
52 120.02 0.074 N 6Arg 15N 
53 8.25 0.004 H 6Arg 1H 
54 59.86 0.088 Ca 6Arg 13C 
55 29.76 0.122 Cb 6Arg 13C 
56 177.33 0.023 C 6Arg 13C 
57 3.93 0.010 Ha 6Arg 1H 
58 3.19 0.011 Hd3 6Arg 1H 
59 3.19 0.011 Hd2 6Arg 1H 
60 43.26 0.023 Cd 6Arg 13C 
61 27.41 0.045 Cg 6Arg 13C 
62 1.64 0.003 Hgb 6Arg 1H 
63 1.64 0.004 Hga 6Arg 1H 
64 1.93 0.009 Hb3 6Arg 1H 
65 1.93 0.009 Hb2 6Arg 1H 
66 7.95 0.004 H 7Glu 1H 
67 117.80 0.072 N 7Glu 15N 
68 59.38 0.055 Ca 7Glu 13C 
69 179.39 0.028 C 7Glu 13C 
70 36.88 0.115 Cg 7Glu 13C 
71 29.62 0.076 Cb 7Glu 13C 
72 3.91 0.005 Ha 7Glu 1H 
73 2.10 0.010 Hbb 7Glu 1H 
74 2.00 0.008 Hba 7Glu 1H 
75 2.37 0.007 Hgb 7Glu 1H 
76 2.22 0.008 Hga 7Glu 1H 
77 119.79 0.057 N 8Leu 15N 
78 7.73 0.007 H 8Leu 1H 
79 58.12 0.056 Ca 8Leu 13C 
80 41.93 0.043 Cb 8Leu 13C 
81 178.37 0.018 C 8Leu 13C 
82 1.47 0.009 Hg 8Leu 1H 
83 23.52 0.112 Cdb 8Leu 13C 
84 26.24 0.072 Cg 8Leu 13C 
85 0.12 0.004 Hdb* 8Leu 1H 
86 24.29 0.106 Cda 8Leu 13C 
87 -0.02 0.005 Hda* 8Leu 1H 
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88 1.79 0.012 Hbb 8Leu 1H 
89 1.29 0.011 Hba 8Leu 1H 
90 3.87 0.013 Ha 8Leu 1H 
91 7.76 0.006 H 9Val 1H 
92 117.82 0.040 N 9Val 15N 
93 67.77 0.099 Ca 9Val 13C 
94 32.43 0.041 Cb 9Val 13C 
95 177.08 0.046 C 9Val 13C 
96 3.68 0.009 Ha 9Val 1H 
97 1.22 0.015 Hgb* 9Val 1H 
98 1.07 0.008 Hga* 9Val 1H 
99 2.42 0.006 Hb 9Val 1H 
100 22.94 0.113 Cgb 9Val 13C 
101 24.14 0.119 Cga 9Val 13C 
102 31.40 0.068 Cb 10Val 13C 
103 8.33 0.008 H 10Val 1H 
104 117.32 0.071 N 10Val 15N 
105 67.03 0.073 Ca 10Val 13C 
106 178.59 0.042 C 10Val 13C 
107 2.93 0.011 Ha 10Val 1H 
108 0.86 0.010 Hgb* 10Val 1H 
109 0.13 0.006 Hga* 10Val 1H 
110 22.82 0.128 Cgb 10Val 13C 
111 20.18 0.049 Cga 10Val 13C 
112 1.76 0.005 Hb 10Val 1H 
113 43.35 0.093 Cb 11Asp 13C 
114 8.07 0.005 H 11Asp 1H 
115 120.86 0.096 N 11Asp 15N 
116 58.95 0.026 Ca 11Asp 13C 
117 177.50 0.012 C 11Asp 13C 
118 2.68 0.046 Hbb 11Asp 1H 
119 2.56 0.011 Hba 11Asp 1H 
120 4.08 0.009 Ha 11Asp 1H 
121 63.22 0.049 Ca 12Phe 13C 
122 120.29 0.054 N 12Phe 15N 
123 40.13 0.064 Cb 12Phe 13C 
124 8.33 0.005 H 12Phe 1H 
125 178.08 0.023 C 12Phe 13C 
126 3.13 0.009 Hba 12Phe 1H 
127 3.50 0.014 Hbb 12Phe 1H 
128 3.95 0.013 Ha 12Phe 1H 
129 7.09 0.014 Hd* 12Phe 1H 
130 131.49 0.078 Cd* 12Phe 13C 
131 131.37 0.083 Ce* 12Phe 13C 
132 7.47 0.005 He* 12Phe 1H 
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133 116.84 0.064 N 13Leu 15N 
134 8.91 0.004 H 13Leu 1H 
135 58.29 0.059 Ca 13Leu 13C 
136 41.74 0.070 Cb 13Leu 13C 
137 179.45 0.018 C 13Leu 13C 
138 3.99 0.008 Ha 13Leu 1H 
139 0.95 0.011 Hd1* 13Leu 1H 
140 25.77 0.163 Cdb 13Leu 13C 
141 26.66 0.142 Cg 13Leu 13C 
142 0.95 0.010 Hd2* 13Leu 1H 
143 2.27 0.009 Hg 13Leu 1H 
144 1.82 0.010 Hbb 13Leu 1H 
145 21.85 0.049 Cda 13Leu 13C 
146 1.51 0.009 Hba 13Leu 1H 
147 8.50 0.005 H 14Ser 1H 
148 114.31 0.098 N 14Ser 15N 
149 62.59 0.000 Cb 14Ser 13C 
150 177.28 0.021 C 14Ser 13C 
151 62.64 0.065 Ca 14Ser 13C 
152 4.26 0.014 Ha 14Ser 1H 
153 3.96 0.011 Hbb 14Ser 1H 
154 3.83 0.003 Hba 14Ser 1H 
155 124.99 0.063 N 15Tyr 15N 
156 8.25 0.007 H 15Tyr 1H 
157 60.31 0.087 Ca 15Tyr 13C 
158 37.99 0.156 Cb 15Tyr 13C 
159 178.25 0.003 C 15Tyr 13C 
160 3.04 0.005 Hba 15Tyr 1H 
161 4.39 0.013 Ha 15Tyr 1H 
162 6.77 0.013 Hd* 15Tyr 1H 
163 132.18 0.073 Cd* 15Tyr 13C 
164 6.89 0.002 He* 15Tyr 1H 
165 117.41 0.000 Ce* 15Tyr 13C 
166 120.26 0.065 N 16Lys 15N 
167 8.33 0.005 H 16Lys 1H 
168 180.27 0.035 C 16Lys 13C 
169 57.06 0.042 Ca 16Lys 13C 
170 29.85 0.051 Cb 16Lys 13C 
171 3.83 0.017 Ha 16Lys 1H 
172 41.18 0.081 Cb 17Leu 13C 
173 27.93 0.158 Cg 17Leu 13C 
174 26.40 0.110 Cdb 17Leu 13C 
175 23.99 0.056 Cda 17Leu 13C 
176 2.14 0.014 Hbb 17Leu 1H 
177 4.08 0.009 Ha 17Leu 1H 
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178 1.52 0.012 Hba 17Leu 1H 
179 0.93 0.010 Hdb* 17Leu 1H 
180 0.76 0.007 Hda* 17Leu 1H 
181 1.85 0.010 Hg 17Leu 1H 
182 118.56 0.046 N 17Leu 15N 
183 8.73 0.003 H 17Leu 1H 
184 58.69 0.101 Ca 17Leu 13C 
185 179.92 0.010 C 17Leu 13C 
186 8.39 0.019 H 18Ser 1H 
187 117.86 0.049 N 18Ser 15N 
188 61.78 0.089 Ca 18Ser 13C 
189 62.61 0.138 Cb 18Ser 13C 
190 178.61 0.002 C 18Ser 13C 
191 4.70 0.007 Ha 18Ser 1H 
192 4.21 0.012 Hbb 18Ser 1H 
193 4.10 0.005 Hba 18Ser 1H 
194 122.90 0.060 N 19Gln 15N 
195 7.69 0.005 H 19Gln 1H 
196 7.52 0.009 He2b 19Gln 1H 
197 6.85 0.008 He2a 19Gln 1H 
198 114.61 0.250 Ne2 19Gln 15N 
199 58.54 0.154 Ca 19Gln 13C 
200 28.80 0.195 Cb 19Gln 13C 
201 4.02 0.005 Ha 19Gln 1H 
202 34.46 0.106 Cg 19Gln 13C 
203 177.24 0.017 C 19Gln 13C 
204 2.11 0.010 Hgb 19Gln 1H 
205 2.00 0.027 Hga 19Gln 1H 
206 179.72 0.007 Cd 19Gln 13C 
207 42.27 0.136 Ce 20Lys 13C 
208 116.43 0.049 N 20Lys 15N 
209 7.27 0.003 H 20Lys 1H 
210 54.03 0.168 Ca 20Lys 13C 
211 32.66 0.150 Cb 20Lys 13C 
212 4.43 0.008 Ha 20Lys 1H 
213 1.68 0.009 Hdb 20Lys 1H 
214 3.03 0.015 He2 20Lys 1H 
215 2.12 0.008 Hbb 20Lys 1H 
216 28.27 0.070 Cd 20Lys 13C 
217 1.68 0.009 Hda 20Lys 1H 
218 3.03 0.015 He3 20Lys 1H 
219 25.11 0.071 Cg 20Lys 13C 
220 1.04 0.028 Hga 20Lys 1H 
221 1.78 0.025 Hba 20Lys 1H 
222 1.57 0.010 Hgb 20Lys 1H 
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223 175.58 0.024 C 20Lys 13C 
224 7.62 0.005 H 21Gly 1H 
225 105.59 0.078 N 21Gly 15N 
226 45.32 0.077 Ca 21Gly 13C 
227 3.68 0.007 Haa 21Gly 1H 
228 4.00 0.006 Hab 21Gly 1H 
229 174.01 0.000 C 21Gly 13C 
230 2.79 0.008 Hba 22Tyr 1H 
231 5.05 0.006 Ha 22Tyr 1H 
232 3.22 0.008 Hbb 22Tyr 1H 
233 7.89 0.004 H 22Tyr 1H 
234 119.88 0.049 N 22Tyr 15N 
235 55.65 0.027 Ca 22Tyr 13C 
236 40.97 0.077 Cb 22Tyr 13C 
237 175.02 0.005 C 22Tyr 13C 
238 6.83 0.008 He* 22Tyr 1H 
239 131.92 0.053 Cd* 22Tyr 13C 
240 118.16 0.048 Ce* 22Tyr 13C 
241 7.07 0.006 Hd* 22Tyr 1H 
242 4.86 0.005 Ha 23Ser 1H 
243 3.83 0.003 Hb3 23Ser 1H 
244 3.83 0.004 Hb2 23Ser 1H 
245 115.41 0.046 N 23Ser 15N 
246 8.56 0.006 H 23Ser 1H 
247 64.78 0.047 Cb 23Ser 13C 
248 56.78 0.066 Ca 23Ser 13C 
249 174.48 0.032 C 23Ser 13C 
250 4.35 0.015 Ha 24Trp 1H 
251 3.47 0.010 Hbb 24Trp 1H 
252 3.20 0.008 Hba 24Trp 1H 
253 10.07 0.001 He1 24Trp 1H 
254 128.94 0.070 Ne1 24Trp 15N 
255 9.03 0.006 H 24Trp 1H 
256 127.53 0.057 N 24Trp 15N 
257 60.05 0.075 Ca 24Trp 13C 
258 30.82 0.071 Cb 24Trp 13C 
259 176.88 0.042 C 24Trp 13C 
260 7.29 0.015 He3 24Trp 1H 
261 7.03 0.011 Hd1 24Trp 1H 
262 6.72 0.008 Hz3 24Trp 1H 
263 6.81 0.009 Hh2 24Trp 1H 
264 119.19 0.067 Ce3 24Trp 13C 
265 131.43 0.000 Cd1 24Trp 13C 
266 7.29 0.007 Hz2 24Trp 1H 
267 121.18 0.102 Cz3 24Trp 13C 
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268 122.83 0.026 Ch2 24Trp 13C 
269 114.37 0.040 Cz2 24Trp 13C 
270 60.03 0.044 Ca 25Ser 13C 
271 4.10 0.004 Ha 25Ser 1H 
272 3.87 0.014 Hb3 25Ser 1H 
273 3.87 0.013 Hb2 25Ser 1H 
274 112.24 0.081 N 25Ser 15N 
275 8.24 0.006 H 25Ser 1H 
276 62.93 0.132 Cb 25Ser 13C 
277 175.16 0.022 C 25Ser 13C 
278 34.24 0.070 Cg 26Gln 13C 
279 3.89 0.008 Ha 26Gln 1H 
280 1.84 0.007 Hga 26Gln 1H 
281 1.96 0.003 Hgb 26Gln 1H 
282 1.38 0.004 Hba 26Gln 1H 
283 1.50 0.008 Hbb 26Gln 1H 
284 7.47 0.005 H 26Gln 1H 
285 119.53 0.052 N 26Gln 15N 
286 7.35 0.005 He2b 26Gln 1H 
287 111.10 0.201 Ne2 26Gln 15N 
288 6.82 0.005 He2a 26Gln 1H 
289 56.96 0.106 Ca 26Gln 13C 
290 28.76 0.104 Cb 26Gln 13C 
291 176.07 0.030 C 26Gln 13C 
292 180.23 0.012 Cd 26Gln 13C 
293 3.04 0.008 Hbb 27Phe 1H 
294 4.59 0.006 Ha 27Phe 1H 
295 2.17 0.010 Hba 27Phe 1H 
296 116.67 0.047 N 27Phe 15N 
297 7.34 0.005 H 27Phe 1H 
298 39.91 0.056 Cb 27Phe 13C 
299 56.63 0.118 Ca 27Phe 13C 
300 129.28 0.012 Cz 27Phe 13C 
301 6.87 0.018 Hz 27Phe 1H 
302 130.98 0.053 Ce* 27Phe 13C 
303 7.06 0.006 He* 27Phe 1H 
304 175.11 0.014 C 27Phe 13C 
305 7.02 0.009 Hd* 27Phe 1H 
306 131.46 0.147 Cd* 27Phe 13C 
307 7.34 0.007 H 28Ser 1H 
308 114.12 0.093 N 28Ser 15N 
309 57.66 0.063 Ca 28Ser 13C 
310 63.93 0.079 Cb 28Ser 13C 
311 4.15 0.005 Ha 28Ser 1H 
312 3.18 0.014 Hba 28Ser 1H 
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313 3.24 0.016 Hbb 28Ser 1H 
314 173.70 0.015 C 28Ser 13C 
315 8.37 0.005 H 29Asp 1H 
316 122.73 0.065 N 29Asp 15N 
317 54.19 0.101 Ca 29Asp 13C 
318 41.15 0.062 Cb 29Asp 13C 
319 4.60 0.010 Ha 29Asp 1H 
320 2.66 0.007 Hb3 29Asp 1H 
321 2.66 0.007 Hb2 29Asp 1H 
322 176.32 0.007 C 29Asp 13C 
323 7.97 0.002 H 30Val 1H 
324 119.20 0.089 N 30Val 15N 
325 62.42 0.040 Ca 30Val 13C 
326 33.02 0.079 Cb 30Val 13C 
327 0.90 0.003 Hg2* 30Val 1H 
328 4.10 0.002 Ha 30Val 1H 
329 0.90 0.003 Hg1* 30Val 1H 
330 2.07 0.021 Hb 30Val 1H 
331 21.09 0.347 Cga 30Val 13C 
332 20.50 0.090 Cga 30Val 13C 
333 176.23 0.001 C 30Val 13C 
334 8.50 0.010 H 31Glu 1H 
335 124.47 0.051 N 31Glu 15N 
336 56.71 0.098 Ca 31Glu 13C 
337 30.25 0.026 Cb 31Glu 13C 
338 36.37 0.000 Cg 31Glu 13C 
339 2.26 0.004 Hb3 31Glu 1H 
340 2.26 0.005 Hg2 31Glu 1H 
341 4.26 0.004 Ha 31Glu 1H 
342 176.53 0.007 C 31Glu 13C 
343 2.26 0.004 Hg3 31Glu 1H 
344 2.26 0.004 Hb2 31Glu 1H 
345 122.14 0.082 N 32Glu 15N 
346 8.43 0.003 H 32Glu 1H 
347 30.64 0.195 Cb 32Glu 13C 
348 56.73 0.064 Ca 32Glu 13C 
349 2.26 0.013 Hbb 32Glu 1H 
350 2.26 0.013 Hba 32Glu 1H 
351 36.33 0.031 Cg 32Glu 13C 
352 4.23 0.014 Ha 32Glu 1H 
353 1.94 0.008 Hg2 32Glu 1H 
354 1.94 0.008 Hg3 32Glu 1H 
355 176.17 0.017 C 32Glu 13C 
356 8.50 0.013 H 33Asn 1H 
357 119.56 0.103 N 33Asn 15N 
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358 6.92 0.003 Hd2a 33Asn 1H 
359 112.70 0.218 Nd2 33Asn 15N 
360 7.60 0.015 Hd2b 33Asn 1H 
361 53.36 0.154 Ca 33Asn 13C 
362 38.99 0.109 Cb 33Asn 13C 
363 4.71 0.037 Ha 33Asn 1H 
364 2.83 0.013 Hbb 33Asn 1H 
365 2.73 0.011 Hba 33Asn 1H 
366 174.98 0.006 C 33Asn 13C 
367 177.04 0.005 Cg 33Asn 13C 
368 8.33 0.007 H 34Arg 1H 
369 122.04 0.048 N 34Arg 15N 
370 56.15 0.027 Ca 34Arg 13C 
371 30.89 0.081 Cb 34Arg 13C 
372 27.05 0.044 Cg 34Arg 13C 
373 4.41 0.009 Ha 34Arg 1H 
374 3.19 0.007 Hdb 34Arg 1H 
375 43.36 0.106 Cd 34Arg 13C 
376 1.62 0.010 Hg3 34Arg 1H 
377 1.77 0.003 Hba 34Arg 1H 
378 1.89 0.007 Hbb 34Arg 1H 
379 1.62 0.010 Hg2 34Arg 1H 
380 176.47 0.016 C 34Arg 13C 
381 3.19 0.003 Hda 34Arg 1H 
382 8.28 0.004 H 35Thr 1H 
383 115.85 0.051 N 35Thr 15N 
384 62.08 0.061 Ca 35Thr 13C 
385 69.83 0.062 Cb 35Thr 13C 
386 4.22 0.005 Hb 35Thr 1H 
387 21.60 0.123 Cg2 35Thr 13C 
388 1.20 0.005 Hg1 35Thr 1H 
389 174.43 0.008 C 35Thr 13C 
390 4.33 0.008 Ha 35Thr 1H 
391 8.40 0.004 H 36Glu 1H 
392 123.07 0.046 N 36Glu 15N 
393 56.40 0.164 Ca 36Glu 13C 
394 30.38 0.022 Cb 36Glu 13C 
395 36.22 0.000 Cg 36Glu 13C 
396 4.31 0.008 Ha 36Glu 1H 
397 2.25 0.002 Hba 36Glu 1H 
398 175.64 0.002 C 36Glu 13C 
399 8.31 0.007 H 37Ala 1H 
400 126.19 0.039 N 37Ala 15N 
401 50.53 0.098 Ca 37Ala 13C 
402 18.63 0.098 Cb 37Ala 13C 
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403 1.35 0.002 Hb* 37Ala 1H 
404 4.61 0.002 Ha 37Ala 1H 
405 175.42 0.000 C 37Ala 13C 
406 3.66 0.006 Hda 38Pro 1H 
407 1.93 0.010 Hga 38Pro 1H 
408 63.22 0.110 Ca 38Pro 13C 
409 32.13 0.102 Cb 38Pro 13C 
410 27.58 0.051 Cg 38Pro 13C 
411 3.77 0.005 Hdb 38Pro 1H 
412 4.43 0.005 Ha 38Pro 1H 
413 50.61 0.042 Cd 38Pro 13C 
414 2.29 0.006 Hbb 38Pro 1H 
415 2.02 0.012 Hgb 38Pro 1H 
416 177.03 0.000 C 38Pro 13C 
417 1.94 0.011 Hba 38Pro 1H 
418 8.64 0.002 H 39Glu 1H 
419 121.30 0.093 N 39Glu 15N 
420 56.84 0.031 Ca 39Glu 13C 
421 30.44 0.228 Cb 39Glu 13C 
422 36.33 0.015 Cg 39Glu 13C 
423 4.30 0.009 Ha 39Glu 1H 
424 2.30 0.005 Hg2 39Glu 1H 
425 177.08 0.009 C 39Glu 13C 
426 1.99 0.023 Hba 39Glu 1H 
427 2.05 0.023 Hbb 39Glu 1H 
428 2.30 0.005 Hg3 39Glu 1H 
429 110.32 0.034 N 40Gly 15N 
430 8.52 0.003 H 40Gly 1H 
431 45.49 0.010 Ca 40Gly 13C 
432 4.08 0.007 Hab 40Gly 1H 
433 4.08 0.007 Haa 40Gly 1H 
434 174.60 0.037 C 40Gly 13C 
435 8.27 0.004 H 41Thr 1H 
436 113.18 0.040 N 41Thr 15N 
437 62.27 0.111 Ca 41Thr 13C 
438 69.92 0.032 Cb 41Thr 13C 
439 4.39 0.024 Ha 41Thr 1H 
440 1.20 0.005 Hg1 41Thr 1H 
441 21.79 0.000 Cg2 41Thr 13C 
442 175.50 0.040 C 41Thr 13C 
443 4.31 0.005 Hb 41Thr 1H 
444 123.14 0.060 N 42Glu 15N 
445 8.85 0.010 H 42Glu 1H 
446 57.49 0.055 Ca 42Glu 13C 
447 29.92 0.190 Cb 42Glu 13C 
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448 2.31 0.006 Hgb 42Glu 1H 
449 36.31 0.031 Cg 42Glu 13C 
450 4.37 0.009 Ha 42Glu 1H 
451 1.96 0.006 Hba 42Glu 1H 
452 177.16 0.053 C 42Glu 13C 
453 2.31 0.005 Hga 42Glu 1H 
454 2.07 0.013 Hbb 42Glu 1H 
455 115.68 0.117 N 43Ser 15N 
456 8.51 0.016 H 43Ser 1H 
457 58.92 0.044 Ca 43Ser 13C 
458 63.71 0.044 Cb 43Ser 13C 
459 4.43 0.007 Ha 43Ser 1H 
460 3.98 0.012 Hbb 43Ser 1H 
461 3.89 0.011 Hba 43Ser 1H 
462 175.67 0.022 C 43Ser 13C 
463 29.41 0.040 Cb 44Glu 13C 
464 123.10 0.044 N 44Glu 15N 
465 8.35 0.023 H 44Glu 1H 
466 36.05 0.000 Cg 44Glu 13C 
467 59.07 0.051 Ca 44Glu 13C 
468 2.32 0.001 Hgb 44Glu 1H 
469 2.32 0.003 Hga 44Glu 1H 
470 3.99 0.004 Ha 44Glu 1H 
471 2.06 0.010 Hba 44Glu 1H 
472 177.92 0.014 C 44Glu 13C 
473 2.06 0.010 Hbb 44Glu 1H 
474 120.96 0.067 N 45Ala 15N 
475 8.23 0.005 H 45Ala 1H 
476 55.16 0.081 Ca 45Ala 13C 
477 18.58 0.148 Cb 45Ala 13C 
478 4.13 0.005 Ha 45Ala 1H 
479 1.47 0.009 Hb* 45Ala 1H 
480 180.64 0.004 C 45Ala 13C 
481 118.87 0.057 N 46Val 15N 
482 7.57 0.009 H 46Val 1H 
483 66.19 0.030 Ca 46Val 13C 
484 31.81 0.068 Cb 46Val 13C 
485 1.04 0.006 Hgb* 46Val 1H 
486 0.55 0.004 Hga* 46Val 1H 
487 3.50 0.004 Ha 46Val 1H 
488 1.96 0.006 Hb 46Val 1H 
489 22.45 0.074 Cga 46Val 13C 
490 22.91 0.201 Cgb 46Val 13C 
491 176.72 0.015 C 46Val 13C 
492 32.51 0.084 Cb 47Lys 13C 
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493 117.92 0.047 N 47Lys 15N 
494 7.44 0.008 H 47Lys 1H 
495 59.80 0.063 Ca 47Lys 13C 
496 1.60 0.022 Hba 47Lys 1H 
497 1.87 0.008 Hbb 47Lys 1H 
498 2.72 0.008 Heb 47Lys 1H 
499 1.13 0.010 Hga 47Lys 1H 
500 1.31 0.000 Hgb 47Lys 1H 
501 2.72 0.008 Hea 47Lys 1H 
502 30.20 0.000 Cd 47Lys 13C 
503 3.72 0.008 Ha 47Lys 1H 
504 178.89 0.014 C 47Lys 13C 
505 116.49 0.075 N 48Gln 15N 
506 8.17 0.004 H 48Gln 1H 
507 7.88 0.002 He2b 48Gln 1H 
508 6.65 0.032 He2a 48Gln 1H 
509 112.09 0.276 Ne2 48Gln 15N 
510 59.03 0.085 Ca 48Gln 13C 
511 28.10 0.068 Cb 48Gln 13C 
512 2.37 0.004 Hgb 48Gln 1H 
513 33.21 0.100 Cg 48Gln 13C 
514 2.37 0.004 Hga 48Gln 1H 
515 1.98 0.008 Hba 48Gln 1H 
516 2.08 0.007 Hbb 48Gln 1H 
517 3.71 0.011 Ha 48Gln 1H 
518 177.63 0.039 C 48Gln 13C 
519 179.78 0.069 Cd 48Gln 13C 
520 120.36 0.078 N 49Ala 15N 
521 7.79 0.007 H 49Ala 1H 
522 54.93 0.055 Ca 49Ala 13C 
523 18.71 0.061 Cb 49Ala 13C 
524 1.46 0.008 Hb* 49Ala 1H 
525 4.23 0.004 Ha 49Ala 1H 
526 179.81 0.045 C 49Ala 13C 
527 23.49 0.115 Cdb 50Leu 13C 
528 8.49 0.006 H 50Leu 1H 
529 120.59 0.052 N 50Leu 15N 
530 58.58 0.052 Ca 50Leu 13C 
531 42.28 0.075 Cb 50Leu 13C 
532 23.33 0.068 Cda 50Leu 13C 
533 4.15 0.007 Ha 50Leu 1H 
534 0.12 0.006 Hdb* 50Leu 1H 
535 -0.37 0.004 Hda* 50Leu 1H 
536 1.23 0.009 Hg 50Leu 1H 
537 26.97 0.092 Cg 50Leu 13C 
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538 1.50 0.020 Hbb 50Leu 1H 
539 1.43 0.018 Hba 50Leu 1H 
540 179.23 0.009 C 50Leu 13C 
541 30.89 0.091 Cb 51Arg 13C 
542 118.93 0.060 N 51Arg 15N 
543 8.17 0.008 H 51Arg 1H 
544 60.95 0.034 Ca 51Arg 13C 
545 178.62 0.027 C 51Arg 13C 
546 3.77 0.009 Ha 51Arg 1H 
547 116.53 0.059 N 52Glu 15N 
548 7.91 0.006 H 52Glu 1H 
549 59.38 0.038 Ca 52Glu 13C 
550 36.76 0.047 Cg 52Glu 13C 
551 4.16 0.006 Ha 52Glu 1H 
552 29.64 0.036 Cb 52Glu 13C 
553 2.38 0.005 Hga 52Glu 1H 
554 2.17 0.022 Hb3 52Glu 1H 
555 2.59 0.007 Hgb 52Glu 1H 
556 2.17 0.020 Hb2 52Glu 1H 
557 179.94 0.001 C 52Glu 13C 
558 123.23 0.084 N 53Ala 15N 
559 8.90 0.004 H 53Ala 1H 
560 55.11 0.025 Ca 53Ala 13C 
561 19.48 0.097 Cb 53Ala 13C 
562 1.69 0.009 Hb* 53Ala 1H 
563 4.47 0.004 Ha 53Ala 1H 
564 181.68 0.067 C 53Ala 13C 
565 9.19 0.003 H 54Gly 1H 
566 108.71 0.059 N 54Gly 15N 
567 47.11 0.093 Ca 54Gly 13C 
568 4.05 0.009 Hab 54Gly 1H 
569 175.33 0.000 C 54Gly 13C 
570 4.04 0.020 Haa 54Gly 1H 
571 39.84 0.047 Cb 55Asp 13C 
572 122.89 0.072 N 55Asp 15N 
573 8.22 0.007 H 55Asp 1H 
574 57.75 0.016 Ca 55Asp 13C 
575 179.02 0.036 C 55Asp 13C 
576 2.75 0.005 Hba 55Asp 1H 
577 3.04 0.014 Hbb 55Asp 1H 
578 120.75 0.088 N 56Glu 15N 
579 8.28 0.003 H 56Glu 1H 
580 59.60 0.026 Ca 56Glu 13C 
581 36.37 0.040 Cg 56Glu 13C 
582 178.47 0.007 C 56Glu 13C 
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583 29.78 0.093 Cb 56Glu 13C 
584 2.30 0.007 Hb3 56Glu 1H 
585 2.30 0.007 Hb2 56Glu 1H 
586 2.44 0.006 Hga 56Glu 1H 
587 4.18 0.011 Ha 56Glu 1H 
588 2.44 0.006 Hgb 56Glu 1H 
589 8.67 0.006 H 57Phe 1H 
590 121.60 0.058 N 57Phe 15N 
591 61.91 0.119 Ca 57Phe 13C 
592 177.01 0.004 C 57Phe 13C 
593 40.03 0.091 Cb 57Phe 13C 
594 3.45 0.019 Hb3 57Phe 1H 
595 3.45 0.019 Hb2 57Phe 1H 
596 7.41 0.019 Hd* 57Phe 1H 
597 131.76 0.079 Cd* 57Phe 13C 
598 131.91 0.005 Ce* 57Phe 13C 
599 7.25 0.009 He* 57Phe 1H 
600 4.34 0.005 Ha 57Phe 1H 
601 8.14 0.008 H 58Glu 1H 
602 116.77 0.045 N 58Glu 15N 
603 29.78 0.124 Cb 58Glu 13C 
604 58.79 0.068 Ca 58Glu 13C 
605 36.69 0.080 Cg 58Glu 13C 
606 177.66 0.021 C 58Glu 13C 
607 3.67 0.007 Ha 58Glu 1H 
608 2.14 0.003 Hbb 58Glu 1H 
609 2.62 0.005 Hgb 58Glu 1H 
610 2.01 0.007 Hga 58Glu 1H 
611 2.02 0.008 Hba 58Glu 1H 
612 7.51 0.008 H 59Leu 1H 
613 117.34 0.054 N 59Leu 15N 
614 56.97 0.049 Ca 59Leu 13C 
615 42.98 0.051 Cb 59Leu 13C 
616 178.95 0.015 C 59Leu 13C 
617 24.55 0.063 Cdb 59Leu 13C 
618 4.20 0.009 Ha 59Leu 1H 
619 1.79 0.004 Hbb 59Leu 1H 
620 1.68 0.013 Hg 59Leu 1H 
621 1.70 0.011 Hba 59Leu 1H 
622 27.38 0.264 Cg 59Leu 13C 
623 24.55 0.063 Cda 59Leu 13C 
624 0.91 0.008 Hda* 59Leu 1H 
625 0.91 0.008 Hdb* 59Leu 1H 
626 57.90 0.087 Ca 60Arg 13C 
627 31.15 0.059 Cb 60Arg 13C 
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628 117.78 0.096 N 60Arg 15N 
629 8.07 0.011 H 60Arg 1H 
630 177.34 0.043 C 60Arg 13C 
631 27.41 0.125 Cg 60Arg 13C 
632 43.38 0.085 Cd 60Arg 13C 
633 1.15 0.005 Hga 60Arg 1H 
634 1.48 0.008 Hgb 60Arg 1H 
635 3.02 0.002 Hd3 60Arg 1H 
636 1.25 0.013 Hba 60Arg 1H 
637 3.02 0.003 Hd2 60Arg 1H 
638 3.96 0.003 Ha 60Arg 1H 
639 1.52 0.011 Hbb 60Arg 1H 
640 2.24 0.007 Hba 61Tyr 1H 
641 2.79 0.006 Hbb 61Tyr 1H 
642 8.05 0.007 H 61Tyr 1H 
643 119.06 0.055 N 61Tyr 15N 
644 56.29 0.027 Ca 61Tyr 13C 
645 37.02 0.069 Cb 61Tyr 13C 
646 4.74 0.011 Ha 61Tyr 1H 
647 175.21 0.020 C 61Tyr 13C 
648 133.46 0.032 Cd* 61Tyr 13C 
649 6.89 0.007 Hd* 61Tyr 1H 
650 6.77 0.006 He* 61Tyr 1H 
651 117.44 0.058 Ce* 61Tyr 13C 
652 7.42 0.006 H 62Arg 1H 
653 119.96 0.059 N 62Arg 15N 
654 30.14 0.059 Cb 62Arg 13C 
655 59.02 0.184 Ca 62Arg 13C 
656 4.06 0.006 Ha 62Arg 1H 
657 178.18 0.000 C 62Arg 13C 
658 1.72 0.005 Hg2 62Arg 1H 
659 3.28 0.005 Hd2 62Arg 1H 
660 1.72 0.005 Hg3 62Arg 1H 
661 3.28 0.005 Hd3 62Arg 1H 
662 27.10 0.082 Cg 62Arg 13C 
663 1.97 0.005 Hbb 62Arg 1H 
664 43.34 0.051 Cd 62Arg 13C 
665 1.82 0.015 Hba 62Arg 1H 
666 177.39 0.011 C 63Arg 13C 
667 43.10 0.115 Cd 63Arg 13C 
668 4.22 0.003 Ha 63Arg 1H 
669 57.73 0.057 Ca 63Arg 13C 
670 1.64 0.003 Hg3 63Arg 1H 
671 1.64 0.003 Hg2 63Arg 1H 
672 3.21 0.009 Hd3 63Arg 1H 
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673 1.82 0.015 Hba 63Arg 1H 
674 3.21 0.009 Hd2 63Arg 1H 
675 27.28 0.116 Cg 63Arg 13C 
676 29.18 0.157 Cb 63Arg 13C 
677 1.97 0.006 Hbb 63Arg 1H 
678 122.00 0.061 N 64Ala 15N 
679 7.87 0.008 H 64Ala 1H 
680 54.58 0.121 Ca 64Ala 13C 
681 18.64 0.112 Cb 64Ala 13C 
682 1.30 0.005 Hb* 64Ala 1H 
683 4.10 0.004 Ha 64Ala 1H 
684 179.97 0.014 C 64Ala 13C 
685 8.58 0.007 H 65Phe 1H 
686 115.86 0.077 N 65Phe 15N 
687 58.22 0.090 Ca 65Phe 13C 
688 38.88 0.057 Cb 65Phe 13C 
689 177.38 0.017 C 65Phe 13C 
690 3.38 0.008 Hbb 65Phe 1H 
691 3.15 0.008 Hba 65Phe 1H 
692 4.80 0.014 Ha 65Phe 1H 
693 7.33 0.012 Hd* 65Phe 1H 
694 131.01 0.059 Cd* 65Phe 13C 
695 116.94 0.193 N 66Ser 15N 
696 8.23 0.025 H 66Ser 1H 
697 61.76 0.094 Ca 66Ser 13C 
698 63.01 0.048 Cb 66Ser 13C 
699 176.47 0.038 C 66Ser 13C 
700 4.22 0.008 Ha 66Ser 1H 
701 3.98 0.004 Hb2 66Ser 1H 
702 3.98 0.004 Hb3 66Ser 1H 
703 8.48 0.006 H 67Asp 1H 
704 121.62 0.117 N 67Asp 15N 
705 56.83 0.019 Ca 67Asp 13C 
706 40.18 0.076 Cb 67Asp 13C 
707 178.40 0.042 C 67Asp 13C 
708 2.71 0.002 Hb3 67Asp 1H 
709 2.71 0.003 Hb2 67Asp 1H 
710 4.49 0.009 Ha 67Asp 1H 
711 121.20 0.071 N 68Leu 15N 
712 7.89 0.016 H 68Leu 1H 
713 57.97 0.088 Ca 68Leu 13C 
714 42.56 0.041 Cb 68Leu 13C 
715 179.05 0.017 C 68Leu 13C 
716 1.73 0.005 Hbb 68Leu 1H 
717 1.58 0.007 Hg 68Leu 1H 
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718 4.10 0.005 Ha 68Leu 1H 
719 1.46 0.006 Hba 68Leu 1H 
720 24.48 0.295 Cdb 68Leu 13C 
721 24.56 0.100 Cdb 68Leu 13C 
722 0.60 0.011 Hdb* 68Leu 1H 
723 27.04 0.050 Cg 68Leu 13C 
724 0.60 0.014 Hda* 68Leu 1H 
725 4.09 0.028 Ha 69Thr 1H 
726 68.44 0.186 Cb 69Thr 13C 
727 1.15 0.006 Hg2* 69Thr 1H 
728 65.84 0.114 Ca 69Thr 13C 
729 4.31 0.008 Hb 69Thr 1H 
730 110.28 0.084 N 69Thr 15N 
731 8.49 0.012 H 69Thr 1H 
732 177.46 0.041 C 69Thr 13C 
733 22.69 0.026 Cg2 69Thr 13C 
734 7.75 0.006 H 70Ser 1H 
735 116.58 0.099 N 70Ser 15N 
736 60.68 0.056 Ca 70Ser 13C 
737 63.30 0.129 Cb 70Ser 13C 
738 4.04 0.002 Hb2 70Ser 1H 
739 4.04 0.002 Hb3 70Ser 1H 
740 4.33 0.013 Ha 70Ser 1H 
741 175.61 0.028 C 70Ser 13C 
742 34.13 0.075 Cg 71Gln 13C 
743 119.13 0.081 N 71Gln 15N 
744 7.75 0.005 H 71Gln 1H 
745 7.25 0.003 He2b 71Gln 1H 
746 111.43 0.274 Ne2 71Gln 15N 
747 6.77 0.030 He2a 71Gln 1H 
748 57.41 0.075 Ca 71Gln 13C 
749 29.53 0.121 Cb 71Gln 13C 
750 2.50 0.008 Hgb 71Gln 1H 
751 176.34 0.017 C 71Gln 13C 
752 2.12 0.022 Hbb 71Gln 1H 
753 4.11 0.004 Ha 71Gln 1H 
754 2.38 0.006 Hga 71Gln 1H 
755 2.12 0.022 Hba 71Gln 1H 
756 179.83 0.038 Cd 71Gln 13C 
757 55.44 0.097 Ca 72Leu 13C 
758 118.80 0.067 N 72Leu 15N 
759 7.58 0.004 H 72Leu 1H 
760 43.89 0.068 Cb 72Leu 13C 
761 1.54 0.008 Hba 72Leu 1H 
762 1.96 0.012 Hbb 72Leu 1H 
 197 
 
763 0.95 0.006 Hda* 72Leu 1H 
764 4.31 0.006 Ha 72Leu 1H 
765 174.29 0.000 C 72Leu 13C 
766 1.08 0.013 Hdb* 72Leu 1H 
767 1.64 0.006 Hg 72Leu 1H 
768 27.15 0.075 Cdb 72Leu 13C 
769 23.86 0.048 Cda 72Leu 13C 
770 27.12 0.116 Cg 72Leu 13C 
771 4.64 0.006 Ha 73His 1H 
772 3.02 0.005 Hba 73His 1H 
773 3.25 0.006 Hbb 73His 1H 
774 28.75 0.049 Cb 73His 13C 
775 54.96 0.022 Ca 73His 13C 
776 174.45 0.000 C 73His 13C 
777 122.47 0.040 N 74Ile 15N 
778 8.77 0.010 H 74Ile 1H 
779 61.96 0.057 Ca 74Ile 13C 
780 14.40 0.122 Cd1 74Ile 13C 
781 0.90 0.014 Hg2* 74Ile 1H 
782 0.94 0.008 Hd1* 74Ile 1H 
783 17.50 0.162 Cg2 74Ile 13C 
784 1.39 0.007 Hg1a 74Ile 1H 
785 28.32 0.082 Cg1 74Ile 13C 
786 1.59 0.004 Hg1b 74Ile 1H 
787 1.79 0.005 Hb 74Ile 1H 
788 4.21 0.006 Ha 74Ile 1H 
789 38.95 0.120 Cb 74Ile 13C 
790 7.95 0.005 H 75Thr 1H 
791 120.54 0.072 N 75Thr 15N 
792 1.52 0.002 Hg2* 75Thr 1H 
793 23.02 0.024 Cg2 75Thr 13C 
794 4.34 0.004 Hb 75Thr 1H 
795 4.32 0.014 Ha 75Thr 1H 
796 4.33 0.012 Hab 77Gly 1H 
797 3.68 0.008 Haa 77Gly 1H 
798 44.79 0.105 Ca 77Gly 13C 
799 130.04 0.033 N 78Thr 15N 
800 8.80 0.012 H 78Thr 1H 
801 4.15 0.007 Hb 78Thr 1H 
802 1.52 0.007 Hg2* 78Thr 1H 
803 4.15 0.006 Ha 78Thr 1H 
804 51.12 0.080 Ca 79Ala 13C 
805 177.64 0.000 C 79Ala 13C 
806 21.52 0.043 Cb 79Ala 13C 
807 1.65 0.003 Hb* 79Ala 1H 
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808 4.83 0.000 Ha 79Ala 1H 
809 121.37 0.069 N 80Tyr 15N 
810 8.86 0.011 H 80Tyr 1H 
811 60.85 0.013 Ca 80Tyr 13C 
812 4.65 0.000 Ha 80Tyr 1H 
813 38.16 0.072 Cb 80Tyr 13C 
814 176.56 0.017 C 80Tyr 13C 
815 7.03 0.009 He* 80Tyr 1H 
816 2.76 0.022 Hbb 80Tyr 1H 
817 2.51 0.008 Hba 80Tyr 1H 
818 6.56 0.008 Hd* 80Tyr 1H 
819 118.18 0.029 Ce* 80Tyr 13C 
820 132.47 0.011 Cd* 80Tyr 13C 
821 115.12 0.088 N 81Gln 15N 
822 8.53 0.007 H 81Gln 1H 
823 7.78 0.002 He2b 81Gln 1H 
824 7.00 0.003 He2a 81Gln 1H 
825 112.66 0.251 Ne2 81Gln 15N 
826 59.91 0.076 Ca 81Gln 13C 
827 28.02 0.066 Cb 81Gln 13C 
828 178.33 0.040 C 81Gln 13C 
829 3.80 0.016 Ha 81Gln 1H 
830 2.04 0.011 Hba 81Gln 1H 
831 2.13 0.005 Hbb 81Gln 1H 
832 2.52 0.005 Hg2 81Gln 1H 
833 34.76 0.142 Cg 81Gln 13C 
834 2.52 0.005 Hg3 81Gln 1H 
835 180.79 0.011 Cd 81Gln 13C 
836 7.36 0.012 H 82Ser 1H 
837 114.42 0.075 N 82Ser 15N 
838 3.92 0.008 Hba 82Ser 1H 
839 3.92 0.010 Hbb 82Ser 1H 
840 4.25 0.002 Ha 82Ser 1H 
841 62.09 0.000 Ca 82Ser 13C 
842 63.34 0.000 Cb 82Ser 13C 
843 3.94 0.008 Ha 83Phe 1H 
844 2.67 0.010 Hbb 83Phe 1H 
845 61.34 0.036 Ca 83Phe 13C 
846 175.14 0.001 C 83Phe 13C 
847 39.43 0.067 Cb 83Phe 13C 
848 2.47 0.029 Hba 83Phe 1H 
849 132.16 0.031 Cd* 83Phe 13C 
850 7.01 0.007 Hd* 83Phe 1H 
851 119.92 0.067 N 84Glu 15N 
852 8.66 0.003 H 84Glu 1H 
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853 59.15 0.048 Ca 84Glu 13C 
854 30.46 0.082 Cb 84Glu 13C 
855 177.01 0.002 C 84Glu 13C 
856 1.91 0.008 Hbb 84Glu 1H 
857 36.20 0.092 Cg 84Glu 13C 
858 3.33 0.009 Ha 84Glu 1H 
859 2.23 0.008 Hgb 84Glu 1H 
860 2.14 0.006 Hga 84Glu 1H 
861 1.31 0.008 Hba 84Glu 1H 
862 59.10 0.057 Ca 85Gln 13C 
863 115.03 0.058 N 85Gln 15N 
864 7.59 0.005 H 85Gln 1H 
865 6.79 0.019 He2a 85Gln 1H 
866 7.52 0.001 He2b 85Gln 1H 
867 111.76 0.309 Ne2 85Gln 15N 
868 28.59 0.066 Cb 85Gln 13C 
869 33.89 0.082 Cg 85Gln 13C 
870 3.89 0.009 Ha 85Gln 1H 
871 2.10 0.019 Hba 85Gln 1H 
872 2.48 0.004 Hgb 85Gln 1H 
873 2.40 0.006 Hga 85Gln 1H 
874 2.13 0.007 Hbb 85Gln 1H 
875 178.57 0.010 C 85Gln 13C 
876 180.22 0.007 Cd 85Gln 13C 
877 31.80 0.090 Cb 86Val 13C 
878 7.16 0.007 H 86Val 1H 
879 118.48 0.044 N 86Val 15N 
880 66.10 0.068 Ca 86Val 13C 
881 23.38 0.086 Cgb 86Val 13C 
882 1.00 0.014 Hgb* 86Val 1H 
883 22.12 0.108 Cga 86Val 13C 
884 1.88 0.005 Hb 86Val 1H 
885 0.65 0.015 Hga* 86Val 1H 
886 3.64 0.003 Ha 86Val 1H 
887 177.90 0.000 C 86Val 13C 
888 119.83 0.105 N 87Val 15N 
889 7.98 0.003 H 87Val 1H 
890 66.39 0.082 Ca 87Val 13C 
891 31.04 0.118 Cb 87Val 13C 
892 22.68 0.048 Cga 87Val 13C 
893 0.15 0.008 Hgb* 87Val 1H 
894 -0.02 0.004 Hga* 87Val 1H 
895 23.09 0.240 Cgb 87Val 13C 
896 1.12 0.007 Hb 87Val 1H 
897 3.03 0.006 Ha 87Val 1H 
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898 177.85 0.015 C 87Val 13C 
899 7.49 0.004 Hd2b 88Asn 1H 
900 6.73 0.008 Hd2a 88Asn 1H 
901 109.11 0.065 Nd2 88Asn 15N 
902 117.63 0.099 N 88Asn 15N 
903 55.45 0.104 Ca 88Asn 13C 
904 8.44 0.004 H 88Asn 1H 
905 37.33 0.059 Cb 88Asn 13C 
906 4.28 0.006 Ha 88Asn 1H 
907 2.66 0.004 Hba 88Asn 1H 
908 2.98 0.010 Hbb 88Asn 1H 
909 178.99 0.067 C 88Asn 13C 
910 175.98 0.000 Cg 88Asn 13C 
911 118.94 0.104 N 89Glu 15N 
912 7.38 0.006 H 89Glu 1H 
913 59.02 0.119 Ca 89Glu 13C 
914 29.12 0.152 Cb 89Glu 13C 
915 4.00 0.005 Ha 89Glu 1H 
916 35.80 0.070 Cg 89Glu 13C 
917 179.30 0.024 C 89Glu 13C 
918 2.31 0.010 Hgb 89Glu 1H 
919 2.29 0.009 Hga 89Glu 1H 
920 2.08 0.012 Hbb 89Glu 1H 
921 2.06 0.013 Hba 89Glu 1H 
922 120.80 0.068 N 90Leu 15N 
923 7.61 0.007 H 90Leu 1H 
924 57.49 0.040 Ca 90Leu 13C 
925 1.10 0.009 Hba 90Leu 1H 
926 41.50 0.108 Cb 90Leu 13C 
927 3.82 0.011 Ha 90Leu 1H 
928 1.18 0.026 Hbb 90Leu 1H 
929 0.98 0.008 Hg 90Leu 1H 
930 24.31 0.049 Cdb 90Leu 13C 
931 27.00 0.048 Cg 90Leu 13C 
932 0.48 0.011 Hdb* 90Leu 1H 
933 0.43 0.009 Hda* 90Leu 1H 
934 23.93 0.126 Cda 90Leu 13C 
935 178.25 0.032 C 90Leu 13C 
936 7.02 0.005 H 91Phe 1H 
937 113.37 0.059 N 91Phe 15N 
938 39.47 0.055 Cb 91Phe 13C 
939 57.50 0.048 Ca 91Phe 13C 
940 6.70 0.005 He* 91Phe 1H 
941 129.94 0.000 Ce* 91Phe 13C 
942 4.53 0.012 Ha 91Phe 1H 
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943 3.28 0.009 Hbb 91Phe 1H 
944 2.41 0.011 Hba 91Phe 1H 
945 176.47 0.026 C 91Phe 13C 
946 7.15 0.008 Hd* 91Phe 1H 
947 132.18 0.072 Cd* 91Phe 13C 
948 123.99 0.046 N 92Arg 15N 
949 7.24 0.003 H 92Arg 1H 
950 59.74 0.092 Ca 92Arg 13C 
951 30.17 0.062 Cb 92Arg 13C 
952 3.96 0.007 Ha 92Arg 1H 
953 1.62 0.013 Hg3 92Arg 1H 
954 1.62 0.013 Hg2 92Arg 1H 
955 26.37 0.058 Cg 92Arg 13C 
956 3.20 0.004 Hd3 92Arg 1H 
957 43.21 0.016 Cd 92Arg 13C 
958 3.20 0.004 Hd2 92Arg 1H 
959 1.97 0.013 Hbb 92Arg 1H 
960 1.74 0.007 Hba 92Arg 1H 
961 177.15 0.025 C 92Arg 13C 
962 4.82 0.004 Ha 93Asp 1H 
963 8.71 0.003 H 93Asp 1H 
964 116.87 0.049 N 93Asp 15N 
965 54.07 0.015 Ca 93Asp 13C 
966 40.75 0.034 Cb 93Asp 13C 
967 2.85 0.005 Hbb 93Asp 1H 
968 2.48 0.010 Hba 93Asp 1H 
969 175.59 0.022 C 93Asp 13C 
970 7.58 0.005 H 94Gly 1H 
971 108.98 0.088 N 94Gly 15N 
972 43.82 0.045 Ca 94Gly 13C 
973 3.68 0.003 Haa 94Gly 1H 
974 4.48 0.029 Hab 94Gly 1H 
975 172.64 0.026 C 94Gly 13C 
976 3.54 0.008 Ha 95Val 1H 
977 0.36 0.012 Hgb* 95Val 1H 
978 -0.66 0.004 Hga* 95Val 1H 
979 21.10 0.106 Cgb 95Val 13C 
980 22.97 0.114 Cga 95Val 13C 
981 0.34 0.019 Hb 95Val 1H 
982 62.88 0.074 Ca 95Val 13C 
983 8.29 0.003 H 95Val 1H 
984 32.15 0.103 Cb 95Val 13C 
985 120.78 0.063 N 95Val 15N 
986 174.45 0.013 C 95Val 13C 
987 116.20 0.070 N 96Asn 15N 
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988 6.40 0.005 H 96Asn 1H 
989 113.20 0.049 Nd2 96Asn 15N 
990 6.51 0.004 Hd2a 96Asn 1H 
991 51.78 0.080 Ca 96Asn 13C 
992 39.85 0.051 Cb 96Asn 13C 
993 3.29 0.009 Hbb 96Asn 1H 
994 4.07 0.006 Ha 96Asn 1H 
995 3.03 0.014 Hba 96Asn 1H 
996 175.24 0.014 C 96Asn 13C 
997 7.65 0.005 Hd2b 96Asn 1H 
998 10.28 0.003 He1 97Trp 1H 
999 128.74 0.046 Ne1 97Trp 15N 
1000 8.53 0.009 H 97Trp 1H 
1001 118.78 0.106 N 97Trp 15N 
1002 124.91 0.040 Ch2 97Trp 13C 
1003 6.24 0.011 Hh2 97Trp 1H 
1004 7.17 0.007 Hz2 97Trp 1H 
1005 61.08 0.073 Ca 97Trp 13C 
1006 30.68 0.220 Cb 97Trp 13C 
1007 4.59 0.012 Ha 97Trp 1H 
1008 3.66 0.014 Hbb 97Trp 1H 
1009 3.53 0.014 Hba 97Trp 1H 
1010 178.21 0.037 C 97Trp 13C 
1011 7.69 0.005 Hd1 97Trp 1H 
1012 128.47 0.061 Cd1 97Trp 13C 
1013 115.06 0.046 Cz2 97Trp 13C 
1014 6.81 0.005 He3 97Trp 1H 
1015 117.29 0.042 Ce3 97Trp 13C 
1016 4.01 0.034 Ha2 98Gly 1H 
1017 4.01 0.032 Ha3 98Gly 1H 
1018 106.57 0.061 N 98Gly 15N 
1019 8.63 0.009 H 98Gly 1H 
1020 47.51 0.095 Ca 98Gly 13C 
1021 177.48 0.060 C 98Gly 13C 
1022 31.36 0.086 Cb 99Arg 13C 
1023 8.21 0.008 H 99Arg 1H 
1024 121.63 0.124 N 99Arg 15N 
1025 58.49 0.038 Ca 99Arg 13C 
1026 1.46 0.006 Hba 99Arg 1H 
1027 2.96 0.010 Hd2 99Arg 1H 
1028 43.83 0.087 Cd 99Arg 13C 
1029 1.54 0.016 Hbb 99Arg 1H 
1030 2.96 0.010 Hd3 99Arg 1H 
1031 1.79 0.011 Hgb 99Arg 1H 
1032 1.52 0.024 Hga 99Arg 1H 
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1033 28.67 0.044 Cg 99Arg 13C 
1034 177.69 0.015 C 99Arg 13C 
1035 4.00 0.008 Ha 99Arg 1H 
1036 7.81 0.006 H 100Ile 1H 
1037 121.38 0.069 N 100Ile 15N 
1038 67.15 0.105 Ca 100Ile 13C 
1039 37.10 0.096 Cb 100Ile 13C 
1040 2.46 0.009 Hb 100Ile 1H 
1041 3.99 0.012 Ha 100Ile 1H 
1042 1.30 0.005 Hg2* 100Ile 1H 
1043 0.31 0.004 Hd1* 100Ile 1H 
1044 30.78 0.065 Cg1 100Ile 13C 
1045 1.74 0.006 Hg1b 100Ile 1H 
1046 0.79 0.006 Hg1a 100Ile 1H 
1047 14.25 0.095 Cd1 100Ile 13C 
1048 17.79 0.072 Cg2 100Ile 13C 
1049 178.14 0.062 C 100Ile 13C 
1050 121.44 0.074 N 101Val 15N 
1051 8.38 0.009 H 101Val 1H 
1052 68.16 0.041 Ca 101Val 13C 
1053 0.83 0.015 Hga* 101Val 1H 
1054 1.12 0.007 Hgb* 101Val 1H 
1055 31.42 0.041 Cb 101Val 13C 
1056 3.46 0.007 Ha 101Val 1H 
1057 21.41 0.054 Cga 101Val 13C 
1058 2.32 0.007 Hb 101Val 1H 
1059 23.77 0.038 Cgb 101Val 13C 
1060 177.75 0.037 C 101Val 13C 
1061 7.69 0.006 H 102Ala 1H 
1062 121.86 0.100 N 102Ala 15N 
1063 55.26 0.078 Ca 102Ala 13C 
1064 18.63 0.104 Cb 102Ala 13C 
1065 3.17 0.006 Ha 102Ala 1H 
1066 1.22 0.006 Hb* 102Ala 1H 
1067 178.22 0.007 C 102Ala 13C 
1068 8.10 0.006 H 103Phe 1H 
1069 119.56 0.068 N 103Phe 15N 
1070 60.81 0.220 Ca 103Phe 13C 
1071 38.59 0.092 Cb 103Phe 13C 
1072 3.20 0.009 Hba 103Phe 1H 
1073 176.26 0.071 C 103Phe 13C 
1074 3.99 0.013 Ha 103Phe 1H 
1075 3.84 0.011 Hbb 103Phe 1H 
1076 7.02 0.007 Hd* 103Phe 1H 
1077 132.26 0.085 Cd* 103Phe 13C 
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1078 8.09 0.006 H 104Phe 1H 
1079 120.69 0.072 N 104Phe 15N 
1080 62.99 0.055 Ca 104Phe 13C 
1081 36.63 0.082 Cb 104Phe 13C 
1082 1.23 0.011 Hba 104Phe 1H 
1083 3.35 0.005 Ha 104Phe 1H 
1084 2.58 0.010 Hbb 104Phe 1H 
1085 177.60 0.000 C 104Phe 13C 
1086 7.16 0.016 Hd* 104Phe 1H 
1087 131.61 0.094 Cd* 104Phe 13C 
1088 114.78 0.072 N 105Ser 15N 
1089 8.51 0.003 H 105Ser 1H 
1090 63.77 0.040 Ca 105Ser 13C 
1091 4.44 0.018 Ha 105Ser 1H 
1092 63.41 0.002 Cb 105Ser 13C 
1093 177.60 0.014 C 105Ser 13C 
1094 4.04 0.018 Hb3 105Ser 1H 
1095 4.04 0.018 Hb2 105Ser 1H 
1096 38.64 0.090 Cb 106Phe 13C 
1097 3.03 0.008 Hbb 106Phe 1H 
1098 2.80 0.006 Hba 106Phe 1H 
1099 9.15 0.004 H 106Phe 1H 
1100 124.63 0.052 N 106Phe 15N 
1101 60.19 0.120 Ca 106Phe 13C 
1102 176.64 0.034 C 106Phe 13C 
1103 4.07 0.005 Ha 106Phe 1H 
1104 130.61 0.032 Ce* 106Phe 13C 
1105 6.79 0.012 Hd* 106Phe 1H 
1106 130.62 0.032 Cd* 106Phe 13C 
1107 7.00 0.023 He* 106Phe 1H 
1108 106.50 0.032 N 107Gly 15N 
1109 8.06 0.004 H 107Gly 1H 
1110 48.00 0.067 Ca 107Gly 13C 
1111 3.33 0.011 Haa 107Gly 1H 
1112 4.27 0.006 Hab 107Gly 1H 
1113 176.65 0.000 C 107Gly 13C 
1114 107.79 0.065 N 108Gly 15N 
1115 8.90 0.003 H 108Gly 1H 
1116 3.95 0.006 Hab 108Gly 1H 
1117 47.93 0.071 Ca 108Gly 13C 
1118 3.73 0.011 Haa 108Gly 1H 
1119 174.59 0.000 C 108Gly 13C 
1120 8.34 0.010 H 109Ala 1H 
1121 124.96 0.062 N 109Ala 15N 
1122 55.10 0.040 Ca 109Ala 13C 
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1123 18.42 0.073 Cb 109Ala 13C 
1124 4.22 0.005 Ha 109Ala 1H 
1125 1.65 0.003 Hb* 109Ala 1H 
1126 181.11 0.020 C 109Ala 13C 
1127 8.30 0.012 H 110Leu 1H 
1128 119.34 0.094 N 110Leu 15N 
1129 42.56 0.058 Cb 110Leu 13C 
1130 57.40 0.083 Ca 110Leu 13C 
1131 25.62 0.056 Cda 110Leu 13C 
1132 0.61 0.006 Hda* 110Leu 1H 
1133 23.77 0.067 Cdb 110Leu 13C 
1134 0.81 0.012 Hdb* 110Leu 1H 
1135 4.02 0.010 Ha 110Leu 1H 
1136 1.34 0.018 Hba 110Leu 1H 
1137 1.73 0.026 Hbb 110Leu 1H 
1138 26.04 0.152 Cg 110Leu 13C 
1139 1.44 0.010 Hg 110Leu 1H 
1140 180.10 0.014 C 110Leu 13C 
1141 26.72 0.104 Cb 111Cys 13C 
1142 8.21 0.003 H 111Cys 1H 
1143 64.66 0.087 Ca 111Cys 13C 
1144 119.47 0.040 N 111Cys 15N 
1145 3.21 0.004 Hbb 111Cys 1H 
1146 2.70 0.009 Hba 111Cys 1H 
1147 3.82 0.009 Ha 111Cys 1H 
1148 175.95 0.028 C 111Cys 13C 
1149 8.11 0.007 H 112Val 1H 
1150 119.09 0.055 N 112Val 15N 
1151 67.32 0.067 Ca 112Val 13C 
1152 31.94 0.067 Cb 112Val 13C 
1153 1.04 0.005 Hga* 112Val 1H 
1154 23.09 0.050 Cga 112Val 13C 
1155 3.38 0.005 Ha 112Val 1H 
1156 22.31 0.063 Cgb 112Val 13C 
1157 2.17 0.011 Hb 112Val 1H 
1158 1.05 0.004 Hgb* 112Val 1H 
1159 177.36 0.040 C 112Val 13C 
1160 119.45 0.058 N 113Glu 15N 
1161 8.19 0.004 H 113Glu 1H 
1162 59.34 0.053 Ca 113Glu 13C 
1163 2.04 0.002 Hb2 113Glu 1H 
1164 2.04 0.002 Hb3 113Glu 1H 
1165 29.33 0.095 Cb 113Glu 13C 
1166 36.30 0.096 Cg 113Glu 13C 
1167 4.09 0.013 Ha 113Glu 1H 
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1168 178.26 0.006 C 113Glu 13C 
1169 2.20 0.030 Hga 113Glu 1H 
1170 2.36 0.014 Hgb 113Glu 1H 
1171 7.76 0.007 H 114Ser 1H 
1172 113.85 0.029 N 114Ser 15N 
1173 63.25 0.076 Ca 114Ser 13C 
1174 3.89 0.026 Ha 114Ser 1H 
1175 62.23 0.101 Cb 114Ser 13C 
1176 3.68 0.012 Hb3 114Ser 1H 
1177 3.68 0.012 Hb2 114Ser 1H 
1178 175.49 0.022 C 114Ser 13C 
1179 7.42 0.006 H 115Val 1H 
1180 121.09 0.048 N 115Val 15N 
1181 66.75 0.072 Ca 115Val 13C 
1182 31.41 0.107 Cb 115Val 13C 
1183 0.35 0.005 Hgb* 115Val 1H 
1184 21.36 0.083 Cga 115Val 13C 
1185 22.84 0.096 Cgb 115Val 13C 
1186 3.20 0.006 Ha 115Val 1H 
1187 1.66 0.008 Hb 115Val 1H 
1188 0.13 0.003 Hga* 115Val 1H 
1189 179.47 0.032 C 115Val 13C 
1190 8.37 0.003 H 116Asp 1H 
1191 57.47 0.036 Ca 116Asp 13C 
1192 123.02 0.065 N 116Asp 15N 
1193 41.00 0.074 Cb 116Asp 13C 
1194 4.40 0.008 Ha 116Asp 1H 
1195 2.92 0.004 Hbb 116Asp 1H 
1196 2.70 0.008 Hba 116Asp 1H 
1197 178.03 0.019 C 116Asp 13C 
1198 25.77 0.058 Cg 117Lys 13C 
1199 29.03 0.127 Cd 117Lys 13C 
1200 2.99 0.009 He3 117Lys 1H 
1201 2.99 0.009 He2 117Lys 1H 
1202 4.38 0.010 Ha 117Lys 1H 
1203 1.65 0.008 Hgb 117Lys 1H 
1204 3.00 0.017 Heb 117Lys 1H 
1205 1.68 0.022 Hb3 117Lys 1H 
1206 3.00 0.017 Hea 117Lys 1H 
1207 1.46 0.007 Hga 117Lys 1H 
1208 1.68 0.021 Hb2 117Lys 1H 
1209 7.70 0.005 H 117Lys 1H 
1210 116.21 0.057 N 117Lys 15N 
1211 55.68 0.072 Ca 117Lys 13C 
1212 32.32 0.151 Cb 117Lys 13C 
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1213 42.43 0.070 Ce 117Lys 13C 
1214 175.05 0.011 C 117Lys 13C 
1215 2.12 0.004 Hd2 117Lys 1H 
1216 2.12 0.004 Hd3 117Lys 1H 
1217 114.27 0.071 N 118Glu 15N 
1218 7.96 0.005 H 118Glu 1H 
1219 57.77 0.095 Ca 118Glu 13C 
1220 26.54 0.008 Cb 118Glu 13C 
1221 36.92 0.012 Cg 118Glu 13C 
1222 3.97 0.009 Ha 118Glu 1H 
1223 176.06 0.016 C 118Glu 13C 
1224 2.24 0.003 Hga 118Glu 1H 
1225 2.41 0.002 Hba 118Glu 1H 
1226 2.32 0.008 Hgb 118Glu 1H 
1227 8.54 0.003 H 119Met 1H 
1228 119.26 0.066 N 119Met 15N 
1229 53.68 0.077 Ca 119Met 13C 
1230 31.87 0.344 Cb 119Met 13C 
1231 31.79 0.184 Cg 119Met 13C 
1232 4.82 0.004 Ha 119Met 1H 
1233 2.55 0.011 Hgb 119Met 1H 
1234 1.90 0.012 Hba 119Met 1H 
1235 1.97 0.011 Hbb 119Met 1H 
1236 2.42 0.021 Hga 119Met 1H 
1237 176.82 0.013 C 119Met 13C 
1238 2.12 0.005 He* 119Met 1H 
1239 17.69 0.032 Ce 119Met 13C 
1240 111.02 0.229 Ne2 120Gln 15N 
1241 7.00 0.012 He2a 120Gln 1H 
1242 7.53 0.008 He2b 120Gln 1H 
1243 8.80 0.002 H 120Gln 1H 
1244 119.77 0.072 N 120Gln 15N 
1245 60.17 0.088 Ca 120Gln 13C 
1246 27.67 0.091 Cb 120Gln 13C 
1247 34.18 0.064 Cg 120Gln 13C 
1248 2.50 0.006 Hgb 120Gln 1H 
1249 177.47 0.022 C 120Gln 13C 
1250 1.98 0.008 Hb3 120Gln 1H 
1251 1.98 0.009 Hb2 120Gln 1H 
1252 2.31 0.004 Hga 120Gln 1H 
1253 3.49 0.005 Ha 120Gln 1H 
1254 179.85 0.050 Cd 120Gln 13C 
1255 7.96 0.006 H 121Val 1H 
1256 117.29 0.062 N 121Val 15N 
1257 63.61 0.037 Ca 121Val 13C 
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1258 31.49 0.126 Cb 121Val 13C 
1259 2.21 0.004 Hb 121Val 1H 
1260 4.06 0.008 Ha 121Val 1H 
1261 0.93 0.023 Hgb* 121Val 1H 
1262 0.89 0.008 Hga* 121Val 1H 
1263 20.07 0.063 Cga 121Val 13C 
1264 20.05 0.049 Cgb 121Val 13C 
1265 175.68 0.017 C 121Val 13C 
1266 117.44 0.048 N 122Leu 15N 
1267 55.53 0.097 Ca 122Leu 13C 
1268 7.89 0.005 H 122Leu 1H 
1269 41.37 0.069 Cb 122Leu 13C 
1270 1.25 0.011 Hba 122Leu 1H 
1271 3.87 0.012 Ha 122Leu 1H 
1272 0.68 0.005 Hda* 122Leu 1H 
1273 1.88 0.009 Hbb 122Leu 1H 
1274 0.78 0.005 Hdb* 122Leu 1H 
1275 1.57 0.006 Hg 122Leu 1H 
1276 26.40 0.079 Cdb 122Leu 13C 
1277 22.81 0.078 Cda 122Leu 13C 
1278 27.07 0.050 Cg 122Leu 13C 
1279 177.96 0.075 C 122Leu 13C 
1280 67.82 0.089 Ca 123Val 13C 
1281 30.89 0.169 Cb 123Val 13C 
1282 7.44 0.006 H 123Val 1H 
1283 120.03 0.071 N 123Val 15N 
1284 21.78 0.095 Cga 123Val 13C 
1285 23.29 0.072 Cgb 123Val 13C 
1286 3.38 0.011 Ha 123Val 1H 
1287 0.41 0.011 Hga* 123Val 1H 
1288 1.77 0.011 Hb 123Val 1H 
1289 0.43 0.012 Hgb* 123Val 1H 
1290 177.04 0.010 C 123Val 13C 
1291 8.39 0.010 H 124Ser 1H 
1292 111.17 0.065 N 124Ser 15N 
1293 61.25 0.065 Ca 124Ser 13C 
1294 62.40 0.129 Cb 124Ser 13C 
1295 177.07 0.073 C 124Ser 13C 
1296 3.84 0.012 Hb2 124Ser 1H 
1297 3.98 0.005 Ha 124Ser 1H 
1298 3.84 0.011 Hb3 124Ser 1H 
1299 29.85 0.140 Cb 125Arg 13C 
1300 123.53 0.049 N 125Arg 15N 
1301 6.70 0.007 H 125Arg 1H 
1302 58.74 0.035 Ca 125Arg 13C 
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1303 175.75 0.011 C 125Arg 13C 
1304 44.08 0.105 Cd 125Arg 13C 
1305 2.78 0.014 Hda 125Arg 1H 
1306 1.09 0.020 Hba 125Arg 1H 
1307 3.20 0.005 Hdb 125Arg 1H 
1308 1.49 0.014 Hbb 125Arg 1H 
1309 3.71 0.006 Ha 125Arg 1H 
1310 25.77 0.109 Cg 125Arg 13C 
1311 0.78 0.024 Hga 125Arg 1H 
1312 1.26 0.012 Hgb 125Arg 1H 
1313 118.80 0.088 N 126Ile 15N 
1314 8.12 0.005 H 126Ile 1H 
1315 37.67 0.050 Cb 126Ile 13C 
1316 64.96 0.036 Ca 126Ile 13C 
1317 177.97 0.038 C 126Ile 13C 
1318 0.69 0.005 Hg2* 126Ile 1H 
1319 2.86 0.005 Ha 126Ile 1H 
1320 0.54 0.005 Hg1a 126Ile 1H 
1321 29.90 0.081 Cg1 126Ile 13C 
1322 1.22 0.008 Hg1b 126Ile 1H 
1323 1.62 0.014 Hb 126Ile 1H 
1324 18.33 0.046 Cg2 126Ile 13C 
1325 0.53 0.005 Hd1* 126Ile 1H 
1326 14.73 0.057 Cd1 126Ile 13C 
1327 7.71 0.007 H 127Ala 1H 
1328 55.29 0.150 Ca 127Ala 13C 
1329 119.67 0.082 N 127Ala 15N 
1330 18.52 0.144 Cb 127Ala 13C 
1331 3.90 0.010 Ha 127Ala 1H 
1332 179.40 0.033 C 127Ala 13C 
1333 1.50 0.006 Hb* 127Ala 1H 
1334 7.36 0.003 H 128Ala 1H 
1335 120.85 0.066 N 128Ala 15N 
1336 17.82 0.141 Cb 128Ala 13C 
1337 55.26 0.102 Ca 128Ala 13C 
1338 1.57 0.010 Hb* 128Ala 1H 
1339 4.17 0.004 Ha 128Ala 1H 
1340 181.04 0.026 C 128Ala 13C 
1341 3.00 0.014 Hbb 129Trp 1H 
1342 2.68 0.010 Hba 129Trp 1H 
1343 126.61 0.065 Ne1 129Trp 15N 
1344 10.14 0.003 He1 129Trp 1H 
1345 9.09 0.006 H 129Trp 1H 
1346 121.65 0.070 N 129Trp 15N 
1347 57.79 0.029 Ca 129Trp 13C 
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1348 28.92 0.084 Cb 129Trp 13C 
1349 179.56 0.033 C 129Trp 13C 
1350 124.34 0.069 Cd1 129Trp 13C 
1351 124.00 0.030 Ch2 129Trp 13C 
1352 7.17 0.022 Hd1 129Trp 1H 
1353 7.42 0.011 Hz2 129Trp 1H 
1354 6.85 0.010 Hh2 129Trp 1H 
1355 113.65 0.031 Cz2 129Trp 13C 
1356 6.60 0.021 Hz3 129Trp 1H 
1357 120.01 0.036 Cz3 129Trp 13C 
1358 34.93 0.085 Cb 130Met 13C 
1359 9.03 0.009 H 130Met 1H 
1360 117.54 0.085 N 130Met 15N 
1361 60.18 0.055 Ca 130Met 13C 
1362 178.17 0.025 C 130Met 13C 
1363 33.01 0.057 Cg 130Met 13C 
1364 4.35 0.009 Ha 130Met 1H 
1365 2.05 0.004 Hba 130Met 1H 
1366 2.38 0.014 Hbb 130Met 1H 
1367 2.16 0.010 Hga 130Met 1H 
1368 2.88 0.010 Hgb 130Met 1H 
1369 1.46 0.007 He* 130Met 1H 
1370 16.60 0.033 Ce 130Met 13C 
1371 8.27 0.010 H 131Ala 1H 
1372 120.97 0.085 N 131Ala 15N 
1373 17.63 0.120 Cb 131Ala 13C 
1374 4.10 0.009 Ha 131Ala 1H 
1375 1.60 0.006 Hb* 131Ala 1H 
1376 56.18 0.050 Ca 131Ala 13C 
1377 176.25 0.045 C 131Ala 13C 
1378 67.31 0.118 Ca 132Thr 13C 
1379 69.18 0.323 Cb 132Thr 13C 
1380 117.21 0.056 N 132Thr 15N 
1381 175.03 0.024 C 132Thr 13C 
1382 8.65 0.007 H 132Thr 1H 
1383 21.19 0.173 Cg2 132Thr 13C 
1384 4.29 0.007 Hb 132Thr 1H 
1385 3.96 0.014 Ha 132Thr 1H 
1386 1.02 0.015 Hg2* 132Thr 1H 
1387 8.96 0.008 H 133Tyr 1H 
1388 123.70 0.107 N 133Tyr 15N 
1389 63.58 0.084 Ca 133Tyr 13C 
1390 179.55 0.032 C 133Tyr 13C 
1391 39.31 0.075 Cb 133Tyr 13C 
1392 4.02 0.018 Ha 133Tyr 1H 
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1393 3.49 0.017 Hba 133Tyr 1H 
1394 3.75 0.009 Hbb 133Tyr 1H 
1395 7.08 0.024 Hd* 133Tyr 1H 
1396 131.36 0.055 Cd* 133Tyr 13C 
1397 6.79 0.028 He* 133Tyr 1H 
1398 116.59 0.000 Ce* 133Tyr 13C 
1399 8.85 0.006 H 134Leu 1H 
1400 119.67 0.094 N 134Leu 15N 
1401 59.59 0.109 Ca 134Leu 13C 
1402 42.90 0.080 Cb 134Leu 13C 
1403 1.15 0.008 Hda* 134Leu 1H 
1404 1.87 0.006 Hba 134Leu 1H 
1405 2.14 0.010 Hbb 134Leu 1H 
1406 178.32 0.030 C 134Leu 13C 
1407 26.16 0.078 Cda 134Leu 13C 
1408 1.16 0.018 Hdb* 134Leu 1H 
1409 26.14 0.080 Cdb 134Leu 13C 
1410 3.83 0.007 Ha 134Leu 1H 
1411 1.87 0.006 Hg 134Leu 1H 
1412 28.41 0.085 Cg 134Leu 13C 
1413 8.45 0.007 H 135Asn 1H 
1414 117.66 0.086 N 135Asn 15N 
1415 112.73 0.228 Nd2 135Asn 15N 
1416 7.69 0.005 Hd2b 135Asn 1H 
1417 56.88 0.104 Ca 135Asn 13C 
1418 39.22 0.084 Cb 135Asn 13C 
1419 4.35 0.010 Ha 135Asn 1H 
1420 3.01 0.007 Hbb 135Asn 1H 
1421 2.91 0.005 Hba 135Asn 1H 
1422 176.41 0.024 C 135Asn 13C 
1423 176.33 0.005 Cg 135Asn 13C 
1424 7.01 0.010 Hd2a 135Asn 1H 
1425 115.94 0.041 N 136Asp 15N 
1426 8.58 0.003 H 136Asp 1H 
1427 40.86 0.103 Cb 136Asp 13C 
1428 177.80 0.006 C 136Asp 13C 
1429 56.50 0.146 Ca 136Asp 13C 
1430 4.34 0.011 Ha 136Asp 1H 
1431 2.02 0.008 Hba 136Asp 1H 
1432 2.42 0.011 Hbb 136Asp 1H 
1433 8.20 0.012 H 137His 1H 
1434 112.07 0.058 N 137His 15N 
1435 56.53 0.019 Ca 137His 13C 
1436 30.89 0.086 Cb 137His 13C 
1437 175.78 0.039 C 137His 13C 
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1438 2.27 0.012 Hba 137His 1H 
1439 2.46 0.008 Hbb 137His 1H 
1440 4.55 0.009 Ha 137His 1H 
1441 43.47 0.121 Cb 138Leu 13C 
1442 117.36 0.080 N 138Leu 15N 
1443 7.31 0.019 H 138Leu 1H 
1444 55.70 0.060 Ca 138Leu 13C 
1445 176.37 0.012 C 138Leu 13C 
1446 2.13 0.010 Hbb 138Leu 1H 
1447 4.55 0.009 Ha 138Leu 1H 
1448 -0.23 0.004 Hda* 138Leu 1H 
1449 24.86 0.101 Cdb 138Leu 13C 
1450 22.02 0.081 Cda 138Leu 13C 
1451 0.29 0.005 Hdb* 138Leu 1H 
1452 1.15 0.010 Hba 138Leu 1H 
1453 26.41 0.017 Cg 138Leu 13C 
1454 1.19 0.039 Hg 138Leu 1H 
1455 121.92 0.067 N 139Glu 15N 
1456 8.71 0.026 H 139Glu 1H 
1457 60.53 0.178 Ca 139Glu 13C 
1458 27.77 0.065 Cb 139Glu 13C 
1459 173.82 0.000 C 139Glu 13C 
1460 2.25 0.007 Hba 139Glu 1H 
1461 2.39 0.011 Hg2 139Glu 1H 
1462 4.35 0.007 Ha 139Glu 1H 
1463 35.86 0.034 Cg 139Glu 13C 
1464 2.25 0.007 Hbb 139Glu 1H 
1465 2.39 0.011 Hg3 139Glu 1H 
1466 179.16 0.000 C 140Pro 13C 
1467 66.58 0.159 Ca 140Pro 13C 
1468 49.92 0.083 Cd 140Pro 13C 
1469 30.75 0.074 Cb 140Pro 13C 
1470 1.98 0.006 Hgb 140Pro 1H 
1471 3.61 0.010 Hdb 140Pro 1H 
1472 4.23 0.006 Ha 140Pro 1H 
1473 1.87 0.010 Hga 140Pro 1H 
1474 2.28 0.010 Hbb 140Pro 1H 
1475 3.18 0.006 Hda 140Pro 1H 
1476 1.78 0.006 Hba 140Pro 1H 
1477 28.70 0.080 Cg 140Pro 13C 
1478 9.52 0.003 He1 141Trp 1H 
1479 129.42 0.036 Ne1 141Trp 15N 
1480 118.37 0.042 N 141Trp 15N 
1481 7.20 0.004 H 141Trp 1H 
1482 62.20 0.077 Ca 141Trp 13C 
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1483 5.41 0.004 Hh2 141Trp 1H 
1484 120.66 0.000 Ch2 141Trp 13C 
1485 3.15 0.010 Hba 141Trp 1H 
1486 179.41 0.004 C 141Trp 13C 
1487 3.86 0.006 Ha 141Trp 1H 
1488 28.93 0.113 Cb 141Trp 13C 
1489 3.17 0.009 Hbb 141Trp 1H 
1490 7.08 0.010 Hd1 141Trp 1H 
1491 126.30 0.046 Cd1 141Trp 13C 
1492 6.97 0.015 Hz2 141Trp 1H 
1493 114.04 0.028 Cz2 141Trp 13C 
1494 122.55 0.055 N 142Ile 15N 
1495 8.51 0.006 H 142Ile 1H 
1496 178.92 0.035 C 142Ile 13C 
1497 66.24 0.046 Ca 142Ile 13C 
1498 0.48 0.013 Hg1a 142Ile 1H 
1499 1.61 0.008 Hg1b 142Ile 1H 
1500 0.46 0.005 Hg2* 142Ile 1H 
1501 29.00 0.087 Cg1 142Ile 13C 
1502 0.63 0.004 Hd1* 142Ile 1H 
1503 1.91 0.013 Hb 142Ile 1H 
1504 16.26 0.091 Cg2 142Ile 13C 
1505 38.31 0.073 Cb 142Ile 13C 
1506 13.94 0.057 Cd1 142Ile 13C 
1507 2.89 0.007 Ha 142Ile 1H 
1508 33.58 0.101 Cg 143Gln 13C 
1509 3.92 0.008 Ha 143Gln 1H 
1510 116.78 0.073 N 143Gln 15N 
1511 8.51 0.005 H 143Gln 1H 
1512 8.01 0.010 He2b 143Gln 1H 
1513 112.76 0.221 Ne2 143Gln 15N 
1514 6.85 0.006 He2a 143Gln 1H 
1515 58.57 0.097 Ca 143Gln 13C 
1516 28.07 0.117 Cb 143Gln 13C 
1517 2.53 0.007 Hg3 143Gln 1H 
1518 2.53 0.007 Hg2 143Gln 1H 
1519 179.45 0.003 C 143Gln 13C 
1520 2.13 0.008 Hbb 143Gln 1H 
1521 2.04 0.010 Hba 143Gln 1H 
1522 180.13 0.035 Cd 143Gln 13C 
1523 7.65 0.005 H 144Glu 1H 
1524 119.47 0.030 N 144Glu 15N 
1525 57.90 0.076 Ca 144Glu 13C 
1526 29.92 0.044 Cb 144Glu 13C 
1527 36.37 0.042 Cg 144Glu 13C 
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1528 4.08 0.003 Ha 144Glu 1H 
1529 2.24 0.009 Hgb 144Glu 1H 
1530 2.14 0.008 Hga 144Glu 1H 
1531 176.78 0.005 C 144Glu 13C 
1532 1.87 0.010 Hbb 144Glu 1H 
1533 1.83 0.015 Hba 144Glu 1H 
1534 116.90 0.052 N 145Asn 15N 
1535 7.20 0.005 H 145Asn 1H 
1536 6.14 0.031 Hd2b 145Asn 1H 
1537 5.90 0.005 Hd2a 145Asn 1H 
1538 115.38 0.053 Nd2 145Asn 15N 
1539 53.65 0.077 Ca 145Asn 13C 
1540 38.20 0.088 Cb 145Asn 13C 
1541 0.98 0.026 Hba 145Asn 1H 
1542 4.45 0.007 Ha 145Asn 1H 
1543 2.22 0.017 Hbb 145Asn 1H 
1544 173.89 0.008 C 145Asn 13C 
1545 105.17 0.085 N 146Gly 15N 
1546 7.44 0.010 H 146Gly 1H 
1547 45.72 0.038 Ca 146Gly 13C 
1548 4.51 0.013 Hab 146Gly 1H 
1549 3.72 0.005 Haa 146Gly 1H 
1550 175.98 0.000 C 146Gly 13C 
1551 108.77 0.051 N 147Gly 15N 
1552 8.58 0.003 H 147Gly 1H 
1553 44.53 0.100 Ca 147Gly 13C 
1554 4.52 0.008 Hab 147Gly 1H 
1555 3.67 0.011 Haa 147Gly 1H 
1556 173.37 0.000 C 147Gly 13C 
1557 10.58 0.004 He1 148Trp 1H 
1558 129.16 0.056 Ne1 148Trp 15N 
1559 8.71 0.004 H 148Trp 1H 
1560 60.56 0.082 Ca 148Trp 13C 
1561 118.43 0.025 N 148Trp 15N 
1562 3.53 0.008 Hbb 148Trp 1H 
1563 4.43 0.010 Ha 148Trp 1H 
1564 3.13 0.008 Hba 148Trp 1H 
1565 29.87 0.108 Cb 148Trp 13C 
1566 178.43 0.002 C 148Trp 13C 
1567 126.81 0.084 Cd1 148Trp 13C 
1568 7.47 0.015 Hd1 148Trp 1H 
1569 7.27 0.006 Hz2 148Trp 1H 
1570 6.80 0.010 Hh2 148Trp 1H 
1571 113.82 0.036 Cz2 148Trp 13C 
1572 123.08 0.009 Ch2 148Trp 13C 
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1573 124.24 0.000 Ce3 148Trp 13C 
1574 7.23 0.045 He3 148Trp 1H 
1575 131.76 0.000 Cz3 148Trp 13C 
1576 7.16 0.015 Hz3 148Trp 1H 
1577 8.90 0.004 H 149Asp 1H 
1578 118.21 0.056 N 149Asp 15N 
1579 57.85 0.063 Ca 149Asp 13C 
1580 40.38 0.097 Cb 149Asp 13C 
1581 4.45 0.011 Ha 149Asp 1H 
1582 2.71 0.014 Hba 149Asp 1H 
1583 2.71 0.014 Hbb 149Asp 1H 
1584 179.63 0.011 C 149Asp 13C 
1585 117.18 0.056 N 150Thr 15N 
1586 7.63 0.007 H 150Thr 1H 
1587 66.38 0.162 Ca 150Thr 13C 
1588 68.34 0.162 Cb 150Thr 13C 
1589 1.45 0.005 Hg2* 150Thr 1H 
1590 22.63 0.053 Cg2 150Thr 13C 
1591 4.01 0.004 Ha 150Thr 1H 
1592 4.45 0.013 Hb 150Thr 1H 
1593 175.22 0.013 C 150Thr 13C 
1594 6.64 0.004 H 151Phe 1H 
1595 122.60 0.070 N 151Phe 15N 
1596 61.85 0.046 Ca 151Phe 13C 
1597 37.95 0.070 Cb 151Phe 13C 
1598 6.58 0.003 Hz 151Phe 1H 
1599 128.29 0.082 Cz 151Phe 13C 
1600 176.70 0.013 C 151Phe 13C 
1601 4.42 0.012 Ha 151Phe 1H 
1602 3.20 0.012 Hbb 151Phe 1H 
1603 3.11 0.009 Hba 151Phe 1H 
1604 6.81 0.010 Hd* 151Phe 1H 
1605 131.22 0.050 Cd* 151Phe 13C 
1606 130.30 0.201 Ce* 151Phe 13C 
1607 6.68 0.026 He* 151Phe 1H 
1608 117.68 0.148 N 152Val 15N 
1609 66.78 0.036 Ca 152Val 13C 
1610 7.84 0.032 H 152Val 1H 
1611 3.06 0.006 Ha 152Val 1H 
1612 2.19 0.013 Hb 152Val 1H 
1613 0.89 0.009 Hga* 152Val 1H 
1614 1.14 0.007 Hgb* 152Val 1H 
1615 21.72 0.180 Cga 152Val 13C 
1616 31.89 0.116 Cb 152Val 13C 
1617 24.66 0.052 Cgb 152Val 13C 
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1618 178.31 0.004 C 152Val 13C 
1619 29.57 0.042 Cb 153Glu 13C 
1620 36.03 0.000 Cg 153Glu 13C 
1621 3.93 0.009 Ha 153Glu 1H 
1622 120.16 0.090 N 153Glu 15N 
1623 7.48 0.018 H 153Glu 1H 
1624 59.29 0.055 Ca 153Glu 13C 
1625 178.16 0.033 C 153Glu 13C 
1626 2.18 0.028 Hga 153Glu 1H 
1627 2.35 0.012 Hgb 153Glu 1H 
1628 4.05 0.005 Ha 154Leu 1H 
1629 23.24 0.075 Cda 154Leu 13C 
1630 0.87 0.009 Hda* 154Leu 1H 
1631 1.10 0.014 Hba 154Leu 1H 
1632 1.55 0.026 Hbb 154Leu 1H 
1633 7.70 0.019 H 154Leu 1H 
1634 117.52 0.099 N 154Leu 15N 
1635 56.84 0.066 Ca 154Leu 13C 
1636 43.74 0.067 Cb 154Leu 13C 
1637 0.88 0.010 Hdb* 154Leu 1H 
1638 25.70 0.103 Cdb 154Leu 13C 
1639 178.56 0.101 C 154Leu 13C 
1640 2.71 0.008 Hbb 155Tyr 1H 
1641 1.77 0.029 Hba 155Tyr 1H 
1642 8.21 0.004 H 155Tyr 1H 
1643 116.47 0.304 N 155Tyr 15N 
1644 59.64 0.153 Ca 155Tyr 13C 
1645 38.89 0.058 Cb 155Tyr 13C 
1646 4.23 0.006 Ha 155Tyr 1H 
1647 176.83 0.031 C 155Tyr 13C 
1648 6.81 0.004 He* 155Tyr 1H 
1649 117.36 0.044 Ce* 155Tyr 13C 
1650 6.85 0.005 Hd* 155Tyr 1H 
1651 133.25 0.036 Cd* 155Tyr 13C 
1652 3.76 0.011 Haa 156Gly 1H 
1653 4.09 0.022 Hab 156Gly 1H 
1654 8.12 0.015 H 156Gly 1H 
1655 108.68 0.059 N 156Gly 15N 
1656 45.63 0.076 Ca 156Gly 13C 
1657 173.89 0.043 C 156Gly 13C 
1658 38.73 0.080 Cb 157Asn 13C 
1659 4.64 0.013 Ha 157Asn 1H 
1660 118.54 0.082 N 157Asn 15N 
1661 8.43 0.015 H 157Asn 1H 
1662 53.48 0.030 Ca 157Asn 13C 
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1663 2.85 0.018 Hba 157Asn 1H 
1664 2.85 0.015 Hbb 157Asn 1H 
1665 175.44 0.005 C 157Asn 13C 
1666 38.84 0.039 Cb 158Asn 13C 
1667 8.44 0.024 H 158Asn 1H 
1668 119.25 0.075 N 158Asn 15N 
1669 7.65 0.009 Hd2b 158Asn 1H 
1670 112.95 0.204 Nd2 158Asn 15N 
1671 6.89 0.047 Hd2a 158Asn 1H 
1672 53.84 0.018 Ca 158Asn 13C 
1673 4.63 0.008 Ha 158Asn 1H 
1674 2.79 0.000 Hba 158Asn 1H 
1675 2.79 0.000 Hbb 158Asn 1H 
1676 175.57 0.016 C 158Asn 13C 
1677 123.56 0.042 N 159Ala 15N 
1678 8.22 0.008 H 159Ala 1H 
1679 18.79 0.064 Cb 159Ala 13C 
1680 53.73 0.046 Ca 159Ala 13C 
1681 1.38 0.007 Hb* 159Ala 1H 
1682 4.19 0.008 Ha 159Ala 1H 
1683 178.45 0.036 C 159Ala 13C 
1684 8.16 0.008 H 160Ala 1H 
1685 121.92 0.100 N 160Ala 15N 
1686 53.13 0.031 Ca 160Ala 13C 
1687 18.62 0.037 Cb 160Ala 13C 
1688 1.41 0.005 Hb* 160Ala 1H 
1689 4.24 0.012 Ha 160Ala 1H 
1690 178.49 0.085 C 160Ala 13C 
1691 122.55 0.055 N 161Ala 15N 
1692 8.05 0.002 H 161Ala 1H 
1693 53.81 0.048 Ca 161Ala 13C 
1694 1.41 0.004 Hb* 161Ala 1H 
1695 18.84 0.069 Cb 161Ala 13C 
1696 4.16 0.008 Ha 161Ala 1H 
1697 178.99 0.052 C 161Ala 13C 
1698 36.15 0.000 Cg 162Glu 13C 
1699 2.29 0.001 Hb2 162Glu 1H 
1700 2.29 0.001 Hg3 162Glu 1H 
1701 2.29 0.001 Hg2 162Glu 1H 
1702 4.17 0.012 Ha 162Glu 1H 
1703 2.29 0.001 Hb3 162Glu 1H 
1704 8.33 0.003 H 162Glu 1H 
1705 118.71 0.087 N 162Glu 15N 
1706 57.79 0.059 Ca 162Glu 13C 
1707 29.77 0.031 Cb 162Glu 13C 
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1708 177.63 0.023 C 162Glu 13C 
1709 4.38 0.010 Ha 163Ser 1H 
1710 3.93 0.002 Hbb 163Ser 1H 
1711 3.93 0.001 Hba 163Ser 1H 
1712 8.12 0.003 H 163Ser 1H 
1713 115.34 0.046 N 163Ser 15N 
1714 59.42 0.053 Ca 163Ser 13C 
1715 63.46 0.072 Cb 163Ser 13C 
1716 175.24 0.028 C 163Ser 13C 
1717 43.42 0.000 Cd 164Arg 13C 
1718 27.48 0.000 Cg 164Arg 13C 
1719 121.90 0.060 N 164Arg 15N 
1720 8.05 0.002 H 164Arg 1H 
1721 30.51 0.068 Cb 164Arg 13C 
1722 56.77 0.038 Ca 164Arg 13C 
1723 4.33 0.000 Ha 164Arg 1H 
1724 3.17 0.000 Hd3 164Arg 1H 
1725 3.17 0.000 Hd2 164Arg 1H 
1726 176.81 0.018 C 164Arg 13C 
1727 1.66 0.000 Hg3 164Arg 1H 
1728 1.86 0.000 Hb3 164Arg 1H 
1729 1.86 0.000 Hb2 164Arg 1H 
1730 1.66 0.000 Hg2 164Arg 1H 
1731 121.16 0.044 N 165Lys 15N 
1732 8.11 0.002 H 165Lys 1H 
1733 57.27 0.030 Ca 165Lys 13C 
1734 32.85 0.046 Cb 165Lys 13C 
1735 29.36 0.070 Cd 165Lys 13C 
1736 25.05 0.055 Cg 165Lys 13C 
1737 4.25 0.000 Ha 165Lys 1H 
1738 2.98 0.008 He3 165Lys 1H 
1739 1.83 0.000 Hb3 165Lys 1H 
1740 2.98 0.008 He2 165Lys 1H 
1741 1.66 0.027 Hd3 165Lys 1H 
1742 1.66 0.027 Hd2 165Lys 1H 
1743 1.83 0.000 Hb2 165Lys 1H 
1744 1.45 0.000 Hg2 165Lys 1H 
1745 1.45 0.000 Hg3 165Lys 1H 
1746 177.58 0.051 C 165Lys 13C 
1747 8.44 0.003 H 166Gly 1H 
1748 109.47 0.040 N 166Gly 15N 
1749 45.69 0.043 Ca 166Gly 13C 
1750 3.98 0.001 Ha2 166Gly 1H 
1751 3.98 0.001 Ha3 166Gly 1H 
1752 174.70 0.000 C 166Gly 13C 
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1753 119.70 0.121 N 167Gln 15N 
1754 8.14 0.010 H 167Gln 1H 
1755 6.86 0.006 He2a 167Gln 1H 
1756 111.92 0.201 Ne2 167Gln 15N 
1757 7.57 0.003 He2b 167Gln 1H 
1758 56.16 0.108 Ca 167Gln 13C 
1759 29.40 0.027 Cb 167Gln 13C 
1760 33.79 0.065 Cg 167Gln 13C 
1761 4.34 0.001 Ha 167Gln 1H 
1762 2.36 0.003 Hg2 167Gln 1H 
1763 2.06 0.002 Hba 167Gln 1H 
1764 2.36 0.003 Hg3 167Gln 1H 
1765 2.14 0.001 Hbb 167Gln 1H 
1766 176.09 0.054 C 167Gln 13C 
1767 180.52 0.001 Cd 167Gln 13C 
1768 8.53 0.005 H 168Glu 1H 
1769 121.76 0.098 N 168Glu 15N 
1770 57.34 0.036 Ca 168Glu 13C 
1771 1.93 0.000 Hba 168Glu 1H 
1772 2.29 0.000 Hg2 168Glu 1H 
1773 2.05 0.000 Hbb 168Glu 1H 
1774 2.29 0.000 Hg3 168Glu 1H 
1775 29.99 0.072 Cb 168Glu 13C 
1776 36.32 0.000 Cg 168Glu 13C 
1777 4.22 0.000 Ha 168Glu 1H 
1778 176.75 0.022 C 168Glu 13C 
1779 3.17 0.009 Hd3 169Arg 1H 
1780 3.17 0.009 Hd2 169Arg 1H 
1781 1.78 0.005 Hb2 169Arg 1H 
1782 1.60 0.000 Hga 169Arg 1H 
1783 1.64 0.001 Hgb 169Arg 1H 
1784 4.29 0.008 Ha 169Arg 1H 
1785 1.78 0.005 Hb3 169Arg 1H 
1786 121.11 0.154 N 169Arg 15N 
1787 30.52 0.087 Cb 169Arg 13C 
1788 56.34 0.037 Ca 169Arg 13C 
1789 8.28 0.003 H 169Arg 1H 
1790 43.43 0.015 Cd 169Arg 13C 
1791 27.29 0.066 Cg 169Arg 13C 
1792 177.59 0.047 C 169Arg 13C 
1793 42.42 0.119 Cb 170Leu 13C 
1794 55.29 0.057 Ca 170Leu 13C 
1795 122.85 0.043 N 170Leu 15N 
1796 8.18 0.003 H 170Leu 1H 
1797 4.40 0.003 Ha 170Leu 1H 
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1798 0.92 0.003 Hdb* 170Leu 1H 
1799 0.86 0.002 Hda* 170Leu 1H 
1800 1.63 0.014 Hba 170Leu 1H 
1801 1.63 0.015 Hg 170Leu 1H 
1802 1.63 0.015 Hbb 170Leu 1H 
1803 26.98 0.018 Cg 170Leu 13C 
1804 23.32 0.079 Cda 170Leu 13C 
1805 25.12 0.039 Cdb 170Leu 13C 
1806 177.36 0.005 C 170Leu 13C 
1807 8.35 0.002 H 171Glu 1H 
1808 120.82 0.061 N 171Glu 15N 
1809 56.72 0.024 Ca 171Glu 13C 
1810 30.29 0.000 Cb 171Glu 13C 
1811 176.26 0.000 C 171Glu 13C 
Table 21: Bcl-xL NMR assignments. Residues are numbered ignoring the loop deletion between residues 44-85; SD is 
standard deviation. 
Number Shift (ppm) SD (ppm) Assign Name Residue Isotope 
1 176.53 0.000 C 3Gln 13C 
2 56.75 0.059 Ca 3Gln 13C 
3 29.32 0.051 Cb 3Gln 13C 
4 33.92 0.047 Cg 3Gln 13C 
5 4.37 0.004 Ha 3Gln 1H 
6 2.11 0.005 Hbb 3Gln 1H 
7 2.11 0.005 Hba 3Gln 1H 
8 2.29 0.009 Hga 3Gln 1H 
9 2.31 0.017 Hgb 3Gln 1H 
10 112.53 0.020 Ne2 3Gln 15N 
11 6.86 0.005 He2a 3Gln 1H 
12 7.69 0.006 He2b 3Gln 1H 
13 116.82 0.064 N 4Ser 15N 
14 8.64 0.018 H 4Ser 1H 
15 59.15 0.039 Ca 4Ser 13C 
16 63.46 0.048 Cb 4Ser 13C 
17 4.04 0.007 Hbb 4Ser 1H 
18 3.91 0.005 Hba 4Ser 1H 
19 4.45 0.005 Ha 4Ser 1H 
20 176.10 0.000 C 4Ser 13C 
21 122.82 0.057 N 5Asn 15N 
22 8.59 0.015 H 5Asn 1H 
23 56.22 0.017 Ca 5Asn 13C 
24 176.37 0.000 C 5Asn 13C 
25 38.47 0.015 Cb 5Asn 13C 
26 2.69 0.006 Hba 5Asn 1H 
27 3.12 0.010 Hbb 5Asn 1H 
 221 
 
28 4.04 0.004 Ha 5Asn 1H 
29 112.68 0.036 Nd2 5Asn 15N 
30 7.55 0.012 Hd2a 5Asn 1H 
31 8.04 0.009 Hd2b 5Asn 1H 
32 8.23 0.013 H 6Arg 1H 
33 120.09 0.092 N 6Arg 15N 
34 59.91 0.051 Ca 6Arg 13C 
35 177.29 0.000 C 6Arg 13C 
36 3.18 0.008 Hdb 6Arg 1H 
37 3.18 0.009 Hda 6Arg 1H 
38 3.92 0.010 Ha 6Arg 1H 
39 2.35 0.010 Hbb 6Arg 1H 
40 2.35 0.012 Hba 6Arg 1H 
41 1.63 0.014 Hga 6Arg 1H 
42 1.63 0.014 Hgb 6Arg 1H 
43 43.25 0.021 Cd 6Arg 13C 
44 36.98 0.057 Cg 7Glu 13C 
45 7.98 0.012 H 7Glu 1H 
46 117.91 0.082 N 7Glu 15N 
47 59.47 0.049 Ca 7Glu 13C 
48 29.69 0.029 Cb 7Glu 13C 
49 179.30 0.000 C 7Glu 13C 
50 2.20 0.005 Hga 7Glu 1H 
51 2.37 0.005 Hgb 7Glu 1H 
52 3.88 0.010 Ha 7Glu 1H 
53 2.00 0.001 Hba 7Glu 1H 
54 2.10 0.008 Hbb 7Glu 1H 
55 119.77 0.074 N 8Leu 15N 
56 7.75 0.014 H 8Leu 1H 
57 58.25 0.062 Ca 8Leu 13C 
58 42.10 0.061 Cb 8Leu 13C 
59 0.15 0.007 Hdb* 8Leu 1H 
60 24.41 0.028 Cda 8Leu 13C 
61 0.06 0.007 Hda* 8Leu 1H 
62 23.75 0.022 Cdb 8Leu 13C 
63 3.86 0.007 Ha 8Leu 1H 
64 1.48 0.005 Hg 8Leu 1H 
65 1.33 0.008 Hba 8Leu 1H 
66 1.80 0.006 Hbb 8Leu 1H 
67 26.22 0.076 Cg 8Leu 13C 
68 178.38 0.000 C 8Leu 13C 
69 117.74 0.055 N 9Val 15N 
70 7.72 0.009 H 9Val 1H 
71 67.82 0.067 Ca 9Val 13C 
72 22.84 0.030 Cgb 9Val 13C 
 222 
 
73 1.20 0.006 Hgb* 9Val 1H 
74 2.36 0.004 Hb 9Val 1H 
75 1.07 0.006 Hga* 9Val 1H 
76 3.67 0.004 Ha 9Val 1H 
77 24.22 0.038 Cga 9Val 13C 
78 32.50 0.046 Cb 9Val 13C 
79 179.84 0.000 C 9Val 13C 
80 8.43 0.008 H 10Val 1H 
81 67.11 0.146 Ca 10Val 13C 
82 117.76 0.038 N 10Val 15N 
83 2.81 0.008 Ha 10Val 1H 
84 31.47 0.077 Cb 10Val 13C 
85 1.70 0.006 Hb 10Val 1H 
86 22.88 0.035 Cgb 10Val 13C 
87 0.78 0.004 Hgb* 10Val 1H 
88 19.83 0.093 Cga 10Val 13C 
89 -0.01 0.005 Hga* 10Val 1H 
90 178.67 0.000 C 10Val 13C 
91 121.14 0.048 N 11Asp 15N 
92 8.19 0.008 H 11Asp 1H 
93 59.00 0.049 Ca 11Asp 13C 
94 43.39 0.031 Cb 11Asp 13C 
95 2.56 0.007 Hba 11Asp 1H 
96 2.69 0.011 Hbb 11Asp 1H 
97 4.06 0.006 Ha 11Asp 1H 
98 177.49 0.000 C 11Asp 13C 
99 120.22 0.061 N 12Phe 15N 
100 8.25 0.009 H 12Phe 1H 
101 40.08 0.055 Cb 12Phe 13C 
102 63.43 0.069 Ca 12Phe 13C 
103 178.01 0.000 C 12Phe 13C 
104 3.96 0.011 Ha 12Phe 1H 
105 3.12 0.009 Hba 12Phe 1H 
106 3.53 0.008 Hbb 12Phe 1H 
107 116.85 0.067 N 13Leu 15N 
108 8.92 0.007 H 13Leu 1H 
109 58.42 0.064 Ca 13Leu 13C 
110 179.51 0.000 C 13Leu 13C 
111 3.98 0.006 Ha 13Leu 1H 
112 1.53 0.019 Hba 13Leu 1H 
113 1.78 0.010 Hbb 13Leu 1H 
114 41.73 0.058 Cb 13Leu 13C 
115 2.25 0.006 Hg 13Leu 1H 
116 25.62 0.039 Cd1 13Leu 13C 
117 0.95 0.011 Hdb* 13Leu 1H 
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118 26.95 0.024 Cg 13Leu 13C 
119 25.62 0.034 Cd2 13Leu 13C 
120 0.95 0.011 Hda* 13Leu 1H 
121 114.27 0.057 N 14Ser 15N 
122 8.56 0.015 H 14Ser 1H 
123 62.93 0.065 Ca 14Ser 13C 
124 177.17 0.000 C 14Ser 13C 
125 3.85 0.002 Hba 14Ser 1H 
126 4.27 0.006 Ha 14Ser 1H 
127 62.68 0.038 Cb 14Ser 13C 
128 3.98 0.005 Hbb 14Ser 1H 
129 125.29 0.067 N 15Tyr 15N 
130 8.31 0.014 H 15Tyr 1H 
131 60.21 0.069 Ca 15Tyr 13C 
132 178.27 0.000 C 15Tyr 13C 
133 38.15 0.113 Cb 15Tyr 13C 
134 3.07 0.003 Hba 15Tyr 1H 
135 3.07 0.003 Hbb 15Tyr 1H 
136 4.39 0.005 Ha 15Tyr 1H 
137 120.17 0.050 N 16Lys 15N 
138 8.26 0.013 H 16Lys 1H 
139 57.44 0.066 Ca 16Lys 13C 
140 180.42 0.000 C 16Lys 13C 
141 41.62 0.029 Ce 16Lys 13C 
142 2.95 0.004 Heb 16Lys 1H 
143 2.61 0.005 Hea 16Lys 1H 
144 3.80 0.007 Ha 16Lys 1H 
145 24.26 0.024 Cg 16Lys 13C 
146 1.26 0.011 Hgb 16Lys 1H 
147 1.26 0.011 Hga 16Lys 1H 
148 26.68 0.031 Cd 16Lys 13C 
149 1.26 0.005 Hda 16Lys 1H 
150 1.51 0.010 Hdb 16Lys 1H 
151 30.04 0.030 Cb 16Lys 13C 
152 1.62 0.007 Hba 16Lys 1H 
153 1.79 0.004 Hbb 16Lys 1H 
154 8.69 0.010 H 17Leu 1H 
155 118.80 0.051 N 17Leu 15N 
156 58.79 0.068 Ca 17Leu 13C 
157 41.42 0.062 Cb 17Leu 13C 
158 0.98 0.008 Hdb* 17Leu 1H 
159 0.79 0.007 Hda* 17Leu 1H 
160 24.27 0.027 Cda 17Leu 13C 
161 26.50 0.032 Cdb 17Leu 13C 
162 1.86 0.006 Hg 17Leu 1H 
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163 27.98 0.080 Cg 17Leu 13C 
164 1.51 0.008 Hba 17Leu 1H 
165 2.15 0.006 Hbb 17Leu 1H 
166 4.06 0.008 Ha 17Leu 1H 
167 177.11 0.000 C 17Leu 13C 
168 117.76 0.068 N 18Ser 15N 
169 8.44 0.006 H 18Ser 1H 
170 61.70 0.049 Ca 18Ser 13C 
171 62.86 0.051 Cb 18Ser 13C 
172 178.50 0.000 C 18Ser 13C 
173 4.10 0.004 Hba 18Ser 1H 
174 4.22 0.004 Hbb 18Ser 1H 
175 4.71 0.006 Ha 18Ser 1H 
176 122.82 0.056 N 19Gln 15N 
177 7.65 0.008 H 19Gln 1H 
178 58.50 0.063 Ca 19Gln 13C 
179 28.99 0.029 Cb 19Gln 13C 
180 177.17 0.000 C 19Gln 13C 
181 4.02 0.008 Ha 19Gln 1H 
182 1.92 0.004 Hba 19Gln 1H 
183 2.13 0.011 Hbb 19Gln 1H 
184 34.49 0.017 Cg 19Gln 13C 
185 2.01 0.007 Hga 19Gln 1H 
186 2.10 0.008 Hgb 19Gln 1H 
187 114.59 0.134 Ne2 19Gln 15N 
188 7.45 0.013 He2b 19Gln 1H 
189 6.76 0.006 He2a 19Gln 1H 
190 179.56 0.025 Cd 19Gln 13C 
191 116.69 0.029 N 20Lys 15N 
192 7.27 0.006 H 20Lys 1H 
193 54.15 0.162 Ca 20Lys 13C 
194 32.92 0.035 Cb 20Lys 13C 
195 25.21 0.037 Cg 20Lys 13C 
196 28.31 0.114 Cd 20Lys 13C 
197 1.68 0.005 Hda 20Lys 1H 
198 1.68 0.006 Hdb 20Lys 1H 
199 1.57 0.016 Hgb 20Lys 1H 
200 1.52 0.010 Hga 20Lys 1H 
201 4.43 0.005 Ha 20Lys 1H 
202 42.38 0.084 Ce 20Lys 13C 
203 3.01 0.004 Hea 20Lys 1H 
204 3.01 0.004 Heb 20Lys 1H 
205 2.07 0.006 Hbb 20Lys 1H 
206 1.70 0.008 Hba 20Lys 1H 
207 175.54 0.000 C 20Lys 13C 
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208 105.46 0.032 N 21Gly 15N 
209 7.59 0.006 H 21Gly 1H 
210 45.46 0.076 Ca 21Gly 13C 
211 174.02 0.000 C 21Gly 13C 
212 3.97 0.005 Hab 21Gly 1H 
213 3.67 0.002 Haa 21Gly 1H 
214 119.67 0.050 N 22Tyr 15N 
215 7.84 0.004 H 22Tyr 1H 
216 55.44 0.043 Ca 22Tyr 13C 
217 41.22 0.065 Cb 22Tyr 13C 
218 5.12 0.007 Ha 22Tyr 1H 
219 3.28 0.008 Hbb 22Tyr 1H 
220 175.04 0.000 C 22Tyr 13C 
221 2.81 0.009 Hba 22Tyr 1H 
222 115.03 0.028 N 23Ser 15N 
223 8.63 0.007 H 23Ser 1H 
224 65.09 0.070 Cb 23Ser 13C 
225 56.71 0.057 Ca 23Ser 13C 
226 3.85 0.008 Hbb 23Ser 1H 
227 3.83 0.005 Hba 23Ser 1H 
228 4.94 0.004 Ha 23Ser 1H 
229 174.56 0.000 C 23Ser 13C 
230 9.09 0.008 H 24Trp 1H 
231 127.81 0.076 N 24Trp 15N 
232 128.95 0.063 Ne1 24Trp 15N 
233 10.10 0.008 He1 24Trp 1H 
234 60.59 0.049 Ca 24Trp 13C 
235 30.89 0.041 Cb 24Trp 13C 
236 3.21 0.007 Hba 24Trp 1H 
237 3.51 0.007 Hbb 24Trp 1H 
238 177.00 0.000 C 24Trp 13C 
239 4.30 0.011 Ha 24Trp 1H 
240 111.11 0.052 N 25Ser 15N 
241 8.30 0.006 H 25Ser 1H 
242 62.97 0.042 Cb 25Ser 13C 
243 60.44 0.072 Ca 25Ser 13C 
244 4.08 0.006 Ha 25Ser 1H 
245 3.90 0.009 Hba 25Ser 1H 
246 3.90 0.009 Hbb 25Ser 1H 
247 175.30 0.000 C 25Ser 13C 
248 6.84 0.008 He2a 26Gln 1H 
249 7.48 0.004 H 26Gln 1H 
250 119.25 0.058 N 26Gln 15N 
251 111.07 0.218 Ne2 26Gln 15N 
252 7.35 0.006 He2b 26Gln 1H 
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253 57.26 0.068 Ca 26Gln 13C 
254 28.74 0.106 Cb 26Gln 13C 
255 34.43 0.084 Cg 26Gln 13C 
256 3.86 0.009 Ha 26Gln 1H 
257 1.40 0.005 Hbb 26Gln 1H 
258 1.23 0.007 Hba 26Gln 1H 
259 1.84 0.005 Hga 26Gln 1H 
260 1.94 0.007 Hgb 26Gln 1H 
261 176.32 0.000 C 26Gln 13C 
262 180.23 0.016 Cd 26Gln 13C 
263 115.74 0.050 N 27Phe 15N 
264 7.22 0.014 H 27Phe 1H 
265 56.47 0.035 Ca 27Phe 13C 
266 40.31 0.057 Cb 27Phe 13C 
267 4.60 0.006 Ha 27Phe 1H 
268 3.08 0.009 Hbb 27Phe 1H 
269 2.08 0.011 Hba 27Phe 1H 
270 174.85 0.000 C 27Phe 13C 
271 113.53 0.078 N 28Ser 15N 
272 7.16 0.011 H 28Ser 1H 
273 63.95 0.069 Cb 28Ser 13C 
274 57.45 0.073 Ca 28Ser 13C 
275 4.09 0.007 Ha 28Ser 1H 
276 3.06 0.008 Hbb 28Ser 1H 
277 2.99 0.006 Hba 28Ser 1H 
278 173.63 0.000 C 28Ser 13C 
279 122.86 0.049 N 29Asp 15N 
280 8.36 0.004 H 29Asp 1H 
281 54.11 0.070 Ca 29Asp 13C 
282 41.25 0.076 Cb 29Asp 13C 
283 2.66 0.006 Hbb 29Asp 1H 
284 2.66 0.006 Hba 29Asp 1H 
285 4.59 0.007 Ha 29Asp 1H 
286 176.30 0.000 C 29Asp 13C 
287 119.30 0.055 N 30Val 15N 
288 7.97 0.006 H 30Val 1H 
289 62.42 0.091 Ca 30Val 13C 
290 33.19 0.076 Cb 30Val 13C 
291 2.07 0.005 Hb 30Val 1H 
292 0.90 0.008 Hgb* 30Val 1H 
293 0.90 0.009 Hga* 30Val 1H 
294 4.09 0.005 Ha 30Val 1H 
295 21.38 0.045 Cga 30Val 13C 
296 20.58 0.045 Cga 30Val 13C 
297 176.19 0.000 C 30Val 13C 
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298 124.78 0.039 N 31Glu 15N 
299 8.55 0.007 H 31Glu 1H 
300 56.58 0.042 Ca 31Glu 13C 
301 30.34 0.065 Cb 31Glu 13C 
302 36.49 0.018 Cg 31Glu 13C 
303 4.29 0.006 Ha 31Glu 1H 
304 2.27 0.006 Hgb 31Glu 1H 
305 2.26 0.006 Hga 31Glu 1H 
306 2.04 0.001 Hbb 31Glu 1H 
307 1.93 0.013 Hba 31Glu 1H 
308 176.50 0.000 C 31Glu 13C 
309 8.46 0.005 H 32Glu 1H 
310 122.42 0.028 N 32Glu 15N 
311 56.67 0.055 Ca 32Glu 13C 
312 30.50 0.073 Cb 32Glu 13C 
313 36.34 0.071 Cg 32Glu 13C 
314 4.23 0.006 Ha 32Glu 1H 
315 2.26 0.009 Hgb 32Glu 1H 
316 2.26 0.009 Hga 32Glu 1H 
317 1.92 0.005 Hba 32Glu 1H 
318 2.04 0.010 Hbb 32Glu 1H 
319 176.16 0.000 C 32Glu 13C 
320 119.78 0.045 N 33Asn 15N 
321 8.53 0.005 H 33Asn 1H 
322 112.81 0.205 Nd2 33Asn 15N 
323 7.60 0.006 Hd2b 33Asn 1H 
324 6.93 0.004 Hd2a 33Asn 1H 
325 39.00 0.080 Cb 33Asn 13C 
326 53.40 0.105 Ca 33Asn 13C 
327 2.83 0.010 Hbb 33Asn 1H 
328 2.73 0.011 Hba 33Asn 1H 
329 4.69 0.017 Ha 33Asn 1H 
330 175.00 0.000 C 33Asn 13C 
331 177.07 0.033 Cg 33Asn 13C 
332 122.22 0.066 N 34Arg 15N 
333 8.37 0.004 H 34Arg 1H 
334 27.33 0.066 Cg 34Arg 13C 
335 30.96 0.038 Cb 34Arg 13C 
336 56.15 0.030 Ca 34Arg 13C 
337 43.41 0.060 Cd 34Arg 13C 
338 4.42 0.005 Ha 34Arg 1H 
339 1.61 0.007 Hga 34Arg 1H 
340 1.61 0.007 Hgb 34Arg 1H 
341 1.77 0.010 Hba 34Arg 1H 
342 1.89 0.006 Hbb 34Arg 1H 
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343 3.19 0.007 Hda 34Arg 1H 
344 3.19 0.007 Hdb 34Arg 1H 
345 176.46 0.000 C 34Arg 13C 
346 8.30 0.004 H 35Thr 1H 
347 115.99 0.041 N 35Thr 15N 
348 69.85 0.116 Cb 35Thr 13C 
349 62.11 0.073 Ca 35Thr 13C 
350 21.89 0.165 Cg2 35Thr 13C 
351 1.20 0.004 Hg2* 35Thr 1H 
352 4.33 0.005 Ha 35Thr 1H 
353 4.22 0.004 Hb 35Thr 1H 
354 174.41 0.000 C 35Thr 13C 
355 123.18 0.073 N 36Glu 15N 
356 8.42 0.004 H 36Glu 1H 
357 30.43 0.034 Cb 36Glu 13C 
358 56.35 0.026 Ca 36Glu 13C 
359 36.28 0.054 Cg 36Glu 13C 
360 4.31 0.008 Ha 36Glu 1H 
361 2.06 0.002 Hbb 36Glu 1H 
362 1.92 0.002 Hba 36Glu 1H 
363 2.26 0.003 Hga 36Glu 1H 
364 2.26 0.003 Hgb 36Glu 1H 
365 175.64 0.000 C 36Glu 13C 
366 126.24 0.050 N 37Ala 15N 
367 8.32 0.004 H 37Ala 1H 
368 50.60 0.088 Ca 37Ala 13C 
369 18.66 0.062 Cb 37Ala 13C 
370 1.35 0.003 Hb* 37Ala 1H 
371 4.61 0.004 Ha 37Ala 1H 
372 63.23 0.137 Ca 38Pro 13C 
373 4.43 0.008 Ha 38Pro 1H 
374 3.77 0.005 Hdb 38Pro 1H 
375 50.68 0.091 Cd 38Pro 13C 
376 3.66 0.003 Hda 38Pro 1H 
377 32.22 0.055 Cb 38Pro 13C 
378 2.29 0.008 Hbb 38Pro 1H 
379 1.94 0.004 Hba 38Pro 1H 
380 27.59 0.086 Cg 38Pro 13C 
381 177.06 0.000 C 38Pro 13C 
382 2.03 0.011 Hgb 38Pro 1H 
383 2.02 0.007 Hga 38Pro 1H 
384 121.25 0.020 N 39Glu 15N 
385 8.65 0.007 H 39Glu 1H 
386 30.52 0.041 Cb 39Glu 13C 
387 56.99 0.085 Ca 39Glu 13C 
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388 36.48 0.046 Cg 39Glu 13C 
389 4.30 0.004 Ha 39Glu 1H 
390 2.07 0.002 Hbb 39Glu 1H 
391 1.99 0.002 Hba 39Glu 1H 
392 2.31 0.004 Hga 39Glu 1H 
393 2.31 0.004 Hgb 39Glu 1H 
394 177.12 0.000 C 39Glu 13C 
395 110.35 0.059 N 40Gly 15N 
396 8.53 0.007 H 40Gly 1H 
397 45.64 0.094 Ca 40Gly 13C 
398 4.09 0.007 Haa 40Gly 1H 
399 4.09 0.007 Hab 40Gly 1H 
400 174.65 0.000 C 40Gly 13C 
401 113.03 0.052 N 41Thr 15N 
402 8.23 0.004 H 41Thr 1H 
403 21.88 0.079 Cg2 41Thr 13C 
404 70.01 0.127 Cb 41Thr 13C 
405 62.43 0.104 Ca 41Thr 13C 
406 1.20 0.007 Hg2* 41Thr 1H 
407 4.39 0.006 Ha 41Thr 1H 
408 4.32 0.008 Hb 41Thr 1H 
409 175.57 0.000 C 41Thr 13C 
410 123.33 0.133 N 42Glu 15N 
411 8.89 0.007 H 42Glu 1H 
412 29.84 0.113 Cb 42Glu 13C 
413 57.76 0.076 Ca 42Glu 13C 
414 36.48 0.056 Cg 42Glu 13C 
415 4.34 0.004 Ha 42Glu 1H 
416 2.32 0.008 Hga 42Glu 1H 
417 2.32 0.008 Hgb 42Glu 1H 
418 2.10 0.007 Hbb 42Glu 1H 
419 2.00 0.002 Hba 42Glu 1H 
420 177.28 0.000 C 42Glu 13C 
421 115.44 0.053 N 43Ser 15N 
422 8.47 0.007 H 43Ser 1H 
423 59.06 0.059 Ca 43Ser 13C 
424 63.78 0.034 Cb 43Ser 13C 
425 4.42 0.003 Ha 43Ser 1H 
426 3.92 0.011 Hbb 43Ser 1H 
427 3.88 0.009 Hba 43Ser 1H 
428 175.80 0.000 C 43Ser 13C 
429 123.11 0.073 N 44Glu 15N 
430 8.28 0.009 H 44Glu 1H 
431 59.11 0.049 Ca 44Glu 13C 
432 3.99 0.008 Ha 44Glu 1H 
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433 2.32 0.006 Hga 44Glu 1H 
434 2.32 0.006 Hgb 44Glu 1H 
435 2.05 0.006 Hbb 44Glu 1H 
436 2.05 0.004 Hba 44Glu 1H 
437 36.20 0.040 Cg 44Glu 13C 
438 29.56 0.012 Cb 44Glu 13C 
439 177.93 0.000 C 44Glu 13C 
440 120.85 0.079 N 45Ala 15N 
441 8.23 0.005 H 45Ala 1H 
442 18.72 0.047 Cb 45Ala 13C 
443 1.49 0.009 Hb* 45Ala 1H 
444 4.15 0.005 Ha 45Ala 1H 
445 55.24 0.045 Ca 45Ala 13C 
446 180.64 0.000 C 45Ala 13C 
447 118.91 0.035 N 46Val 15N 
448 7.55 0.007 H 46Val 1H 
449 66.23 0.111 Ca 46Val 13C 
450 3.50 0.006 Ha 46Val 1H 
451 22.92 0.031 Cgb 46Val 13C 
452 1.02 0.006 Hgb* 46Val 1H 
453 0.49 0.005 Hga* 46Val 1H 
454 22.39 0.080 Cga 46Val 13C 
455 31.87 0.084 Cb 46Val 13C 
456 1.93 0.007 Hb 46Val 1H 
457 176.77 0.000 C 46Val 13C 
458 7.46 0.007 H 47Lys 1H 
459 117.94 0.040 N 47Lys 15N 
460 59.83 0.044 Ca 47Lys 13C 
461 178.95 0.000 C 47Lys 13C 
462 3.74 0.009 Ha 47Lys 1H 
463 42.30 0.028 Ce 47Lys 13C 
464 2.54 0.005 Hea 47Lys 1H 
465 2.71 0.007 Heb 47Lys 1H 
466 32.57 0.031 Cb 47Lys 13C 
467 1.87 0.011 Hbb 47Lys 1H 
468 1.62 0.007 Hba 47Lys 1H 
469 30.45 0.028 Cd 47Lys 13C 
470 26.79 0.051 Cg 47Lys 13C 
471 1.56 0.005 Hdb 47Lys 1H 
472 1.42 0.005 Hda 47Lys 1H 
473 1.31 0.009 Hgb 47Lys 1H 
474 1.15 0.014 Hga 47Lys 1H 
475 7.88 0.007 He2b 48Gln 1H 
476 6.68 0.007 He2a 48Gln 1H 
477 112.30 0.181 Ne2 48Gln 15N 
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478 116.29 0.069 N 48Gln 15N 
479 8.18 0.009 H 48Gln 1H 
480 59.08 0.078 Ca 48Gln 13C 
481 3.72 0.005 Ha 48Gln 1H 
482 33.32 0.087 Cg 48Gln 13C 
483 2.39 0.005 Hga 48Gln 1H 
484 2.39 0.004 Hgb 48Gln 1H 
485 2.09 0.007 Hbb 48Gln 1H 
486 2.00 0.012 Hba 48Gln 1H 
487 177.59 0.000 C 48Gln 13C 
488 179.75 0.016 Cd 48Gln 13C 
489 28.16 0.097 Cb 48Gln 13C 
490 120.45 0.040 N 49Ala 15N 
491 7.81 0.007 H 49Ala 1H 
492 55.09 0.055 Ca 49Ala 13C 
493 18.77 0.067 Cb 49Ala 13C 
494 1.45 0.008 Hb* 49Ala 1H 
495 179.63 0.000 C 49Ala 13C 
496 4.27 0.010 Ha 49Ala 1H 
497 120.43 0.065 N 50Leu 15N 
498 8.48 0.010 H 50Leu 1H 
499 58.65 0.078 Ca 50Leu 13C 
500 42.39 0.069 Cb 50Leu 13C 
501 -0.43 0.005 Hda* 50Leu 1H 
502 23.17 0.082 Cda 50Leu 13C 
503 23.57 0.069 Cdb 50Leu 13C 
504 0.07 0.005 Hdb* 50Leu 1H 
505 26.83 0.093 Cg 50Leu 13C 
506 1.19 0.003 Hg 50Leu 1H 
507 1.45 0.007 Hbb 50Leu 1H 
508 1.45 0.006 Hba 50Leu 1H 
509 4.15 0.008 Ha 50Leu 1H 
510 179.31 0.000 C 50Leu 13C 
511 118.90 0.066 N 51Arg 15N 
512 8.25 0.008 H 51Arg 1H 
513 61.07 0.066 Ca 51Arg 13C 
514 178.53 0.000 C 51Arg 13C 
515 3.82 0.007 Ha 51Arg 1H 
516 44.36 0.025 Cd 51Arg 13C 
517 2.21 0.007 Hdb 51Arg 1H 
518 27.31 0.037 Cg 51Arg 13C 
519 0.65 0.005 Hga 51Arg 1H 
520 1.98 0.007 Hgb 51Arg 1H 
521 1.98 0.004 Hda 51Arg 1H 
522 30.93 0.032 Cb 51Arg 13C 
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523 1.10 0.007 Hba 51Arg 1H 
524 1.70 0.010 Hbb 51Arg 1H 
525 116.70 0.068 N 52Glu 15N 
526 8.00 0.007 H 52Glu 1H 
527 36.97 0.044 Cg 52Glu 13C 
528 59.60 0.060 Ca 52Glu 13C 
529 180.04 0.000 C 52Glu 13C 
530 2.60 0.004 Hgb 52Glu 1H 
531 2.39 0.004 Hga 52Glu 1H 
532 4.17 0.006 Ha 52Glu 1H 
533 2.17 0.011 Hba 52Glu 1H 
534 2.29 0.001 Hbb 52Glu 1H 
535 29.71 0.019 Cb 52Glu 13C 
536 8.90 0.010 H 53Ala 1H 
537 123.84 0.071 N 53Ala 15N 
538 19.17 0.044 Cb 53Ala 13C 
539 55.33 0.053 Ca 53Ala 13C 
540 4.50 0.012 Ha 53Ala 1H 
541 1.68 0.005 Hb* 53Ala 1H 
542 181.21 0.000 C 53Ala 13C 
543 9.23 0.009 H 54Gly 1H 
544 107.44 0.083 N 54Gly 15N 
545 47.13 0.093 Ca 54Gly 13C 
546 176.29 0.000 C 54Gly 13C 
547 4.05 0.008 Haa 54Gly 1H 
548 4.07 0.015 Hab 54Gly 1H 
549 124.09 0.038 N 55Asp 15N 
550 8.67 0.009 H 55Asp 1H 
551 57.97 0.065 Ca 55Asp 13C 
552 39.80 0.043 Cb 55Asp 13C 
553 4.55 0.004 Ha 55Asp 1H 
554 3.10 0.004 Hbb 55Asp 1H 
555 2.74 0.006 Hba 55Asp 1H 
556 179.13 0.000 C 55Asp 13C 
557 121.67 0.049 N 56Glu 15N 
558 8.28 0.009 H 56Glu 1H 
559 59.69 0.047 Ca 56Glu 13C 
560 36.34 0.059 Cg 56Glu 13C 
561 178.66 0.000 C 56Glu 13C 
562 29.57 0.009 Cb 56Glu 13C 
563 2.32 0.006 Hbb 56Glu 1H 
564 2.32 0.006 Hba 56Glu 1H 
565 2.45 0.003 Hgb 56Glu 1H 
566 2.32 0.007 Hga 56Glu 1H 
567 4.17 0.004 Ha 56Glu 1H 
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568 8.70 0.012 H 57Phe 1H 
569 122.19 0.055 N 57Phe 15N 
570 62.54 0.072 Ca 57Phe 13C 
571 176.94 0.000 C 57Phe 13C 
572 40.42 0.020 Cb 57Phe 13C 
573 3.28 0.012 Hba 57Phe 1H 
574 3.70 0.007 Hbb 57Phe 1H 
575 4.06 0.002 Ha 57Phe 1H 
576 8.69 0.007 H 58Glu 1H 
577 118.26 0.034 N 58Glu 15N 
578 59.74 0.077 Ca 58Glu 13C 
579 177.69 0.000 C 58Glu 13C 
580 30.01 0.015 Cb 58Glu 13C 
581 2.28 0.005 Hbb 58Glu 1H 
582 2.23 0.003 Hba 58Glu 1H 
583 37.30 0.042 Cg 58Glu 13C 
584 2.56 0.003 Hgb 58Glu 1H 
585 2.29 0.008 Hga 58Glu 1H 
586 3.79 0.003 Ha 58Glu 1H 
587 118.68 0.033 N 59Leu 15N 
588 7.94 0.007 H 59Leu 1H 
589 58.03 0.081 Ca 59Leu 13C 
590 24.95 0.204 Cdb 59Leu 13C 
591 0.90 0.007 Hda* 59Leu 1H 
592 0.91 0.006 Hdb* 59Leu 1H 
593 24.49 0.157 Cda 59Leu 13C 
594 4.03 0.004 Ha 59Leu 1H 
595 1.77 0.006 Hba 59Leu 1H 
596 1.77 0.006 Hbb 59Leu 1H 
597 1.63 0.004 Hg 59Leu 1H 
598 42.27 0.072 Cb 59Leu 13C 
599 27.22 0.026 Cg 59Leu 13C 
600 179.38 0.000 C 59Leu 13C 
601 117.23 0.116 N 60Arg 15N 
602 7.59 0.008 H 60Arg 1H 
603 58.72 0.068 Ca 60Arg 13C 
604 30.43 0.000 Cb 60Arg 13C 
605 3.77 0.009 Ha 60Arg 1H 
606 44.00 0.023 Cd 60Arg 13C 
607 2.89 0.004 Hdb 60Arg 1H 
608 2.83 0.001 Hda 60Arg 1H 
609 1.25 0.002 Hga 60Arg 1H 
610 1.25 0.002 Hgb 60Arg 1H 
611 121.70 0.066 N 64Ala 15N 
612 8.08 0.005 H 64Ala 1H 
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613 1.50 0.004 Hb* 64Ala 1H 
614 19.54 0.050 Cb 64Ala 13C 
615 53.76 0.067 Ca 64Ala 13C 
616 4.38 0.011 Ha 64Ala 1H 
617 176.28 0.000 C 65Phe 13C 
618 115.36 0.078 N 65Phe 15N 
619 8.19 0.008 H 65Phe 1H 
620 39.03 0.020 Cb 65Phe 13C 
621 3.34 0.004 Hbb 65Phe 1H 
622 3.23 0.000 Hba 65Phe 1H 
623 115.19 0.044 N 66Ser 15N 
624 7.83 0.011 H 66Ser 1H 
625 60.57 0.064 Ca 66Ser 13C 
626 63.36 0.087 Cb 66Ser 13C 
627 3.97 0.004 Hba 66Ser 1H 
628 4.33 0.003 Ha 66Ser 1H 
629 175.46 0.000 C 66Ser 13C 
630 3.97 0.000 Hbb 66Ser 1H 
631 124.04 0.064 N 67Asp 15N 
632 8.48 0.012 H 67Asp 1H 
633 55.30 0.076 Ca 67Asp 13C 
634 40.58 0.058 Cb 67Asp 13C 
635 2.95 0.003 Hbb 67Asp 1H 
636 2.67 0.007 Hba 67Asp 1H 
637 4.66 0.013 Ha 67Asp 1H 
638 177.57 0.000 C 67Asp 13C 
639 122.45 0.067 N 68Leu 15N 
640 9.03 0.010 H 68Leu 1H 
641 58.41 0.072 Ca 68Leu 13C 
642 23.86 0.036 Cdb 68Leu 13C 
643 0.91 0.008 Hda* 68Leu 1H 
644 0.93 0.008 Hdb* 68Leu 1H 
645 1.41 0.004 Hba 68Leu 1H 
646 4.03 0.007 Ha 68Leu 1H 
647 1.93 0.009 Hbb 68Leu 1H 
648 26.14 0.033 Cda 68Leu 13C 
649 43.05 0.040 Cb 68Leu 13C 
650 179.27 0.000 C 68Leu 13C 
651 1.95 0.023 Hg 68Leu 1H 
652 26.96 0.020 Cg 68Leu 13C 
653 9.01 0.016 H 69Thr 1H 
654 110.57 0.067 N 69Thr 15N 
655 66.65 0.077 Ca 69Thr 13C 
656 68.12 0.087 Cb 69Thr 13C 
657 4.16 0.005 Hb 69Thr 1H 
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658 3.82 0.011 Ha 69Thr 1H 
659 1.12 0.011 Hg2* 69Thr 1H 
660 22.20 0.034 Cg2 69Thr 13C 
661 178.07 0.000 C 69Thr 13C 
662 117.64 0.068 N 70Ser 15N 
663 7.77 0.011 H 70Ser 1H 
664 61.14 0.134 Ca 70Ser 13C 
665 3.94 0.007 Hba 70Ser 1H 
666 4.35 0.007 Ha 70Ser 1H 
667 3.94 0.007 Hbb 70Ser 1H 
668 62.78 0.061 Cb 70Ser 13C 
669 178.47 0.000 C 70Ser 13C 
670 111.39 0.029 Ne2 71Gln 15N 
671 7.39 0.008 He2b 71Gln 1H 
672 119.35 0.050 N 71Gln 15N 
673 7.94 0.008 H 71Gln 1H 
674 58.32 0.058 Ca 71Gln 13C 
675 177.01 0.000 C 71Gln 13C 
676 4.03 0.006 Ha 71Gln 1H 
677 34.69 0.020 Cg 71Gln 13C 
678 2.41 0.005 Hga 71Gln 1H 
679 2.52 0.006 Hgb 71Gln 1H 
680 6.78 0.004 He2a 71Gln 1H 
681 2.11 0.013 Hba 71Gln 1H 
682 2.11 0.013 Hbb 71Gln 1H 
683 115.01 0.060 N 72Leu 15N 
684 7.71 0.010 H 72Leu 1H 
685 54.49 0.036 Ca 72Leu 13C 
686 42.49 0.051 Cb 72Leu 13C 
687 23.10 0.014 Cda 72Leu 13C 
688 0.87 0.004 Hda* 72Leu 1H 
689 26.61 0.030 Cdb 72Leu 13C 
690 1.05 0.010 Hdb* 72Leu 1H 
691 4.33 0.006 Ha 72Leu 1H 
692 1.83 0.004 Hg 72Leu 1H 
693 27.12 0.074 Cg 72Leu 13C 
694 1.84 0.008 Hbb 72Leu 1H 
695 1.59 0.010 Hba 72Leu 1H 
696 118.08 0.088 N 73His 15N 
697 7.59 0.007 H 73His 1H 
698 56.19 0.055 Ca 73His 13C 
699 27.20 0.148 Cb 73His 13C 
700 174.83 0.000 C 73His 13C 
701 3.23 0.010 Hba 73His 1H 
702 3.23 0.010 Hbb 73His 1H 
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703 4.34 0.006 Ha 73His 1H 
704 118.49 0.098 N 74Ile 15N 
705 8.40 0.008 H 74Ile 1H 
706 62.20 0.059 Ca 74Ile 13C 
707 37.71 0.033 Cb 74Ile 13C 
708 12.00 0.024 Cd1 74Ile 13C 
709 0.82 0.009 Hd1* 74Ile 1H 
710 1.81 0.009 Hb 74Ile 1H 
711 0.80 0.008 Hg2* 74Ile 1H 
712 17.81 0.024 Cg2 74Ile 13C 
713 3.88 0.011 Ha 74Ile 1H 
714 175.45 0.000 C 74Ile 13C 
715 27.43 0.029 Cg1 74Ile 13C 
716 1.42 0.009 Hg1b 74Ile 1H 
717 1.41 0.006 Hg1a 74Ile 1H 
718 115.05 0.035 N 75Thr 15N 
719 7.30 0.010 H 75Thr 1H 
720 59.16 0.033 Ca 75Thr 13C 
721 4.98 0.010 Ha 75Thr 1H 
722 22.31 0.012 Cg2 75Thr 13C 
723 1.25 0.004 Hg2* 75Thr 1H 
724 71.03 0.038 Cb 75Thr 13C 
725 4.54 0.005 Hb 75Thr 1H 
726 50.55 0.022 Cd 76Pro 13C 
727 4.12 0.007 Hdb 76Pro 1H 
728 3.93 0.008 Hda 76Pro 1H 
729 28.98 0.036 Cg 76Pro 13C 
730 2.42 0.007 Hgb 76Pro 1H 
731 1.70 0.007 Hga 76Pro 1H 
732 67.04 0.021 Ca 76Pro 13C 
733 4.38 0.005 Ha 76Pro 1H 
734 31.56 0.059 Cb 76Pro 13C 
735 2.29 0.014 Hbb 76Pro 1H 
736 2.10 0.008 Hba 76Pro 1H 
737 46.13 0.095 Ca 77Gly 13C 
738 175.29 0.000 C 77Gly 13C 
739 4.23 0.008 Hab 77Gly 1H 
740 3.97 0.006 Haa 77Gly 1H 
741 108.62 0.048 N 78Thr 15N 
742 7.63 0.007 H 78Thr 1H 
743 61.61 0.074 Ca 78Thr 13C 
744 1.18 0.005 Hg2* 78Thr 1H 
745 21.50 0.036 Cg2 78Thr 13C 
746 4.87 0.018 Ha 78Thr 1H 
747 4.76 0.033 Hb 78Thr 1H 
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748 69.83 0.000 Cb 78Thr 13C 
749 175.81 0.000 C 78Thr 13C 
750 125.56 0.096 N 79Ala 15N 
751 7.85 0.006 H 79Ala 1H 
752 56.44 0.101 Ca 79Ala 13C 
753 20.44 0.032 Cb 79Ala 13C 
754 1.80 0.004 Hb* 79Ala 1H 
755 4.12 0.008 Ha 79Ala 1H 
756 177.75 0.000 C 79Ala 13C 
757 8.87 0.009 H 80Tyr 1H 
758 117.96 0.045 N 80Tyr 15N 
759 61.65 0.055 Ca 80Tyr 13C 
760 37.16 0.010 Cb 80Tyr 13C 
761 176.60 0.000 C 80Tyr 13C 
762 2.83 0.005 Ha 80Tyr 1H 
763 2.45 0.015 Hbb 80Tyr 1H 
764 2.42 0.016 Hba 80Tyr 1H 
765 132.12 0.048 Cd* 80Tyr 13C 
766 5.76 0.005 Hd* 80Tyr 1H 
767 117.82 0.070 Ce* 80Tyr 13C 
768 6.49 0.003 He* 80Tyr 1H 
769 117.80 0.051 N 81Gln 15N 
770 8.08 0.007 H 81Gln 1H 
771 6.90 0.004 He2a 81Gln 1H 
772 111.81 0.225 Ne2 81Gln 15N 
773 7.65 0.004 He2b 81Gln 1H 
774 59.29 0.068 Ca 81Gln 13C 
775 28.16 0.113 Cb 81Gln 13C 
776 34.75 0.084 Cg 81Gln 13C 
777 2.49 0.014 Hgb 81Gln 1H 
778 2.44 0.005 Hga 81Gln 1H 
779 3.83 0.005 Ha 81Gln 1H 
780 2.19 0.006 Hbb 81Gln 1H 
781 2.09 0.003 Hba 81Gln 1H 
782 179.28 0.000 C 81Gln 13C 
783 180.63 0.004 Cd 81Gln 13C 
784 115.76 0.076 N 82Ser 15N 
785 7.85 0.009 H 82Ser 1H 
786 62.99 0.064 Ca 82Ser 13C 
787 174.49 0.000 C 82Ser 13C 
788 4.28 0.005 Ha 82Ser 1H 
789 63.27 0.036 Cb 82Ser 13C 
790 3.84 0.008 Hba 82Ser 1H 
791 4.03 0.006 Hbb 82Ser 1H 
792 39.96 0.022 Cb 83Phe 13C 
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793 122.57 0.034 N 83Phe 15N 
794 8.46 0.008 H 83Phe 1H 
795 62.82 0.053 Ca 83Phe 13C 
796 2.93 0.005 Hba 83Phe 1H 
797 3.14 0.011 Hbb 83Phe 1H 
798 3.93 0.007 Ha 83Phe 1H 
799 175.54 0.000 C 83Phe 13C 
800 117.92 0.054 N 84Glu 15N 
801 8.58 0.006 H 84Glu 1H 
802 59.32 0.051 Ca 84Glu 13C 
803 36.82 0.061 Cg 84Glu 13C 
804 1.95 0.007 Hga 84Glu 1H 
805 2.01 0.006 Hgb 84Glu 1H 
806 1.72 0.007 Hbb 84Glu 1H 
807 1.53 0.005 Hba 84Glu 1H 
808 3.47 0.005 Ha 84Glu 1H 
809 30.04 0.075 Cb 84Glu 13C 
810 177.76 0.000 C 84Glu 13C 
811 7.46 0.005 He2b 85Gln 1H 
812 110.84 0.225 Ne2 85Gln 15N 
813 6.78 0.006 He2a 85Gln 1H 
814 116.90 0.071 N 85Gln 15N 
815 7.82 0.006 H 85Gln 1H 
816 59.11 0.059 Ca 85Gln 13C 
817 28.64 0.052 Cb 85Gln 13C 
818 34.20 0.051 Cg 85Gln 13C 
819 3.86 0.007 Ha 85Gln 1H 
820 2.56 0.005 Hgb 85Gln 1H 
821 2.30 0.003 Hga 85Gln 1H 
822 2.17 0.006 Hbb 85Gln 1H 
823 2.01 0.012 Hba 85Gln 1H 
824 179.12 0.000 C 85Gln 13C 
825 180.07 0.001 Cd 85Gln 13C 
826 118.35 0.050 N 86Val 15N 
827 7.66 0.008 H 86Val 1H 
828 66.67 0.081 Ca 86Val 13C 
829 -0.42 0.005 Hga* 86Val 1H 
830 20.60 0.063 Cga 86Val 13C 
831 0.90 0.007 Hgb* 86Val 1H 
832 3.22 0.007 Ha 86Val 1H 
833 1.56 0.011 Hb 86Val 1H 
834 23.07 0.053 Cgb 86Val 13C 
835 31.72 0.021 Cb 86Val 13C 
836 177.65 0.000 C 86Val 13C 
837 116.93 0.076 N 87Val 15N 
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838 7.92 0.008 H 87Val 1H 
839 66.67 0.078 Ca 87Val 13C 
840 21.30 0.023 Cga 87Val 13C 
841 0.11 0.008 Hga* 87Val 1H 
842 0.21 0.006 Hgb* 87Val 1H 
843 1.36 0.004 Hb 87Val 1H 
844 3.15 0.006 Ha 87Val 1H 
845 21.83 0.024 Cgb 87Val 13C 
846 31.14 0.031 Cb 87Val 13C 
847 176.86 0.000 C 87Val 13C 
848 116.21 0.039 N 88Asn 15N 
849 8.23 0.005 H 88Asn 1H 
850 7.50 0.008 Hd2b 88Asn 1H 
851 111.25 0.227 Nd2 88Asn 15N 
852 6.93 0.006 Hd2a 88Asn 1H 
853 37.56 0.057 Cb 88Asn 13C 
854 55.19 0.051 Ca 88Asn 13C 
855 4.32 0.004 Ha 88Asn 1H 
856 2.84 0.005 Hbb 88Asn 1H 
857 2.57 0.004 Hba 88Asn 1H 
858 178.46 0.000 C 88Asn 13C 
859 176.52 0.007 Cg 88Asn 13C 
860 118.59 0.102 N 89Glu 15N 
861 7.16 0.008 H 89Glu 1H 
862 58.46 0.093 Ca 89Glu 13C 
863 36.10 0.065 Cg 89Glu 13C 
864 4.03 0.008 Ha 89Glu 1H 
865 2.41 0.004 Hgb 89Glu 1H 
866 2.05 0.016 Hga 89Glu 1H 
867 177.34 0.000 C 89Glu 13C 
868 29.97 0.035 Cb 89Glu 13C 
869 1.99 0.011 Hbb 89Glu 1H 
870 1.74 0.012 Hba 89Glu 1H 
871 123.83 0.073 N 90Leu 15N 
872 8.10 0.011 H 90Leu 1H 
873 57.82 0.057 Ca 90Leu 13C 
874 0.25 0.010 Hda* 90Leu 1H 
875 25.71 0.015 Cda 90Leu 13C 
876 3.66 0.004 Ha 90Leu 1H 
877 0.34 0.006 Hdb* 90Leu 1H 
878 42.35 0.071 Cb 90Leu 13C 
879 1.51 0.011 Hbb 90Leu 1H 
880 0.97 0.006 Hba 90Leu 1H 
881 -0.02 0.007 Hg 90Leu 1H 
882 22.54 0.021 Cdb 90Leu 13C 
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883 26.80 0.083 Cg 90Leu 13C 
884 175.77 0.000 C 90Leu 13C 
885 108.65 0.022 N 91Phe 15N 
886 6.87 0.005 H 91Phe 1H 
887 38.62 0.024 Cb 91Phe 13C 
888 56.74 0.046 Ca 91Phe 13C 
889 177.36 0.000 C 91Phe 13C 
890 5.15 0.004 Ha 91Phe 1H 
891 3.25 0.009 Hbb 91Phe 1H 
892 2.49 0.008 Hba 91Phe 1H 
893 123.52 0.032 N 92Arg 15N 
894 7.32 0.008 H 92Arg 1H 
895 29.89 0.015 Cb 92Arg 13C 
896 60.21 0.077 Ca 92Arg 13C 
897 3.89 0.004 Ha 92Arg 1H 
898 26.03 0.030 Cg 92Arg 13C 
899 1.53 0.006 Hga 92Arg 1H 
900 1.53 0.006 Hgb 92Arg 1H 
901 43.37 0.031 Cd 92Arg 13C 
902 3.17 0.008 Hda 92Arg 1H 
903 3.18 0.012 Hdb 92Arg 1H 
904 177.64 0.000 C 92Arg 13C 
905 2.16 0.005 Hbb 92Arg 1H 
906 1.70 0.007 Hba 92Arg 1H 
907 113.43 0.057 N 93Asp 15N 
908 8.42 0.006 H 93Asp 1H 
909 40.29 0.069 Cb 93Asp 13C 
910 52.75 0.029 Ca 93Asp 13C 
911 2.80 0.004 Hbb 93Asp 1H 
912 2.59 0.005 Hba 93Asp 1H 
913 4.78 0.005 Ha 93Asp 1H 
914 175.71 0.000 C 93Asp 13C 
915 107.77 0.048 N 94Gly 15N 
916 7.22 0.005 H 94Gly 1H 
917 44.90 0.084 Ca 94Gly 13C 
918 3.69 0.005 Haa 94Gly 1H 
919 4.35 0.005 Hab 94Gly 1H 
920 170.50 0.000 C 94Gly 13C 
921 116.92 0.078 N 95Val 15N 
922 7.79 0.005 H 95Val 1H 
923 61.71 0.061 Ca 95Val 13C 
924 3.63 0.007 Ha 95Val 1H 
925 20.85 0.075 Cgb 95Val 13C 
926 0.40 0.005 Hgb* 95Val 1H 
927 0.16 0.012 Hb 95Val 1H 
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928 -0.55 0.006 Hga* 95Val 1H 
929 23.05 0.032 Cga 95Val 13C 
930 34.27 0.077 Cb 95Val 13C 
931 174.18 0.000 C 95Val 13C 
932 115.06 0.052 N 96Asn 15N 
933 6.26 0.006 H 96Asn 1H 
934 52.34 0.110 Ca 96Asn 13C 
935 174.67 0.000 C 96Asn 13C 
936 39.77 0.041 Cb 96Asn 13C 
937 3.01 0.003 Hba 96Asn 1H 
938 3.26 0.006 Hbb 96Asn 1H 
939 3.97 0.007 Ha 96Asn 1H 
940 7.45 0.011 Hd2b 96Asn 1H 
941 7.31 0.014 Hd2a 96Asn 1H 
942 114.85 0.017 Nd2 96Asn 15N 
943 118.32 0.077 N 97Trp 15N 
944 8.21 0.021 H 97Trp 1H 
945 10.37 0.009 He1 97Trp 1H 
946 128.94 0.047 Ne1 97Trp 15N 
947 60.65 0.038 Ca 97Trp 13C 
948 31.88 0.088 Cb 97Trp 13C 
949 178.52 0.000 C 97Trp 13C 
950 3.82 0.019 Ha 97Trp 1H 
951 3.83 0.010 Hba 97Trp 1H 
952 3.83 0.015 Hbb 97Trp 1H 
953 8.66 0.013 H 98Gly 1H 
954 107.03 0.050 N 98Gly 15N 
955 47.74 0.076 Ca 98Gly 13C 
956 176.75 0.000 C 98Gly 13C 
957 3.87 0.012 Haa 98Gly 1H 
958 4.47 0.009 Hab 98Gly 1H 
959 120.21 0.044 N 99Arg 15N 
960 8.46 0.009 H 99Arg 1H 
961 60.01 0.081 Ca 99Arg 13C 
962 177.86 0.000 C 99Arg 13C 
963 3.77 0.008 Ha 99Arg 1H 
964 43.76 0.041 Cd 99Arg 13C 
965 3.16 0.020 Hdb 99Arg 1H 
966 2.54 0.015 Hda 99Arg 1H 
967 1.39 0.003 Hba 99Arg 1H 
968 31.62 0.000 Cb 99Arg 13C 
969 1.51 0.000 Hbb 99Arg 1H 
970 120.63 0.040 N 100Ile 15N 
971 7.88 0.008 H 100Ile 1H 
972 67.56 0.071 Ca 100Ile 13C 
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973 14.33 0.031 Cd1 100Ile 13C 
974 0.35 0.004 Hd1* 100Ile 1H 
975 0.73 0.008 Hg1a 100Ile 1H 
976 1.74 0.007 Hg1b 100Ile 1H 
977 1.25 0.006 Hg2* 100Ile 1H 
978 17.60 0.056 Cg2 100Ile 13C 
979 2.42 0.006 Hb 100Ile 1H 
980 3.96 0.011 Ha 100Ile 1H 
981 31.23 0.096 Cg1 100Ile 13C 
982 37.61 0.048 Cb 100Ile 13C 
983 177.97 0.000 C 100Ile 13C 
984 122.80 0.028 N 101Val 15N 
985 8.47 0.008 H 101Val 1H 
986 68.27 0.060 Ca 101Val 13C 
987 3.43 0.006 Ha 101Val 1H 
988 21.46 0.079 Cga 101Val 13C 
989 0.77 0.005 Hga* 101Val 1H 
990 1.05 0.005 Hgb* 101Val 1H 
991 23.43 0.056 Cgb 101Val 13C 
992 2.46 0.009 Hb 101Val 1H 
993 178.38 0.000 C 101Val 13C 
994 31.35 0.020 Cb 101Val 13C 
995 123.57 0.024 N 102Ala 15N 
996 8.16 0.003 H 102Ala 1H 
997 55.18 0.056 Ca 102Ala 13C 
998 1.27 0.008 Hb* 102Ala 1H 
999 2.86 0.007 Ha 102Ala 1H 
1000 19.38 0.066 Cb 102Ala 13C 
1001 177.55 0.000 C 102Ala 13C 
1002 119.59 0.050 N 103Phe 15N 
1003 8.21 0.018 H 103Phe 1H 
1004 61.02 0.080 Ca 103Phe 13C 
1005 176.40 0.000 C 103Phe 13C 
1006 39.03 0.031 Cb 103Phe 13C 
1007 3.40 0.006 Hba 103Phe 1H 
1008 3.91 0.006 Hbb 103Phe 1H 
1009 3.93 0.012 Ha 103Phe 1H 
1010 8.27 0.007 H 104Phe 1H 
1011 119.76 0.028 N 104Phe 15N 
1012 63.02 0.082 Ca 104Phe 13C 
1013 37.28 0.042 Cb 104Phe 13C 
1014 177.64 0.000 C 104Phe 13C 
1015 3.39 0.007 Ha 104Phe 1H 
1016 1.41 0.008 Hba 104Phe 1H 
1017 2.53 0.007 Hbb 104Phe 1H 
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1018 114.44 0.054 N 105Ser 15N 
1019 8.56 0.009 H 105Ser 1H 
1020 63.51 0.094 Ca 105Ser 13C 
1021 177.36 0.000 C 105Ser 13C 
1022 4.45 0.017 Ha 105Ser 1H 
1023 3.78 0.009 Hba 105Ser 1H 
1024 63.54 0.032 Cb 105Ser 13C 
1025 3.89 0.008 Hbb 105Ser 1H 
1026 9.08 0.010 H 106Phe 1H 
1027 123.95 0.059 N 106Phe 15N 
1028 60.77 0.073 Ca 106Phe 13C 
1029 39.25 0.068 Cb 106Phe 13C 
1030 175.91 0.000 C 106Phe 13C 
1031 4.24 0.002 Ha 106Phe 1H 
1032 3.20 0.010 Hbb 106Phe 1H 
1033 3.05 0.007 Hba 106Phe 1H 
1034 106.60 0.032 N 107Gly 15N 
1035 8.07 0.006 H 107Gly 1H 
1036 48.12 0.094 Ca 107Gly 13C 
1037 3.19 0.013 Haa 107Gly 1H 
1038 4.20 0.006 Hab 107Gly 1H 
1039 176.34 0.000 C 107Gly 13C 
1040 107.14 0.030 N 108Gly 15N 
1041 8.92 0.007 H 108Gly 1H 
1042 47.98 0.090 Ca 108Gly 13C 
1043 174.28 0.000 C 108Gly 13C 
1044 3.86 0.013 Hab 108Gly 1H 
1045 3.73 0.004 Haa 108Gly 1H 
1046 124.54 0.058 N 109Ala 15N 
1047 8.20 0.006 H 109Ala 1H 
1048 55.01 0.087 Ca 109Ala 13C 
1049 18.53 0.063 Cb 109Ala 13C 
1050 1.42 0.004 Hb* 109Ala 1H 
1051 4.18 0.003 Ha 109Ala 1H 
1052 180.62 0.000 C 109Ala 13C 
1053 118.74 0.065 N 110Leu 15N 
1054 8.37 0.008 H 110Leu 1H 
1055 42.14 0.148 Cb 110Leu 13C 
1056 57.50 0.061 Ca 110Leu 13C 
1057 24.56 0.025 Cda 110Leu 13C 
1058 0.71 0.012 Hda* 110Leu 1H 
1059 0.76 0.015 Hdb* 110Leu 1H 
1060 3.83 0.005 Ha 110Leu 1H 
1061 1.38 0.007 Hg 110Leu 1H 
1062 1.31 0.006 Hba 110Leu 1H 
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1063 1.45 0.010 Hbb 110Leu 1H 
1064 26.48 0.026 Cg 110Leu 13C 
1065 179.52 0.000 C 110Leu 13C 
1066 24.56 0.018 Cda 110Leu 13C 
1067 64.64 0.052 Ca 111Cys 13C 
1068 8.23 0.008 H 111Cys 1H 
1069 119.29 0.031 N 111Cys 15N 
1070 26.77 0.017 Cb 111Cys 13C 
1071 175.62 0.000 C 111Cys 13C 
1072 3.77 0.009 Ha 111Cys 1H 
1073 2.79 0.006 Hba 111Cys 1H 
1074 3.13 0.005 Hbb 111Cys 1H 
1075 118.07 0.042 N 112Val 15N 
1076 8.00 0.006 H 112Val 1H 
1077 67.34 0.063 Ca 112Val 13C 
1078 3.40 0.008 Ha 112Val 1H 
1079 32.02 0.064 Cb 112Val 13C 
1080 2.13 0.006 Hb 112Val 1H 
1081 22.44 0.023 Cgb 112Val 13C 
1082 1.05 0.008 Hgb* 112Val 1H 
1083 22.99 0.029 Cga 112Val 13C 
1084 1.03 0.007 Hga* 112Val 1H 
1085 177.55 0.000 C 112Val 13C 
1086 119.38 0.088 N 113Glu 15N 
1087 8.22 0.006 H 113Glu 1H 
1088 59.52 0.061 Ca 113Glu 13C 
1089 178.34 0.000 C 113Glu 13C 
1090 4.13 0.007 Ha 113Glu 1H 
1091 36.40 0.032 Cg 113Glu 13C 
1092 2.24 0.008 Hga 113Glu 1H 
1093 2.40 0.013 Hgb 113Glu 1H 
1094 29.70 0.034 Cb 113Glu 13C 
1095 1.94 0.007 Hba 113Glu 1H 
1096 2.11 0.010 Hbb 113Glu 1H 
1097 113.85 0.034 N 114Ser 15N 
1098 7.84 0.008 H 114Ser 1H 
1099 63.69 0.016 Ca 114Ser 13C 
1100 62.04 0.039 Cb 114Ser 13C 
1101 175.56 0.000 C 114Ser 13C 
1102 3.84 0.009 Ha 114Ser 1H 
1103 3.67 0.010 Hba 114Ser 1H 
1104 3.83 0.013 Hbb 114Ser 1H 
1105 121.11 0.082 N 115Val 15N 
1106 7.26 0.009 H 115Val 1H 
1107 66.82 0.087 Ca 115Val 13C 
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1108 31.52 0.065 Cb 115Val 13C 
1109 1.61 0.007 Hb 115Val 1H 
1110 21.32 0.091 Cga 115Val 13C 
1111 0.01 0.004 Hga* 115Val 1H 
1112 0.22 0.004 Hgb* 115Val 1H 
1113 22.97 0.036 Cgb 115Val 13C 
1114 175.58 0.000 C 115Val 13C 
1115 3.17 0.005 Ha 115Val 1H 
1116 122.08 0.057 N 116Asp 15N 
1117 8.13 0.010 H 116Asp 1H 
1118 57.52 0.055 Ca 116Asp 13C 
1119 41.44 0.052 Cb 116Asp 13C 
1120 4.39 0.003 Ha 116Asp 1H 
1121 2.93 0.006 Hbb 116Asp 1H 
1122 2.73 0.003 Hba 116Asp 1H 
1123 177.94 0.000 C 116Asp 13C 
1124 115.68 0.057 N 117Lys 15N 
1125 7.78 0.006 H 117Lys 1H 
1126 55.12 0.036 Ca 117Lys 13C 
1127 31.74 0.059 Cb 117Lys 13C 
1128 25.63 0.023 Cg 117Lys 13C 
1129 1.60 0.009 Hgb 117Lys 1H 
1130 1.48 0.011 Hga 117Lys 1H 
1131 4.46 0.009 Ha 117Lys 1H 
1132 1.68 0.007 Hdb 117Lys 1H 
1133 28.88 0.013 Cd 117Lys 13C 
1134 1.61 0.007 Hda 117Lys 1H 
1135 42.83 0.062 Ce 117Lys 13C 
1136 3.01 0.008 Hea 117Lys 1H 
1137 3.01 0.008 Heb 117Lys 1H 
1138 175.15 0.000 C 117Lys 13C 
1139 2.21 0.007 Hbb 117Lys 1H 
1140 1.68 0.012 Hba 117Lys 1H 
1141 113.47 0.039 N 118Glu 15N 
1142 7.85 0.005 H 118Glu 1H 
1143 58.05 0.080 Ca 118Glu 13C 
1144 26.58 0.039 Cb 118Glu 13C 
1145 2.36 0.011 Hbb 118Glu 1H 
1146 2.27 0.015 Hba 118Glu 1H 
1147 2.24 0.006 Hgb 118Glu 1H 
1148 2.24 0.006 Hga 118Glu 1H 
1149 4.02 0.005 Ha 118Glu 1H 
1150 37.15 0.076 Cg 118Glu 13C 
1151 176.10 0.000 C 118Glu 13C 
1152 119.28 0.047 N 119Met 15N 
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1153 8.73 0.006 H 119Met 1H 
1154 33.22 0.052 Cb 119Met 13C 
1155 53.90 0.080 Ca 119Met 13C 
1156 32.26 0.023 Cg 119Met 13C 
1157 4.84 0.008 Ha 119Met 1H 
1158 176.79 0.000 C 119Met 13C 
1159 1.97 0.008 Hbb 119Met 1H 
1160 1.89 0.004 Hba 119Met 1H 
1161 2.56 0.005 Hgb 119Met 1H 
1162 2.41 0.011 Hga 119Met 1H 
1163 17.63 0.023 Ce 119Met 13C 
1164 2.11 0.007 He* 119Met 1H 
1165 111.27 0.235 Ne2 120Gln 15N 
1166 7.59 0.011 He2b 120Gln 1H 
1167 7.06 0.008 He2a 120Gln 1H 
1168 119.39 0.056 N 120Gln 15N 
1169 8.92 0.008 H 120Gln 1H 
1170 27.74 0.060 Cb 120Gln 13C 
1171 60.12 0.083 Ca 120Gln 13C 
1172 34.07 0.058 Cg 120Gln 13C 
1173 3.46 0.010 Ha 120Gln 1H 
1174 2.01 0.004 Hba 120Gln 1H 
1175 2.01 0.005 Hbb 120Gln 1H 
1176 2.37 0.003 Hga 120Gln 1H 
1177 2.54 0.004 Hgb 120Gln 1H 
1178 177.22 0.000 C 120Gln 13C 
1179 180.02 0.011 Cd 120Gln 13C 
1180 118.29 0.065 N 121Val 15N 
1181 7.96 0.008 H 121Val 1H 
1182 63.57 0.078 Ca 121Val 13C 
1183 19.92 0.071 Cga 121Val 13C 
1184 0.91 0.014 Hga* 121Val 1H 
1185 2.21 0.003 Hb 121Val 1H 
1186 0.94 0.012 Hgb* 121Val 1H 
1187 20.32 0.171 Cga 121Val 13C 
1188 4.06 0.004 Ha 121Val 1H 
1189 31.51 0.076 Cb 121Val 13C 
1190 177.44 0.000 C 121Val 13C 
1191 8.00 0.012 H 122Leu 1H 
1192 116.05 0.072 N 122Leu 15N 
1193 55.92 0.044 Ca 122Leu 13C 
1194 23.79 0.031 Cdb 122Leu 13C 
1195 0.98 0.009 Hdb* 122Leu 1H 
1196 26.22 0.017 Cda 122Leu 13C 
1197 0.86 0.011 Hda* 122Leu 1H 
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1198 177.91 0.000 C 122Leu 13C 
1199 3.89 0.010 Ha 122Leu 1H 
1200 1.96 0.006 Hbb 122Leu 1H 
1201 41.91 0.018 Cb 122Leu 13C 
1202 1.25 0.007 Hba 122Leu 1H 
1203 1.69 0.008 Hg 122Leu 1H 
1204 119.99 0.056 N 123Val 15N 
1205 7.43 0.009 H 123Val 1H 
1206 68.20 0.072 Ca 123Val 13C 
1207 0.44 0.010 Hgb* 123Val 1H 
1208 0.42 0.008 Hga* 123Val 1H 
1209 23.20 0.417 Cga 123Val 13C 
1210 21.93 0.026 Cgb 123Val 13C 
1211 1.78 0.007 Hb 123Val 1H 
1212 3.34 0.005 Ha 123Val 1H 
1213 176.88 0.000 C 123Val 13C 
1214 31.13 0.013 Cb 123Val 13C 
1215 110.53 0.037 N 124Ser 15N 
1216 8.58 0.005 H 124Ser 1H 
1217 61.20 0.063 Ca 124Ser 13C 
1218 62.47 0.032 Cb 124Ser 13C 
1219 177.36 0.000 C 124Ser 13C 
1220 3.76 0.008 Hba 124Ser 1H 
1221 3.82 0.012 Hbb 124Ser 1H 
1222 3.92 0.013 Ha 124Ser 1H 
1223 121.90 0.058 N 125Arg 15N 
1224 6.54 0.008 H 125Arg 1H 
1225 58.54 0.043 Ca 125Arg 13C 
1226 175.05 0.000 C 125Arg 13C 
1227 3.60 0.005 Ha 125Arg 1H 
1228 29.28 0.067 Cb 125Arg 13C 
1229 1.03 0.007 Hba 125Arg 1H 
1230 1.13 0.006 Hbb 125Arg 1H 
1231 44.04 0.022 Cd 125Arg 13C 
1232 3.02 0.005 Hda 125Arg 1H 
1233 3.24 0.004 Hdb 125Arg 1H 
1234 27.10 0.016 Cg 125Arg 13C 
1235 1.54 0.008 Hga 125Arg 1H 
1236 1.73 0.004 Hgb 125Arg 1H 
1237 118.19 0.060 N 126Ile 15N 
1238 8.14 0.008 H 126Ile 1H 
1239 65.01 0.098 Ca 126Ile 13C 
1240 15.03 0.025 Cd1 126Ile 13C 
1241 0.56 0.006 Hd1* 126Ile 1H 
1242 0.67 0.009 Hg2* 126Ile 1H 
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1243 18.16 0.046 Cg2 126Ile 13C 
1244 2.75 0.006 Ha 126Ile 1H 
1245 1.53 0.010 Hb 126Ile 1H 
1246 38.04 0.063 Cb 126Ile 13C 
1247 0.62 0.032 Hg1a 126Ile 1H 
1248 30.66 0.102 Cg1 126Ile 13C 
1249 1.33 0.010 Hg1b 126Ile 1H 
1250 177.94 0.000 C 126Ile 13C 
1251 118.58 0.078 N 127Ala 15N 
1252 7.37 0.007 H 127Ala 1H 
1253 18.76 0.067 Cb 127Ala 13C 
1254 55.14 0.042 Ca 127Ala 13C 
1255 1.49 0.009 Hb* 127Ala 1H 
1256 3.85 0.008 Ha 127Ala 1H 
1257 179.17 0.000 C 127Ala 13C 
1258 120.59 0.065 N 128Ala 15N 
1259 7.12 0.007 H 128Ala 1H 
1260 55.22 0.061 Ca 128Ala 13C 
1261 17.85 0.071 Cb 128Ala 13C 
1262 1.51 0.005 Hb* 128Ala 1H 
1263 4.18 0.004 Ha 128Ala 1H 
1264 180.82 0.000 C 128Ala 13C 
1265 8.93 0.007 H 129Trp 1H 
1266 121.71 0.047 N 129Trp 15N 
1267 127.95 0.045 Ne1 129Trp 15N 
1268 9.91 0.006 He1 129Trp 1H 
1269 58.00 0.007 Ca 129Trp 13C 
1270 28.59 0.012 Cb 129Trp 13C 
1271 181.45 0.000 C 129Trp 13C 
1272 4.74 0.006 Ha 129Trp 1H 
1273 2.68 0.010 Hba 129Trp 1H 
1274 2.85 0.008 Hbb 129Trp 1H 
1275 117.93 0.041 N 130Met 15N 
1276 9.05 0.006 H 130Met 1H 
1277 60.29 0.071 Ca 130Met 13C 
1278 177.76 0.000 C 130Met 13C 
1279 4.38 0.007 Ha 130Met 1H 
1280 2.34 0.006 Hbb 130Met 1H 
1281 2.02 0.017 Hba 130Met 1H 
1282 35.40 0.039 Cb 130Met 13C 
1283 33.07 0.030 Cg 130Met 13C 
1284 2.09 0.003 Hga 130Met 1H 
1285 2.89 0.006 Hgb 130Met 1H 
1286 16.55 0.016 Ce 130Met 13C 
1287 1.41 0.006 He* 130Met 1H 
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1288 121.76 0.052 N 131Ala 15N 
1289 8.56 0.005 H 131Ala 1H 
1290 17.70 0.057 Cb 131Ala 13C 
1291 56.36 0.070 Ca 131Ala 13C 
1292 1.59 0.005 Hb* 131Ala 1H 
1293 4.04 0.006 Ha 131Ala 1H 
1294 179.02 0.000 C 131Ala 13C 
1295 115.13 0.057 N 132Thr 15N 
1296 8.76 0.009 H 132Thr 1H 
1297 67.29 0.097 Ca 132Thr 13C 
1298 69.25 0.149 Cb 132Thr 13C 
1299 4.41 0.007 Hb 132Thr 1H 
1300 1.43 0.004 Hg2* 132Thr 1H 
1301 4.08 0.005 Ha 132Thr 1H 
1302 22.26 0.035 Cg2 132Thr 13C 
1303 176.16 0.000 C 132Thr 13C 
1304 122.94 0.029 N 133Tyr 15N 
1305 8.29 0.008 H 133Tyr 1H 
1306 63.81 0.065 Ca 133Tyr 13C 
1307 39.22 0.032 Cb 133Tyr 13C 
1308 179.17 0.000 C 133Tyr 13C 
1309 4.18 0.006 Ha 133Tyr 1H 
1310 3.57 0.006 Hbb 133Tyr 1H 
1311 3.27 0.008 Hba 133Tyr 1H 
1312 8.72 0.009 H 134Leu 1H 
1313 119.45 0.053 N 134Leu 15N 
1314 59.29 0.076 Ca 134Leu 13C 
1315 42.79 0.088 Cb 134Leu 13C 
1316 1.17 0.008 Hdb* 134Leu 1H 
1317 26.50 0.022 Cdb 134Leu 13C 
1318 26.63 0.042 Cda 134Leu 13C 
1319 1.15 0.008 Hda* 134Leu 1H 
1320 1.83 0.009 Hg 134Leu 1H 
1321 1.89 0.017 Hba 134Leu 1H 
1322 2.01 0.013 Hbb 134Leu 1H 
1323 3.86 0.009 Ha 134Leu 1H 
1324 28.28 0.013 Cg 134Leu 13C 
1325 177.70 0.000 C 134Leu 13C 
1326 112.35 0.025 Nd2 135Asn 15N 
1327 7.03 0.005 Hd2a 135Asn 1H 
1328 116.57 0.044 N 135Asn 15N 
1329 8.50 0.005 H 135Asn 1H 
1330 56.67 0.049 Ca 135Asn 13C 
1331 39.25 0.032 Cb 135Asn 13C 
1332 3.02 0.004 Hbb 135Asn 1H 
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1333 2.89 0.008 Hba 135Asn 1H 
1334 4.35 0.011 Ha 135Asn 1H 
1335 176.53 0.000 C 135Asn 13C 
1336 7.70 0.010 Hd2b 135Asn 1H 
1337 115.54 0.049 N 136Asp 15N 
1338 8.57 0.006 H 136Asp 1H 
1339 40.84 0.082 Cb 136Asp 13C 
1340 56.38 0.063 Ca 136Asp 13C 
1341 4.36 0.008 Ha 136Asp 1H 
1342 2.39 0.006 Hbb 136Asp 1H 
1343 1.95 0.008 Hba 136Asp 1H 
1344 177.39 0.000 C 136Asp 13C 
1345 113.43 0.066 N 137His 15N 
1346 7.96 0.007 H 137His 1H 
1347 56.63 0.051 Ca 137His 13C 
1348 30.91 0.043 Cb 137His 13C 
1349 175.88 0.000 C 137His 13C 
1350 4.58 0.005 Ha 137His 1H 
1351 1.85 0.004 Hba 137His 1H 
1352 2.39 0.006 Hbb 137His 1H 
1353 117.77 0.034 N 138Leu 15N 
1354 7.23 0.006 H 138Leu 1H 
1355 55.94 0.040 Ca 138Leu 13C 
1356 22.08 0.060 Cda 138Leu 13C 
1357 -0.31 0.004 Hda* 138Leu 1H 
1358 0.15 0.007 Hdb* 138Leu 1H 
1359 4.45 0.009 Ha 138Leu 1H 
1360 24.75 0.049 Cdb 138Leu 13C 
1361 26.18 0.038 Cg 138Leu 13C 
1362 1.09 0.006 Hg 138Leu 1H 
1363 43.16 0.026 Cb 138Leu 13C 
1364 2.04 0.007 Hbb 138Leu 1H 
1365 1.08 0.007 Hba 138Leu 1H 
1366 177.10 0.000 C 138Leu 13C 
1367 121.78 0.055 N 139Glu 15N 
1368 8.69 0.008 H 139Glu 1H 
1369 60.97 0.036 Ca 139Glu 13C 
1370 4.28 0.013 Ha 139Glu 1H 
1371 36.20 0.030 Cg 139Glu 13C 
1372 2.39 0.010 Hgb 139Glu 1H 
1373 2.34 0.004 Hga 139Glu 1H 
1374 27.73 0.024 Cb 139Glu 13C 
1375 2.28 0.003 Hbb 139Glu 1H 
1376 2.21 0.003 Hba 139Glu 1H 
1377 66.51 0.068 Ca 140Pro 13C 
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1378 4.21 0.010 Ha 140Pro 1H 
1379 179.20 0.000 C 140Pro 13C 
1380 49.87 0.025 Cd 140Pro 13C 
1381 30.83 0.014 Cb 140Pro 13C 
1382 3.52 0.005 Hdb 140Pro 1H 
1383 3.14 0.004 Hda 140Pro 1H 
1384 2.27 0.004 Hbb 140Pro 1H 
1385 1.76 0.007 Hba 140Pro 1H 
1386 28.73 0.045 Cg 140Pro 13C 
1387 1.94 0.004 Hgb 140Pro 1H 
1388 1.85 0.005 Hga 140Pro 1H 
1389 117.99 0.062 N 141Trp 15N 
1390 7.13 0.008 H 141Trp 1H 
1391 129.64 0.064 Ne1 141Trp 15N 
1392 9.56 0.005 He1 141Trp 1H 
1393 62.30 0.069 Ca 141Trp 13C 
1394 3.84 0.005 Ha 141Trp 1H 
1395 179.33 0.000 C 141Trp 13C 
1396 3.14 0.007 Hbb 141Trp 1H 
1397 3.14 0.007 Hba 141Trp 1H 
1398 28.90 0.027 Cb 141Trp 13C 
1399 122.78 0.036 N 142Ile 15N 
1400 8.45 0.008 H 142Ile 1H 
1401 66.27 0.062 Ca 142Ile 13C 
1402 16.09 0.023 Cg2 142Ile 13C 
1403 0.38 0.007 Hg2* 142Ile 1H 
1404 38.41 0.046 Cb 142Ile 13C 
1405 1.87 0.006 Hb 142Ile 1H 
1406 2.87 0.005 Ha 142Ile 1H 
1407 13.96 0.026 Cd1 142Ile 13C 
1408 0.53 0.009 Hd1* 142Ile 1H 
1409 179.07 0.000 C 142Ile 13C 
1410 29.05 0.024 Cg1 142Ile 13C 
1411 0.50 0.018 Hg1a 142Ile 1H 
1412 1.57 0.005 Hg1b 142Ile 1H 
1413 112.75 0.209 Ne2 143Gln 15N 
1414 8.01 0.009 He2b 143Gln 1H 
1415 6.85 0.004 He2a 143Gln 1H 
1416 116.65 0.034 N 143Gln 15N 
1417 8.58 0.007 H 143Gln 1H 
1418 58.57 0.059 Ca 143Gln 13C 
1419 28.17 0.035 Cb 143Gln 13C 
1420 33.68 0.100 Cg 143Gln 13C 
1421 3.92 0.003 Ha 143Gln 1H 
1422 2.53 0.004 Hga 143Gln 1H 
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1423 2.53 0.004 Hgb 143Gln 1H 
1424 2.12 0.006 Hbb 143Gln 1H 
1425 2.03 0.005 Hba 143Gln 1H 
1426 179.27 0.000 C 143Gln 13C 
1427 180.10 0.004 Cd 143Gln 13C 
1428 7.52 0.007 H 144Glu 1H 
1429 119.09 0.039 N 144Glu 15N 
1430 57.75 0.067 Ca 144Glu 13C 
1431 36.45 0.058 Cg 144Glu 13C 
1432 30.03 0.016 Cb 144Glu 13C 
1433 4.12 0.006 Ha 144Glu 1H 
1434 2.25 0.003 Hgb 144Glu 1H 
1435 2.15 0.014 Hga 144Glu 1H 
1436 1.85 0.006 Hbb 144Glu 1H 
1437 1.85 0.006 Hba 144Glu 1H 
1438 176.69 0.000 C 144Glu 13C 
1439 117.32 0.035 N 145Asn 15N 
1440 7.16 0.007 H 145Asn 1H 
1441 53.67 0.050 Ca 145Asn 13C 
1442 38.37 0.054 Cb 145Asn 13C 
1443 4.48 0.006 Ha 145Asn 1H 
1444 173.81 0.000 C 145Asn 13C 
1445 0.88 0.008 Hba 145Asn 1H 
1446 2.21 0.008 Hbb 145Asn 1H 
1447 115.77 0.004 Nd2 145Asn 15N 
1448 5.96 0.004 Hd2a 145Asn 1H 
1449 6.14 0.006 Hd2b 145Asn 1H 
1450 105.26 0.055 N 146Gly 15N 
1451 7.48 0.008 H 146Gly 1H 
1452 45.78 0.085 Ca 146Gly 13C 
1453 4.59 0.004 Hab 146Gly 1H 
1454 3.69 0.007 Haa 146Gly 1H 
1455 176.10 0.000 C 146Gly 13C 
1456 108.82 0.026 N 147Gly 15N 
1457 8.59 0.005 H 147Gly 1H 
1458 44.74 0.084 Ca 147Gly 13C 
1459 4.51 0.011 Hab 147Gly 1H 
1460 3.66 0.008 Haa 147Gly 1H 
1461 173.41 0.000 C 147Gly 13C 
1462 129.19 0.034 Ne1 148Trp 15N 
1463 10.60 0.008 He1 148Trp 1H 
1464 118.45 0.025 N 148Trp 15N 
1465 8.76 0.008 H 148Trp 1H 
1466 60.58 0.050 Ca 148Trp 13C 
1467 29.87 0.043 Cb 148Trp 13C 
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1468 3.12 0.005 Hba 148Trp 1H 
1469 3.54 0.007 Hbb 148Trp 1H 
1470 4.48 0.011 Ha 148Trp 1H 
1471 178.50 0.000 C 148Trp 13C 
1472 113.99 0.000 Cz2 148Trp 13C 
1473 118.02 0.057 N 149Asp 15N 
1474 8.88 0.006 H 149Asp 1H 
1475 57.92 0.100 Ca 149Asp 13C 
1476 40.56 0.111 Cb 149Asp 13C 
1477 4.45 0.005 Ha 149Asp 1H 
1478 2.73 0.007 Hbb 149Asp 1H 
1479 2.73 0.007 Hba 149Asp 1H 
1480 179.70 0.000 C 149Asp 13C 
1481 117.89 0.084 N 150Thr 15N 
1482 7.63 0.007 H 150Thr 1H 
1483 66.72 0.094 Ca 150Thr 13C 
1484 68.40 0.084 Cb 150Thr 13C 
1485 22.54 0.028 Cg2 150Thr 13C 
1486 1.45 0.005 Hg2* 150Thr 1H 
1487 4.01 0.005 Ha 150Thr 1H 
1488 4.46 0.007 Hb 150Thr 1H 
1489 175.00 0.000 C 150Thr 13C 
1490 122.34 0.031 N 151Phe 15N 
1491 6.60 0.006 H 151Phe 1H 
1492 62.53 0.070 Ca 151Phe 13C 
1493 38.31 0.055 Cb 151Phe 13C 
1494 177.00 0.000 C 151Phe 13C 
1495 3.12 0.005 Ha 151Phe 1H 
1496 1.55 0.004 Hba 151Phe 1H 
1497 3.30 0.008 Hbb 151Phe 1H 
1498 118.29 0.043 N 152Val 15N 
1499 8.11 0.006 H 152Val 1H 
1500 67.03 0.103 Ca 152Val 13C 
1501 3.10 0.021 Ha 152Val 1H 
1502 21.99 0.095 Cga 152Val 13C 
1503 1.17 0.005 Hgb* 152Val 1H 
1504 0.91 0.006 Hga* 152Val 1H 
1505 178.49 0.000 C 152Val 13C 
1506 2.23 0.005 Hb 152Val 1H 
1507 31.87 0.023 Cb 152Val 13C 
1508 24.83 0.026 Cgb 152Val 13C 
1509 121.03 0.040 N 153Glu 15N 
1510 7.62 0.006 H 153Glu 1H 
1511 59.58 0.076 Ca 153Glu 13C 
1512 36.28 0.061 Cg 153Glu 13C 
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1513 29.66 0.039 Cb 153Glu 13C 
1514 3.92 0.005 Ha 153Glu 1H 
1515 2.21 0.011 Hga 153Glu 1H 
1516 2.37 0.006 Hgb 153Glu 1H 
1517 178.37 0.000 C 153Glu 13C 
1518 2.18 0.013 Hba 153Glu 1H 
1519 2.20 0.008 Hbb 153Glu 1H 
1520 116.60 0.057 N 154Leu 15N 
1521 7.64 0.010 H 154Leu 1H 
1522 56.71 0.053 Ca 154Leu 13C 
1523 44.81 0.057 Cb 154Leu 13C 
1524 22.17 0.041 Cdb 154Leu 13C 
1525 0.79 0.004 Hda* 154Leu 1H 
1526 0.80 0.006 Hdb* 154Leu 1H 
1527 4.05 0.005 Ha 154Leu 1H 
1528 26.22 0.028 Cdb 154Leu 13C 
1529 178.63 0.000 C 154Leu 13C 
1530 1.64 0.009 Hbb 154Leu 1H 
1531 0.82 0.014 Hba 154Leu 1H 
1532 26.55 0.022 Cg 154Leu 13C 
1533 1.78 0.006 Hg 154Leu 1H 
1534 114.59 0.053 N 155Tyr 15N 
1535 8.41 0.008 H 155Tyr 1H 
1536 59.64 0.053 Ca 155Tyr 13C 
1537 176.32 0.000 C 155Tyr 13C 
1538 39.26 0.034 Cb 155Tyr 13C 
1539 1.56 0.005 Hba 155Tyr 1H 
1540 2.74 0.006 Hbb 155Tyr 1H 
1541 4.19 0.007 Ha 155Tyr 1H 
1542 109.18 0.069 N 156Gly 15N 
1543 8.29 0.009 H 156Gly 1H 
1544 45.57 0.089 Ca 156Gly 13C 
1545 4.18 0.008 Hab 156Gly 1H 
1546 3.79 0.011 Haa 156Gly 1H 
1547 173.65 0.000 C 156Gly 13C 
1548 113.20 0.248 Nd2 157Asn 15N 
1549 7.72 0.007 Hd2b 157Asn 1H 
1550 6.89 0.014 Hd2a 157Asn 1H 
1551 8.70 0.013 H 157Asn 1H 
1552 118.72 0.087 N 157Asn 15N 
1553 53.56 0.034 Ca 157Asn 13C 
1554 38.87 0.121 Cb 157Asn 13C 
1555 2.86 0.007 Hbb 157Asn 1H 
1556 2.78 0.005 Hba 157Asn 1H 
1557 4.64 0.005 Ha 157Asn 1H 
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1558 175.37 0.000 C 157Asn 13C 
1559 177.35 0.032 Cg 157Asn 13C 
1560 7.67 0.006 Hd2b 158Asn 1H 
1561 113.21 0.015 Nd2 158Asn 15N 
1562 8.62 0.004 H 158Asn 1H 
1563 119.47 0.079 N 158Asn 15N 
1564 53.75 0.035 Ca 158Asn 13C 
1565 39.09 0.057 Cb 158Asn 13C 
1566 2.72 0.003 Hba 158Asn 1H 
1567 2.89 0.005 Hbb 158Asn 1H 
1568 4.65 0.010 Ha 158Asn 1H 
1569 178.08 0.000 C 158Asn 13C 
1570 6.92 0.004 Hd2a 158Asn 1H 
1571 123.43 0.119 N 159Ala 15N 
1572 8.12 0.018 H 159Ala 1H 
1573 19.15 0.073 Cb 159Ala 13C 
1574 53.81 0.051 Ca 159Ala 13C 
1575 1.36 0.004 Hb* 159Ala 1H 
1576 4.17 0.005 Ha 159Ala 1H 
1577 175.01 0.000 C 159Ala 13C 
1578 121.76 0.030 N 160Ala 15N 
1579 8.27 0.011 H 160Ala 1H 
1580 53.29 0.115 Ca 160Ala 13C 
1581 1.43 0.007 Hb* 160Ala 1H 
1582 4.24 0.004 Ha 160Ala 1H 
1583 18.92 0.074 Cb 160Ala 13C 
1584 177.69 0.000 C 160Ala 13C 
1585 122.47 0.026 N 161Ala 15N 
1586 8.02 0.004 H 161Ala 1H 
1587 53.66 0.027 Ca 161Ala 13C 
1588 4.18 0.004 Ha 161Ala 1H 
1589 1.42 0.008 Hb* 161Ala 1H 
1590 19.22 0.071 Cb 161Ala 13C 
1591 178.47 0.000 C 161Ala 13C 
1592 118.80 0.083 N 162Glu 15N 
1593 8.32 0.007 H 162Glu 1H 
1594 57.70 0.067 Ca 162Glu 13C 
1595 29.96 0.031 Cb 162Glu 13C 
1596 4.18 0.004 Ha 162Glu 1H 
1597 2.02 0.010 Hba 162Glu 1H 
1598 2.07 0.014 Hbb 162Glu 1H 
1599 2.31 0.008 Hga 162Glu 1H 
1600 2.31 0.008 Hgb 162Glu 1H 
1601 36.32 0.011 Cg 162Glu 13C 
1602 177.01 0.000 C 162Glu 13C 
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1603 115.53 0.080 N 163Ser 15N 
1604 8.15 0.009 H 163Ser 1H 
1605 63.57 0.097 Cb 163Ser 13C 
1606 59.41 0.058 Ca 163Ser 13C 
1607 3.94 0.010 Hbb 163Ser 1H 
1608 4.38 0.006 Ha 163Ser 1H 
1609 3.94 0.010 Hba 163Ser 1H 
1610 174.86 0.000 C 163Ser 13C 
1611 122.19 0.020 N 164Arg 15N 
1612 8.05 0.008 H 164Arg 1H 
1613 56.75 0.022 Ca 164Arg 13C 
1614 30.64 0.060 Cb 164Arg 13C 
1615 4.32 0.010 Ha 164Arg 1H 
1616 3.18 0.005 Hda 164Arg 1H 
1617 3.18 0.005 Hdb 164Arg 1H 
1618 43.55 0.000 Cd 164Arg 13C 
1619 1.80 0.003 Hba 164Arg 1H 
1620 1.92 0.002 Hbb 164Arg 1H 
1621 1.63 0.003 Hga 164Arg 1H 
1622 1.69 0.003 Hgb 164Arg 1H 
1623 121.38 0.037 N 165Lys 15N 
1624 8.15 0.006 H 165Lys 1H 
1625 57.33 0.052 Ca 165Lys 13C 
1626 33.00 0.036 Cb 165Lys 13C 
1627 4.25 0.005 Ha 165Lys 1H 
1628 1.81 0.009 Hba 165Lys 1H 
1629 1.86 0.017 Hbb 165Lys 1H 
1630 25.07 0.053 Cg 165Lys 13C 
1631 42.32 0.058 Ce 165Lys 13C 
1632 2.97 0.004 Hea 165Lys 1H 
1633 2.97 0.004 Heb 165Lys 1H 
1634 1.68 0.007 Hda 165Lys 1H 
1635 1.68 0.007 Hdb 165Lys 1H 
1636 1.51 0.010 Hgb 165Lys 1H 
1637 1.44 0.007 Hga 165Lys 1H 
1638 29.32 0.003 Cd 165Lys 13C 
1639 109.57 0.117 N 166Gly 15N 
1640 8.47 0.004 H 166Gly 1H 
1641 45.77 0.055 Ca 166Gly 13C 
1642 176.21 0.000 C 166Gly 13C 
1643 3.98 0.011 Haa 166Gly 1H 
1644 3.98 0.011 Hab 166Gly 1H 
1645 119.82 0.030 N 167Gln 15N 
1646 8.16 0.005 H 167Gln 1H 
1647 112.10 0.224 Ne2 167Gln 15N 
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1648 7.57 0.002 He2b 167Gln 1H 
1649 6.87 0.005 He2a 167Gln 1H 
1650 29.53 0.072 Cb 167Gln 13C 
1651 56.24 0.078 Ca 167Gln 13C 
1652 2.15 0.007 Hbb 167Gln 1H 
1653 2.01 0.005 Hba 167Gln 1H 
1654 4.32 0.004 Ha 167Gln 1H 
1655 33.98 0.101 Cg 167Gln 13C 
1656 2.36 0.011 Hgb 167Gln 1H 
1657 2.36 0.011 Hga 167Gln 1H 
1658 179.56 0.012 Cd 167Gln 13C 
1659 121.81 0.021 N 168Glu 15N 
1660 8.55 0.004 H 168Glu 1H 
1661 57.38 0.044 Ca 168Glu 13C 
1662 30.09 0.007 Cb 168Glu 13C 
1663 4.22 0.007 Ha 168Glu 1H 
1664 2.28 0.000 Hga 168Glu 1H 
1665 2.28 0.000 Hgb 168Glu 1H 
1666 2.01 0.003 Hba 168Glu 1H 
1667 2.01 0.003 Hbb 168Glu 1H 
1668 121.36 0.014 N 169Arg 15N 
1669 8.30 0.006 H 169Arg 1H 
1670 56.26 0.021 Ca 169Arg 13C 
1671 30.95 0.165 Cb 169Arg 13C 
1672 4.42 0.006 Ha 169Arg 1H 
1673 27.39 0.000 Cg 169Arg 13C 
1674 1.61 0.007 Hga 169Arg 1H 
1675 1.61 0.010 Hgb 169Arg 1H 
1676 43.54 0.052 Cd 169Arg 13C 
1677 3.19 0.003 Hda 169Arg 1H 
1678 3.19 0.003 Hdb 169Arg 1H 
1679 1.88 0.014 Hbb 169Arg 1H 
1680 1.76 0.004 Hba 169Arg 1H 
1681 123.13 0.027 N 170Leu 15N 
1682 8.19 0.008 H 170Leu 1H 
1683 55.39 0.065 Ca 170Leu 13C 
1684 42.45 0.075 Cb 170Leu 13C 
1685 23.59 0.039 Cda 170Leu 13C 
1686 25.18 0.027 Cdb 170Leu 13C 
1687 4.30 0.003 Ha 170Leu 1H 
1688 0.83 0.007 Hda* 170Leu 1H 
1689 0.89 0.006 Hdb* 170Leu 1H 
1690 1.60 0.004 Hbb 170Leu 1H 
1691 1.51 0.004 Hba 170Leu 1H 
1692 1.59 0.004 Hg 170Leu 1H 
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1693 27.22 0.010 Cg 170Leu 13C 
1694 4.49 0.004 Ha 1003Cyl 1H 
1695 3.17 0.005 Hb1 1003Cyl 1H 
1696 3.08 0.014 Hb2 1003Cyl 1H 
1697 10.46 0.003 H3 1003Cyl 1H 
1698 3.73 0.004 H12 1003Cyl 1H 
1699 3.42 0.010 H11 1003Cyl 1H 
1700 8.30 0.003 H5 1003Cyl 1H 
1701 7.87 0.002 H7 1003Cyl 1H 
1702 8.43 0.010 H8 1003Cyl 1H 
1703 8.68 0.006 H18 1003Cyl 1H 
1704 8.44 0.007 H14 1003Cyl 1H 
1705 3.82 0.001 H21 1003Cyl 1H 
1706 3.74 0.000 H22 1003Cyl 1H 
1707 7.91 0.005 H13 1003Cyl 1H 
1708 8.30 0.003 H15 1003Cyl 1H 
1709 0.96 0.006 Hgb* 1004Val 1H 
1710 0.65 0.006 Hga* 1004Val 1H 
1711 3.44 0.008 Ha 1004Val 1H 
1712 1.96 0.009 Hb 1004Val 1H 
1713 7.55 0.007 H 1004Val 1H 
1714 3.71 0.005 Haa 1005Gly 1H 
1715 3.90 0.011 Hab 1005Gly 1H 
1716 8.41 0.007 H 1005Gly 1H 
1717 3.84 0.007 Ha 1006Arg 1H 
1718 3.26 0.007 Hdb 1006Arg 1H 
1719 1.73 0.009 Hgb 1006Arg 1H 
1720 3.16 0.009 Hda 1006Arg 1H 
1721 1.65 0.011 Hga 1006Arg 1H 
1722 1.73 0.010 Hba 1006Arg 1H 
1723 1.82 0.010 Hbb 1006Arg 1H 
1724 7.70 0.005 H 1006Arg 1H 
1725 2.39 0.012 Ha 1007Ala 1H 
1726 7.84 0.005 H 1007Ala 1H 
1727 0.53 0.005 Hb* 1007Ala 1H 
1728 0.29 0.006 Hda* 1008Leu 1H 
1729 0.79 0.006 Hdb* 1008Leu 1H 
1730 1.70 0.006 Hg 1008Leu 1H 
1731 3.46 0.009 Ha 1008Leu 1H 
1732 3.52 0.014 Ha 1009Ala 1H 
1733 1.31 0.008 Hb* 1009Ala 1H 
1734 7.61 0.011 H 1009Ala 1H 
1735 3.93 0.006 Ha 1010Ala 1H 
1736 7.10 0.006 H 1010Ala 1H 
1737 1.06 0.013 Hb* 1010Ala 1H 
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1738 7.03 0.008 Hd* 1011Phe 1H 
1739 6.91 0.007 He* 1011Phe 1H 
1740 6.02 0.008 Hz 1011Phe 1H 
1741 3.67 0.014 Hab 1012Gly 1H 
1742 3.11 0.016 Haa 1012Gly 1H 
1743 8.88 0.007 H 1012Gly 1H 
1744 4.41 0.005 Ha 1013Asp 1H 
1745 2.83 0.010 Hbb 1013Asp 1H 
1746 2.66 0.008 Hba 1013Asp 1H 
1747 8.57 0.008 H 1013Asp 1H 
1748 2.95 0.008 Hba 1014Cys 1H 
1749 4.38 0.007 Ha 1014Cys 1H 
1750 3.70 0.011 Hbb 1014Cys 1H 
1751 7.85 0.004 H 1014Cys 1H 
1752 3.69 0.000 Ha 1015Ile 1H 
1753 1.35 0.008 Hg2* 1015Ile 1H 
1754 2.57 0.002 Hb 1015Ile 1H 
1755 1.85 0.001 Hg1a 1015Ile 1H 
1756 1.99 0.004 Hg1b 1015Ile 1H 
1757 0.77 0.005 Hd1* 1015Ile 1H 
Table 22: Bcl-xL/BakI81Fi, i+11-XL-SO3H NMR assignments. Residues in Bcl-xL are numbered ignoring the loop deletion 
between residues 44-85; resiudes in BakI81Fi, i+11-XL-SO3H are numbered from 1001 (being the acetyl 
group) to 1017; SD is standard deviation. 
Residue Ω Ω/Ωmax 
4Ser 0.06 0.05 
5Asn 0.06 0.05 
6Arg 0.03 0.02 
7Glu 0.05 0.04 
8Leu 0.03 0.03 
9Val 0.05 0.04 
10Val 0.14 0.11 
11Asp 0.14 0.11 
12Phe 0.08 0.07 
13Leu 0.02 0.02 
14Ser 0.06 0.05 
15Tyr 0.08 0.07 
16Lys 0.07 0.06 
17Leu 0.05 0.04 
18Ser 0.05 0.05 
19Gln 0.04 0.03 
20Lys 0.05 0.04 
21Gly 0.05 0.04 
22Tyr 0.05 0.05 
23Ser 0.11 0.09 
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24Trp 0.09 0.07 
25Ser 0.23 0.19 
26Gln 0.05 0.05 
27Phe 0.21 0.17 
28Ser 0.20 0.17 
29Asp 0.02 0.02 
30Val 0.03 0.02 
31Glu 0.07 0.06 
32Glu 0.06 0.05 
33Asn 0.04 0.04 
34Arg 0.04 0.03 
35Thr 0.03 0.02 
36Glu 0.03 0.02 
37Ala 0.01 0.00 
39Glu 0.01 0.01 
40Gly 0.01 0.01 
41Thr 0.04 0.04 
42Glu 0.04 0.03 
43Ser 0.05 0.04 
44Glu 0.03 0.03 
45Ala 0.02 0.01 
46Val 0.01 0.01 
47Lys 0.01 0.01 
48Gln 0.04 0.03 
49Ala 0.04 0.03 
50Leu 0.05 0.05 
51Arg 0.08 0.07 
52Glu 0.11 0.10 
53Ala 0.13 0.11 
54Gly 0.26 0.22 
55Asp 0.51 0.43 
56Glu 0.21 0.18 
57Phe 0.13 0.11 
58Glu 0.61 0.52 
59Leu 0.51 0.43 
60Arg 0.49 0.41 
66Ser 0.56 0.47 
67Asp 0.48 0.41 
68Leu 1.18 1.00 
69Thr 0.55 0.46 
70Ser 0.23 0.19 
71Gln 0.19 0.16 
72Leu 0.77 0.65 
74Ile 0.86 0.72 
80Tyr 0.69 0.58 
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81Gln 0.70 0.59 
82Ser 0.57 0.48 
84Glu 0.40 0.34 
85Gln 0.45 0.38 
86Val 0.50 0.42 
87Val 0.57 0.48 
88Asn 0.35 0.29 
89Glu 0.22 0.18 
90Leu 0.78 0.66 
91Phe 0.96 0.81 
92Arg 0.13 0.11 
93Asp 0.76 0.64 
94Gly 0.42 0.35 
95Val 0.91 0.77 
96Asn 0.25 0.21 
97Trp 0.32 0.27 
98Gly 0.09 0.08 
99Arg 0.39 0.33 
100Ile 0.17 0.14 
101Val 0.31 0.26 
102Ala 0.58 0.49 
103Phe 0.11 0.09 
104Phe 0.26 0.22 
105Ser 0.09 0.08 
106Phe 0.15 0.13 
107Gly 0.03 0.03 
108Gly 0.13 0.11 
109Ala 0.15 0.13 
110Leu 0.14 0.12 
111Cys 0.05 0.04 
112Val 0.22 0.18 
113Glu 0.05 0.04 
114Ser 0.09 0.08 
115Val 0.16 0.13 
116Asp 0.30 0.26 
117Lys 0.13 0.11 
118Glu 0.19 0.16 
119Met 0.19 0.16 
120Gln 0.16 0.13 
121Val 0.21 0.18 
122Leu 0.29 0.24 
123Val 0.01 0.01 
124Ser 0.24 0.20 
125Arg 0.35 0.29 
126Ile 0.10 0.08 
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127Ala 0.38 0.32 
128Ala 0.23 0.20 
129Trp 0.14 0.12 
130Met 0.09 0.07 
131Ala 0.33 0.28 
132Thr 0.42 0.35 
133Tyr 0.68 0.58 
134Leu 0.13 0.11 
135Asn 0.22 0.18 
136Asp 0.08 0.07 
137His 0.36 0.30 
138Leu 0.10 0.08 
139Glu 0.04 0.03 
141Trp 0.10 0.09 
142Ile 0.06 0.05 
143Gln 0.07 0.06 
144Glu 0.14 0.12 
145Asn 0.08 0.06 
146Gly 0.03 0.03 
147Gly 0.02 0.01 
148Trp 0.04 0.04 
149Asp 0.04 0.03 
150Thr 0.15 0.12 
151Phe 0.06 0.05 
152Val 0.26 0.22 
153Glu 0.20 0.17 
154Leu 0.20 0.17 
155Tyr 0.33 0.28 
156Gly 0.19 0.16 
157Asn 0.27 0.23 
158Asn 0.17 0.14 
159Ala 0.11 0.10 
160Ala 0.13 0.11 
161Ala 0.04 0.04 
162Glu 0.01 0.01 
163Ser 0.03 0.03 
164Arg 0.06 0.05 
165Lys 0.06 0.05 
166Gly 0.02 0.02 
167Gln 0.02 0.01 
168Glu 0.04 0.03 
169Arg 0.03 0.02 
170Leu 0.05 0.04 
Table 23: Isotope-weighted chemical shift changes (Ω) in the 1H, 15N HSQC spectrum between Bcl-xL and Bcl-
xL/BakI81Fi, i+11-XL-SO3H. Residues in Bcl-xL are numbered ignoring the loop deletion between residues 44. 
